CN108676076A - 制备鸟苷酸环化酶c激动剂的方法 - Google Patents
制备鸟苷酸环化酶c激动剂的方法 Download PDFInfo
- Publication number
- CN108676076A CN108676076A CN201810573998.2A CN201810573998A CN108676076A CN 108676076 A CN108676076 A CN 108676076A CN 201810573998 A CN201810573998 A CN 201810573998A CN 108676076 A CN108676076 A CN 108676076A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- peptide
- segment
- sequence
- acid unit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000556 agonist Substances 0.000 title claims abstract description 203
- 238000000034 method Methods 0.000 title claims abstract description 121
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 title abstract description 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 338
- 235000001014 amino acid Nutrition 0.000 claims description 190
- 150000001413 amino acids Chemical group 0.000 claims description 177
- -1 Amino Chemical group 0.000 claims description 165
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 141
- 239000002253 acid Substances 0.000 claims description 64
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 60
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 34
- 150000003839 salts Chemical group 0.000 claims description 34
- 239000000243 solution Substances 0.000 claims description 32
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 24
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 23
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 20
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- 229910021529 ammonia Inorganic materials 0.000 claims description 17
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 16
- 239000007790 solid phase Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000004471 Glycine Substances 0.000 claims description 15
- 235000004279 alanine Nutrition 0.000 claims description 15
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 14
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 14
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 13
- 238000010647 peptide synthesis reaction Methods 0.000 claims description 13
- 229910001868 water Inorganic materials 0.000 claims description 13
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 12
- 238000010511 deprotection reaction Methods 0.000 claims description 12
- 238000001556 precipitation Methods 0.000 claims description 9
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 8
- 239000004475 Arginine Substances 0.000 claims description 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 7
- 238000001179 sorption measurement Methods 0.000 claims description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 6
- 238000010168 coupling process Methods 0.000 claims description 6
- 238000005859 coupling reaction Methods 0.000 claims description 6
- 238000006116 polymerization reaction Methods 0.000 claims description 6
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims description 5
- 230000008878 coupling Effects 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 101100522751 Xenorhabdus nematophila (strain ATCC 19061 / DSM 3370 / CCUG 14189 / LMG 1036 / NCIMB 9965 / AN6) pvcA gene Proteins 0.000 claims description 2
- 150000003863 ammonium salts Chemical class 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 230000018044 dehydration Effects 0.000 claims description 2
- 238000006297 dehydration reaction Methods 0.000 claims description 2
- 238000005897 peptide coupling reaction Methods 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims 1
- XTUSEBKMEQERQV-UHFFFAOYSA-N propan-2-ol;hydrate Chemical compound O.CC(C)O XTUSEBKMEQERQV-UHFFFAOYSA-N 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 description 187
- 239000002585 base Substances 0.000 description 110
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 72
- 239000003153 chemical reaction reagent Substances 0.000 description 58
- 125000003275 alpha amino acid group Chemical group 0.000 description 51
- 239000003795 chemical substances by application Substances 0.000 description 49
- 239000003112 inhibitor Substances 0.000 description 41
- 239000003814 drug Substances 0.000 description 40
- 150000001875 compounds Chemical class 0.000 description 39
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 38
- 229920001184 polypeptide Polymers 0.000 description 34
- 108010018859 plecanatide Proteins 0.000 description 33
- NSPHQWLKCGGCQR-DLJDZFDSSA-N (2s)-2-[[(1r,4s,7s,10s,13s,16r,21r,27s,34r,37s,40s)-10-(2-amino-2-oxoethyl)-34-[[(2s)-4-carboxy-2-[[(2s)-3-carboxy-2-[[(2s)-2,4-diamino-4-oxobutanoyl]amino]propanoyl]amino]butanoyl]amino]-37-(2-carboxyethyl)-27-[(1r)-1-hydroxyethyl]-4-methyl-40-(2-methylp Chemical compound N1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(N)=O)CSSC[C@@H]2NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC2=O NSPHQWLKCGGCQR-DLJDZFDSSA-N 0.000 description 31
- 229950008515 plecanatide Drugs 0.000 description 31
- 238000002360 preparation method Methods 0.000 description 30
- 239000000203 mixture Substances 0.000 description 27
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 26
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 24
- 229960001153 serine Drugs 0.000 description 23
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 22
- 206010010774 Constipation Diseases 0.000 description 22
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 22
- 238000009472 formulation Methods 0.000 description 22
- 235000004400 serine Nutrition 0.000 description 22
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 21
- 239000001301 oxygen Substances 0.000 description 21
- 229910052760 oxygen Inorganic materials 0.000 description 21
- 239000004305 biphenyl Substances 0.000 description 20
- 235000010290 biphenyl Nutrition 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 20
- 102000005962 receptors Human genes 0.000 description 19
- 108020003175 receptors Proteins 0.000 description 19
- 150000002148 esters Chemical class 0.000 description 18
- 235000019441 ethanol Nutrition 0.000 description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 18
- 229940124597 therapeutic agent Drugs 0.000 description 18
- 230000000968 intestinal effect Effects 0.000 description 17
- 235000005772 leucine Nutrition 0.000 description 17
- 229960003136 leucine Drugs 0.000 description 17
- 229920005989 resin Polymers 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 17
- 229960004441 tyrosine Drugs 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 16
- 125000006267 biphenyl group Chemical group 0.000 description 16
- 238000002648 combination therapy Methods 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 239000011347 resin Substances 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- 239000005557 antagonist Substances 0.000 description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 15
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 15
- 235000002374 tyrosine Nutrition 0.000 description 15
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 14
- 230000000202 analgesic effect Effects 0.000 description 13
- 230000000670 limiting effect Effects 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 12
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 12
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 12
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 229940029575 guanosine Drugs 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 12
- WGEWYYPHYMGJNT-HLHYUOOASA-N CC(C)C[C@@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(=O)N)C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](N)CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)O)C(=O)O Chemical compound CC(C)C[C@@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(=O)N)C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](N)CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)O)C(=O)O WGEWYYPHYMGJNT-HLHYUOOASA-N 0.000 description 11
- 206010009900 Colitis ulcerative Diseases 0.000 description 11
- 208000011231 Crohn disease Diseases 0.000 description 11
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 11
- 201000006704 Ulcerative Colitis Diseases 0.000 description 11
- 102400000230 Uroguanylin Human genes 0.000 description 11
- 101800000255 Uroguanylin Proteins 0.000 description 11
- 108010022410 dolcanatide Proteins 0.000 description 11
- 230000002496 gastric effect Effects 0.000 description 11
- 210000001035 gastrointestinal tract Anatomy 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 229960005190 phenylalanine Drugs 0.000 description 11
- 208000011580 syndromic disease Diseases 0.000 description 11
- SJMPVWVIVWEWJK-AXEIBBKLSA-N uroguanylin Chemical compound SC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(N)=O SJMPVWVIVWEWJK-AXEIBBKLSA-N 0.000 description 11
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 10
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 10
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 10
- 239000004473 Threonine Substances 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 150000003851 azoles Chemical class 0.000 description 10
- 230000003750 conditioning effect Effects 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 10
- 230000004224 protection Effects 0.000 description 10
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 10
- 229960002898 threonine Drugs 0.000 description 10
- 235000008521 threonine Nutrition 0.000 description 10
- 208000018522 Gastrointestinal disease Diseases 0.000 description 9
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 9
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 108010033276 Peptide Fragments Proteins 0.000 description 9
- 102000007079 Peptide Fragments Human genes 0.000 description 9
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 9
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 150000002576 ketones Chemical group 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- 235000013930 proline Nutrition 0.000 description 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 229940044551 receptor antagonist Drugs 0.000 description 9
- 239000002464 receptor antagonist Substances 0.000 description 9
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 9
- 239000004474 valine Substances 0.000 description 9
- 229960004295 valine Drugs 0.000 description 9
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 8
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 8
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 8
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 235000018417 cysteine Nutrition 0.000 description 8
- 208000010643 digestive system disease Diseases 0.000 description 8
- 208000018685 gastrointestinal system disease Diseases 0.000 description 8
- 235000013922 glutamic acid Nutrition 0.000 description 8
- 239000004220 glutamic acid Substances 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- SUSQOBVLVYHIEX-UHFFFAOYSA-N phenylacetonitrile Chemical compound N#CCC1=CC=CC=C1 SUSQOBVLVYHIEX-UHFFFAOYSA-N 0.000 description 8
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 7
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 7
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 7
- 239000012535 impurity Substances 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 229960000310 isoleucine Drugs 0.000 description 7
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 7
- KXGCNMMJRFDFNR-WDRJZQOASA-N linaclotide Chemical compound C([C@H](NC(=O)[C@@H]1CSSC[C@H]2C(=O)N[C@H]3CSSC[C@H](N)C(=O)N[C@H](C(N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N2)=O)CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC3=O)C(=O)N[C@H](C(NCC(=O)N1)=O)[C@H](O)C)C(O)=O)C1=CC=C(O)C=C1 KXGCNMMJRFDFNR-WDRJZQOASA-N 0.000 description 7
- 108010024409 linaclotide Proteins 0.000 description 7
- 229960000812 linaclotide Drugs 0.000 description 7
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 6
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 6
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 6
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 6
- 101100135868 Dictyostelium discoideum pde3 gene Proteins 0.000 description 6
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 6
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 6
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 6
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 6
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 6
- 230000003276 anti-hypertensive effect Effects 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 201000006549 dyspepsia Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229910052731 fluorine Inorganic materials 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 201000002313 intestinal cancer Diseases 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- 229960005141 piperazine Drugs 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 6
- REZGGXNDEMKIQB-UHFFFAOYSA-N zaprinast Chemical compound CCCOC1=CC=CC=C1C1=NC(=O)C2=NNNC2=N1 REZGGXNDEMKIQB-UHFFFAOYSA-N 0.000 description 6
- 229950005371 zaprinast Drugs 0.000 description 6
- ZHGNHOOVYPHPNJ-UHFFFAOYSA-N Amigdalin Chemical compound FC(F)(F)C(=O)OCC1OC(OCC2OC(OC(C#N)C3=CC=CC=C3)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C2OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C1OC(=O)C(F)(F)F ZHGNHOOVYPHPNJ-UHFFFAOYSA-N 0.000 description 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 5
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 5
- ZNIFSRGNXRYGHF-UHFFFAOYSA-N Clonidine hydrochloride Chemical compound Cl.ClC1=CC=CC(Cl)=C1NC1=NCCN1 ZNIFSRGNXRYGHF-UHFFFAOYSA-N 0.000 description 5
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical class OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 5
- 108010011459 Exenatide Proteins 0.000 description 5
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
- BXSVDJUWKSRQMD-ITMJLNKNSA-N O.O.CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c3ccccc3.CN4[C@@H]5CC[C@H]4C[C@H](C5)OC(=O)[C@H](CO)c6ccccc6.OS(=O)(=O)O Chemical compound O.O.CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(=O)[C@H](CO)c3ccccc3.CN4[C@@H]5CC[C@H]4C[C@H](C5)OC(=O)[C@H](CO)c6ccccc6.OS(=O)(=O)O BXSVDJUWKSRQMD-ITMJLNKNSA-N 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical class OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 description 5
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 5
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 235000009582 asparagine Nutrition 0.000 description 5
- 229960001230 asparagine Drugs 0.000 description 5
- 235000003704 aspartic acid Nutrition 0.000 description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 238000009833 condensation Methods 0.000 description 5
- 230000005494 condensation Effects 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 5
- 229960001519 exenatide Drugs 0.000 description 5
- 229940060037 fluorine Drugs 0.000 description 5
- 239000011737 fluorine Substances 0.000 description 5
- 206010017758 gastric cancer Diseases 0.000 description 5
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical group C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 5
- 230000004968 inflammatory condition Effects 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N n-propyl alcohol Natural products CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 229930002330 retinoic acid Natural products 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 201000011549 stomach cancer Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 4
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 4
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 4
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 4
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 4
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 4
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 4
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 4
- NPFVRBCDMFKOPY-UHFFFAOYSA-N 3-(4-imidazol-1-ylthiophen-2-yl)-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC(N2C=NC=C2)=CS1 NPFVRBCDMFKOPY-UHFFFAOYSA-N 0.000 description 4
- UTUUPXBCDMQYRR-HSZRJFAPSA-N 4-[(2r)-2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine Chemical compound COC1=CC=C([C@H](CC=2C=CN=CC=2)C=2C=CC=CC=2)C=C1OC1CCCC1 UTUUPXBCDMQYRR-HSZRJFAPSA-N 0.000 description 4
- IZLRMTJLQCLMKF-UHFFFAOYSA-N 5-[1-(3,4-dimethoxybenzoyl)-3,4-dihydro-2h-quinolin-6-yl]-6-methyl-3,6-dihydro-1,3,4-thiadiazin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1C2=CC=C(C=3C(SC(=O)NN=3)C)C=C2CCC1 IZLRMTJLQCLMKF-UHFFFAOYSA-N 0.000 description 4
- QWGUGDYWUADMGB-UHFFFAOYSA-N 5-bromo-3-[3-(4-chlorophenyl)propoxy]-4-(pyridin-3-ylmethylamino)-1h-pyridazin-6-one;hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1CCCOC1=NNC(=O)C(Br)=C1NCC1=CC=CN=C1 QWGUGDYWUADMGB-UHFFFAOYSA-N 0.000 description 4
- FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical compound CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 description 4
- 239000002083 C09CA01 - Losartan Substances 0.000 description 4
- 229940127291 Calcium channel antagonist Drugs 0.000 description 4
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 4
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 4
- 241000214780 Galega Species 0.000 description 4
- 108060003199 Glucagon Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 108010078321 Guanylate Cyclase Proteins 0.000 description 4
- 102000014469 Guanylate cyclase Human genes 0.000 description 4
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 229910002651 NO3 Inorganic materials 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 229930012538 Paclitaxel Natural products 0.000 description 4
- 229940123263 Phosphodiesterase 3 inhibitor Drugs 0.000 description 4
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 4
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 101001032756 Rattus norvegicus Granzyme-like protein 1 Proteins 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- DOQPXTMNIUCOSY-UHFFFAOYSA-N [4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]-[2-(3,4-dimethoxyphenyl)ethyl]-methylazanium;chloride Chemical compound [H+].[Cl-].C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 DOQPXTMNIUCOSY-UHFFFAOYSA-N 0.000 description 4
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 4
- 229950007884 alacepril Drugs 0.000 description 4
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 235000009697 arginine Nutrition 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- KVWNWTZZBKCOPM-UHFFFAOYSA-M bretylium tosylate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.CC[N+](C)(C)CC1=CC=CC=C1Br KVWNWTZZBKCOPM-UHFFFAOYSA-M 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 235000013877 carbamide Nutrition 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 4
- 229960001523 chlortalidone Drugs 0.000 description 4
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 239000003344 environmental pollutant Substances 0.000 description 4
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 4
- 238000013265 extended release Methods 0.000 description 4
- 150000004665 fatty acids Chemical group 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 229960004580 glibenclamide Drugs 0.000 description 4
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 235000013928 guanylic acid Nutrition 0.000 description 4
- 235000014304 histidine Nutrition 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 4
- 229960004592 isopropanol Drugs 0.000 description 4
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical class NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 4
- 229950002910 motapizone Drugs 0.000 description 4
- 229960003086 naltrexone Drugs 0.000 description 4
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 229960001592 paclitaxel Drugs 0.000 description 4
- 229960001639 penicillamine Drugs 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 description 4
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 4
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- 231100000719 pollutant Toxicity 0.000 description 4
- 239000001103 potassium chloride Substances 0.000 description 4
- 235000011164 potassium chloride Nutrition 0.000 description 4
- DURULFYMVIFBIR-UHFFFAOYSA-N practolol Chemical compound CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1 DURULFYMVIFBIR-UHFFFAOYSA-N 0.000 description 4
- 108010029667 pramlintide Proteins 0.000 description 4
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 229960004586 rosiglitazone Drugs 0.000 description 4
- 239000011877 solvent mixture Substances 0.000 description 4
- 229960001940 sulfasalazine Drugs 0.000 description 4
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 4
- 229960002876 tegaserod Drugs 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 229960001727 tretinoin Drugs 0.000 description 4
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 4
- 229960002381 vardenafil Drugs 0.000 description 4
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 3
- NKQJVOJUSQJZPX-QMMMGPOBSA-N (2S)-3-(3,4-dihydroxyphenyl)-2-(ethylamino)propanoic acid Chemical compound CCN[C@@H](Cc1ccc(O)c(O)c1)C(O)=O NKQJVOJUSQJZPX-QMMMGPOBSA-N 0.000 description 3
- XLEKQZHPKBRJNB-BKLSDQPFSA-N (2r)-3-sulfanylpyrrolidine-2-carboxylic acid Chemical class OC(=O)[C@H]1NCCC1S XLEKQZHPKBRJNB-BKLSDQPFSA-N 0.000 description 3
- VEPOHXYIFQMVHW-PVJVQHJQSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;(2s,3s)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 VEPOHXYIFQMVHW-PVJVQHJQSA-N 0.000 description 3
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 3
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 3
- KJFRSZASZNLCDF-UHFFFAOYSA-N 1,5-benzothiazepine Chemical class S1C=CC=NC2=CC=CC=C12 KJFRSZASZNLCDF-UHFFFAOYSA-N 0.000 description 3
- KFNNPQDSPLWLCX-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-n,n,3-trimethylbutan-1-amine;hydron;chloride;hydrate Chemical compound O.Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 KFNNPQDSPLWLCX-UHFFFAOYSA-N 0.000 description 3
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 3
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 206010001497 Agitation Diseases 0.000 description 3
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- 229940123208 Biguanide Drugs 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 101710095468 Cyclase Proteins 0.000 description 3
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102000038624 GSKs Human genes 0.000 description 3
- 108091007911 GSKs Proteins 0.000 description 3
- 235000007025 Galega officinalis Nutrition 0.000 description 3
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 3
- 102000051325 Glucagon Human genes 0.000 description 3
- 206010020850 Hyperthyroidism Diseases 0.000 description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 3
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 description 3
- QNQZBKQEIFTHFZ-UHFFFAOYSA-N Loxizin Chemical compound CCCCCN(CCCOC)C(=O)C(CCC(O)=O)NC(=O)C1=CC=C(Cl)C(Cl)=C1 QNQZBKQEIFTHFZ-UHFFFAOYSA-N 0.000 description 3
- 108010008364 Melanocortins Proteins 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 3
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 description 3
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 3
- 102400000064 Neuropeptide Y Human genes 0.000 description 3
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 102100037346 Substance-P receptor Human genes 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 3
- 229960002122 acebutolol Drugs 0.000 description 3
- 238000001994 activation Methods 0.000 description 3
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 3
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 3
- 229960002576 amiloride Drugs 0.000 description 3
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 3
- 229960000528 amlodipine Drugs 0.000 description 3
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000002876 beta blocker Substances 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 3
- 239000000480 calcium channel blocker Substances 0.000 description 3
- HTQMVQVXFRQIKW-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 HTQMVQVXFRQIKW-UHFFFAOYSA-N 0.000 description 3
- 229960000932 candesartan Drugs 0.000 description 3
- 229960000830 captopril Drugs 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 3
- OGHNVEJMJSYVRP-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2 OGHNVEJMJSYVRP-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 229960002155 chlorothiazide Drugs 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 229960002896 clonidine Drugs 0.000 description 3
- 229960002925 clonidine hydrochloride Drugs 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 229960005227 delapril Drugs 0.000 description 3
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 description 3
- 229960001259 diclofenac Drugs 0.000 description 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
- MPFLRYZEEAQMLQ-UHFFFAOYSA-N dinicotinic acid Chemical class OC(=O)C1=CN=CC(C(O)=O)=C1 MPFLRYZEEAQMLQ-UHFFFAOYSA-N 0.000 description 3
- ZJKNESGOIKRXQY-UHFFFAOYSA-N enoximone Chemical compound C1=CC(SC)=CC=C1C(=O)C1=C(C)NC(=O)N1 ZJKNESGOIKRXQY-UHFFFAOYSA-N 0.000 description 3
- 229960000972 enoximone Drugs 0.000 description 3
- 208000037902 enteropathy Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- 229950000484 exisulind Drugs 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 229960000390 fludarabine Drugs 0.000 description 3
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 229960002390 flurbiprofen Drugs 0.000 description 3
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 201000010175 gallbladder cancer Diseases 0.000 description 3
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 3
- 229960004666 glucagon Drugs 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 235000004554 glutamine Nutrition 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229960002474 hydralazine Drugs 0.000 description 3
- 208000003532 hypothyroidism Diseases 0.000 description 3
- 230000002989 hypothyroidism Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 150000002466 imines Chemical class 0.000 description 3
- 229940073062 imuran Drugs 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000028774 intestinal disease Diseases 0.000 description 3
- 208000003243 intestinal obstruction Diseases 0.000 description 3
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 3
- 229960000991 ketoprofen Drugs 0.000 description 3
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 3
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 3
- 229960004338 leuprorelin Drugs 0.000 description 3
- 229940080159 levsin Drugs 0.000 description 3
- 229960001571 loperamide Drugs 0.000 description 3
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 3
- 229960004773 losartan Drugs 0.000 description 3
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 3
- 229950009386 loxiglumide Drugs 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 239000002865 melanocortin Substances 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- 229940042003 metamucil Drugs 0.000 description 3
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 3
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 3
- 229960003632 minoxidil Drugs 0.000 description 3
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 3
- 229960004255 nadolol Drugs 0.000 description 3
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 3
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 3
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 3
- 229960001597 nifedipine Drugs 0.000 description 3
- 229960000227 nisoldipine Drugs 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical compound C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000006320 pegylation Effects 0.000 description 3
- BRBAEHHXGZRCBK-UHFFFAOYSA-N pentrinitrol Chemical compound [O-][N+](=O)OCC(CO)(CO[N+]([O-])=O)CO[N+]([O-])=O BRBAEHHXGZRCBK-UHFFFAOYSA-N 0.000 description 3
- 239000000813 peptide hormone Substances 0.000 description 3
- 229960002582 perindopril Drugs 0.000 description 3
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 3
- 230000008855 peristalsis Effects 0.000 description 3
- NCAIGTHBQTXTLR-UHFFFAOYSA-N phentermine hydrochloride Chemical compound [Cl-].CC(C)([NH3+])CC1=CC=CC=C1 NCAIGTHBQTXTLR-UHFFFAOYSA-N 0.000 description 3
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- RRRUXBQSQLKHEL-UHFFFAOYSA-N piclamilast Chemical compound COC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OC1CCCC1 RRRUXBQSQLKHEL-UHFFFAOYSA-N 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 3
- 229960004641 rituximab Drugs 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000006104 solid solution Substances 0.000 description 3
- VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 3
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- MVGSNCBCUWPVDA-MFOYZWKCSA-N sulindac sulfone Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)(=O)=O)C=C1 MVGSNCBCUWPVDA-MFOYZWKCSA-N 0.000 description 3
- 229960001603 tamoxifen Drugs 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960000278 theophylline Drugs 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 3
- 229960001641 troglitazone Drugs 0.000 description 3
- 229960004699 valsartan Drugs 0.000 description 3
- 229960000881 verapamil hydrochloride Drugs 0.000 description 3
- 229960002066 vinorelbine Drugs 0.000 description 3
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 3
- QSLPNSWXUQHVLP-UHFFFAOYSA-N $l^{1}-sulfanylmethane Chemical compound [S]C QSLPNSWXUQHVLP-UHFFFAOYSA-N 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 2
- FDYHSJCNTRLQCR-LREBCSMRSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;7-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-5h-[1,3]dioxolo[4,5-f]indole Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.COC1=CC=CC=C1N1CCN(CCC=2C3=CC=4OCOC=4C=C3NC=2)CC1 FDYHSJCNTRLQCR-LREBCSMRSA-N 0.000 description 2
- BAVDEDVBIHTHJQ-UVJOBNTFSA-N (2s)-1-[(2s)-6-amino-2-[[(1s)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid;hydrate Chemical compound O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 BAVDEDVBIHTHJQ-UVJOBNTFSA-N 0.000 description 2
- GDPHPXYFLPDZGH-XBTMSFKCSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 GDPHPXYFLPDZGH-XBTMSFKCSA-N 0.000 description 2
- LPUDGHQMOAHMMF-JBACZVJFSA-N (2s)-2-[[[(2s)-6-amino-2-(methanesulfonamido)hexanoyl]amino]methyl]-3-[1-[[(1s)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl]cyclopentyl]propanoic acid Chemical compound N([C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C(=O)C1(C[C@@H](CNC(=O)[C@H](CCCCN)NS(=O)(=O)C)C(O)=O)CCCC1 LPUDGHQMOAHMMF-JBACZVJFSA-N 0.000 description 2
- ZSOPWZQRZHWYFY-NUXPJIRBSA-N (2s,3s)-2-amino-3-methyl-1-(1,3-thiazolidin-3-yl)pentan-1-one;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.CC[C@H](C)[C@H](N)C(=O)N1CCSC1 ZSOPWZQRZHWYFY-NUXPJIRBSA-N 0.000 description 2
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 2
- MFYLRNKOXORIPK-UHFFFAOYSA-N (3-nitrophenyl)-phenylmethanone Chemical class [O-][N+](=O)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 MFYLRNKOXORIPK-UHFFFAOYSA-N 0.000 description 2
- FXKFFTMLFPWYFH-RDGPPVDQSA-N (4s,7s,12br)-7-[[(2s)-2-acetylsulfanyl-3-methylbutanoyl]amino]-6-oxo-2,3,4,7,8,12b-hexahydro-1h-pyrido[2,1-a][2]benzazepine-4-carboxylic acid Chemical compound O=C1[C@@H](NC(=O)[C@@H](SC(C)=O)C(C)C)CC2=CC=CC=C2[C@H]2CCC[C@@H](C(O)=O)N21 FXKFFTMLFPWYFH-RDGPPVDQSA-N 0.000 description 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 2
- NWIUTZDMDHAVTP-KRWDZBQOSA-N (S)-betaxolol Chemical compound C1=CC(OC[C@@H](O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-KRWDZBQOSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- JDZOTSLZMQDFLG-BTJKTKAUSA-N (z)-but-2-enedioic acid;2-(2,2-dicyclohexylethyl)piperidine Chemical compound OC(=O)\C=C/C(O)=O.C1CCCNC1CC(C1CCCCC1)C1CCCCC1 JDZOTSLZMQDFLG-BTJKTKAUSA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- HJPRDDKCXVCFOH-UHFFFAOYSA-N 1,3-dibutyl-7-(2-oxopropyl)purine-2,6-dione Chemical compound O=C1N(CCCC)C(=O)N(CCCC)C2=C1N(CC(C)=O)C=N2 HJPRDDKCXVCFOH-UHFFFAOYSA-N 0.000 description 2
- ZPQOPVIELGIULI-UHFFFAOYSA-N 1,3-dichlorobenzene Chemical class ClC1=CC=CC(Cl)=C1 ZPQOPVIELGIULI-UHFFFAOYSA-N 0.000 description 2
- GZIISXIDAZYOLI-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-(3-phenylpyrrolidin-1-yl)propan-1-one Chemical compound C=1C=C2OCCOC2=CC=1C(=O)CCN(C1)CCC1C1=CC=CC=C1 GZIISXIDAZYOLI-UHFFFAOYSA-N 0.000 description 2
- ODWXZMXQBDEIBF-UHFFFAOYSA-N 1-(2-cyclohexylphenoxy)-3-(propan-2-ylamino)propan-2-ol;hydron;chloride Chemical compound Cl.CC(C)NCC(O)COC1=CC=CC=C1C1CCCCC1 ODWXZMXQBDEIBF-UHFFFAOYSA-N 0.000 description 2
- XILWEASNBDKGSA-AWEZNQCLSA-N 1-(4-methylphenyl)sulfonyl-3-[(2s)-1-phenylpropan-2-yl]urea Chemical compound C([C@H](C)NC(=O)NS(=O)(=O)C=1C=CC(C)=CC=1)C1=CC=CC=C1 XILWEASNBDKGSA-AWEZNQCLSA-N 0.000 description 2
- UUOJIACWOAYWEZ-UHFFFAOYSA-N 1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl benzoate Chemical compound C1=CC=C2NC(C)=CC2=C1OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1 UUOJIACWOAYWEZ-UHFFFAOYSA-N 0.000 description 2
- IFQJSQQPCCLGLZ-UHFFFAOYSA-N 1-[4-[2-(cyclopropylmethoxy)ethoxy]phenoxy]-3-(propan-2-ylamino)propan-2-ol;hydron;chloride Chemical compound Cl.C1=CC(OCC(O)CNC(C)C)=CC=C1OCCOCC1CC1 IFQJSQQPCCLGLZ-UHFFFAOYSA-N 0.000 description 2
- IFYLTXNCFVRALQ-UHFFFAOYSA-N 1-[6-amino-2-[hydroxy(4-phenylbutyl)phosphoryl]oxyhexanoyl]pyrrolidine-2-carboxylic acid Chemical compound C1CCC(C(O)=O)N1C(=O)C(CCCCN)OP(O)(=O)CCCCC1=CC=CC=C1 IFYLTXNCFVRALQ-UHFFFAOYSA-N 0.000 description 2
- NUHPODZZKHQQET-UHFFFAOYSA-N 1-cyano-2-methyl-3-[4-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)phenyl]guanidine Chemical compound C1=CC(NC(NC#N)=NC)=CC=C1C1=NNC(=O)CC1C NUHPODZZKHQQET-UHFFFAOYSA-N 0.000 description 2
- JHPWSIOCWUJGJE-UHFFFAOYSA-N 1-methyl-6-(4-methyl-6-oxo-4,5-dihydro-1h-pyridazin-3-yl)-3,4-dihydroquinolin-2-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N(C)C(=O)CC2)C2=C1 JHPWSIOCWUJGJE-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 2
- PQTJTRTXCNZDFT-UHFFFAOYSA-N 2-(2-propoxyphenyl)-3,7-dihydropurin-6-one Chemical compound CCCOC1=CC=CC=C1C(N1)=NC(=O)C2=C1N=CN2 PQTJTRTXCNZDFT-UHFFFAOYSA-N 0.000 description 2
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 description 2
- NSVFSAJIGAJDMR-UHFFFAOYSA-N 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate Chemical compound CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 NSVFSAJIGAJDMR-UHFFFAOYSA-N 0.000 description 2
- XKSAJZSJKURQRX-UHFFFAOYSA-N 2-acetyloxy-5-(4-fluorophenyl)benzoic acid Chemical compound C1=C(C(O)=O)C(OC(=O)C)=CC=C1C1=CC=C(F)C=C1 XKSAJZSJKURQRX-UHFFFAOYSA-N 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- VNRJGEMERJZKLQ-UHFFFAOYSA-N 2-piperazin-1-ylacetamide Chemical class NC(=O)CN1CCNCC1 VNRJGEMERJZKLQ-UHFFFAOYSA-N 0.000 description 2
- LZCQFJKUAIWHRW-UHFFFAOYSA-N 3,3-dimethyl-5-(6-oxo-4,5-dihydro-1h-pyridazin-3-yl)-1h-indol-2-one Chemical compound C1=C2C(C)(C)C(=O)NC2=CC=C1C1=NNC(=O)CC1 LZCQFJKUAIWHRW-UHFFFAOYSA-N 0.000 description 2
- LORDFXWUHHSAQU-UHFFFAOYSA-N 3,4,5-trimethoxybenzoic acid [2-(dimethylamino)-2-phenylbutyl] ester Chemical compound C=1C=CC=CC=1C(CC)(N(C)C)COC(=O)C1=CC(OC)=C(OC)C(OC)=C1 LORDFXWUHHSAQU-UHFFFAOYSA-N 0.000 description 2
- WPGHPGAUFIJVJF-UHFFFAOYSA-N 3,5-dichloropyridine Chemical compound ClC1=CN=CC(Cl)=C1 WPGHPGAUFIJVJF-UHFFFAOYSA-N 0.000 description 2
- VXMYWVMXSWJFCV-UHFFFAOYSA-N 3-(4-imidazol-1-ylphenyl)-4,5-dihydro-1h-pyridazin-6-one Chemical compound N1C(=O)CCC(C=2C=CC(=CC=2)N2C=NC=C2)=N1 VXMYWVMXSWJFCV-UHFFFAOYSA-N 0.000 description 2
- AEZZPAQOEUQNBB-UHFFFAOYSA-N 3-(4-imidazol-1-ylphenyl)-4-methyl-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N2C=NC=C2)C=C1 AEZZPAQOEUQNBB-UHFFFAOYSA-N 0.000 description 2
- CABBMMXFOOZVMS-PMERELPUSA-N 3-[[(3s)-2,4-dioxo-1-[2-oxo-2-(n-propan-2-ylanilino)ethyl]-5-phenyl-1,5-benzodiazepin-3-yl]carbamoylamino]benzoic acid Chemical compound C=1C=CC=CC=1N(C(C)C)C(=O)CN(C([C@H](NC(=O)NC=1C=C(C=CC=1)C(O)=O)C1=O)=O)C2=CC=CC=C2N1C1=CC=CC=C1 CABBMMXFOOZVMS-PMERELPUSA-N 0.000 description 2
- OGIYDFVHFQEFKQ-UHFFFAOYSA-N 3-[n-(4,5-dihydro-1h-imidazol-2-ylmethyl)-4-methylanilino]phenol;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 OGIYDFVHFQEFKQ-UHFFFAOYSA-N 0.000 description 2
- XTFPDGZNWTZCMF-DHZHZOJOSA-N 3-o-methyl 5-o-[(e)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 XTFPDGZNWTZCMF-DHZHZOJOSA-N 0.000 description 2
- 150000008085 4,5-dihydro-1H-imidazoles Chemical class 0.000 description 2
- MIXLZCYFMQNQDD-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)-N'-hydroxy-1,3-thiazole-2-carboximidamide Chemical compound C1=C(OC)C(OC)=CC=C1C1=CSC(C(N)=NO)=N1 MIXLZCYFMQNQDD-UHFFFAOYSA-N 0.000 description 2
- LUGKHBNNJJSVLE-UHFFFAOYSA-N 4-(8-benzylsulfanyl-2-piperazin-1-ylpyrimido[5,4-d]pyrimidin-4-yl)morpholine Chemical compound C=1C=CC=CC=1CSC(C1=N2)=NC=NC1=C(N1CCOCC1)N=C2N1CCNCC1 LUGKHBNNJJSVLE-UHFFFAOYSA-N 0.000 description 2
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 2
- SKQDKFOTIPJUSV-UHFFFAOYSA-N 4-[2-[[2-hydroxy-3-(2-methylphenoxy)propyl]amino]ethoxy]benzamide Chemical compound CC1=CC=CC=C1OCC(O)CNCCOC1=CC=C(C(N)=O)C=C1 SKQDKFOTIPJUSV-UHFFFAOYSA-N 0.000 description 2
- QBQLYIISSRXYKL-UHFFFAOYSA-N 4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,2-oxazolidine-3,5-dione Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCOC(C=C1)=CC=C1CC1C(=O)NOC1=O QBQLYIISSRXYKL-UHFFFAOYSA-N 0.000 description 2
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 2
- OQGWJZOWLHWFME-UHFFFAOYSA-N 4-ethyl-5-(pyridine-4-carbonyl)-1,3-dihydroimidazol-2-one Chemical compound N1C(=O)NC(C(=O)C=2C=CN=CC=2)=C1CC OQGWJZOWLHWFME-UHFFFAOYSA-N 0.000 description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- OOTPDLYEDHRWNL-UHFFFAOYSA-N 4-methyl-3-[4-(4-oxopyridin-1-yl)phenyl]-4,5-dihydro-1h-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N2C=CC(=O)C=C2)C=C1 OOTPDLYEDHRWNL-UHFFFAOYSA-N 0.000 description 2
- PDUXMHXBBXXJFQ-UHFFFAOYSA-N 5,6-diethoxy-1-benzothiophene-2-carboxylic acid Chemical compound C1=C(OCC)C(OCC)=CC2=C1SC(C(O)=O)=C2 PDUXMHXBBXXJFQ-UHFFFAOYSA-N 0.000 description 2
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 2
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 2
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 description 2
- DNTDOBSIBZKFCP-UHFFFAOYSA-N 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-2h-naphthalen-1-one;hydron;chloride Chemical compound [Cl-].O=C1CCCC2=C1C=CC=C2OCC(O)C[NH2+]C(C)(C)C DNTDOBSIBZKFCP-UHFFFAOYSA-N 0.000 description 2
- KLEKLDFUYOZELG-UHFFFAOYSA-N 5-[4-[2-hydroxy-3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]phenyl]-6-methyl-2-oxo-1h-pyridine-3-carbonitrile Chemical compound COC1=CC=CC=C1N1CCN(CC(O)COC=2C=CC(=CC=2)C2=C(NC(=O)C(C#N)=C2)C)CC1 KLEKLDFUYOZELG-UHFFFAOYSA-N 0.000 description 2
- MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 description 2
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 2
- GJGNHSWJROFFMV-UHFFFAOYSA-N 6,11-dihydrobenzo[c][1]benzothiepine Chemical compound C1SC2=CC=CC=C2CC2=CC=CC=C12 GJGNHSWJROFFMV-UHFFFAOYSA-N 0.000 description 2
- ZWLHNUOGIZYKHZ-UHFFFAOYSA-N 6-methyl-2-oxo-5-quinolin-6-yl-1h-pyridine-3-carbonitrile Chemical compound N1C(=O)C(C#N)=CC(C=2C=C3C=CC=NC3=CC=2)=C1C ZWLHNUOGIZYKHZ-UHFFFAOYSA-N 0.000 description 2
- JSUZBWHUZJJRII-UHFFFAOYSA-N 6-pyridin-4-yl-5-(trifluoromethyl)-1,3-dihydroimidazo[4,5-b]pyridin-2-one Chemical compound FC(F)(F)C1=NC=2NC(=O)NC=2C=C1C1=CC=NC=C1 JSUZBWHUZJJRII-UHFFFAOYSA-N 0.000 description 2
- KODNKGAUSNMURM-UHFFFAOYSA-N 7-[4-[4-(cyclohexylmethyl)piperazin-1-yl]-4-oxobutoxy]-1,3-dihydroimidazo[4,5-b]quinolin-2-one Chemical compound C=1C=C2N=C3NC(=O)NC3=CC2=CC=1OCCCC(=O)N(CC1)CCN1CC1CCCCC1 KODNKGAUSNMURM-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Natural products CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102100027840 Acyl-CoA wax alcohol acyltransferase 1 Human genes 0.000 description 2
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 2
- 108700029992 Ala(2)-Arg(6)- enkephalin-Leu Proteins 0.000 description 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- 206010001935 American trypanosomiasis Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 208000007860 Anus Neoplasms Diseases 0.000 description 2
- NCUCGYYHUFIYNU-UHFFFAOYSA-N Aranidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)=O)C1C1=CC=CC=C1[N+]([O-])=O NCUCGYYHUFIYNU-UHFFFAOYSA-N 0.000 description 2
- 206010061666 Autonomic neuropathy Diseases 0.000 description 2
- ZKFQEACEUNWPMT-UHFFFAOYSA-N Azelnidipine Chemical compound CC(C)OC(=O)C1=C(C)NC(N)=C(C(=O)OC2CN(C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZKFQEACEUNWPMT-UHFFFAOYSA-N 0.000 description 2
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 2
- 102100028628 Bombesin receptor subtype-3 Human genes 0.000 description 2
- RHLJLALHBZGAFM-UHFFFAOYSA-N Bunazosinum Chemical compound C1CN(C(=O)CCC)CCCN1C1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 RHLJLALHBZGAFM-UHFFFAOYSA-N 0.000 description 2
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 2
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 2
- 239000002081 C09CA05 - Tasosartan Substances 0.000 description 2
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 2
- 229940123681 CCK receptor agonist Drugs 0.000 description 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 2
- 244000025596 Cassia laevigata Species 0.000 description 2
- 235000006693 Cassia laevigata Nutrition 0.000 description 2
- JOATXPAWOHTVSZ-UHFFFAOYSA-N Celiprolol Chemical compound CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(C(C)=O)=C1 JOATXPAWOHTVSZ-UHFFFAOYSA-N 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 208000024699 Chagas disease Diseases 0.000 description 2
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 2
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 2
- KJEBULYHNRNJTE-DHZHZOJOSA-N Cinalong Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 KJEBULYHNRNJTE-DHZHZOJOSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 108010069514 Cyclic Peptides Proteins 0.000 description 2
- 102000001189 Cyclic Peptides Human genes 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 2
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 230000008836 DNA modification Effects 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 2
- 108010061435 Enalapril Proteins 0.000 description 2
- 208000017701 Endocrine disease Diseases 0.000 description 2
- 108010092674 Enkephalins Proteins 0.000 description 2
- 241000305071 Enterobacterales Species 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- XQLWNAFCTODIRK-UHFFFAOYSA-N Gallopamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC(OC)=C(OC)C(OC)=C1 XQLWNAFCTODIRK-UHFFFAOYSA-N 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- DGFYECXYGUIODH-UHFFFAOYSA-N Guanfacine hydrochloride Chemical compound Cl.NC(N)=NC(=O)CC1=C(Cl)C=CC=C1Cl DGFYECXYGUIODH-UHFFFAOYSA-N 0.000 description 2
- 101000698136 Homo sapiens Acyl-CoA wax alcohol acyltransferase 1 Proteins 0.000 description 2
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 2
- 101001125071 Homo sapiens Neuromedin-K receptor Proteins 0.000 description 2
- 102000013266 Human Regular Insulin Human genes 0.000 description 2
- 108010090613 Human Regular Insulin Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- OMCPLEZZPVJJIS-UHFFFAOYSA-N Hypadil (TN) Chemical compound C1C(O[N+]([O-])=O)COC2=C1C=CC=C2OCC(O)CNC(C)C OMCPLEZZPVJJIS-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 208000013038 Hypocalcemia Diseases 0.000 description 2
- ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 108010065920 Insulin Lispro Proteins 0.000 description 2
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 2
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- WQVZLXWQESQGIF-UHFFFAOYSA-N Labetalol hydrochloride Chemical compound Cl.C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 WQVZLXWQESQGIF-UHFFFAOYSA-N 0.000 description 2
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 108010007859 Lisinopril Proteins 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 102400001132 Melanin-concentrating hormone Human genes 0.000 description 2
- 101800002739 Melanin-concentrating hormone Proteins 0.000 description 2
- 101710151321 Melanostatin Proteins 0.000 description 2
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 2
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 2
- ZDZXCYHMVFLGMT-BTJKTKAUSA-N Monatepil maleate Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(F)=CC=C1N1CCN(CCCC(=O)NC2C3=CC=CC=C3SCC3=CC=CC=C32)CC1 ZDZXCYHMVFLGMT-BTJKTKAUSA-N 0.000 description 2
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 2
- WPNJAUFVNXKLIM-UHFFFAOYSA-N Moxonidine Chemical compound COC1=NC(C)=NC(Cl)=C1NC1=NCCN1 WPNJAUFVNXKLIM-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- RXSVYGIGWRDVQC-UHFFFAOYSA-N N-[6-[[(cyclohexylideneamino)oxy-oxomethyl]amino]hexyl]carbamic acid (cyclohexylideneamino) ester Chemical compound C1CCCCC1=NOC(=O)NCCCCCCNC(=O)ON=C1CCCCC1 RXSVYGIGWRDVQC-UHFFFAOYSA-N 0.000 description 2
- UIAYVIIHMORPSJ-UHFFFAOYSA-N N-cyclohexyl-N-methyl-4-[(2-oxo-1H-quinolin-6-yl)oxy]butanamide Chemical compound C=1C=C2NC(=O)C=CC2=CC=1OCCCC(=O)N(C)C1CCCCC1 UIAYVIIHMORPSJ-UHFFFAOYSA-N 0.000 description 2
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 2
- HRRBJVNMSRJFHQ-UHFFFAOYSA-N Naftopidil Chemical compound COC1=CC=CC=C1N1CCN(CC(O)COC=2C3=CC=CC=C3C=CC=2)CC1 HRRBJVNMSRJFHQ-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 108090000028 Neprilysin Proteins 0.000 description 2
- 102000003729 Neprilysin Human genes 0.000 description 2
- 208000009905 Neurofibromatoses Diseases 0.000 description 2
- 102100029409 Neuromedin-K receptor Human genes 0.000 description 2
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- PSZDOEIIIJFCFE-UHFFFAOYSA-N Oleanolic alcohol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C)(C)CC5C4=CCC3C21C PSZDOEIIIJFCFE-UHFFFAOYSA-N 0.000 description 2
- 239000005480 Olmesartan Substances 0.000 description 2
- 229940123257 Opioid receptor antagonist Drugs 0.000 description 2
- 108010016731 PPAR gamma Proteins 0.000 description 2
- 102000000536 PPAR gamma Human genes 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 2
- 102000015731 Peptide Hormones Human genes 0.000 description 2
- 108010038988 Peptide Hormones Proteins 0.000 description 2
- MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 description 2
- ISFHAYSTHMVOJR-UHFFFAOYSA-N Phenindamine Chemical compound C1N(C)CCC(C2=CC=CC=C22)=C1C2C1=CC=CC=C1 ISFHAYSTHMVOJR-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 2
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 208000025844 Prostatic disease Diseases 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- CQXADFVORZEARL-UHFFFAOYSA-N Rilmenidine Chemical compound C1CC1C(C1CC1)NC1=NCCO1 CQXADFVORZEARL-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 108010086019 Secretin Proteins 0.000 description 2
- 102100037505 Secretin Human genes 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Natural products CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 102400000096 Substance P Human genes 0.000 description 2
- 101800003906 Substance P Proteins 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- ODKDMMTXTVCCLJ-UHFFFAOYSA-N TMC-2A Natural products C1=CC=C2C(CC(N)C(=O)N3C(CC4=CC(O)=C(C(=C4C3)O)OC)C(=O)NC(CC(CO)CO)C(O)=O)=CNC2=C1 ODKDMMTXTVCCLJ-UHFFFAOYSA-N 0.000 description 2
- 108010062740 TRPV Cation Channels Proteins 0.000 description 2
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-CSCXCSGISA-N Teprotide Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)[C@@H]1CCC(=O)N1 UUUHXMGGBIUAPW-CSCXCSGISA-N 0.000 description 2
- HTWFXPCUFWKXOP-UHFFFAOYSA-N Tertatalol Chemical compound C1CCSC2=C1C=CC=C2OCC(O)CNC(C)(C)C HTWFXPCUFWKXOP-UHFFFAOYSA-N 0.000 description 2
- 241001072888 Teucrium Species 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 2
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 2
- 102100029613 Transient receptor potential cation channel subfamily V member 1 Human genes 0.000 description 2
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 2
- 241000223109 Trypanosoma cruzi Species 0.000 description 2
- JXNRXNCCROJZFB-RYUDHWBXSA-N Tyr-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JXNRXNCCROJZFB-RYUDHWBXSA-N 0.000 description 2
- ICMGLRUYEQNHPF-UHFFFAOYSA-N Uraprene Chemical compound COC1=CC=CC=C1N1CCN(CCCNC=2N(C(=O)N(C)C(=O)C=2)C)CC1 ICMGLRUYEQNHPF-UHFFFAOYSA-N 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 2
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 description 2
- GHBUMWHHZFGRDI-AWEZNQCLSA-N [(3s)-1-(3,5-dimethoxyphenyl)-6,7-dimethoxy-3,4-dihydroisoquinolin-3-yl]methanol Chemical compound COC1=CC(OC)=CC(C=2C3=CC(OC)=C(OC)C=C3C[C@@H](CO)N=2)=C1 GHBUMWHHZFGRDI-AWEZNQCLSA-N 0.000 description 2
- MKFFGUZYVNDHIH-UHFFFAOYSA-N [2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]-propan-2-ylazanium;sulfate Chemical compound OS(O)(=O)=O.CC(C)NCC(O)C1=CC(O)=CC(O)=C1.CC(C)NCC(O)C1=CC(O)=CC(O)=C1 MKFFGUZYVNDHIH-UHFFFAOYSA-N 0.000 description 2
- QLCLNERFMKNCBZ-UHFFFAOYSA-N [3-[[1-(carbamoylamino)-2-methylpropan-2-yl]amino]-2-hydroxypropyl] 2-fluorobenzoate;sulfuric acid Chemical compound OS(O)(=O)=O.NC(=O)NCC(C)(C)NCC(O)COC(=O)C1=CC=CC=C1F QLCLNERFMKNCBZ-UHFFFAOYSA-N 0.000 description 2
- DXHWOBBGGCYHNV-UHFFFAOYSA-N [4-[3-(dibutylamino)propoxy]phenyl]-(2-ethylindolizin-3-yl)methanone;hydron;chloride Chemical compound Cl.C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CC)C=C2N1C=CC=C2 DXHWOBBGGCYHNV-UHFFFAOYSA-N 0.000 description 2
- QTBMDDQRDDABNC-UHFFFAOYSA-N [4-dibutoxyphosphoryl-3-(dibutoxyphosphorylmethyl)butoxy]benzene Chemical compound CCCCOP(=O)(OCCCC)CC(CP(=O)(OCCCC)OCCCC)CCOC1=CC=CC=C1 QTBMDDQRDDABNC-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- XXLYIUKAFIEFHW-UHFFFAOYSA-N ac1l2yxx Chemical compound Cl.C1CCCC2=C1SC1=C2CN2CC(=O)NC2=N1 XXLYIUKAFIEFHW-UHFFFAOYSA-N 0.000 description 2
- 229960001466 acetohexamide Drugs 0.000 description 2
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- TVLQBBHUNDMTEC-UHFFFAOYSA-N adibendan Chemical compound N=1C=2C=C3C(C)(C)C(=O)NC3=CC=2NC=1C1=CC=NC=C1 TVLQBBHUNDMTEC-UHFFFAOYSA-N 0.000 description 2
- 229950004648 adibendan Drugs 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- QNHQEUFMIKRNTB-UHFFFAOYSA-N aesculetin Natural products C1CC(=O)OC2=C1C=C(O)C(O)=C2 QNHQEUFMIKRNTB-UHFFFAOYSA-N 0.000 description 2
- GUAFOGOEJLSQBT-UHFFFAOYSA-N aesculetin dimethyl ether Natural products C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2 GUAFOGOEJLSQBT-UHFFFAOYSA-N 0.000 description 2
- 229960002478 aldosterone Drugs 0.000 description 2
- 229940083712 aldosterone antagonist Drugs 0.000 description 2
- 239000002170 aldosterone antagonist Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 239000002160 alpha blocker Substances 0.000 description 2
- 108090000637 alpha-Amylases Proteins 0.000 description 2
- 102000004139 alpha-Amylases Human genes 0.000 description 2
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 2
- 235000008206 alpha-amino acids Nutrition 0.000 description 2
- 229940024171 alpha-amylase Drugs 0.000 description 2
- UPNUIXSCZBYVBB-JVFUWBCBSA-N alvimopan Chemical compound C([C@@H](CN1C[C@@H]([C@](CC1)(C)C=1C=C(O)C=CC=1)C)C(=O)NCC(O)=O)C1=CC=CC=C1 UPNUIXSCZBYVBB-JVFUWBCBSA-N 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229960004909 aminosalicylic acid Drugs 0.000 description 2
- 229950010351 amosulalol Drugs 0.000 description 2
- LVEXHFZHOIWIIP-UHFFFAOYSA-N amosulalol Chemical compound COC1=CC=CC=C1OCCNCC(O)C1=CC=C(C)C(S(N)(=O)=O)=C1 LVEXHFZHOIWIIP-UHFFFAOYSA-N 0.000 description 2
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 description 2
- 229960002105 amrinone Drugs 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 230000000561 anti-psychotic effect Effects 0.000 description 2
- 230000002921 anti-spasmodic effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 201000011165 anus cancer Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229950007556 aranidipine Drugs 0.000 description 2
- GVTLDPJNRVMCAL-UHFFFAOYSA-N arofylline Chemical compound C1=2N=CNC=2C(=O)N(CCC)C(=O)N1C1=CC=C(Cl)C=C1 GVTLDPJNRVMCAL-UHFFFAOYSA-N 0.000 description 2
- 229950009746 arofylline Drugs 0.000 description 2
- 229960002274 atenolol Drugs 0.000 description 2
- 229950004646 azelnidipine Drugs 0.000 description 2
- 229960002992 barnidipine Drugs 0.000 description 2
- VXMOONUMYLCFJD-DHLKQENFSA-N barnidipine Chemical compound C1([C@@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@@H]2CN(CC=3C=CC=CC=3)CC2)=CC=CC([N+]([O-])=O)=C1 VXMOONUMYLCFJD-DHLKQENFSA-N 0.000 description 2
- 229940092705 beclomethasone Drugs 0.000 description 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 2
- 229950006837 benafentrine Drugs 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- ANFSNXAXVLRZCG-RSAXXLAASA-N benzphetamine hydrochloride Chemical compound [Cl-].C([C@H](C)[NH+](C)CC=1C=CC=CC=1)C1=CC=CC=C1 ANFSNXAXVLRZCG-RSAXXLAASA-N 0.000 description 2
- NDTSRXAMMQDVSW-UHFFFAOYSA-N benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 description 2
- KKBIUAUSZKGNOA-HNAYVOBHSA-N benzyl (2s)-2-[[(2s)-2-(acetylsulfanylmethyl)-3-(1,3-benzodioxol-5-yl)propanoyl]amino]propanoate Chemical compound O=C([C@@H](NC(=O)[C@@H](CSC(C)=O)CC=1C=C2OCOC2=CC=1)C)OCC1=CC=CC=C1 KKBIUAUSZKGNOA-HNAYVOBHSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 description 2
- 229960003665 bepridil Drugs 0.000 description 2
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960002781 bisoprolol Drugs 0.000 description 2
- 108010063504 bombesin receptor subtype 3 Proteins 0.000 description 2
- 239000007767 bonding agent Substances 0.000 description 2
- 229960001035 bopindolol Drugs 0.000 description 2
- 229960002624 bretylium tosilate Drugs 0.000 description 2
- 229960004436 budesonide Drugs 0.000 description 2
- 229960002467 bunazosin Drugs 0.000 description 2
- AYMYWHCQALZEGT-ORCRQEGFSA-N butein Chemical compound OC1=CC(O)=CC=C1C(=O)\C=C\C1=CC=C(O)C(O)=C1 AYMYWHCQALZEGT-ORCRQEGFSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- FYBXRCFPOTXTJF-UHFFFAOYSA-N carteolol hydrochloride Chemical compound [Cl-].N1C(=O)CCC2=C1C=CC=C2OCC(O)C[NH2+]C(C)(C)C FYBXRCFPOTXTJF-UHFFFAOYSA-N 0.000 description 2
- 229960004195 carvedilol Drugs 0.000 description 2
- 229960002320 celiprolol Drugs 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- MCMSJVMUSBZUCN-YYDJUVGSSA-N chembl285913 Chemical compound C1=2C=C(OC)C(OC)=CC=2CCN(C(N2C)=O)C1=C\C2=N/C1=C(C)C=C(C)C=C1C MCMSJVMUSBZUCN-YYDJUVGSSA-N 0.000 description 2
- 208000003167 cholangitis Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229940117229 cialis Drugs 0.000 description 2
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 2
- 229960005025 cilazapril Drugs 0.000 description 2
- JQRZBPFGBRIWSN-YOTVLOEGSA-N cilazapril monohydrate Chemical compound O.C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 JQRZBPFGBRIWSN-YOTVLOEGSA-N 0.000 description 2
- 229960003020 cilnidipine Drugs 0.000 description 2
- 229950001653 cilomilast Drugs 0.000 description 2
- 229950002934 cilostamide Drugs 0.000 description 2
- 229960004588 cilostazol Drugs 0.000 description 2
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 2
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 2
- 229960001380 cimetidine Drugs 0.000 description 2
- XDUOTWNXVDBCDY-SREVYHEPSA-N cinepazet Chemical compound C1CN(CC(=O)OCC)CCN1C(=O)\C=C/C1=CC(OC)=C(OC)C(OC)=C1 XDUOTWNXVDBCDY-SREVYHEPSA-N 0.000 description 2
- 229960000352 cinepazet Drugs 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229960003597 clevidipine Drugs 0.000 description 2
- KPBZROQVTHLCDU-GOSISDBHSA-N clevidipine Chemical compound CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@H]1C1=CC=CC(Cl)=C1Cl KPBZROQVTHLCDU-GOSISDBHSA-N 0.000 description 2
- SUAJWTBTMNHVBZ-UHFFFAOYSA-N clonitrate Chemical compound [O-][N+](=O)OCC(CCl)O[N+]([O-])=O SUAJWTBTMNHVBZ-UHFFFAOYSA-N 0.000 description 2
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- LYHIYZUYZIHTCV-UHFFFAOYSA-N cyclopenta[b]pyran Chemical compound C1=COC2=CC=CC2=C1 LYHIYZUYZIHTCV-UHFFFAOYSA-N 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- BOCUKUHCLICSIY-UHFFFAOYSA-N cyclothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2C1C(C=C2)CC2C1 BOCUKUHCLICSIY-UHFFFAOYSA-N 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- QQKNSPHAFATFNQ-UHFFFAOYSA-N darglitazone Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCC(=O)C(C=C1)=CC=C1CC1SC(=O)NC1=O QQKNSPHAFATFNQ-UHFFFAOYSA-N 0.000 description 2
- 229950004687 denbufylline Drugs 0.000 description 2
- 229960000632 dexamfetamine Drugs 0.000 description 2
- GJQPMPFPNINLKP-UHFFFAOYSA-N diclofenamide Chemical compound NS(=O)(=O)C1=CC(Cl)=C(Cl)C(S(N)(=O)=O)=C1 GJQPMPFPNINLKP-UHFFFAOYSA-N 0.000 description 2
- 229960005081 diclofenamide Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
- 229960000616 diflunisal Drugs 0.000 description 2
- WQVZLXWQESQGIF-WJKBNZMCSA-N dilevalol hydrochloride Chemical compound Cl.C([C@@H](C)NC[C@H](O)C=1C=C(C(O)=CC=1)C(N)=O)CC1=CC=CC=C1 WQVZLXWQESQGIF-WJKBNZMCSA-N 0.000 description 2
- 229960004166 diltiazem Drugs 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229940074619 diovan Drugs 0.000 description 2
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 2
- 229960004192 diphenoxylate Drugs 0.000 description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 2
- QZIQJIKUVJMTDG-JSTPYPERSA-L disodium;[(2r,3s)-3-methyloxiran-2-yl]-dioxido-oxo-$l^{5}-phosphane Chemical compound [Na+].[Na+].C[C@@H]1O[C@@H]1P([O-])([O-])=O QZIQJIKUVJMTDG-JSTPYPERSA-L 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 2
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 2
- 229960001389 doxazosin Drugs 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- ODUOJXZPIYUATO-LJQANCHMSA-N ecadotril Chemical compound C([C@H](CSC(=O)C)C(=O)NCC(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 ODUOJXZPIYUATO-LJQANCHMSA-N 0.000 description 2
- 229950001184 ecadotril Drugs 0.000 description 2
- 229950003102 efonidipine Drugs 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229960000873 enalapril Drugs 0.000 description 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 2
- 208000030172 endocrine system disease Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000002792 enkephalinase inhibitor Substances 0.000 description 2
- 229960002179 ephedrine Drugs 0.000 description 2
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 2
- 229960001208 eplerenone Drugs 0.000 description 2
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 2
- 229960004563 eprosartan Drugs 0.000 description 2
- SNFOERUNNSHUGP-ZXZARUISSA-N erythrityl tetranitrate Chemical compound [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@@H](O[N+]([O-])=O)CO[N+]([O-])=O SNFOERUNNSHUGP-ZXZARUISSA-N 0.000 description 2
- PSZDOEIIIJFCFE-OSQDELBUSA-N erythrodiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C PSZDOEIIIJFCFE-OSQDELBUSA-N 0.000 description 2
- HTZRWCSRPTWJCT-UHFFFAOYSA-N erythrodiol Natural products CC1(C)CCC2(CO)CCC3C(CCC4C3(C)CCC5C(C)(C)C(O)CCC45C)C2C1 HTZRWCSRPTWJCT-UHFFFAOYSA-N 0.000 description 2
- ILEDWLMCKZNDJK-UHFFFAOYSA-N esculetin Chemical compound C1=CC(=O)OC2=C1C=C(O)C(O)=C2 ILEDWLMCKZNDJK-UHFFFAOYSA-N 0.000 description 2
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 2
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 2
- 229960003199 etacrynic acid Drugs 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229950008449 fedotozine Drugs 0.000 description 2
- MVKIWCDXKCUDEH-QFIPXVFZSA-N fedotozine Chemical compound C([C@](CC)(N(C)C)C=1C=CC=CC=1)OCC1=CC(OC)=C(OC)C(OC)=C1 MVKIWCDXKCUDEH-QFIPXVFZSA-N 0.000 description 2
- 229960003580 felodipine Drugs 0.000 description 2
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 2
- 229960001395 fenbufen Drugs 0.000 description 2
- 229960001582 fenfluramine Drugs 0.000 description 2
- 229960001022 fenoterol Drugs 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- STTRYQAGHGJXJJ-LICLKQGHSA-N filaminast Chemical compound COC1=CC=C(C(\C)=N\OC(N)=O)C=C1OC1CCCC1 STTRYQAGHGJXJJ-LICLKQGHSA-N 0.000 description 2
- 229950006884 filaminast Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229950007979 flufenisal Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229960002490 fosinopril Drugs 0.000 description 2
- FVYRUSCZCWSFLT-UHFFFAOYSA-N fostedil Chemical compound C1=CC(CP(=O)(OCC)OCC)=CC=C1C1=NC2=CC=CC=C2S1 FVYRUSCZCWSFLT-UHFFFAOYSA-N 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 229960003883 furosemide Drugs 0.000 description 2
- 229960000457 gallopamil Drugs 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 2
- 229960001381 glipizide Drugs 0.000 description 2
- 229940095884 glucophage Drugs 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 2
- 239000004226 guanylic acid Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 208000024798 heartburn Diseases 0.000 description 2
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- SGJNQVTUYXCBKH-HNQUOIGGSA-N hispidin Chemical compound O1C(=O)C=C(O)C=C1\C=C\C1=CC=C(O)C(O)=C1 SGJNQVTUYXCBKH-HNQUOIGGSA-N 0.000 description 2
- SGJNQVTUYXCBKH-UHFFFAOYSA-N hispidin Natural products O1C(=O)C=C(O)C=C1C=CC1=CC=C(O)C(O)=C1 SGJNQVTUYXCBKH-UHFFFAOYSA-N 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 229940103471 humulin Drugs 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 description 2
- 229960003313 hydroflumethiazide Drugs 0.000 description 2
- PZWMMXHCUXTDQM-UHFFFAOYSA-N hydron;1-(2-methylsulfanylphenoxy)-3-(propan-2-ylamino)propan-2-ol;chloride Chemical compound [Cl-].CSC1=CC=CC=C1OCC(O)C[NH2+]C(C)C PZWMMXHCUXTDQM-UHFFFAOYSA-N 0.000 description 2
- QVIZGERPBBPGRI-UHFFFAOYSA-N hydron;1-phenyl-4-[2-(2h-tetrazol-5-yl)ethyl]piperazine;chloride Chemical compound Cl.C1CN(C=2C=CC=CC=2)CCN1CCC=1N=NNN=1 QVIZGERPBBPGRI-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 229960000930 hydroxyzine Drugs 0.000 description 2
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 2
- 230000000705 hypocalcaemia Effects 0.000 description 2
- 229960002491 ibudilast Drugs 0.000 description 2
- 229950000254 imazodan Drugs 0.000 description 2
- 229960001195 imidapril Drugs 0.000 description 2
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 2
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 2
- 229960004569 indapamide Drugs 0.000 description 2
- 229950008838 indenolol Drugs 0.000 description 2
- MPGBPFMOOXKQRX-UHFFFAOYSA-N indenolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CC2 MPGBPFMOOXKQRX-UHFFFAOYSA-N 0.000 description 2
- 150000002475 indoles Chemical class 0.000 description 2
- 229950009856 indolidan Drugs 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- HHMSPIAOYISBOU-IYQBICMXSA-N insulin rabbit Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 HHMSPIAOYISBOU-IYQBICMXSA-N 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229960002198 irbesartan Drugs 0.000 description 2
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 2
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 2
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 2
- 229960003827 isosorbide mononitrate Drugs 0.000 description 2
- 108010053037 kyotorphin Proteins 0.000 description 2
- 229960003091 labetalol hydrochloride Drugs 0.000 description 2
- 229960004340 lacidipine Drugs 0.000 description 2
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 230000002475 laxative effect Effects 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical class O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 229940097443 levitra Drugs 0.000 description 2
- 229960004771 levobetaxolol Drugs 0.000 description 2
- 229960001508 levocetirizine Drugs 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 229960002394 lisinopril Drugs 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000010871 livestock manure Substances 0.000 description 2
- 229950009035 lixazinone Drugs 0.000 description 2
- KSMAGQUYOIHWFS-UHFFFAOYSA-N lofexidine Chemical compound N=1CCNC=1C(C)OC1=C(Cl)C=CC=C1Cl KSMAGQUYOIHWFS-UHFFFAOYSA-N 0.000 description 2
- 229960005209 lofexidine Drugs 0.000 description 2
- 239000002171 loop diuretic Substances 0.000 description 2
- 229940080288 lotrel Drugs 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 229960003464 mefenamic acid Drugs 0.000 description 2
- 229950004994 meglitinide Drugs 0.000 description 2
- ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 description 2
- 229960000582 mepyramine Drugs 0.000 description 2
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- YTFBNFMILWHYAP-UWJYYQICSA-N methyl (3s,4s)-3-acetyl-4-(3-cyclopentyloxy-4-methoxyphenyl)-3-methylpyrrolidine-1-carboxylate Chemical compound CC(=O)[C@]1(C)CN(C(=O)OC)C[C@H]1C1=CC=C(OC)C(OC2CCCC2)=C1 YTFBNFMILWHYAP-UWJYYQICSA-N 0.000 description 2
- OUXGIOLQOYAZLS-UHFFFAOYSA-N methyl n-[2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]ethyl]carbamate;sulfuric acid Chemical compound OS(O)(=O)=O.COC(=O)NCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COC(=O)NCCC1=CC=C(OCC(O)CNC(C)C)C=C1 OUXGIOLQOYAZLS-UHFFFAOYSA-N 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 229960002237 metoprolol Drugs 0.000 description 2
- 229960005170 moexipril Drugs 0.000 description 2
- 229960004027 molsidomine Drugs 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 229960005127 montelukast Drugs 0.000 description 2
- FOYWNSCCNCUEPU-UHFFFAOYSA-N mopidamol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 description 2
- 229950010718 mopidamol Drugs 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229960003938 moxonidine Drugs 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- DVWBMWJOYIFITF-UHFFFAOYSA-N n'-hydroxy-5,6-dimethoxy-1-benzothiophene-2-carboximidamide;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC2=C1SC(C(\N)=N\O)=C2 DVWBMWJOYIFITF-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- RRLYGXRMVLYFNX-UHFFFAOYSA-N n-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide;hydron;chloride Chemical compound Cl.CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1C(C)=O RRLYGXRMVLYFNX-UHFFFAOYSA-N 0.000 description 2
- VZXIAVMLJCJLPP-UHFFFAOYSA-N n-[4-(3-oxo-2h-pyrazin-6-yl)phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C1=NCC(=O)N=C1 VZXIAVMLJCJLPP-UHFFFAOYSA-N 0.000 description 2
- FVZJIAUYFDQQKJ-DQEYMECFSA-N n-[4-[(4as,10br)-8,9-dimethoxy-2-methyl-3,4,4a,10b-tetrahydro-1h-benzo[c][1,6]naphthyridin-6-yl]phenyl]-4-methylbenzenesulfonamide Chemical compound N([C@H]1CCN(C)C[C@H]1C=1C=C(C(=CC=11)OC)OC)=C1C(C=C1)=CC=C1NS(=O)(=O)C1=CC=C(C)C=C1 FVZJIAUYFDQQKJ-DQEYMECFSA-N 0.000 description 2
- DCDXHGMCXGHXBM-PMACEKPBSA-N n-[4-[(4as,10br)-8,9-dimethoxy-2-methyl-3,4,4a,10b-tetrahydro-1h-benzo[c][1,6]naphthyridin-6-yl]phenyl]acetamide Chemical compound N([C@H]1CCN(C)C[C@H]1C=1C=C(C(=CC=11)OC)OC)=C1C1=CC=C(NC(C)=O)C=C1 DCDXHGMCXGHXBM-PMACEKPBSA-N 0.000 description 2
- TUYWTLTWNJOZNY-UHFFFAOYSA-N n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(2h-tetrazol-5-yl)pyridin-4-yl]pyrimidin-4-yl]-5-propan-2-ylpyridine-2-sulfonamide Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2C=C(N=CC=2)C2=NNN=N2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)C)C=N1 TUYWTLTWNJOZNY-UHFFFAOYSA-N 0.000 description 2
- VHDUUXNHZLBGHQ-XLVZBRSZSA-N n-cyclohexyl-n-methyl-2-[(e)-[(2-oxo-5,10-dihydro-3h-imidazo[2,1-b]quinazolin-7-yl)-phenylmethylidene]amino]oxyacetamide Chemical compound C=1C=CC=CC=1\C(C=1C=C2CN3CC(=O)N=C3NC2=CC=1)=N/OCC(=O)N(C)C1CCCCC1 VHDUUXNHZLBGHQ-XLVZBRSZSA-N 0.000 description 2
- WUECXCBONAGRSA-UHFFFAOYSA-N n-cyclohexyl-n-methyl-4-[(2-oxo-5,10-dihydro-3h-imidazo[2,1-b]quinazolin-7-yl)oxy]butanamide Chemical compound C=1C=C2NC3=NC(=O)CN3CC2=CC=1OCCCC(=O)N(C)C1CCCCC1 WUECXCBONAGRSA-UHFFFAOYSA-N 0.000 description 2
- 229950005705 naftopidil Drugs 0.000 description 2
- 229960005297 nalmefene Drugs 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 2
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 2
- PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 2
- 201000004931 neurofibromatosis Diseases 0.000 description 2
- 229960001783 nicardipine Drugs 0.000 description 2
- 229950000754 nipradilol Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 2
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 2
- 229960005117 olmesartan Drugs 0.000 description 2
- JPAWFIIYTJQOKW-UHFFFAOYSA-N olprinone Chemical compound N1C(=O)C(C#N)=CC(C2=CN3C=CN=C3C=C2)=C1C JPAWFIIYTJQOKW-UHFFFAOYSA-N 0.000 description 2
- 229950005421 olprinone Drugs 0.000 description 2
- 229950000973 omapatrilat Drugs 0.000 description 2
- 238000000879 optical micrograph Methods 0.000 description 2
- 229960002657 orciprenaline Drugs 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- DZOJBGLFWINFBF-UMSFTDKQSA-N osanetant Chemical compound C([C@](C1)(CCCN2CCC(CC2)(N(C(C)=O)C)C=2C=CC=CC=2)C=2C=C(Cl)C(Cl)=CC=2)CCN1C(=O)C1=CC=CC=C1 DZOJBGLFWINFBF-UMSFTDKQSA-N 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- DUQOOLBWGUKRAJ-UHFFFAOYSA-N oxagrelate Chemical compound OCC1=NNC(=O)C2=C(C)C(C(=O)OCC)=C(C)C=C21 DUQOOLBWGUKRAJ-UHFFFAOYSA-N 0.000 description 2
- 229950004599 oxagrelate Drugs 0.000 description 2
- 238000007243 oxidative cyclization reaction Methods 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- FEDSNBHHWZEYTP-ZFQYHYQMSA-N penbutolol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1.CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 FEDSNBHHWZEYTP-ZFQYHYQMSA-N 0.000 description 2
- 229960001476 pentoxifylline Drugs 0.000 description 2
- 229950006286 pentrinitrol Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 229960000436 phendimetrazine Drugs 0.000 description 2
- 229960003534 phenindamine Drugs 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 229960002895 phenylbutazone Drugs 0.000 description 2
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 2
- 229960000395 phenylpropanolamine Drugs 0.000 description 2
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 2
- 150000003009 phosphonic acids Chemical class 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 229950005184 piclamilast Drugs 0.000 description 2
- 229960002164 pimobendan Drugs 0.000 description 2
- GLBJJMFZWDBELO-UHFFFAOYSA-N pimobendane Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=C(C=3C(CC(=O)NN=3)C)C=C2N1 GLBJJMFZWDBELO-UHFFFAOYSA-N 0.000 description 2
- 229960002508 pindolol Drugs 0.000 description 2
- JZQKKSLKJUAGIC-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CN2 JZQKKSLKJUAGIC-UHFFFAOYSA-N 0.000 description 2
- 229960005095 pioglitazone Drugs 0.000 description 2
- 150000003053 piperidines Chemical class 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 229950010078 piroximone Drugs 0.000 description 2
- 238000006068 polycondensation reaction Methods 0.000 description 2
- 229960005483 polythiazide Drugs 0.000 description 2
- 229920000046 polythiazide Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 229960001749 practolol Drugs 0.000 description 2
- 229950004891 pranidipine Drugs 0.000 description 2
- 229960001289 prazosin Drugs 0.000 description 2
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229960003712 propranolol Drugs 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 229940035613 prozac Drugs 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- BHZFZYLBVSWUMT-ZCFIWIBFSA-N quazinone Chemical compound C1=CC=C2NC3=NC(=O)[C@@H](C)N3CC2=C1Cl BHZFZYLBVSWUMT-ZCFIWIBFSA-N 0.000 description 2
- 229950005340 quazinone Drugs 0.000 description 2
- 229960001455 quinapril Drugs 0.000 description 2
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 2
- 229960001007 quinaprilat Drugs 0.000 description 2
- FLSLEGPOVLMJMN-YSSFQJQWSA-N quinaprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)C(O)=O)CC1=CC=CC=C1 FLSLEGPOVLMJMN-YSSFQJQWSA-N 0.000 description 2
- 108700040249 racecadotril Proteins 0.000 description 2
- 229960003401 ramipril Drugs 0.000 description 2
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 2
- 229960000213 ranolazine Drugs 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 229940116176 remicade Drugs 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- 229950004118 revizinone Drugs 0.000 description 2
- 229960000764 rilmenidine Drugs 0.000 description 2
- 229960003015 rimonabant Drugs 0.000 description 2
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 2
- 229960002586 roflumilast Drugs 0.000 description 2
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 2
- 229950005741 rolipram Drugs 0.000 description 2
- 229950001780 sampatrilat Drugs 0.000 description 2
- PGKXDIMONUAMFR-AREMUKBSSA-N saredutant Chemical compound C([C@H](CN(C)C(=O)C=1C=CC=CC=1)C=1C=C(Cl)C(Cl)=CC=1)CN(CC1)CCC1(NC(C)=O)C1=CC=CC=C1 PGKXDIMONUAMFR-AREMUKBSSA-N 0.000 description 2
- 229950009373 saterinone Drugs 0.000 description 2
- JOSMPBVYYKRYLG-OLZOCXBDSA-N sch-51866 Chemical compound N1([C@H]2CCC[C@H]2N=C1N(C(C=1N2)=O)C)C=1N=C2CC1=CC=C(C(F)(F)F)C=C1 JOSMPBVYYKRYLG-OLZOCXBDSA-N 0.000 description 2
- 229960002101 secretin Drugs 0.000 description 2
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 2
- 229940124513 senna glycoside Drugs 0.000 description 2
- IPQVTOJGNYVQEO-KGFNBKMBSA-N sennoside A Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1[C@@H]2[C@H]1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-KGFNBKMBSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229950003177 siguazodan Drugs 0.000 description 2
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 2
- TVTJZMHAIQQZTL-WATAJHSMSA-M sodium;(2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylate Chemical compound [Na+].C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C([O-])=O)CCCC1=CC=CC=C1 TVTJZMHAIQQZTL-WATAJHSMSA-M 0.000 description 2
- JJICLMJFIKGAAU-UHFFFAOYSA-M sodium;2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)purin-6-olate Chemical compound [Na+].NC1=NC([O-])=C2N=CN(COC(CO)CO)C2=N1 JJICLMJFIKGAAU-UHFFFAOYSA-M 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 229960002909 spirapril Drugs 0.000 description 2
- HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 description 2
- 108700035424 spirapril Proteins 0.000 description 2
- 229960002256 spironolactone Drugs 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 229960000894 sulindac Drugs 0.000 description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
- XMFCOYRWYYXZMY-UHFFFAOYSA-N sulmazole Chemical compound COC1=CC(S(C)=O)=CC=C1C1=NC2=NC=CC=C2N1 XMFCOYRWYYXZMY-UHFFFAOYSA-N 0.000 description 2
- 229950006153 sulmazole Drugs 0.000 description 2
- 229940099093 symlin Drugs 0.000 description 2
- 239000012622 synthetic inhibitor Substances 0.000 description 2
- WOXKDUGGOYFFRN-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 description 2
- 229960002613 tamsulosin Drugs 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 229960000651 tasosartan Drugs 0.000 description 2
- ADXGNEYLLLSOAR-UHFFFAOYSA-N tasosartan Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ADXGNEYLLLSOAR-UHFFFAOYSA-N 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- IKBKZGMPCYNSLU-RGVLZGJSSA-N tegaserod Chemical compound C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-RGVLZGJSSA-N 0.000 description 2
- CPDDZSSEAVLMRY-FEQFWAPWSA-N tegaserod maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 CPDDZSSEAVLMRY-FEQFWAPWSA-N 0.000 description 2
- 229960005187 telmisartan Drugs 0.000 description 2
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 2
- 229960001693 terazosin Drugs 0.000 description 2
- 229960003352 tertatolol Drugs 0.000 description 2
- 229950000584 tezosentan Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003451 thiazide diuretic agent Substances 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 108010050939 thrombocytin Proteins 0.000 description 2
- CVWILQHZFWRYPB-UHFFFAOYSA-N tiamenidine Chemical compound CC1=CSC(Cl)=C1NC1=NCCN1 CVWILQHZFWRYPB-UHFFFAOYSA-N 0.000 description 2
- 229950000164 tiamenidine Drugs 0.000 description 2
- 229940035248 tiazac Drugs 0.000 description 2
- 229950009528 tibenelast Drugs 0.000 description 2
- TWVUMMQUXMYOOH-UHFFFAOYSA-N tilisolol Chemical compound C1=CC=C2C(=O)N(C)C=C(OCC(O)CNC(C)(C)C)C2=C1 TWVUMMQUXMYOOH-UHFFFAOYSA-N 0.000 description 2
- 229950008411 tilisolol Drugs 0.000 description 2
- 229960004605 timolol Drugs 0.000 description 2
- ODKDMMTXTVCCLJ-BVSLBCMMSA-N tmc-2-a Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N3[C@@H](CC4=CC(O)=C(C(=C4C3)O)OC)C(=O)N[C@@H](CC(CO)CO)C(O)=O)=CNC2=C1 ODKDMMTXTVCCLJ-BVSLBCMMSA-N 0.000 description 2
- 229950010448 tolafentrine Drugs 0.000 description 2
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 2
- 229960001017 tolmetin Drugs 0.000 description 2
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 2
- 229960004394 topiramate Drugs 0.000 description 2
- 229960005461 torasemide Drugs 0.000 description 2
- 229950005772 tosifen Drugs 0.000 description 2
- 229960002051 trandolapril Drugs 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 229950004127 trequinsin Drugs 0.000 description 2
- 229960001288 triamterene Drugs 0.000 description 2
- 229960005345 trimebutine Drugs 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 2
- 125000005454 tryptophanyl group Chemical group 0.000 description 2
- 229960001130 urapidil Drugs 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- 229950005577 vesnarinone Drugs 0.000 description 2
- 229940094720 viagra Drugs 0.000 description 2
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- HJMQDJPMQIHLPB-UHFFFAOYSA-N zardaverine Chemical compound C1=C(OC(F)F)C(OC)=CC(C2=NNC(=O)C=C2)=C1 HJMQDJPMQIHLPB-UHFFFAOYSA-N 0.000 description 2
- 229950001080 zardaverine Drugs 0.000 description 2
- BPKIMPVREBSLAJ-QTBYCLKRSA-N ziconotide Chemical compound C([C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]2C(=O)N[C@@H]3C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC2)C(N)=O)=O)CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(N1)=O)CCSC)[C@@H](C)O)C1=CC=C(O)C=C1 BPKIMPVREBSLAJ-QTBYCLKRSA-N 0.000 description 2
- 229960002811 ziconotide Drugs 0.000 description 2
- 229960002769 zofenopril Drugs 0.000 description 2
- IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 description 2
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
- YQYVFVRQLZMJKJ-JBBXEZCESA-N (+)-cyclazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CC1CC1 YQYVFVRQLZMJKJ-JBBXEZCESA-N 0.000 description 1
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- WTGQALLALWYDJH-BBCALQAUSA-N (-)-Scopolamine Hydrobromide Chemical compound Br.C1([C@@H](CO)C(=O)O[C@@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-BBCALQAUSA-N 0.000 description 1
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 1
- NHOWDZOIZKMVAI-UHFFFAOYSA-N (2-chlorophenyl)(4-chlorophenyl)pyrimidin-5-ylmethanol Chemical compound C=1N=CN=CC=1C(C=1C(=CC=CC=1)Cl)(O)C1=CC=C(Cl)C=C1 NHOWDZOIZKMVAI-UHFFFAOYSA-N 0.000 description 1
- UJHSIDUUJPTLDY-UHFFFAOYSA-N (2-nitrophenyl)-phenylmethanone Chemical class [O-][N+](=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 UJHSIDUUJPTLDY-UHFFFAOYSA-N 0.000 description 1
- KTECVHMANCWFNF-LREBCSMRSA-N (2R,3R)-2,3-dihydroxybutanedioic acid pyridine Chemical class c1ccncc1.O[C@H]([C@@H](O)C(O)=O)C(O)=O KTECVHMANCWFNF-LREBCSMRSA-N 0.000 description 1
- HBUBKKRHXORPQB-FJFJXFQQSA-N (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O HBUBKKRHXORPQB-FJFJXFQQSA-N 0.000 description 1
- RKUNBYITZUJHSG-VFSICIBPSA-N (2S)-3-hydroxy-2-phenylpropanoic acid [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] ester Chemical compound C1([C@@H](CO)C(=O)OC2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-VFSICIBPSA-N 0.000 description 1
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 1
- RQBSKKBNALPMSL-QUMGSSFMSA-N (2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-6-formamido-n-[2-oxo-2-[[(2s)-1-oxo-1-[[(3r)-2-oxothiolan-3-yl]amino]-3-phenylpropan-2-yl]amino]ethyl]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CCCCNC=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@H]1C(SCC1)=O)C1=CC=C(O)C=C1 RQBSKKBNALPMSL-QUMGSSFMSA-N 0.000 description 1
- QWWVBNODQCWBAZ-WHFBIAKZSA-N (2r)-2-amino-3-[(2r)-2-carboxy-2-(methylamino)ethyl]sulfanylpropanoic acid Chemical compound CN[C@H](C(O)=O)CSC[C@H](N)C(O)=O QWWVBNODQCWBAZ-WHFBIAKZSA-N 0.000 description 1
- YLXIPWWIOISBDD-NDAAPVSOSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;4-[(1r)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CNC[C@H](O)C1=CC=C(O)C(O)=C1 YLXIPWWIOISBDD-NDAAPVSOSA-N 0.000 description 1
- FOZFSEMFCIPOSZ-SPCKQMHLSA-N (2r,3r,4r,5s)-2-(hydroxymethyl)-1-[[(2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methyl]piperidine-3,4,5-triol;trihydrate Chemical compound O.O.O.O[C@H]1[C@H](O)[C@@H](O)[C@@H](OC)O[C@@H]1CN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1.O[C@H]1[C@H](O)[C@@H](O)[C@@H](OC)O[C@@H]1CN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1 FOZFSEMFCIPOSZ-SPCKQMHLSA-N 0.000 description 1
- HAQIRIMIVLFYIX-ZFWWWQNUSA-N (2s)-1-[(2s)-2-aminobutanoyl]-n-butyl-2,3-dihydroindole-2-carboxamide Chemical compound C1=CC=C2N(C(=O)[C@@H](N)CC)[C@H](C(=O)NCCCC)CC2=C1 HAQIRIMIVLFYIX-ZFWWWQNUSA-N 0.000 description 1
- JFCBEFFZEOHJDG-MLWJPKLSSA-N (2s)-2,6-diamino-7-oxooctanoic acid Chemical compound CC(=O)C(N)CCC[C@H](N)C(O)=O JFCBEFFZEOHJDG-MLWJPKLSSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- GUHPRPJDBZHYCJ-SECBINFHSA-N (2s)-2-(5-benzoylthiophen-2-yl)propanoic acid Chemical compound S1C([C@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-SECBINFHSA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- VXGGBPQPMISJCA-STQMWFEESA-N (2s)-2-[[(2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoyl]amino]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 VXGGBPQPMISJCA-STQMWFEESA-N 0.000 description 1
- GKYIONYOYVKKQI-MPGHIAIKSA-N (2s)-2-[[(2s,3r)-2-(benzoylsulfanylmethyl)-3-phenylbutanoyl]amino]propanoic acid Chemical compound C([C@H](C(=O)N[C@@H](C)C(O)=O)[C@@H](C)C=1C=CC=CC=1)SC(=O)C1=CC=CC=C1 GKYIONYOYVKKQI-MPGHIAIKSA-N 0.000 description 1
- YYTDJPUFAVPHQA-VKHMYHEASA-N (2s)-2-amino-3-(2,3,4,5,6-pentafluorophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=C(F)C(F)=C(F)C(F)=C1F YYTDJPUFAVPHQA-VKHMYHEASA-N 0.000 description 1
- PEMUHKUIQHFMTH-QMMMGPOBSA-N (2s)-2-amino-3-(4-bromophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(Br)C=C1 PEMUHKUIQHFMTH-QMMMGPOBSA-N 0.000 description 1
- GTPHQORJKFJIRB-JTQLPTLWSA-N (2s)-2-amino-n-[(2r)-1-[[(2s)-1-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-fluorophenyl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-3-(4-hydroxyphenyl)propanamide Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)N[C@@H](CC=1C=CC(F)=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=C(O)C=C1 GTPHQORJKFJIRB-JTQLPTLWSA-N 0.000 description 1
- NEMHIKRLROONTL-QMMMGPOBSA-N (2s)-2-azaniumyl-3-(4-azidophenyl)propanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N=[N+]=[N-])C=C1 NEMHIKRLROONTL-QMMMGPOBSA-N 0.000 description 1
- OPOTYPXOKUZEKY-QMMMGPOBSA-N (2s)-2-nitramido-3-phenylpropanoic acid Chemical compound [O-][N+](=O)N[C@H](C(=O)O)CC1=CC=CC=C1 OPOTYPXOKUZEKY-QMMMGPOBSA-N 0.000 description 1
- GIANIJCPTPUNBA-QMMMGPOBSA-N (2s)-3-(4-hydroxyphenyl)-2-nitramidopropanoic acid Chemical compound [O-][N+](=O)N[C@H](C(=O)O)CC1=CC=C(O)C=C1 GIANIJCPTPUNBA-QMMMGPOBSA-N 0.000 description 1
- RVWNMGKSNGWLOL-GIIHNPQRSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(2-methyl-1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 RVWNMGKSNGWLOL-GIIHNPQRSA-N 0.000 description 1
- SBBYBXSFWOLDDG-JLTOFOAXSA-N (2s)-n-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-n-methylpiperazine-1-carboxamide Chemical compound C1([C@H]2CNCCN2C(=O)N(C)[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)=CC=C(F)C=C1C SBBYBXSFWOLDDG-JLTOFOAXSA-N 0.000 description 1
- PZIFPMYXXCAOCC-JWQCQUIFSA-N (2s,3r)-3-(2-carboxyethylsulfanyl)-2-hydroxy-3-[2-(8-phenyloctyl)phenyl]propanoic acid Chemical compound OC(=O)CCS[C@@H]([C@@H](O)C(O)=O)C1=CC=CC=C1CCCCCCCCC1=CC=CC=C1 PZIFPMYXXCAOCC-JWQCQUIFSA-N 0.000 description 1
- XPNMCDYOYIKVGB-CONSDPRKSA-N (2s,3s)-2-benzhydryl-n-[(2-methoxy-5-propan-2-ylphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine Chemical compound COC1=CC=C(C(C)C)C=C1CN[C@@H]1[C@H](C(C=2C=CC=CC=2)C=2C=CC=CC=2)N2CCC1CC2 XPNMCDYOYIKVGB-CONSDPRKSA-N 0.000 description 1
- ZIWFCOIGUNPHPM-HKUYNNGSSA-N (2s,3s)-n-[[2-methoxy-5-(trifluoromethoxy)phenyl]methyl]-2-phenylpiperidin-3-amine Chemical compound COC1=CC=C(OC(F)(F)F)C=C1CN[C@@H]1[C@H](C=2C=CC=CC=2)NCCC1 ZIWFCOIGUNPHPM-HKUYNNGSSA-N 0.000 description 1
- XILNRORTJVDYRH-HKUYNNGSSA-N (2s,3s)-n-[[2-methoxy-5-[5-(trifluoromethyl)tetrazol-1-yl]phenyl]methyl]-2-phenylpiperidin-3-amine Chemical compound C1([C@@H]2NCCC[C@@H]2NCC2=CC(=CC=C2OC)N2C(=NN=N2)C(F)(F)F)=CC=CC=C1 XILNRORTJVDYRH-HKUYNNGSSA-N 0.000 description 1
- NAALWFYYHHJEFQ-ZASNTINBSA-N (2s,5r,6r)-6-[[(2r)-2-[[6-[4-[bis(2-hydroxyethyl)sulfamoyl]phenyl]-2-oxo-1h-pyridine-3-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)C(C(N1)=O)=CC=C1C1=CC=C(S(=O)(=O)N(CCO)CCO)C=C1 NAALWFYYHHJEFQ-ZASNTINBSA-N 0.000 description 1
- RLCKHJSFHOZMDR-UHFFFAOYSA-N (3R, 7R, 11R)-1-Phytanoid acid Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-UHFFFAOYSA-N 0.000 description 1
- JWOGUUIOCYMBPV-GMFLJSBRSA-N (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone Chemical compound N1C(=O)[C@H](CCCCCC(=O)CC)NC(=O)[C@H]2CCCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-GMFLJSBRSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- JVLBPIPGETUEET-WIXLDOGYSA-O (3r,4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one Chemical compound C([N@+]1(C)[C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)C1CC1 JVLBPIPGETUEET-WIXLDOGYSA-O 0.000 description 1
- DLOJBPLQFCFYKX-QQYYTUMTSA-N (3s)-4-[[(2r)-1-[2-[[(2s)-2-[[1h-indol-3-ylmethyl-[2-[[(2s)-2-[3-(4-sulfooxyphenyl)propanoylamino]hexanoyl]amino]acetyl]carbamoyl]amino]hexanoyl]carbamoyl]phenyl]propan-2-yl]amino]-3-(methylamino)-4-oxobutanoic acid Chemical compound N([C@@H](CCCC)C(=O)NCC(=O)N(CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCC)C(=O)NC(=O)C=1C(=CC=CC=1)C[C@@H](C)NC(=O)[C@H](CC(O)=O)NC)C(=O)CCC1=CC=C(OS(O)(=O)=O)C=C1 DLOJBPLQFCFYKX-QQYYTUMTSA-N 0.000 description 1
- VMDKRSNUUUUARH-MQDBWYGVSA-N (3s)-4-[[(2s)-1-[[(2s)-2-[[(2s)-3-(1h-indol-3-yl)-2-[[2-[[(2s)-2-[[2-(4-sulfooxyphenyl)acetyl]amino]hexanoyl]amino]acetyl]amino]propanoyl]amino]hexanoyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(methylamino)-4-oxobutanoic acid Chemical compound N([C@@H](CCCC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCC)C(=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC)C(=O)CC1=CC=C(OS(O)(=O)=O)C=C1 VMDKRSNUUUUARH-MQDBWYGVSA-N 0.000 description 1
- KNHCBYMGWWTGSO-ZYADHFCISA-N (3s)-4-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]-methylamino]-3-[[(2s)-2-[[(2s)-3-(1h-indol-3-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]-6-[(2-methylphenyl)carbamoylamino]hexanoyl]amino]-4-oxobutanoic acid Chemical compound C([C@H](N(C)C(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCNC(=O)NC=1C(=CC=CC=1)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)OC(C)(C)C)C(N)=O)C1=CC=CC=C1 KNHCBYMGWWTGSO-ZYADHFCISA-N 0.000 description 1
- PFMXXIJBGKRAJY-ITMZJIMRSA-N (3s)-4-[[(2s)-3-carboxy-1-oxo-1-(2-phenylethoxy)propan-2-yl]amino]-3-[6-[[(2s)-3-(1h-indol-3-yl)-2-[[2-[6-[[(2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(4-sulfooxyphenyl)propanoyl]amino]hexanoylamino]acetyl]amino]propanoyl]amino]hexanoylamino]-4-oxob Chemical compound C([C@H](NC(=O)OC(C)(C)C)C(=O)NCCCCCC(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCCCCCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)OCCC=1C=CC=CC=1)C1=CC=C(OS(O)(=O)=O)C=C1 PFMXXIJBGKRAJY-ITMZJIMRSA-N 0.000 description 1
- QRGQONAZHIKMGC-UHFFFAOYSA-N (4-phenoxyphenyl) 4-methylpiperidine-1-carboxylate Chemical compound C1CC(C)CCN1C(=O)OC(C=C1)=CC=C1OC1=CC=CC=C1 QRGQONAZHIKMGC-UHFFFAOYSA-N 0.000 description 1
- NGJOFQZEYQGZMB-KTKZVXAJSA-N (4S)-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[2-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-2-oxoethyl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-2-oxoethyl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-4-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NGJOFQZEYQGZMB-KTKZVXAJSA-N 0.000 description 1
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
- PCSQOABIHJXZMR-MGQKVWQSSA-O (4r,4as,7ar,12bs)-4a,9-dihydroxy-3-methyl-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CC[N+](C)(CC=C)[C@@H]3CC5=CC=C4O PCSQOABIHJXZMR-MGQKVWQSSA-O 0.000 description 1
- AXJQVVLKUYCICH-OAQYLSRUSA-N (4s)-5-(4-chlorophenyl)-n-(4-chlorophenyl)sulfonyl-n'-methyl-4-phenyl-3,4-dihydropyrazole-2-carboximidamide Chemical compound C=1C=C(Cl)C=CC=1C([C@H](C1)C=2C=CC=CC=2)=NN1C(=NC)NS(=O)(=O)C1=CC=C(Cl)C=C1 AXJQVVLKUYCICH-OAQYLSRUSA-N 0.000 description 1
- QJLPWVUZFKETMK-LLVKDONJSA-N (5r)-1,5,7,9,11,14-hexahydroxy-3-methyl-8,13-dioxo-5,6-dihydrobenzo[a]tetracene-2-carboxylic acid Chemical compound O=C1C2=C(O)C=C(O)C=C2C(=O)C2=C1C(O)=C1C[C@@H](O)C(C=C(C(=C3O)C(O)=O)C)=C3C1=C2O QJLPWVUZFKETMK-LLVKDONJSA-N 0.000 description 1
- YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 description 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RKUNBYITZUJHSG-FXUDXRNXSA-N (S)-atropine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 description 1
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- QRPSQQUYPMFERG-LFYBBSHMSA-N (e)-5-[3-(benzenesulfonamido)phenyl]-n-hydroxypent-2-en-4-ynamide Chemical compound ONC(=O)\C=C\C#CC1=CC=CC(NS(=O)(=O)C=2C=CC=CC=2)=C1 QRPSQQUYPMFERG-LFYBBSHMSA-N 0.000 description 1
- BRIPGNJWPCKDQZ-WXXKFALUSA-N (e)-but-2-enedioic acid;1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound OC(=O)\C=C\C(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 BRIPGNJWPCKDQZ-WXXKFALUSA-N 0.000 description 1
- OPPLDIXFHYTSSR-GLECISQGSA-N (ne)-n-(1-methylpyrrolidin-2-ylidene)-n'-phenylmorpholine-4-carboximidamide Chemical compound CN1CCC\C1=N/C(N1CCOCC1)=NC1=CC=CC=C1 OPPLDIXFHYTSSR-GLECISQGSA-N 0.000 description 1
- GHADIQOLHLUYIM-GZTJUZNOSA-N (ne)-n-[1-[4-[3-(1h-imidazol-5-yl)propoxy]phenyl]ethylidene]hydroxylamine Chemical compound C1=CC(C(=N/O)/C)=CC=C1OCCCC1=CNC=N1 GHADIQOLHLUYIM-GZTJUZNOSA-N 0.000 description 1
- URWISVHSKBDRKE-GVTSEVKNSA-N (z)-but-2-enedioic acid;ethyl 2-[4-[(e)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]piperazin-1-yl]acetate Chemical compound OC(=O)\C=C/C(O)=O.C1CN(CC(=O)OCC)CCN1C(=O)\C=C\C1=CC(OC)=C(OC)C(OC)=C1 URWISVHSKBDRKE-GVTSEVKNSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
- OTEKOJQFKOIXMU-UHFFFAOYSA-N 1,4-bis(trichloromethyl)benzene Chemical compound ClC(Cl)(Cl)C1=CC=C(C(Cl)(Cl)Cl)C=C1 OTEKOJQFKOIXMU-UHFFFAOYSA-N 0.000 description 1
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- AKMNUCBQGHFICM-UHFFFAOYSA-N 1-(2-methyl-1,3-benzoxazol-6-yl)-3-(1,5-naphthyridin-4-yl)urea Chemical compound C1=CN=C2C(NC(=O)NC3=CC=C4N=C(OC4=C3)C)=CC=NC2=C1 AKMNUCBQGHFICM-UHFFFAOYSA-N 0.000 description 1
- UOTMYNBWXDUBNX-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinolin-2-ium;chloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 UOTMYNBWXDUBNX-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- SFOVDSLXFUGAIV-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-n-piperidin-4-ylbenzimidazol-2-amine Chemical compound C1=CC(F)=CC=C1CN1C2=CC=CC=C2N=C1NC1CCNCC1 SFOVDSLXFUGAIV-UHFFFAOYSA-N 0.000 description 1
- XHHLNSWTGQCLAS-MHZLTWQESA-N 1-[2-[(4-chlorophenoxy)methyl]-1-[3-[(3s)-piperidin-3-yl]propyl]indol-3-yl]-2-(4-piperidin-1-ylpiperidin-1-yl)ethanone Chemical compound C1=CC(Cl)=CC=C1OCC(N(C1=CC=CC=C11)CCC[C@H]2CNCCC2)=C1C(=O)CN1CCC(N2CCCCC2)CC1 XHHLNSWTGQCLAS-MHZLTWQESA-N 0.000 description 1
- MTGXEWVJNCWUJP-UHFFFAOYSA-N 1-[4,4-bis(4-fluorophenyl)butyl]-4-[2-(2,6-dichloroanilino)-2-oxoethyl]piperazine-2-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CN(CCCC(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)C(C(=O)N)CN1CC(=O)NC1=C(Cl)C=CC=C1Cl MTGXEWVJNCWUJP-UHFFFAOYSA-N 0.000 description 1
- CAEGSEJNBXUDOD-UHFFFAOYSA-N 1-[4,4-bis(4-fluorophenyl)butyl]-4-[2-(2,6-dichloroanilino)-2-oxoethyl]piperazine-2-carboxamide;hydrate;dihydrochloride Chemical compound O.Cl.Cl.C1CN(CCCC(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)C(C(=O)N)CN1CC(=O)NC1=C(Cl)C=CC=C1Cl CAEGSEJNBXUDOD-UHFFFAOYSA-N 0.000 description 1
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 1
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 1
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical class COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- LPLNSPKKMWHFAU-UHFFFAOYSA-N 11-(1-methylpiperidine-3-carbonyl)-6h-pyrido[3,2-c][1,5]benzodiazepin-5-one Chemical compound C1N(C)CCCC1C(=O)N1C2=NC=CC=C2C(=O)NC2=CC=CC=C21 LPLNSPKKMWHFAU-UHFFFAOYSA-N 0.000 description 1
- GVEZIHKRYBHEFX-MNOVXSKESA-N 13C-Cerulenin Natural products CC=CCC=CCCC(=O)[C@H]1O[C@@H]1C(N)=O GVEZIHKRYBHEFX-MNOVXSKESA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- VVQNAFBGAWCMLU-UHFFFAOYSA-N 1h-benzimidazole-4-carboxylic acid Chemical class OC(=O)C1=CC=CC2=C1N=CN2 VVQNAFBGAWCMLU-UHFFFAOYSA-N 0.000 description 1
- KYWMCFOWDYFYLV-UHFFFAOYSA-N 1h-imidazole-2-carboxylic acid Chemical compound OC(=O)C1=NC=CN1 KYWMCFOWDYFYLV-UHFFFAOYSA-N 0.000 description 1
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 1
- FMVLIEVJRBLHDX-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydroindole-1-carboxylic acid Chemical class C1CCCC2N(C(=O)O)CCC21 FMVLIEVJRBLHDX-UHFFFAOYSA-N 0.000 description 1
- HDIJZFORGDBEKL-UHFFFAOYSA-N 2,3,4-trimethylbenzoic acid Chemical class CC1=CC=C(C(O)=O)C(C)=C1C HDIJZFORGDBEKL-UHFFFAOYSA-N 0.000 description 1
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
- NTQSYIWTDXTRGG-UHFFFAOYSA-N 2-(1-benzazepin-1-yl)acetic acid Chemical compound OC(=O)CN1C=CC=CC2=CC=CC=C12 NTQSYIWTDXTRGG-UHFFFAOYSA-N 0.000 description 1
- KLIVRBFRQSOGQI-UHFFFAOYSA-N 2-(11-oxo-6h-benzo[c][1]benzothiepin-3-yl)acetic acid Chemical compound S1CC2=CC=CC=C2C(=O)C2=CC=C(CC(=O)O)C=C12 KLIVRBFRQSOGQI-UHFFFAOYSA-N 0.000 description 1
- MYQXHLQMZLTSDB-UHFFFAOYSA-N 2-(2-ethyl-2,3-dihydro-1-benzofuran-5-yl)acetic acid Chemical compound OC(=O)CC1=CC=C2OC(CC)CC2=C1 MYQXHLQMZLTSDB-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- GJNNXIYZWIZFRH-UHFFFAOYSA-N 2-(pentylamino)acetamide Chemical compound CCCCCNCC(N)=O GJNNXIYZWIZFRH-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical class COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- VZTMYLWJKCAXMZ-UHFFFAOYSA-N 2-[(2-chloroquinazolin-4-yl)amino]ethanol Chemical compound C1=CC=C2C(NCCO)=NC(Cl)=NC2=C1 VZTMYLWJKCAXMZ-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- DWZFIFZYMHNRRV-UHFFFAOYSA-N 2-[(3,4-dihydroxy-5-methoxyphenyl)methylidene]propanedinitrile Chemical compound COC1=CC(C=C(C#N)C#N)=CC(O)=C1O DWZFIFZYMHNRRV-UHFFFAOYSA-N 0.000 description 1
- FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 description 1
- DCXHLPGLBYHNMU-UHFFFAOYSA-N 2-[1-(4-azidobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(N=[N+]=[N-])C=C1 DCXHLPGLBYHNMU-UHFFFAOYSA-N 0.000 description 1
- TYZQFNOLWJGHRZ-UHFFFAOYSA-N 2-[2-(4,5-dihydro-1h-imidazol-2-yl)-1-phenylethyl]pyridine Chemical compound N=1CCNC=1CC(C=1N=CC=CC=1)C1=CC=CC=C1 TYZQFNOLWJGHRZ-UHFFFAOYSA-N 0.000 description 1
- APBSKHYXXKHJFK-UHFFFAOYSA-N 2-[2-(4-chlorophenyl)-1,3-thiazol-4-yl]acetic acid Chemical compound OC(=O)CC1=CSC(C=2C=CC(Cl)=CC=2)=N1 APBSKHYXXKHJFK-UHFFFAOYSA-N 0.000 description 1
- BAWMMJAUVBLLEE-UHFFFAOYSA-N 2-[2-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 BAWMMJAUVBLLEE-UHFFFAOYSA-N 0.000 description 1
- NFDFTMICKVDYLQ-UHFFFAOYSA-N 2-[2-[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-1,3-thiazol-2-yl]carbamoyl]-5,7-dimethylindol-1-yl]acetic acid Chemical compound C1=C(Cl)C(OC)=CC(C2=C(SC(NC(=O)C=3N(C4=C(C)C=C(C)C=C4C=3)CC(O)=O)=N2)CCC2CCCCC2)=C1OC NFDFTMICKVDYLQ-UHFFFAOYSA-N 0.000 description 1
- KXSKAZFMTGADIV-UHFFFAOYSA-N 2-[3-(2-hydroxyethoxy)propoxy]ethanol Chemical compound OCCOCCCOCCO KXSKAZFMTGADIV-UHFFFAOYSA-N 0.000 description 1
- TYCOFFBAZNSQOJ-UHFFFAOYSA-N 2-[4-(3-fluorophenyl)phenyl]propanoic acid Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC(F)=C1 TYCOFFBAZNSQOJ-UHFFFAOYSA-N 0.000 description 1
- JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 description 1
- ZBIAKUMOEKILTF-UHFFFAOYSA-N 2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-N-(2,6-dimethylphenyl)acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCN(CCCC(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)CC1 ZBIAKUMOEKILTF-UHFFFAOYSA-N 0.000 description 1
- ACZKTJZXXSHIGF-UHFFFAOYSA-N 2-[5-(4-chlorophenyl)pentyl]oxirane-2-carboxylic acid Chemical compound C=1C=C(Cl)C=CC=1CCCCCC1(C(=O)O)CO1 ACZKTJZXXSHIGF-UHFFFAOYSA-N 0.000 description 1
- HMZXLENIFZGWSB-UHFFFAOYSA-N 2-amino-2,2-diethoxyacetic acid Chemical compound CCOC(N)(C(O)=O)OCC HMZXLENIFZGWSB-UHFFFAOYSA-N 0.000 description 1
- UMUPQWIGCOZEOY-JOCHJYFZSA-N 2-amino-2-methyl-n-[(2r)-1-(1-methylsulfonylspiro[2h-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide Chemical compound C([C@@H](NC(=O)C(C)(N)C)C(=O)N1CCC2(C3=CC=CC=C3N(C2)S(C)(=O)=O)CC1)OCC1=CC=CC=C1 UMUPQWIGCOZEOY-JOCHJYFZSA-N 0.000 description 1
- BKQCTMOROFZQNH-HSZRJFAPSA-N 2-amino-2-methyl-n-[(2r)-1-(1-methylsulfonylspiro[2h-indole-3,4'-piperidine]-1'-yl)-1-oxo-5-phenylpentan-2-yl]propanamide Chemical compound C([C@@H](NC(=O)C(C)(N)C)C(=O)N1CCC2(C3=CC=CC=C3N(C2)S(C)(=O)=O)CC1)CCC1=CC=CC=C1 BKQCTMOROFZQNH-HSZRJFAPSA-N 0.000 description 1
- UQDVRVNMIJAGRK-UHFFFAOYSA-N 2-amino-6-methyl-4-propyl-[1,2,4]triazolo[1,5-a]pyrimidin-5-one Chemical compound C1=C(C)C(=O)N(CCC)C2=NC(N)=NN21 UQDVRVNMIJAGRK-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 description 1
- JKFYKCYQEWQPTM-UHFFFAOYSA-N 2-azaniumyl-2-(4-fluorophenyl)acetate Chemical compound OC(=O)C(N)C1=CC=C(F)C=C1 JKFYKCYQEWQPTM-UHFFFAOYSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- ZGZGSVUHXOVDSL-UHFFFAOYSA-N 2-carbamoylcyclopentene-1-carboxylic acid Chemical compound NC(=O)C1=C(C(O)=O)CCC1 ZGZGSVUHXOVDSL-UHFFFAOYSA-N 0.000 description 1
- HABAPWZXRLIZDL-UHFFFAOYSA-N 2-chloro-2-phenoxyacetic acid Chemical class OC(=O)C(Cl)OC1=CC=CC=C1 HABAPWZXRLIZDL-UHFFFAOYSA-N 0.000 description 1
- 125000003541 2-chlorobenzoyl group Chemical group ClC1=C(C(=O)*)C=CC=C1 0.000 description 1
- WKMPTBDYDNUJLF-UHFFFAOYSA-N 2-fluoroadenine Chemical compound NC1=NC(F)=NC2=C1N=CN2 WKMPTBDYDNUJLF-UHFFFAOYSA-N 0.000 description 1
- BWLBGMIXKSTLSX-UHFFFAOYSA-N 2-hydroxyisobutyric acid Chemical compound CC(C)(O)C(O)=O BWLBGMIXKSTLSX-UHFFFAOYSA-N 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- WRJZKSHNBALIGH-UHFFFAOYSA-N 2-piperazin-1-ium-1-ylacetate Chemical compound OC(=O)CN1CCNCC1 WRJZKSHNBALIGH-UHFFFAOYSA-N 0.000 description 1
- KTBABNVBLOAENL-UHFFFAOYSA-N 2-piperazin-1-ylacetamide;hydrochloride Chemical class Cl.NC(=O)CN1CCNCC1 KTBABNVBLOAENL-UHFFFAOYSA-N 0.000 description 1
- 125000006325 2-propenyl amino group Chemical group [H]C([H])=C([H])C([H])([H])N([H])* 0.000 description 1
- UIYCMNZDPMTAKT-UHFFFAOYSA-N 2-sulfonyl-1H-quinazoline Chemical compound C1=CC=C2NC(=S(=O)=O)N=CC2=C1 UIYCMNZDPMTAKT-UHFFFAOYSA-N 0.000 description 1
- GVIYUKXRXPXMQM-BPXGDYAESA-N 221231-10-3 Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CSSC1)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C(C)C)=O)C1=CC=C(O)C=C1 GVIYUKXRXPXMQM-BPXGDYAESA-N 0.000 description 1
- INBGSXNNRGWLJU-ZHHJOTBYSA-N 25-hydroxycholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCCC(C)(C)O)C)[C@@]1(C)CC2 INBGSXNNRGWLJU-ZHHJOTBYSA-N 0.000 description 1
- INBGSXNNRGWLJU-UHFFFAOYSA-N 25epsilon-Hydroxycholesterin Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(CCCC(C)(C)O)C)C1(C)CC2 INBGSXNNRGWLJU-UHFFFAOYSA-N 0.000 description 1
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- QONZJNWWQDCGEZ-UHFFFAOYSA-N 3,5-dibutyl-1h-1,2,4-triazole Chemical compound CCCCC1=NNC(CCCC)=N1 QONZJNWWQDCGEZ-UHFFFAOYSA-N 0.000 description 1
- RLCKHJSFHOZMDR-PWCSWUJKSA-N 3,7R,11R,15-tetramethyl-hexadecanoic acid Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-PWCSWUJKSA-N 0.000 description 1
- UBHYDQAARZKHEZ-RFLHHMENSA-N 3-(1h-imidazol-5-yl)propyl n'-[2-(4-iodanylphenyl)ethyl]carbamimidothioate Chemical compound C=1C=C([125I])C=CC=1CC/N=C(/N)SCCCC1=CN=CN1 UBHYDQAARZKHEZ-RFLHHMENSA-N 0.000 description 1
- JXZZEXZZKAWDSP-UHFFFAOYSA-N 3-(2-(4-Benzamidopiperid-1-yl)ethyl)indole Chemical compound C1CN(CCC=2C3=CC=CC=C3NC=2)CCC1NC(=O)C1=CC=CC=C1 JXZZEXZZKAWDSP-UHFFFAOYSA-N 0.000 description 1
- FKHYYOUFMJBLAF-UHFFFAOYSA-N 3-(3,3-dimethyl-1-phenyl-2-benzothiophen-1-yl)-n-methylpropan-1-amine Chemical compound S1C(C)(C)C2=CC=CC=C2C1(CCCNC)C1=CC=CC=C1 FKHYYOUFMJBLAF-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- VNIOQSAWKLOGLY-UHFFFAOYSA-N 3-[(5-methylfuran-2-yl)methyl]-n-piperidin-4-ylimidazo[4,5-b]pyridin-2-amine Chemical compound O1C(C)=CC=C1CN1C2=NC=CC=C2N=C1NC1CCNCC1 VNIOQSAWKLOGLY-UHFFFAOYSA-N 0.000 description 1
- QNLIUVLFRVYNCV-XIFFEERXSA-N 3-[1-[2-[(2r)-4-benzoyl-2-(3,4-difluorophenyl)morpholin-2-yl]ethyl]-4-phenylpiperidin-4-yl]-1,1-dimethylurea Chemical compound C([C@@](OCC1)(CCN2CCC(CC2)(NC(=O)N(C)C)C=2C=CC=CC=2)C=2C=C(F)C(F)=CC=2)N1C(=O)C1=CC=CC=C1 QNLIUVLFRVYNCV-XIFFEERXSA-N 0.000 description 1
- QOAXSEARPHDXFC-UHFFFAOYSA-N 3-[2-(4-hydroxyphenyl)-3H-benzimidazol-5-yl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one Chemical compound CC1CC(=O)NN=C1C1=CC=C(N=C(N2)C=3C=CC(O)=CC=3)C2=C1 QOAXSEARPHDXFC-UHFFFAOYSA-N 0.000 description 1
- UZOOGOCMUARFDV-KEZCGYQASA-N 3-[[(2s)-2-(2-adamantyloxycarbonylamino)-3-(1h-indol-3-yl)-2-methylpropanoyl]amino]-4-(4-fluorophenyl)butanoic acid Chemical compound O=C([C@](CC=1C2=CC=CC=C2NC=1)(NC(=O)OC1C2CC3CC(C2)CC1C3)C)NC(CC(O)=O)CC1=CC=C(F)C=C1 UZOOGOCMUARFDV-KEZCGYQASA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-O 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS(O)(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-O 0.000 description 1
- WZFZJEPHYDDFCT-UHFFFAOYSA-N 3-chloro-2-methyl-n-[4-[2-(3-oxomorpholin-4-yl)ethyl]-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)NC1=NC(CCN2C(COCC2)=O)=CS1 WZFZJEPHYDDFCT-UHFFFAOYSA-N 0.000 description 1
- MEAPRSDUXBHXGD-UHFFFAOYSA-N 3-chloro-n-(4-propan-2-ylphenyl)propanamide Chemical compound CC(C)C1=CC=C(NC(=O)CCCl)C=C1 MEAPRSDUXBHXGD-UHFFFAOYSA-N 0.000 description 1
- GNWCRBFQZDJFTI-UHFFFAOYSA-N 3-ethyl-1-(3-nitrophenyl)quinazoline-2,4-dione Chemical compound C12=CC=CC=C2C(=O)N(CC)C(=O)N1C1=CC=CC([N+]([O-])=O)=C1 GNWCRBFQZDJFTI-UHFFFAOYSA-N 0.000 description 1
- MZRKHUUDDHJVHS-MOKVOYLWSA-N 3-ethyl-n-[(5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-2-oxobenzimidazole-1-carboxamide Chemical compound C1C(N2C)CC[C@H]2CC1NC(=O)N1C2=CC=CC=C2N(CC)C1=O MZRKHUUDDHJVHS-MOKVOYLWSA-N 0.000 description 1
- BIAVGWDGIJKWRM-FQEVSTJZSA-N 3-hydroxy-2-phenyl-n-[(1s)-1-phenylpropyl]quinoline-4-carboxamide Chemical compound N([C@@H](CC)C=1C=CC=CC=1)C(=O)C(C1=CC=CC=C1N=1)=C(O)C=1C1=CC=CC=C1 BIAVGWDGIJKWRM-FQEVSTJZSA-N 0.000 description 1
- AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 description 1
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- MUFDLGGSOCHQOC-HTKOBJQYSA-N 4-[(1s,2r)-1-hydroxy-2-(propan-2-ylamino)butyl]benzene-1,2-diol;hydrochloride Chemical compound Cl.CC(C)N[C@H](CC)[C@@H](O)C1=CC=C(O)C(O)=C1 MUFDLGGSOCHQOC-HTKOBJQYSA-N 0.000 description 1
- AFSHNJLKCYAWRX-UHFFFAOYSA-N 4-[(5-chloronaphthalen-2-yl)methyl]-5h-1,2,3,5-oxathiadiazole 2-oxide Chemical compound C=1C=C2C(Cl)=CC=CC2=CC=1CC1=NS(=O)ON1 AFSHNJLKCYAWRX-UHFFFAOYSA-N 0.000 description 1
- SOYAGMVKMXZVNZ-UHFFFAOYSA-N 4-[1-hydroxy-2-(propan-2-ylamino)butyl]benzene-1,2-diol;methanesulfonic acid Chemical compound CS(O)(=O)=O.CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 SOYAGMVKMXZVNZ-UHFFFAOYSA-N 0.000 description 1
- FXIPXWLVYIHFEP-OAQYLSRUSA-N 4-[4-[3-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]propoxy]phenyl]benzonitrile Chemical compound C1[C@H](N(C)C)CCN1CCCOC1=CC=C(C=2C=CC(=CC=2)C#N)C=C1 FXIPXWLVYIHFEP-OAQYLSRUSA-N 0.000 description 1
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- SSMIFVHARFVINF-UHFFFAOYSA-N 4-amino-1,8-naphthalimide Chemical compound O=C1NC(=O)C2=CC=CC3=C2C1=CC=C3N SSMIFVHARFVINF-UHFFFAOYSA-N 0.000 description 1
- PPVTTWPBNHFCAJ-XMSQKQJNSA-N 4-amino-5-chloro-2-(cyclopropylmethoxy)-n-[(1r,2r)-2-[(4-methylpiperidin-1-yl)methyl]cyclohexyl]benzamide Chemical compound C1CC(C)CCN1C[C@@H]1[C@H](NC(=O)C=2C(=CC(N)=C(Cl)C=2)OCC2CC2)CCCC1 PPVTTWPBNHFCAJ-XMSQKQJNSA-N 0.000 description 1
- YPELFRMCRYSPKZ-UHFFFAOYSA-N 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide Chemical compound CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1OCCN(CC=2C=CC(F)=CC=2)C1 YPELFRMCRYSPKZ-UHFFFAOYSA-N 0.000 description 1
- CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical group OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 description 1
- FEROPKNOYKURCJ-UHFFFAOYSA-N 4-amino-N-(1-azabicyclo[2.2.2]octan-3-yl)-5-chloro-2-methoxybenzamide Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)NC1C(CC2)CCN2C1 FEROPKNOYKURCJ-UHFFFAOYSA-N 0.000 description 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- BZTKEUQYHVFBHM-UHFFFAOYSA-N 4-chloro-n-(3-morpholin-4-ylpropyl)benzamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C(=O)NCCCN1CCOCC1 BZTKEUQYHVFBHM-UHFFFAOYSA-N 0.000 description 1
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 1
- SYCHUQUJURZQMO-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-n-(1,3-thiazol-2-yl)-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=CS1 SYCHUQUJURZQMO-UHFFFAOYSA-N 0.000 description 1
- PZNQZSRPDOEBMS-QMMMGPOBSA-N 4-iodo-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(I)C=C1 PZNQZSRPDOEBMS-QMMMGPOBSA-N 0.000 description 1
- JCLFHZLOKITRCE-UHFFFAOYSA-N 4-pentoxyphenol Chemical compound CCCCCOC1=CC=C(O)C=C1 JCLFHZLOKITRCE-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- 229940127239 5 Hydroxytryptamine receptor antagonist Drugs 0.000 description 1
- IPRDZAMUYMOJTA-UHFFFAOYSA-N 5,6-dichloro-1h-benzimidazole Chemical class C1=C(Cl)C(Cl)=CC2=C1NC=N2 IPRDZAMUYMOJTA-UHFFFAOYSA-N 0.000 description 1
- SJQRQOKXQKVJGJ-UHFFFAOYSA-N 5-(2-aminoethylamino)naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1S(O)(=O)=O SJQRQOKXQKVJGJ-UHFFFAOYSA-N 0.000 description 1
- WNWALBVQAAIULR-UHFFFAOYSA-N 5-(3-phenylmethoxypropyl)-1H-imidazole Chemical class C=1N=CNC=1CCCOCC1=CC=CC=C1 WNWALBVQAAIULR-UHFFFAOYSA-N 0.000 description 1
- HMXDWDSNPRNUKI-UHFFFAOYSA-N 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-3-pyrazolecarboxamide Chemical compound CCC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Br)C=C1 HMXDWDSNPRNUKI-UHFFFAOYSA-N 0.000 description 1
- MXUNKHLAEDCYJL-UHFFFAOYSA-N 5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one Chemical compound CC1=CC=CC(N2C(OC(CO)C2)=O)=C1 MXUNKHLAEDCYJL-UHFFFAOYSA-N 0.000 description 1
- 108091005435 5-HT6 receptors Proteins 0.000 description 1
- YVQKIDLSVHRBGZ-UHFFFAOYSA-N 5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1C(O)COC(C=C1)=CC=C1CC1SC(=O)NC1=O YVQKIDLSVHRBGZ-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- QYYMDNHUJFIDDQ-UHFFFAOYSA-N 5-chloro-2-methyl-1,2-thiazol-3-one;2-methyl-1,2-thiazol-3-one Chemical compound CN1SC=CC1=O.CN1SC(Cl)=CC1=O QYYMDNHUJFIDDQ-UHFFFAOYSA-N 0.000 description 1
- VNHBYKHXBCYPBJ-UHFFFAOYSA-N 5-ethynylimidazo[1,2-a]pyridine Chemical compound C#CC1=CC=CC2=NC=CN12 VNHBYKHXBCYPBJ-UHFFFAOYSA-N 0.000 description 1
- 102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 description 1
- 101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- VFFZWMWTUSXDCB-ZDUSSCGKSA-N 6-[2-[[2-[(2s)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]ethylamino]pyridine-3-carbonitrile Chemical compound N1([C@@H](CCC1)C#N)C(=O)CNCCNC1=CC=C(C#N)C=N1 VFFZWMWTUSXDCB-ZDUSSCGKSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- VGLGVJVUHYTIIU-UHFFFAOYSA-N 6-chloro-1,1-dioxo-3-[(prop-2-enylthio)methyl]-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(CSCC=C)NS2(=O)=O VGLGVJVUHYTIIU-UHFFFAOYSA-N 0.000 description 1
- IXJCHVMUTFCRBH-SDUHDBOFSA-N 7-[(1r,2s,3e,5z)-10-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-hydroxy-1-[3-(trifluoromethyl)phenyl]deca-3,5-dien-2-yl]sulfanyl-4-oxochromene-2-carboxylic acid Chemical compound CCCC1=C(O)C(C(C)=O)=CC=C1OCCCC\C=C/C=C/[C@@H]([C@H](O)C=1C=C(C=CC=1)C(F)(F)F)SC1=CC=C2C(=O)C=C(C(O)=O)OC2=C1 IXJCHVMUTFCRBH-SDUHDBOFSA-N 0.000 description 1
- FIKFLLIUPUVONI-UHFFFAOYSA-N 8-(2-phenylethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one;hydrochloride Chemical compound Cl.O1C(=O)NCC11CCN(CCC=2C=CC=CC=2)CC1 FIKFLLIUPUVONI-UHFFFAOYSA-N 0.000 description 1
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 1
- 108010023016 A 71378 Proteins 0.000 description 1
- 108700024421 A 71623 Proteins 0.000 description 1
- 108010070305 AOD 9604 Proteins 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229940122937 Actin inhibitor Drugs 0.000 description 1
- 241001552669 Adonis annua Species 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 208000010266 Aggressive Periodontitis Diseases 0.000 description 1
- 101710153593 Albumin A Proteins 0.000 description 1
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 description 1
- BDNVAHNPDXGBIR-UHFFFAOYSA-N Amarin Natural products CC(=O)OCC(=C)C(=O)OC1CC(C)=CCCC(CO)=CC2OC(=O)C(=C)C12 BDNVAHNPDXGBIR-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- DTDADHMBRZKXSC-GKASHWOUSA-N Aricine Chemical compound C1=C(OC)C=C2C(CCN3C[C@H]4[C@H](C)OC=C([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 DTDADHMBRZKXSC-GKASHWOUSA-N 0.000 description 1
- YZQCXOFQZKCETR-UWVGGRQHSA-N Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 YZQCXOFQZKCETR-UWVGGRQHSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- FBMCYYWIBYEOST-GJFSDDNBSA-N BIBO-3304 Chemical compound OC(=O)C(F)(F)F.N([C@H](CCCNC(=N)N)C(=O)NCC=1C=CC(CNC(N)=O)=CC=1)C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 FBMCYYWIBYEOST-GJFSDDNBSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102100034159 Beta-3 adrenergic receptor Human genes 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- DJHSXYPMGGWLLQ-UHFFFAOYSA-N BrC1=CC=CC=C1.C(C=C/C(=O)O)(=O)O Chemical compound BrC1=CC=CC=C1.C(C=C/C(=O)O)(=O)O DJHSXYPMGGWLLQ-UHFFFAOYSA-N 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- SZAPNCVMFUJPKL-UHFFFAOYSA-N C(C1=CC=CC=C1)(=O)O.N1N=NN=C1 Chemical compound C(C1=CC=CC=C1)(=O)O.N1N=NN=C1 SZAPNCVMFUJPKL-UHFFFAOYSA-N 0.000 description 1
- RVQZVVJLIUXDPN-YTTGMZPUSA-N C([C@@](OCC1)(CCN2CCC(CC2)(C(=O)N(C)C)N2CCCCC2)C=2C=C(Cl)C(Cl)=CC=2)N1C(=O)C1=CC=CC=C1 Chemical compound C([C@@](OCC1)(CCN2CCC(CC2)(C(=O)N(C)C)N2CCCCC2)C=2C=C(Cl)C(Cl)=CC=2)N1C(=O)C1=CC=CC=C1 RVQZVVJLIUXDPN-YTTGMZPUSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- UYNYHTXDTCBXTN-UHFFFAOYSA-N CC1=NN(C2=C1C(=O)CC(C2)(C)C)C3=CC(=C(C=C3)C(=O)N)NCCCOCCOCCOCCOCCOCCCNCC4=CC=C(C=C4)/C(=C\C=C\5/C(C6=CC=CC=C6N5CCCCS(=O)(=O)[O-])(C)C)/C=C/C7=[N+](C8=CC=CC=C8C7(C)C)CCCCS(=O)(=O)O Chemical compound CC1=NN(C2=C1C(=O)CC(C2)(C)C)C3=CC(=C(C=C3)C(=O)N)NCCCOCCOCCOCCOCCOCCCNCC4=CC=C(C=C4)/C(=C\C=C\5/C(C6=CC=CC=C6N5CCCCS(=O)(=O)[O-])(C)C)/C=C/C7=[N+](C8=CC=CC=C8C7(C)C)CCCCS(=O)(=O)O UYNYHTXDTCBXTN-UHFFFAOYSA-N 0.000 description 1
- XQCKXOKBWVXUJH-UHFFFAOYSA-N CCOC([O])=O Chemical compound CCOC([O])=O XQCKXOKBWVXUJH-UHFFFAOYSA-N 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 102100038518 Calcitonin Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- KSQIAZKOUOEHSA-UHFFFAOYSA-N Carbocromen hydrochloride Chemical compound [Cl-].CC1=C(CC[NH+](CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KSQIAZKOUOEHSA-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- 102000011045 Chloride Channels Human genes 0.000 description 1
- 101710150887 Cholecystokinin A Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- OIRAEJWYWSAQNG-UHFFFAOYSA-N Clidanac Chemical compound ClC=1C=C2C(C(=O)O)CCC2=CC=1C1CCCCC1 OIRAEJWYWSAQNG-UHFFFAOYSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 201000005078 Colonic Pseudo-Obstruction Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 1
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 244000050510 Cunninghamia lanceolata Species 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 1
- 229930195709 D-tyrosine Natural products 0.000 description 1
- IROWCYIEJAOFOW-UHFFFAOYSA-N DL-Isoprenaline hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(O)C(O)=C1 IROWCYIEJAOFOW-UHFFFAOYSA-N 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 108010002156 Depsipeptides Proteins 0.000 description 1
- DLVJMFOLJOOWFS-UHFFFAOYSA-N Depudecin Natural products CC(O)C1OC1C=CC1C(C(O)C=C)O1 DLVJMFOLJOOWFS-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- JXNRXNCCROJZFB-UHFFFAOYSA-N Di-Me ester-(2R, 3E)-Phytochromobilin Natural products NC(N)=NCCCC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 JXNRXNCCROJZFB-UHFFFAOYSA-N 0.000 description 1
- 102000016862 Dicarboxylic Acid Transporters Human genes 0.000 description 1
- 108010092943 Dicarboxylic Acid Transporters Proteins 0.000 description 1
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- LQKSHSFQQRCAFW-UHFFFAOYSA-N Dolastatin 15 Natural products COC1=CC(=O)N(C(=O)C(OC(=O)C2N(CCC2)C(=O)C2N(CCC2)C(=O)C(C(C)C)N(C)C(=O)C(NC(=O)C(C(C)C)N(C)C)C(C)C)C(C)C)C1CC1=CC=CC=C1 LQKSHSFQQRCAFW-UHFFFAOYSA-N 0.000 description 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- WOISDAHQBUYEAF-UHFFFAOYSA-N Ebelactone A Natural products CCC(C)C(O)C(C)C(=O)C(C)C=C(C)CC(C)C1OC(=O)C1C WOISDAHQBUYEAF-UHFFFAOYSA-N 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- 229940124143 Endopeptidase inhibitor Drugs 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 229940122586 Enkephalinase inhibitor Drugs 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000702224 Enterobacteria phage M13 Species 0.000 description 1
- 241001465251 Ephedra sinica Species 0.000 description 1
- 102000003837 Epithelial Sodium Channels Human genes 0.000 description 1
- 108090000140 Epithelial Sodium Channels Proteins 0.000 description 1
- 241000132521 Erigeron Species 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 240000006890 Erythroxylum coca Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
- 102000000476 Fatty Acid Transport Proteins Human genes 0.000 description 1
- 108010055870 Fatty Acid Transport Proteins Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 108010087894 Fatty acid desaturases Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- RBBWCVQDXDFISW-UHFFFAOYSA-N Feprazone Chemical compound O=C1C(CC=C(C)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 RBBWCVQDXDFISW-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 241000227647 Fucus vesiculosus Species 0.000 description 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- QTQMRBZOBKYXCG-MHZLTWQESA-N GW 1929 Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCN(C)C=1N=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 QTQMRBZOBKYXCG-MHZLTWQESA-N 0.000 description 1
- GGUVRMBIEPYOKL-WMVCGJOFSA-N GW 409544 Chemical compound C([C@H](NC(/C)=C\C(=O)C=1C=CC=CC=1)C(O)=O)C(C=C1)=CC=C1OCCC(=C(O1)C)N=C1C1=CC=CC=C1 GGUVRMBIEPYOKL-WMVCGJOFSA-N 0.000 description 1
- 244000119461 Garcinia xanthochymus Species 0.000 description 1
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010061166 Gastroenteritis bacterial Diseases 0.000 description 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 1
- 101800004295 Glucagon-like peptide 1(7-36) Proteins 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 108700011498 Glucocorticoid Receptor Deficiency Proteins 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 108010077008 HOE 825 Proteins 0.000 description 1
- 108010054782 HS 131 Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 229940124056 Histamine H1 receptor antagonist Drugs 0.000 description 1
- 102000004384 Histamine H3 receptors Human genes 0.000 description 1
- 108090000981 Histamine H3 receptors Proteins 0.000 description 1
- 101000693243 Homo sapiens Paternally-expressed gene 3 protein Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000714920 Homo sapiens Taste receptor type 2 member 13 Proteins 0.000 description 1
- 101000766345 Homo sapiens Tribbles homolog 3 Proteins 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 229940124036 Hydrolase inhibitor Drugs 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- GVDRRZOORHCTAN-MJUUVYJYSA-N Ingliforib Chemical compound C([C@@H]([C@@H](O)C(=O)N1C[C@@H](O)[C@@H](O)C1)NC(=O)C=1NC2=CC=C(Cl)C=C2C=1)C1=CC=CC=C1 GVDRRZOORHCTAN-MJUUVYJYSA-N 0.000 description 1
- 108010089308 Insulin Detemir Proteins 0.000 description 1
- 108010057186 Insulin Glargine Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 108700040553 JMV 180 Proteins 0.000 description 1
- PMRVFZXOCRHXFE-FMEJWYFOSA-L Kad 1229 Chemical compound [Ca+2].C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)[O-])C1=CC=CC=C1.C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)[O-])C1=CC=CC=C1 PMRVFZXOCRHXFE-FMEJWYFOSA-L 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ZEXLJFNSKAHNFH-SYKYGTKKSA-N L-Phenylalaninamide, L-tyrosyl-L-prolyl-L-tryptophyl- Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=C(O)C=C1 ZEXLJFNSKAHNFH-SYKYGTKKSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- MRAUNPAHJZDYCK-BYPYZUCNSA-N L-nitroarginine Chemical compound OC(=O)[C@@H](N)CCCNC(=N)N[N+]([O-])=O MRAUNPAHJZDYCK-BYPYZUCNSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- IWVRVEIKCBFZNF-UHFFFAOYSA-N LSM-1636 Chemical compound C1CNC2CCCC3=C2N1C1=CC=C(C)C=C13 IWVRVEIKCBFZNF-UHFFFAOYSA-N 0.000 description 1
- LUZRJRNZXALNLM-UHFFFAOYSA-N LSM-1639 Chemical compound C1C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 LUZRJRNZXALNLM-UHFFFAOYSA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- STECJAGHUSJQJN-USLFZFAMSA-N LSM-4015 Chemical compound C1([C@@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-USLFZFAMSA-N 0.000 description 1
- 108010018112 LY 315902 Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- WTOVRSWDBLIFHU-UHFFFAOYSA-N Lemildipine Chemical compound COC(=O)C1=C(C)NC(COC(N)=O)=C(C(=O)OC(C)C)C1C1=CC=CC(Cl)=C1Cl WTOVRSWDBLIFHU-UHFFFAOYSA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101150051050 MC3R gene Proteins 0.000 description 1
- 101150110867 MC4R gene Proteins 0.000 description 1
- 101150048659 MC5R gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- 102100027373 Melanin-concentrating hormone receptor 2 Human genes 0.000 description 1
- 101710089759 Melanin-concentrating hormone receptor 2 Proteins 0.000 description 1
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 1
- YGRFXPCHZBRUKP-UHFFFAOYSA-N Methoxamine hydrochloride Chemical compound Cl.COC1=CC=C(OC)C(C(O)C(C)N)=C1 YGRFXPCHZBRUKP-UHFFFAOYSA-N 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- HBNPJJILLOYFJU-VMPREFPWSA-N Mibefradil Chemical compound C1CC2=CC(F)=CC=C2[C@H](C(C)C)[C@@]1(OC(=O)COC)CCN(C)CCCC1=NC2=CC=CC=C2N1 HBNPJJILLOYFJU-VMPREFPWSA-N 0.000 description 1
- 239000005474 Milfasartan Substances 0.000 description 1
- PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 description 1
- JXRAXHBVZQZSIC-JKVLGAQCSA-N Moexipril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 JXRAXHBVZQZSIC-JKVLGAQCSA-N 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- FYYSQDHBALBGHX-YFKPBYRVSA-N N(alpha)-t-butoxycarbonyl-L-asparagine Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC(N)=O FYYSQDHBALBGHX-YFKPBYRVSA-N 0.000 description 1
- RYFOQDQDVYIEHN-ZETCQYMHSA-N N,N-Dimethyllysine Chemical compound CN(C)[C@H](C(O)=O)CCCCN RYFOQDQDVYIEHN-ZETCQYMHSA-N 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- QKDDJDBFONZGBW-UHFFFAOYSA-N N-Cyclohexy-4-(imidazol-4-yl)-1-piperidinecarbothioamide Chemical compound C1CC(C=2NC=NC=2)CCN1C(=S)NC1CCCCC1 QKDDJDBFONZGBW-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- QVLMCRFQGHWOPM-ZKWNWVNESA-N N-arachidonoyl vanillylamine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCC1=CC=C(O)C(OC)=C1 QVLMCRFQGHWOPM-ZKWNWVNESA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- UZIQYAYUUNMDMU-UHFFFAOYSA-N N.[Br+] Chemical compound N.[Br+] UZIQYAYUUNMDMU-UHFFFAOYSA-N 0.000 description 1
- AQGDXJQRVOCUQX-UHFFFAOYSA-N N.[S] Chemical compound N.[S] AQGDXJQRVOCUQX-UHFFFAOYSA-N 0.000 description 1
- AQBBQXMTBYSLER-UHFFFAOYSA-N N1=CC=CC=C1.C(#N)C=1C=CNC1 Chemical class N1=CC=CC=C1.C(#N)C=1C=CNC1 AQBBQXMTBYSLER-UHFFFAOYSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 239000005104 Neeliglow 4-amino-1,8-naphthalimide Substances 0.000 description 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 108010040722 Neurokinin-2 Receptors Proteins 0.000 description 1
- 101800003845 Neuropeptide Y Proteins 0.000 description 1
- 101100386053 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-3 gene Proteins 0.000 description 1
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 1
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- APSUXPSYBJVPPS-YAUKWVCOSA-N Norbinaltorphimine Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C=3C[C@]4(O)[C@]67CCN(CC8CC8)[C@@H]4CC=4C7=C(C(=CC=4)O)O[C@H]6C=3NC=25)O)CC1)O)CC1CC1 APSUXPSYBJVPPS-YAUKWVCOSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- GNYVDZIVQWDUKD-UHFFFAOYSA-N OP(O)(=O)OP(=O)(O)O.ClC([Na])([Na])Cl Chemical compound OP(O)(=O)OP(=O)(O)O.ClC([Na])([Na])Cl GNYVDZIVQWDUKD-UHFFFAOYSA-N 0.000 description 1
- JWOGUUIOCYMBPV-UHFFFAOYSA-N OT-Key 11219 Natural products N1C(=O)C(CCCCCC(=O)CC)NC(=O)C2CCCCN2C(=O)C(C(C)CC)NC(=O)C1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-UHFFFAOYSA-N 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 101150098694 PDE5A gene Proteins 0.000 description 1
- 108010028924 PPAR alpha Proteins 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 108010015181 PPAR delta Proteins 0.000 description 1
- 208000035467 Pancreatic insufficiency Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102100025757 Paternally-expressed gene 3 protein Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropyl alcohol Natural products CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 1
- 102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 description 1
- 108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010063985 Phytosterolaemia Diseases 0.000 description 1
- XRKXJJYSKUIIEN-LLVKDONJSA-N Pivopril Chemical compound CC(C)(C)C(=O)SC[C@@H](C)C(=O)N(CC(O)=O)C1CCCC1 XRKXJJYSKUIIEN-LLVKDONJSA-N 0.000 description 1
- 241001127637 Plantago Species 0.000 description 1
- 241001499733 Plantago asiatica Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 206010068620 Post procedural constipation Diseases 0.000 description 1
- 206010054048 Postoperative ileus Diseases 0.000 description 1
- QJLPWVUZFKETMK-UHFFFAOYSA-N Pradimicin Q Natural products O=C1C2=C(O)C=C(O)C=C2C(=O)C2=C1C(O)=C1CC(O)C(C=C(C(=C3O)C(O)=O)C)=C3C1=C2O QJLPWVUZFKETMK-UHFFFAOYSA-N 0.000 description 1
- 239000005477 Pratosartan Substances 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- IFFPICMESYHZPQ-UHFFFAOYSA-N Prenylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCNC(C)CC1=CC=CC=C1 IFFPICMESYHZPQ-UHFFFAOYSA-N 0.000 description 1
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108010007131 Pulmonary Surfactant-Associated Protein B Proteins 0.000 description 1
- 108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 description 1
- 102000007620 Pulmonary Surfactant-Associated Protein C Human genes 0.000 description 1
- 108010007127 Pulmonary Surfactant-Associated Protein D Proteins 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 108010001742 S-Nitrosoglutathione Proteins 0.000 description 1
- HYHSBSXUHZOYLX-WDSKDSINSA-N S-nitrosoglutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CSN=O)C(=O)NCC(O)=O HYHSBSXUHZOYLX-WDSKDSINSA-N 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- OCTNNXHKAOLDJL-BMGYQPLYSA-N Salbostatin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)OC[C@@H]1N[C@@H]1[C@H](O)[C@@H](O)[C@H](O)C(CO)=C1 OCTNNXHKAOLDJL-BMGYQPLYSA-N 0.000 description 1
- OCTNNXHKAOLDJL-UHFFFAOYSA-N Salbostatin Natural products OC1C(O)C(CO)OCC1NC1C(O)C(O)C(O)C(CO)=C1 OCTNNXHKAOLDJL-UHFFFAOYSA-N 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 101800002751 Sialorphin Proteins 0.000 description 1
- 208000002227 Sitosterolemia Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 102000016553 Stearoyl-CoA Desaturase Human genes 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 102100037342 Substance-K receptor Human genes 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000001163 Tangier disease Diseases 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- OGEAASSLWZDQBM-UHFFFAOYSA-N Temelastine Chemical compound C1=NC(C)=CC=C1CC(C(N1)=O)=CN=C1NCCCCC1=NC=C(Br)C=C1C OGEAASSLWZDQBM-UHFFFAOYSA-N 0.000 description 1
- 108010045759 Teprotide Proteins 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 1
- 241000519996 Teucrium chamaedrys Species 0.000 description 1
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 241000218636 Thuja Species 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- DXEXNWDGDYUITL-FXSSSKFRSA-N Tipredane Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](SC)(SCC)[C@@]1(C)C[C@@H]2O DXEXNWDGDYUITL-FXSSSKFRSA-N 0.000 description 1
- 231100000777 Toxicophore Toxicity 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100028509 Transcription factor IIIA Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102100026390 Tribbles homolog 3 Human genes 0.000 description 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000287433 Turdus Species 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 102000008219 Uncoupling Protein 2 Human genes 0.000 description 1
- 108010021111 Uncoupling Protein 2 Proteins 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 101710137651 Vasoactive intestinal polypeptide receptor 2 Proteins 0.000 description 1
- 102100038286 Vasoactive intestinal polypeptide receptor 2 Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- ZNUAKACHFYTNFX-UHFFFAOYSA-N Wallichenol Natural products CC12CCC(O)C(C)(C)C1CCC1(C)C2CCC2C3C(C(=C)CO)CCC3(C)CCC21C ZNUAKACHFYTNFX-UHFFFAOYSA-N 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 241001123263 Zostera Species 0.000 description 1
- HOBWAPHTEJGALG-LFQBMQRVSA-N [(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2s)-3-hydroxy-2-phenylpropanoate;sulfuric acid Chemical compound OS(O)(=O)=O.C1([C@@H](CO)C(=O)OC2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1.C1([C@@H](CO)C(=O)OC2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 HOBWAPHTEJGALG-LFQBMQRVSA-N 0.000 description 1
- LQKSHSFQQRCAFW-CCVNJFHASA-N [(2s)-1-[(2s)-2-benzyl-3-methoxy-5-oxo-2h-pyrrol-1-yl]-3-methyl-1-oxobutan-2-yl] (2s)-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxyl Chemical compound C([C@@H]1N(C(=O)C=C1OC)C(=O)[C@@H](OC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](C(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C)C(C)C)C1=CC=CC=C1 LQKSHSFQQRCAFW-CCVNJFHASA-N 0.000 description 1
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 description 1
- HOAKOHHSHOCDLI-TUFAYURCSA-N [(8s,9s,10r,11s,13s,14s,17r)-11-hydroxy-10,13-dimethyl-3-oxo-17-(2-sulfanylacetyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CS)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O HOAKOHHSHOCDLI-TUFAYURCSA-N 0.000 description 1
- QJGVXJYGDBSPSJ-UHFFFAOYSA-N [1-(6,7-dimethoxyphthalazin-1-yl)piperidin-4-yl] n-ethylcarbamate Chemical compound C1CC(OC(=O)NCC)CCN1C1=NN=CC2=CC(OC)=C(OC)C=C12 QJGVXJYGDBSPSJ-UHFFFAOYSA-N 0.000 description 1
- RLVLLBHWAQWLKL-UHFFFAOYSA-N [2-[4-(2-methylpropyl)cyclohexyl]-2-oxoethyl] benzenesulfonate Chemical compound C1CC(CC(C)C)CCC1C(=O)COS(=O)(=O)C1=CC=CC=C1 RLVLLBHWAQWLKL-UHFFFAOYSA-N 0.000 description 1
- ZXPSRPAUXQIYID-UHFFFAOYSA-N [N].[Na] Chemical compound [N].[Na] ZXPSRPAUXQIYID-UHFFFAOYSA-N 0.000 description 1
- WRLRISOTNFYPMU-UHFFFAOYSA-N [S].CC1=CC=CC=C1 Chemical compound [S].CC1=CC=CC=C1 WRLRISOTNFYPMU-UHFFFAOYSA-N 0.000 description 1
- 208000004622 abetalipoproteinemia Diseases 0.000 description 1
- 229950010933 abitesartan Drugs 0.000 description 1
- ZUMPSVPHCDJCMD-UHFFFAOYSA-N abitesartan Chemical compound C1CCCC1(C(O)=O)CN(C(=O)CCCC)CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ZUMPSVPHCDJCMD-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- 229940062352 aceon Drugs 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 229960003792 acrivastine Drugs 0.000 description 1
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 description 1
- 231100000764 actin inhibitor Toxicity 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940062328 actos Drugs 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- JIMXXGFJRDUSRO-UHFFFAOYSA-N adamantane-1-carboxylic acid Chemical class C1C(C2)CC3CC2CC1(C(=O)O)C3 JIMXXGFJRDUSRO-UHFFFAOYSA-N 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 229940023375 adipex-p Drugs 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960005142 alclofenac Drugs 0.000 description 1
- ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 description 1
- 229960004607 alfuzosin Drugs 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229960004601 aliskiren Drugs 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 229960004663 alminoprofen Drugs 0.000 description 1
- FPHLBGOJWPEVME-UHFFFAOYSA-N alminoprofen Chemical compound OC(=O)C(C)C1=CC=C(NCC(C)=C)C=C1 FPHLBGOJWPEVME-UHFFFAOYSA-N 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- ORDAZKGHSNRHTD-UHFFFAOYSA-N alpha-Toxicarol Natural products O1C(C)(C)C=CC2=C1C=CC1=C2OC2COC(C=C(C(=C3)OC)OC)=C3C2C1=O ORDAZKGHSNRHTD-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 229960000852 alprenolol hydrochloride Drugs 0.000 description 1
- VGLGVJVUHYTIIU-LLVKDONJSA-N altizide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1N[C@@H](CSCC=C)NS2(=O)=O VGLGVJVUHYTIIU-LLVKDONJSA-N 0.000 description 1
- 229950007522 altizide Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 229940000806 amaryl Drugs 0.000 description 1
- HFQMYSHATTXRTC-JTQLQIEISA-N amiflamine Chemical compound C[C@H](N)CC1=CC=C(N(C)C)C=C1C HFQMYSHATTXRTC-JTQLQIEISA-N 0.000 description 1
- 229950004939 amiflamine Drugs 0.000 description 1
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
- 229960001097 amifostine Drugs 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- BSJGASKRWFKGMV-UHFFFAOYSA-L ammonia dichloroplatinum(2+) Chemical compound N.N.Cl[Pt+2]Cl BSJGASKRWFKGMV-UHFFFAOYSA-L 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940025151 anaspaz Drugs 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 150000004303 annulenes Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229960002469 antazoline Drugs 0.000 description 1
- REYFJDPCWQRWAA-UHFFFAOYSA-N antazoline Chemical compound N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 REYFJDPCWQRWAA-UHFFFAOYSA-N 0.000 description 1
- 150000001454 anthracenes Chemical class 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- NOFOAYPPHIUXJR-APNQCZIXSA-N aphidicolin Chemical compound C1[C@@]23[C@@]4(C)CC[C@@H](O)[C@@](C)(CO)[C@@H]4CC[C@H]3C[C@H]1[C@](CO)(O)CC2 NOFOAYPPHIUXJR-APNQCZIXSA-N 0.000 description 1
- SEKZNWAQALMJNH-YZUCACDQSA-N aphidicolin Natural products C[C@]1(CO)CC[C@]23C[C@H]1C[C@@H]2CC[C@H]4[C@](C)(CO)[C@H](O)CC[C@]34C SEKZNWAQALMJNH-YZUCACDQSA-N 0.000 description 1
- 108010082820 apicidin Proteins 0.000 description 1
- 229930186608 apicidin Natural products 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 1
- 229960001372 aprepitant Drugs 0.000 description 1
- UHDJCSZGZJGMDR-UHFFFAOYSA-N aricine Natural products COC(=O)C1=COC(C)C2(C)CN3CCc4c([nH]c5ccc(OC)cc45)C3(C)CC12C UHDJCSZGZJGMDR-UHFFFAOYSA-N 0.000 description 1
- FOIVPCKZDPCJJY-JQIJEIRASA-N arotinoid acid Chemical compound C=1C=C(C(CCC2(C)C)(C)C)C2=CC=1C(/C)=C/C1=CC=C(C(O)=O)C=C1 FOIVPCKZDPCJJY-JQIJEIRASA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940072224 asacol Drugs 0.000 description 1
- JHLHNYVMZCADTC-LOSJGSFVSA-N asimadoline Chemical compound C([C@@H](N(C)C(=O)C(C=1C=CC=CC=1)C=1C=CC=CC=1)C=1C=CC=CC=1)N1CC[C@H](O)C1 JHLHNYVMZCADTC-LOSJGSFVSA-N 0.000 description 1
- 229950002202 asimadoline Drugs 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229940062310 avandia Drugs 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 108010014210 axokine Proteins 0.000 description 1
- 125000002648 azanetriyl group Chemical group *N(*)* 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 229960000383 azatadine Drugs 0.000 description 1
- SEBMTIQKRHYNIT-UHFFFAOYSA-N azatadine Chemical compound C1CN(C)CCC1=C1C2=NC=CC=C2CCC2=CC=CC=C21 SEBMTIQKRHYNIT-UHFFFAOYSA-N 0.000 description 1
- 229960004574 azelastine Drugs 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- 229960004168 balsalazide Drugs 0.000 description 1
- IPOKCKJONYRRHP-FMQUCBEESA-N balsalazide Chemical compound C1=CC(C(=O)NCCC(=O)O)=CC=C1\N=N\C1=CC=C(O)C(C(O)=O)=C1 IPOKCKJONYRRHP-FMQUCBEESA-N 0.000 description 1
- 229960003060 bambuterol Drugs 0.000 description 1
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical group CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 description 1
- KRNDIPHOJLIHRI-UHFFFAOYSA-N bazinaprine Chemical compound N#CC1=CC(C=2C=CC=CC=2)=NN=C1NCCN1CCOCC1 KRNDIPHOJLIHRI-UHFFFAOYSA-N 0.000 description 1
- 229950005683 bazinaprine Drugs 0.000 description 1
- IALVDLPLCLFBCF-CHWSQXEVSA-N befloxatone Chemical compound O=C1O[C@@H](COC)CN1C1=CC=C(OCC[C@@H](O)C(F)(F)F)C=C1 IALVDLPLCLFBCF-CHWSQXEVSA-N 0.000 description 1
- 229950000017 befloxatone Drugs 0.000 description 1
- 229950000537 belfosdil Drugs 0.000 description 1
- VPSRQEHTHIMDQM-FKLPMGAJSA-N benazepril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 VPSRQEHTHIMDQM-FKLPMGAJSA-N 0.000 description 1
- 229960003619 benazepril hydrochloride Drugs 0.000 description 1
- HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 description 1
- 229960004916 benidipine Drugs 0.000 description 1
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 description 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
- 229960000911 benserazide Drugs 0.000 description 1
- 229940090012 bentyl Drugs 0.000 description 1
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 description 1
- 229960001081 benzatropine Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 150000008641 benzimidazolones Chemical class 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 229960001541 benzthiazide Drugs 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 229960002045 bergapten Drugs 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 description 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- 229940098085 betagan Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 1
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- HXLAFSUPPDYFEO-UHFFFAOYSA-N bevantolol Chemical compound C1=C(OC)C(OC)=CC=C1CCNCC(O)COC1=CC=CC(C)=C1 HXLAFSUPPDYFEO-UHFFFAOYSA-N 0.000 description 1
- 229960003588 bevantolol Drugs 0.000 description 1
- KUWBXRGRMQZCSS-HSZRJFAPSA-N bibp-3226 Chemical compound N([C@H](CCCN=C(N)N)C(=O)NCC=1C=CC(O)=CC=1)C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 KUWBXRGRMQZCSS-HSZRJFAPSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical compound C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 description 1
- 229960003003 biperiden Drugs 0.000 description 1
- VMDFASMUILANOL-WXXKFALUSA-N bisoprolol fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VMDFASMUILANOL-WXXKFALUSA-N 0.000 description 1
- 229960004620 bitolterol Drugs 0.000 description 1
- FZGVEKPRDOIXJY-UHFFFAOYSA-N bitolterol Chemical compound C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)CNC(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 FZGVEKPRDOIXJY-UHFFFAOYSA-N 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229940046049 bontril Drugs 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 229940088499 brethine Drugs 0.000 description 1
- 229940097683 brevibloc Drugs 0.000 description 1
- WZXHSWVDAYOFPE-UHFFFAOYSA-N brofaromine Chemical compound C=1C2=CC(OC)=CC(Br)=C2OC=1C1CCNCC1 WZXHSWVDAYOFPE-UHFFFAOYSA-N 0.000 description 1
- 229950004068 brofaromine Drugs 0.000 description 1
- LHMHCLYDBQOYTO-UHFFFAOYSA-N bromofluoromethane Chemical compound FCBr LHMHCLYDBQOYTO-UHFFFAOYSA-N 0.000 description 1
- ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 description 1
- 229960000725 brompheniramine Drugs 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- IJTPQQVCKPZIMV-UHFFFAOYSA-N bucloxic acid Chemical compound ClC1=CC(C(=O)CCC(=O)O)=CC=C1C1CCCCC1 IJTPQQVCKPZIMV-UHFFFAOYSA-N 0.000 description 1
- 229950005608 bucloxic acid Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
- 229960004111 buformin Drugs 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- 229950001167 butixocort Drugs 0.000 description 1
- HGBFRHCDYZJRAO-UHFFFAOYSA-N butizide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)NC(CC(C)C)NC2=C1 HGBFRHCDYZJRAO-UHFFFAOYSA-N 0.000 description 1
- 229950008955 butizide Drugs 0.000 description 1
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 1
- 229940022418 caduet Drugs 0.000 description 1
- GVEZIHKRYBHEFX-UHFFFAOYSA-N caerulein A Natural products CC=CCC=CCCC(=O)C1OC1C(N)=O GVEZIHKRYBHEFX-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940095498 calcium polycarbophil Drugs 0.000 description 1
- CUZMQPZYCDIHQL-VCTVXEGHSA-L calcium;(2s)-1-[(2s)-3-[(2r)-2-(cyclohexanecarbonylamino)propanoyl]sulfanyl-2-methylpropanoyl]pyrrolidine-2-carboxylate Chemical compound [Ca+2].N([C@H](C)C(=O)SC[C@@H](C)C(=O)N1[C@@H](CCC1)C([O-])=O)C(=O)C1CCCCC1.N([C@H](C)C(=O)SC[C@@H](C)C(=O)N1[C@@H](CCC1)C([O-])=O)C(=O)C1CCCCC1 CUZMQPZYCDIHQL-VCTVXEGHSA-L 0.000 description 1
- 229950001261 camiglibose Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- KVLLHLWBPNCVNR-SKCUWOTOSA-N capromorelin Chemical compound C([C@@]12CN(CCC1=NN(C2=O)C)C(=O)[C@@H](COCC=1C=CC=CC=1)NC(=O)C(C)(C)N)C1=CC=CC=C1 KVLLHLWBPNCVNR-SKCUWOTOSA-N 0.000 description 1
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 229950009114 carbazeran Drugs 0.000 description 1
- QTAOMKOIBXZKND-PPHPATTJSA-N carbidopa Chemical compound O.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 QTAOMKOIBXZKND-PPHPATTJSA-N 0.000 description 1
- 229960004205 carbidopa Drugs 0.000 description 1
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 description 1
- 229960000428 carbinoxamine Drugs 0.000 description 1
- 229960005003 carbocromen Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 208000022033 carcinoma of urethra Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- XGHOVGYJHWQGCC-UHFFFAOYSA-N carebastine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 XGHOVGYJHWQGCC-UHFFFAOYSA-N 0.000 description 1
- 229950010123 carebastine Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- KYCBWEZLKCTALM-UHFFFAOYSA-N caroxazone Chemical compound C1=CC=C2OC(=O)N(CC(=O)N)CC2=C1 KYCBWEZLKCTALM-UHFFFAOYSA-N 0.000 description 1
- 229950006044 caroxazone Drugs 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 229960001222 carteolol Drugs 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- 229960002165 carteolol hydrochloride Drugs 0.000 description 1
- XGGTZCKQRWXCHW-WMTVXVAQSA-N casopitant Chemical compound C1([C@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)N2CCN(CC2)C(C)=O)=CC=C(F)C=C1C XGGTZCKQRWXCHW-WMTVXVAQSA-N 0.000 description 1
- 229940063628 catapres Drugs 0.000 description 1
- SNBUBQHDYVFSQF-HIFRSBDPSA-N cefmetazole Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSCC#N)OC)CC=1CSC1=NN=NN1C SNBUBQHDYVFSQF-HIFRSBDPSA-N 0.000 description 1
- 229960003585 cefmetazole Drugs 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 241000902900 cellular organisms Species 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- GVEZIHKRYBHEFX-NQQPLRFYSA-N cerulenin Chemical compound C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O GVEZIHKRYBHEFX-NQQPLRFYSA-N 0.000 description 1
- 229950005984 cerulenin Drugs 0.000 description 1
- MVCQKIKWYUURMU-UHFFFAOYSA-N cetilistat Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCCCC)=NC2=C1 MVCQKIKWYUURMU-UHFFFAOYSA-N 0.000 description 1
- 229950002397 cetilistat Drugs 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- XRZYELWZLNAXGE-KPKJPENVSA-N chembl539947 Chemical compound CC(C)(C)C1=CC(\C=C(/C#N)C(N)=S)=CC(C(C)(C)C)=C1O XRZYELWZLNAXGE-KPKJPENVSA-N 0.000 description 1
- WRJDCGFHAICFLO-NXVVXOECSA-N chembl75797 Chemical compound C1=C(OC)C(OC)=CC=C1CC\N=C\1N(C)CCC/1 WRJDCGFHAICFLO-NXVVXOECSA-N 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical class ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229940107218 chromium Drugs 0.000 description 1
- 229950003775 cicloprolol Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229950009226 ciglitazone Drugs 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- RBNWAMSGVWEHFP-UHFFFAOYSA-N cis-p-Menthan-1,8-diol Natural products CC(C)(O)C1CCC(C)(O)CC1 RBNWAMSGVWEHFP-UHFFFAOYSA-N 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 229960001117 clenbuterol Drugs 0.000 description 1
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
- 229950010886 clidanac Drugs 0.000 description 1
- UCAIEVHKDLMIFL-UHFFFAOYSA-N clobenpropit Chemical compound C1=CC(Cl)=CC=C1CNC(=N)SCCCC1=CNC=N1 UCAIEVHKDLMIFL-UHFFFAOYSA-N 0.000 description 1
- HJKBJIYDJLVSAO-UHFFFAOYSA-L clodronic acid disodium salt Chemical compound [Na+].[Na+].OP([O-])(=O)C(Cl)(Cl)P(O)([O-])=O HJKBJIYDJLVSAO-UHFFFAOYSA-L 0.000 description 1
- TXCGAZHTZHNUAI-UHFFFAOYSA-N clofibric acid Chemical class OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 TXCGAZHTZHNUAI-UHFFFAOYSA-N 0.000 description 1
- 229950006376 clomoxir Drugs 0.000 description 1
- 229950004347 clonitrate Drugs 0.000 description 1
- 229940047766 co-trimoxazole Drugs 0.000 description 1
- 235000008957 cocaer Nutrition 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229940110933 combipres Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- JGBBVDFNZSRLIF-UHFFFAOYSA-N conivaptan Chemical compound C12=CC=CC=C2C=2[N]C(C)=NC=2CCN1C(=O)C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1C1=CC=CC=C1 JGBBVDFNZSRLIF-UHFFFAOYSA-N 0.000 description 1
- 229960000562 conivaptan Drugs 0.000 description 1
- 229940108924 conjugated linoleic acid Drugs 0.000 description 1
- 108050003126 conotoxin Proteins 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000003179 convulsant agent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 229940069210 coreg Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229940041967 corticotropin-releasing hormone Drugs 0.000 description 1
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 1
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical class C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229950002213 cyclazocine Drugs 0.000 description 1
- ORQXBVXKBGUSBA-UHFFFAOYSA-N cyclohexyl D-alanine Natural products OC(=O)C(N)CC1CCCCC1 ORQXBVXKBGUSBA-UHFFFAOYSA-N 0.000 description 1
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
- SLQAVEDMASVHTL-VXGBXAGGSA-N cyclohexylmethyl n-[(1r,2r)-2-(1h-imidazol-5-yl)cyclopropyl]carbamate Chemical compound C1([C@@H]2C[C@H]2NC(=O)OCC2CCCCC2)=CN=CN1 SLQAVEDMASVHTL-VXGBXAGGSA-N 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- PWOQRKCAHTVFLB-UHFFFAOYSA-N cyclophosphamide hydrate Chemical compound O.ClCCN(CCCl)P1(=O)NCCCO1 PWOQRKCAHTVFLB-UHFFFAOYSA-N 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 229950006689 darglitazone Drugs 0.000 description 1
- 229960003109 daunorubicin hydrochloride Drugs 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- ORDAZKGHSNRHTD-UXHICEINSA-N deguelin Chemical compound O1C(C)(C)C=CC2=C1C=CC1=C2O[C@@H]2COC(C=C(C(=C3)OC)OC)=C3[C@@H]2C1=O ORDAZKGHSNRHTD-UXHICEINSA-N 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- DLVJMFOLJOOWFS-INMLLLKOSA-N depudecin Chemical compound C[C@@H](O)[C@@H]1O[C@H]1\C=C\[C@H]1[C@H]([C@H](O)C=C)O1 DLVJMFOLJOOWFS-INMLLLKOSA-N 0.000 description 1
- BADQRNHAZHSOKC-UHFFFAOYSA-N deriglidole Chemical compound C1C(C2=3)=CC=CC=3CCN2C1(CCC)C1=NCCN1 BADQRNHAZHSOKC-UHFFFAOYSA-N 0.000 description 1
- 229950011527 deriglidole Drugs 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 229960001271 desloratadine Drugs 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 229940099340 desoxyn Drugs 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- SOYKEARSMXGVTM-HNNXBMFYSA-N dexchlorpheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 SOYKEARSMXGVTM-HNNXBMFYSA-N 0.000 description 1
- 229960001882 dexchlorpheniramine Drugs 0.000 description 1
- 229940099242 dexedrine Drugs 0.000 description 1
- 229960004597 dexfenfluramine Drugs 0.000 description 1
- QNQZBKQEIFTHFZ-GOSISDBHSA-N dexloxiglumide Chemical compound CCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)C1=CC=C(Cl)C(Cl)=C1 QNQZBKQEIFTHFZ-GOSISDBHSA-N 0.000 description 1
- 229950010525 dexloxiglumide Drugs 0.000 description 1
- 229950008954 dexpropranolol Drugs 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 229940028367 dhe-45 Drugs 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 229940089126 diabeta Drugs 0.000 description 1
- 150000001470 diamides Chemical class 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- GUBNMFJOJGDCEL-UHFFFAOYSA-N dicyclomine hydrochloride Chemical compound [Cl-].C1CCCCC1C1(C(=O)OCC[NH+](CC)CC)CCCCC1 GUBNMFJOJGDCEL-UHFFFAOYSA-N 0.000 description 1
- 229940120144 didrex Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- VMZCXIGDNRMWGI-GEEYTBSJSA-N diethyl 2-[(dimethylamino)methyl]-6-methyl-4-[2-[(e)-3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]phenyl]-1,4-dihydropyridine-3,5-dicarboxylate;hydrochloride Chemical compound Cl.CCOC(=O)C1=C(C)NC(CN(C)C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C VMZCXIGDNRMWGI-GEEYTBSJSA-N 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- ICFXZZFWRWNZMA-UHFFFAOYSA-N diethylpropion hydrochloride Chemical compound [Cl-].CC[NH+](CC)C(C)C(=O)C1=CC=CC=C1 ICFXZZFWRWNZMA-UHFFFAOYSA-N 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229960005316 diltiazem hydrochloride Drugs 0.000 description 1
- MVMQESMQSYOVGV-UHFFFAOYSA-N dimetindene Chemical compound CN(C)CCC=1CC2=CC=CC=C2C=1C(C)C1=CC=CC=N1 MVMQESMQSYOVGV-UHFFFAOYSA-N 0.000 description 1
- 229960001992 dimetindene Drugs 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- OWQUZNMMYNAXSL-UHFFFAOYSA-N diphenylpyraline Chemical compound C1CN(C)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 OWQUZNMMYNAXSL-UHFFFAOYSA-N 0.000 description 1
- 229960000879 diphenylpyraline Drugs 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940075933 dithionate Drugs 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- 108010045552 dolastatin 15 Proteins 0.000 description 1
- 108010067396 dornase alfa Proteins 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
- HALQELOKLVRWRI-VDBOFHIQSA-N doxycycline hyclate Chemical compound O.[Cl-].[Cl-].CCO.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O HALQELOKLVRWRI-VDBOFHIQSA-N 0.000 description 1
- 229960001172 doxycycline hyclate Drugs 0.000 description 1
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 1
- 229960005178 doxylamine Drugs 0.000 description 1
- HTAFVGKAHGNWQO-UHFFFAOYSA-N droprenilamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCNC(C)CC1CCCCC1 HTAFVGKAHGNWQO-UHFFFAOYSA-N 0.000 description 1
- 229950011072 droprenilamine Drugs 0.000 description 1
- 206010060865 duodenogastric reflux Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 1
- 229960001971 ebastine Drugs 0.000 description 1
- 229950003420 efletirizine Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229950000269 emiglitate Drugs 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- 239000008144 emollient laxative Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 108010015205 endomorphin 1 Proteins 0.000 description 1
- 108010015198 endomorphin 2 Proteins 0.000 description 1
- XIJHWXXXIMEHKW-LJWNLINESA-N endomorphin-2 Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=C(O)C=C1 XIJHWXXXIMEHKW-LJWNLINESA-N 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 229950002375 englitazone Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- QVDKSPUZWYTNQA-UHFFFAOYSA-N enprofylline Chemical compound O=C1NC(=O)N(CCC)C2=NC=N[C]21 QVDKSPUZWYTNQA-UHFFFAOYSA-N 0.000 description 1
- 229950000579 enprofylline Drugs 0.000 description 1
- 229940028816 entereg Drugs 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 229960003449 epinastine Drugs 0.000 description 1
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 1
- 229960003157 epinephrine bitartrate Drugs 0.000 description 1
- 230000008556 epithelial cell proliferation Effects 0.000 description 1
- 229960005450 eritrityl tetranitrate Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229960003745 esmolol Drugs 0.000 description 1
- 229960001015 esmolol hydrochloride Drugs 0.000 description 1
- 230000010856 establishment of protein localization Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- CHDGAVDQRSPBTA-UHFFFAOYSA-N esuprone Chemical compound CC1=C(C)C(=O)OC2=CC(OS(=O)(=O)CC)=CC=C21 CHDGAVDQRSPBTA-UHFFFAOYSA-N 0.000 description 1
- 229950007673 esuprone Drugs 0.000 description 1
- OPQRBXUBWHDHPQ-UHFFFAOYSA-N etazolate Chemical compound CCOC(=O)C1=CN=C2N(CC)N=CC2=C1NN=C(C)C OPQRBXUBWHDHPQ-UHFFFAOYSA-N 0.000 description 1
- 229950009329 etazolate Drugs 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- NWWORXYTJRPSMC-QKPAOTATSA-N ethyl 4-[2-[(2r,3r,4r,5s)-3,4,5-trihydroxy-2-(hydroxymethyl)piperidin-1-yl]ethoxy]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1OCCN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1 NWWORXYTJRPSMC-QKPAOTATSA-N 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229950000331 ezlopitant Drugs 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- ZZCHHVUQYRMYLW-HKBQPEDESA-N farglitazar Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCC=1N=C(OC=1C)C=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 ZZCHHVUQYRMYLW-HKBQPEDESA-N 0.000 description 1
- 229950003707 farglitazar Drugs 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000006275 fascioliasis Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- RZTAMFZIAATZDJ-UHFFFAOYSA-N felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 description 1
- IDKAXRLETRCXKS-UHFFFAOYSA-N fenclofenac Chemical compound OC(=O)CC1=CC=CC=C1OC1=CC=C(Cl)C=C1Cl IDKAXRLETRCXKS-UHFFFAOYSA-N 0.000 description 1
- 229950006236 fenclofenac Drugs 0.000 description 1
- 229950011481 fenclozic acid Drugs 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229960000695 fenspiride hydrochloride Drugs 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 229960002679 fentiazac Drugs 0.000 description 1
- 229960000489 feprazone Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960005355 fluocortin Drugs 0.000 description 1
- XWTIDFOGTCVGQB-FHIVUSPVSA-N fluocortin butyl Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)C(=O)OCCCC)[C@@]2(C)C[C@@H]1O XWTIDFOGTCVGQB-FHIVUSPVSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- XSOUHEXVEOQRKJ-IUCAKERBSA-N fluparoxan Chemical compound O1[C@H]2CNC[C@@H]2OC2=C1C=CC=C2F XSOUHEXVEOQRKJ-IUCAKERBSA-N 0.000 description 1
- 229950006702 fluparoxan Drugs 0.000 description 1
- 229950001284 fluprofen Drugs 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- OATDVDIMNNZTEY-DAXLTYESSA-N flutropium Chemical compound C[N@@+]1(CCF)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1 OATDVDIMNNZTEY-DAXLTYESSA-N 0.000 description 1
- 229950005583 flutropium Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 229960001880 fosinopril sodium Drugs 0.000 description 1
- 229950006562 fostedil Drugs 0.000 description 1
- 108010028490 frakefamide Proteins 0.000 description 1
- 229950001535 frakefamide Drugs 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229950010931 furofenac Drugs 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 208000001288 gastroparesis Diseases 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229950004153 gliamilide Drugs 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 229960003468 gliquidone Drugs 0.000 description 1
- NSJYMFYVNWVGON-UHFFFAOYSA-N glisentide Chemical compound COC1=CC=CC=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCC2)C=C1 NSJYMFYVNWVGON-UHFFFAOYSA-N 0.000 description 1
- 229950008402 glisentide Drugs 0.000 description 1
- GZKDXUIWCNCNBJ-UHFFFAOYSA-N glisolamide Chemical compound O1C(C)=CC(C(=O)NCCC=2C=CC(=CC=2)S(=O)(=O)NC(=O)NC2CCCCC2)=N1 GZKDXUIWCNCNBJ-UHFFFAOYSA-N 0.000 description 1
- 229950005319 glisolamide Drugs 0.000 description 1
- 108010063245 glucagon-like peptide 1 (7-36)amide Proteins 0.000 description 1
- 208000026352 glucocorticoid resistance Diseases 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229940088991 glucotrol Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 150000002308 glutamine derivatives Chemical class 0.000 description 1
- 125000003745 glyceroyl group Chemical group C(C(O)CO)(=O)* 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000003572 glycogen synthase kinase 3 inhibitor Substances 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229940084937 glyset Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960004746 guanfacine hydrochloride Drugs 0.000 description 1
- 230000003694 hair properties Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- FVMMOSQBOWPRQW-UHFFFAOYSA-N heterophylline Natural products CC(=O)OC1C2(C)C(OC(=O)C=3C=CC=CC=3)CC(C(O3)(C)C)C(OC(=O)C=4C=NC=CC=4)C32C(C)CC1OC(=O)C1=CC=CN=C1 FVMMOSQBOWPRQW-UHFFFAOYSA-N 0.000 description 1
- 108091006093 heterotrimeric G proteins Proteins 0.000 description 1
- 102000034345 heterotrimeric G proteins Human genes 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical class CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 108010070965 hexarelin Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 229940088013 hycamtin Drugs 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000004093 hydrolase inhibitor Substances 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- NYQCKFLLTCINSJ-UHFFFAOYSA-N hydron;3-[4-(pyridin-4-ylamino)phenyl]-4,5-dihydro-1h-pyridazin-6-one;chloride Chemical compound Cl.N1C(=O)CCC(C=2C=CC(NC=3C=CN=CC=3)=CC=2)=N1 NYQCKFLLTCINSJ-UHFFFAOYSA-N 0.000 description 1
- TWXDDNPPQUTEOV-UHFFFAOYSA-N hydron;n-methyl-1-phenylpropan-2-amine;chloride Chemical compound Cl.CNC(C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-UHFFFAOYSA-N 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 229930005342 hyoscyamine Natural products 0.000 description 1
- 229960003210 hyoscyamine Drugs 0.000 description 1
- IWBJJCOKGLUQIZ-HQKKAZOISA-N hyperforin Chemical compound OC1=C(CC=C(C)C)C(=O)[C@@]2(CC=C(C)C)C[C@H](CC=C(C)C)[C@](CCC=C(C)C)(C)[C@]1(C(=O)C(C)C)C2=O IWBJJCOKGLUQIZ-HQKKAZOISA-N 0.000 description 1
- MPGWGYQTRSNGDD-UHFFFAOYSA-N hypericin Chemical compound OC1=CC(O)=C(C2=O)C3=C1C1C(O)=CC(=O)C(C4=O)=C1C1=C3C3=C2C(O)=CC(C)=C3C2=C1C4=C(O)C=C2C MPGWGYQTRSNGDD-UHFFFAOYSA-N 0.000 description 1
- 229940005608 hypericin Drugs 0.000 description 1
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 229940090022 hyzaar Drugs 0.000 description 1
- CYWFCPPBTWOZSF-UHFFFAOYSA-N ibufenac Chemical compound CC(C)CC1=CC=C(CC(O)=O)C=C1 CYWFCPPBTWOZSF-UHFFFAOYSA-N 0.000 description 1
- 229950009183 ibufenac Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960001176 idarubicin hydrochloride Drugs 0.000 description 1
- HPMRFMKYPGXPEP-UHFFFAOYSA-N idazoxan Chemical compound N1CCN=C1C1OC2=CC=CC=C2OC1 HPMRFMKYPGXPEP-UHFFFAOYSA-N 0.000 description 1
- 229950001476 idazoxan Drugs 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229950009810 indolapril Drugs 0.000 description 1
- 229960004187 indoprofen Drugs 0.000 description 1
- 229960002056 indoramin Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 229960003948 insulin detemir Drugs 0.000 description 1
- 229960002869 insulin glargine Drugs 0.000 description 1
- 229960002068 insulin lispro Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000001153 interneuron Anatomy 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 229960001178 iodinated glycerol Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229940036543 ionamin Drugs 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 229950000831 iralukast Drugs 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- MDXYQVPFSHFPHS-CVYXXLPWSA-N irp peptide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C(C)C)NC(=O)[C@H](CCC(=O)OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)OC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)NC(=O)[C@@H](N)CCCCN)C1=CC=CC=C1 MDXYQVPFSHFPHS-CVYXXLPWSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 229950011269 isaglidole Drugs 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 229940072673 ismo Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960001268 isoetarine Drugs 0.000 description 1
- 150000002518 isoindoles Chemical class 0.000 description 1
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- KVMMIDQDXZOPAB-UHFFFAOYSA-N isoquinoline-3-carboxylic acid Chemical class C1=CC=C2C=NC(C(=O)O)=CC2=C1 KVMMIDQDXZOPAB-UHFFFAOYSA-N 0.000 description 1
- 229940093268 isordil Drugs 0.000 description 1
- QFGMXJOBTNZHEL-UHFFFAOYSA-N isoxepac Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC(CC(=O)O)=CC=C21 QFGMXJOBTNZHEL-UHFFFAOYSA-N 0.000 description 1
- 229950011455 isoxepac Drugs 0.000 description 1
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 1
- 229950002252 isoxicam Drugs 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 229940057594 isuprel Drugs 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 150000002561 ketenes Chemical class 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229950005862 lazabemide Drugs 0.000 description 1
- 229950001530 lemildipine Drugs 0.000 description 1
- 229960004294 lercanidipine Drugs 0.000 description 1
- ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 229940089520 levbid Drugs 0.000 description 1
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 description 1
- 229960000831 levobunolol Drugs 0.000 description 1
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
- DNTDOBSIBZKFCP-YDALLXLXSA-N levobunolol hydrochloride Chemical compound [Cl-].O=C1CCCC2=C1C=CC=C2OC[C@@H](O)C[NH2+]C(C)(C)C DNTDOBSIBZKFCP-YDALLXLXSA-N 0.000 description 1
- ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 description 1
- 229960001120 levocabastine Drugs 0.000 description 1
- 229960001518 levocarnitine Drugs 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229950008325 levothyroxine Drugs 0.000 description 1
- YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 description 1
- 229960001941 lidoflazine Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229950004872 linogliride Drugs 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 229950008874 lirexapride Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229940089504 lopressor Drugs 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 210000004937 luminal membrane Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000001592 luteinising effect Effects 0.000 description 1
- 108010077127 lymphoguanylin Proteins 0.000 description 1
- 150000002689 maleic acids Chemical class 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229960003963 manidipine Drugs 0.000 description 1
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 1
- 229960000299 mazindol Drugs 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000336 melanocortin receptor agonist Substances 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229960005042 mequitazine Drugs 0.000 description 1
- 229940045623 meridia Drugs 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-M mesalaminate(1-) Chemical compound NC1=CC=C(O)C(C([O-])=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-M 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960004329 metformin hydrochloride Drugs 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical class CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 229960004269 methoxamine hydrochloride Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- QVFVAKQHELFATN-UHFFFAOYSA-N methyl 2-[[4-butyl-2-methyl-6-oxo-5-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]pyrimidin-1-yl]methyl]thiophene-3-carboxylate Chemical compound O=C1C(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C2=NNN=N2)=C(CCCC)N=C(C)N1CC=1SC=CC=1C(=O)OC QVFVAKQHELFATN-UHFFFAOYSA-N 0.000 description 1
- CMUHZRATLMUDJI-UHFFFAOYSA-N methyl 2h-pyridine-1-carboxylate Chemical compound COC(=O)N1CC=CC=C1 CMUHZRATLMUDJI-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 229960002921 methylnaltrexone Drugs 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 description 1
- 229960002817 metolazone Drugs 0.000 description 1
- 229960001300 metoprolol tartrate Drugs 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 229960004438 mibefradil Drugs 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- 229950001332 midaglizole Drugs 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 229950000928 milacemide Drugs 0.000 description 1
- 229950003561 milfasartan Drugs 0.000 description 1
- 229960000600 milnacipran Drugs 0.000 description 1
- 229960003574 milrinone Drugs 0.000 description 1
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940064639 minipress Drugs 0.000 description 1
- 229940060946 miralax Drugs 0.000 description 1
- 229950006616 miroprofen Drugs 0.000 description 1
- OJGQFYYLKNCIJD-UHFFFAOYSA-N miroprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CN(C=CC=C2)C2=N1 OJGQFYYLKNCIJD-UHFFFAOYSA-N 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 229960003365 mitiglinide Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229950005607 mixidine Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960001144 mizolastine Drugs 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- 229960005285 mofebutazone Drugs 0.000 description 1
- REOJLIXKJWXUGB-UHFFFAOYSA-N mofebutazone Chemical compound O=C1C(CCCC)C(=O)NN1C1=CC=CC=C1 REOJLIXKJWXUGB-UHFFFAOYSA-N 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 1
- 229940118178 monopril Drugs 0.000 description 1
- LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 description 1
- 229960001951 montelukast sodium Drugs 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229960004085 mosapride Drugs 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CVABPTLRAQIZJU-UHFFFAOYSA-N n'-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-n-(oxan-4-yl)ethane-1,2-diamine Chemical compound ClC1=CC(OC)=CC(Cl)=C1C1=C2N=C(C)C=C(NCCNC3CCOCC3)N2N=C1C CVABPTLRAQIZJU-UHFFFAOYSA-N 0.000 description 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 1
- YVQXNYOBSUPZMH-UHFFFAOYSA-N n-(2,4-diaminoquinazolin-6-yl)-n-[(3,4-dichlorophenyl)methyl]nitrous amide Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1N(N=O)CC1=CC=C(Cl)C(Cl)=C1 YVQXNYOBSUPZMH-UHFFFAOYSA-N 0.000 description 1
- RJNSNFZXAZXOFX-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide;hydron;dichloride Chemical compound Cl.Cl.COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 RJNSNFZXAZXOFX-UHFFFAOYSA-N 0.000 description 1
- JZXRLKWWVNUZRB-UHFFFAOYSA-N n-(2-aminoethyl)-5-chloropyridine-2-carboxamide Chemical compound NCCNC(=O)C1=CC=C(Cl)C=N1 JZXRLKWWVNUZRB-UHFFFAOYSA-N 0.000 description 1
- ZLVARELBORDLAV-UHFFFAOYSA-N n-(4,5-dihydro-1h-imidazol-2-yl)-4-fluoro-1,3-dihydroisoindol-2-amine Chemical compound C1C=2C(F)=CC=CC=2CN1NC1=NCCN1 ZLVARELBORDLAV-UHFFFAOYSA-N 0.000 description 1
- AFOFVIBWSLOHFR-GOOCMWNKSA-N n-[(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-2-oxo-3-propan-2-ylbenzimidazole-1-carboxamide Chemical compound C1[C@@H](N2C)CC[C@@H]2CC1NC(=O)N1C2=CC=CC=C2N(C(C)C)C1=O AFOFVIBWSLOHFR-GOOCMWNKSA-N 0.000 description 1
- WRJDCGFHAICFLO-UHFFFAOYSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]-1-methylpyrrolidin-2-imine Chemical compound C1=C(OC)C(OC)=CC=C1CCN=C1N(C)CCC1 WRJDCGFHAICFLO-UHFFFAOYSA-N 0.000 description 1
- MQQJZPWSYVPWPF-QYZOEREBSA-N n-[2-[1-[[(1r,4r,5r)-5-bicyclo[2.2.1]hept-2-enyl]methylcarbamoylsulfamoyl]piperidin-4-yl]ethyl]-2-methoxypyridine-3-carboxamide Chemical compound COC1=NC=CC=C1C(=O)NCCC1CCN(S(=O)(=O)NC(=O)NC[C@H]2[C@@H]3C[C@@H](C=C3)C2)CC1 MQQJZPWSYVPWPF-QYZOEREBSA-N 0.000 description 1
- OMGYZLAJZAMSKO-UHFFFAOYSA-N n-[4-[1-hydroxy-2-(methylamino)propyl]phenyl]methanesulfonamide;hydrochloride Chemical compound Cl.CNC(C)C(O)C1=CC=C(NS(C)(=O)=O)C=C1 OMGYZLAJZAMSKO-UHFFFAOYSA-N 0.000 description 1
- UHANVDZCDNSILX-UHFFFAOYSA-N n-phenylbutanamide Chemical compound CCCC(=O)NC1=CC=CC=C1 UHANVDZCDNSILX-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- AJPSBXJNFJCCBI-YOHUGVJRSA-N naloxonazine Chemical compound C([C@@H](N(CC1)CC=C)[C@]2(O)CC\C3=N/N=C4/[C@H]5[C@]67CCN(CC=C)[C@@H]([C@@]7(CC4)O)CC4=CC=C(C(O5)=C46)O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 AJPSBXJNFJCCBI-YOHUGVJRSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- 239000008239 natural water Substances 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229960002497 nicorandil Drugs 0.000 description 1
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 description 1
- 229960000916 niflumic acid Drugs 0.000 description 1
- 229960005366 nilvadipine Drugs 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- UIAGMCDKSXEBJQ-UHFFFAOYSA-N nimodipine Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-UHFFFAOYSA-N 0.000 description 1
- 229940072101 nimotop Drugs 0.000 description 1
- 229950011565 nitraquazone Drugs 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- 229940073015 nitrostat Drugs 0.000 description 1
- 229950009470 noberastine Drugs 0.000 description 1
- 229950006344 nocodazole Drugs 0.000 description 1
- 229960001073 nomifensine Drugs 0.000 description 1
- XXPANQJNYNUNES-UHFFFAOYSA-N nomifensine Chemical compound C12=CC=CC(N)=C2CN(C)CC1C1=CC=CC=C1 XXPANQJNYNUNES-UHFFFAOYSA-N 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 229940036132 norvasc Drugs 0.000 description 1
- 229940112878 nulev Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
- 229960004110 olsalazine Drugs 0.000 description 1
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 1
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 229940100654 ophthalmic suspension Drugs 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 208000020717 oral cavity carcinoma Diseases 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229950009875 osanetant Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229960001834 oxprenolol hydrochloride Drugs 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 125000005704 oxymethylene group Chemical group [H]C([H])([*:2])O[*:1] 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- CNDQSXOVEQXJOE-UHFFFAOYSA-N oxyphenbutazone hydrate Chemical compound O.O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 CNDQSXOVEQXJOE-UHFFFAOYSA-N 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229930006948 p-menthane-3,8-diol Natural products 0.000 description 1
- 229940096689 pacerone Drugs 0.000 description 1
- 229940124707 pain therapeutics Drugs 0.000 description 1
- 229940023569 palmate Drugs 0.000 description 1
- 230000026792 palmitoylation Effects 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical class C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229960003207 papaverine hydrochloride Drugs 0.000 description 1
- 235000006502 papoula Nutrition 0.000 description 1
- TVIDEEHSOPHZBR-AWEZNQCLSA-N para-(benzoyl)-phenylalanine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1C(=O)C1=CC=CC=C1 TVIDEEHSOPHZBR-AWEZNQCLSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 108700027320 pegylated leptin Proteins 0.000 description 1
- 229960002035 penbutolol Drugs 0.000 description 1
- KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 1
- 229960004493 penbutolol sulfate Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940072223 pentasa Drugs 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 229960004803 perhexiline maleate Drugs 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- IYNMDWMQHSMDDE-MHXJNQAMSA-N perindopril erbumine Chemical compound CC(C)(C)N.C1CCC[C@@H]2N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H](C(O)=O)C[C@@H]21 IYNMDWMQHSMDDE-MHXJNQAMSA-N 0.000 description 1
- 201000006727 periodontosis Diseases 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- LQJARUQXWJSDFL-UHFFFAOYSA-N phenamine Chemical compound CCOC1=CC=C(NC(=O)CN)C=C1 LQJARUQXWJSDFL-UHFFFAOYSA-N 0.000 description 1
- 229950010879 phenamine Drugs 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- GJSGGHOYGKMUPT-UHFFFAOYSA-N phenoxathiine Chemical compound C1=CC=C2OC3=CC=CC=C3SC2=C1 GJSGGHOYGKMUPT-UHFFFAOYSA-N 0.000 description 1
- 229950010364 phenpromethamine Drugs 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000002993 phenylalanine derivatives Chemical class 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- XHTJLMYQJHCUPE-UHFFFAOYSA-N phosphanylphosphonic acid Chemical compound OP(O)(P)=O XHTJLMYQJHCUPE-UHFFFAOYSA-N 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 238000007699 photoisomerization reaction Methods 0.000 description 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 1
- HAGVCKULCLQGRF-UHFFFAOYSA-N pifithrin Chemical compound [Br-].C1=CC(C)=CC=C1C(=O)CN1[C+](N)SC2=C1CCCC2 HAGVCKULCLQGRF-UHFFFAOYSA-N 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229960005414 pirbuterol Drugs 0.000 description 1
- 229950002220 pirlindole Drugs 0.000 description 1
- 229960000851 pirprofen Drugs 0.000 description 1
- PIDSZXPFGCURGN-UHFFFAOYSA-N pirprofen Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1N1CC=CC1 PIDSZXPFGCURGN-UHFFFAOYSA-N 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 229950008688 pivopril Drugs 0.000 description 1
- 229940090013 plendil Drugs 0.000 description 1
- 229950011515 pobilukast Drugs 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 150000004032 porphyrins Chemical group 0.000 description 1
- 229960003611 pramlintide Drugs 0.000 description 1
- 229960004457 pramlintide acetate Drugs 0.000 description 1
- KCTFTBCZZUBAKN-UHFFFAOYSA-N pratosartan Chemical compound CCCC1=NC=2CCCCC(=O)C=2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 KCTFTBCZZUBAKN-UHFFFAOYSA-N 0.000 description 1
- 229950005649 pratosartan Drugs 0.000 description 1
- WFXFYZULCQKPIP-UHFFFAOYSA-N prazosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 WFXFYZULCQKPIP-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229940095885 precose Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960001989 prenylamine Drugs 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 229940117282 primatene Drugs 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- CSIGAEASXSGNKS-UHFFFAOYSA-N propane-1,1,3-triol Chemical compound OCCC(O)O CSIGAEASXSGNKS-UHFFFAOYSA-N 0.000 description 1
- 229960003402 propatylnitrate Drugs 0.000 description 1
- YZZCJYJBCUJISI-UHFFFAOYSA-N propatylnitrate Chemical compound [O-][N+](=O)OCC(CC)(CO[N+]([O-])=O)CO[N+]([O-])=O YZZCJYJBCUJISI-UHFFFAOYSA-N 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical class CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960004604 propranolol hydrochloride Drugs 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N propyl acetate Chemical compound CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- 229950006734 proroxan Drugs 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 229940063566 proventil Drugs 0.000 description 1
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 229940107568 pulmozyme Drugs 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- RDRCCJPEJDWSRJ-UHFFFAOYSA-N pyridine;1h-pyrrole Chemical compound C=1C=CNC=1.C1=CC=NC=C1 RDRCCJPEJDWSRJ-UHFFFAOYSA-N 0.000 description 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
- XVIAPHVAGFEFFN-UHFFFAOYSA-N pyrimidine-5-carbonitrile Chemical compound N#CC1=CN=CN=C1 XVIAPHVAGFEFFN-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- AGMMTXLNIQSRCG-UHFFFAOYSA-N quinethazone Chemical compound NS(=O)(=O)C1=C(Cl)C=C2NC(CC)NC(=O)C2=C1 AGMMTXLNIQSRCG-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- ZLQMRLSBXKQKMG-UHFFFAOYSA-N rauniticine Natural products COC(=O)C1=CC2CC3N(CCc4c3[nH]c5ccccc45)CC2C(C)O1 ZLQMRLSBXKQKMG-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- BSHDUMDXSRLRBI-JOYOIKCWSA-N rentiapril Chemical compound SCCC(=O)N1[C@H](C(=O)O)CS[C@@H]1C1=CC=CC=C1O BSHDUMDXSRLRBI-JOYOIKCWSA-N 0.000 description 1
- 229950010098 rentiapril Drugs 0.000 description 1
- GZSKEXSLDPEFPT-IINYFYTJSA-N renzapride Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)N[C@H]1[C@H](C2)CCC[N@]2CC1 GZSKEXSLDPEFPT-IINYFYTJSA-N 0.000 description 1
- 229950003039 renzapride Drugs 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 229960002720 reproterol Drugs 0.000 description 1
- WVLAAKXASPCBGT-UHFFFAOYSA-N reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 235000020945 retinal Nutrition 0.000 description 1
- 239000011604 retinal Substances 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229940116238 revex Drugs 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229940043267 rhodamine b Drugs 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 150000008223 ribosides Chemical class 0.000 description 1
- 229960000885 rifabutin Drugs 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 229960000888 rimantadine Drugs 0.000 description 1
- 229960001457 rimiterol Drugs 0.000 description 1
- IYMMESGOJVNCKV-SKDRFNHKSA-N rimiterol Chemical compound C([C@@H]1[C@@H](O)C=2C=C(O)C(O)=CC=2)CCCN1 IYMMESGOJVNCKV-SKDRFNHKSA-N 0.000 description 1
- 229950005803 rispenzepine Drugs 0.000 description 1
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 229940127100 salmeterol-fluticasone Drugs 0.000 description 1
- 235000015598 salt intake Nutrition 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229950004387 saredutant Drugs 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 201000009881 secretory diarrhea Diseases 0.000 description 1
- 229940082552 sectral Drugs 0.000 description 1
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 1
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- FTKTZRKAVSDSRA-UHFFFAOYSA-N sercloremine Chemical compound C1CN(C)CCC1C1=CC2=CC(Cl)=CC=C2O1 FTKTZRKAVSDSRA-UHFFFAOYSA-N 0.000 description 1
- 150000003355 serines Chemical class 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000003523 serotonin 4 antagonist Substances 0.000 description 1
- 239000002868 serotonin 5-HT1 receptor antagonist Substances 0.000 description 1
- 239000003478 serotonin 5-HT2 receptor agonist Substances 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 239000000387 serotonin 5-HT4 receptor agonist Substances 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 238000005029 sieve analysis Methods 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- IZPNTDOWOBGHEG-UHFFFAOYSA-M sodium benzene formate Chemical compound [Na+].[O-]C=O.C1=CC=CC=C1 IZPNTDOWOBGHEG-UHFFFAOYSA-M 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 1
- XBUIKNRVGYFSHL-IAVQPKKASA-M sodium;[(1e,3r,4r,6r,7z,9z,11e)-3,6,13-trihydroxy-3-methyl-1-[(2r)-6-oxo-2,3-dihydropyran-2-yl]trideca-1,7,9,11-tetraen-4-yl] hydrogen phosphate Chemical compound [Na+].OC/C=C/C=C\C=C/[C@H](O)C[C@@H](OP(O)([O-])=O)[C@@](O)(C)\C=C\[C@H]1CC=CC(=O)O1 XBUIKNRVGYFSHL-IAVQPKKASA-M 0.000 description 1
- 238000003746 solid phase reaction Methods 0.000 description 1
- 238000010671 solid-state reaction Methods 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 229960003579 sotalol hydrochloride Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 229940110862 starlix Drugs 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 229960005137 succinic acid Drugs 0.000 description 1
- 230000035322 succinylation Effects 0.000 description 1
- 238000010613 succinylation reaction Methods 0.000 description 1
- 229950005175 sudoxicam Drugs 0.000 description 1
- YRALAIOMGQZKOW-UHFFFAOYSA-N sulfated caerulein Natural products C=1C=CC=CC=1CC(C(N)=O)NC(=O)C(CC(O)=O)NC(=O)C(CCSC)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(C(C)O)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C1NC(=O)CC1)CC1=CC=C(OS(O)(=O)=O)C=C1 YRALAIOMGQZKOW-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 229940080796 surfaxin Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 229950011332 talnetant Drugs 0.000 description 1
- 229950002139 talsupram Drugs 0.000 description 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
- 229960003454 tamoxifen citrate Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 125000002456 taxol group Chemical group 0.000 description 1
- 229950005829 temelastine Drugs 0.000 description 1
- 229950001790 tendamistat Drugs 0.000 description 1
- 108010037401 tendamistate Proteins 0.000 description 1
- 229940065385 tenex Drugs 0.000 description 1
- 229940108485 tenormin Drugs 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 229940034887 tenuate Drugs 0.000 description 1
- 229950010186 teprotide Drugs 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- RBNWAMSGVWEHFP-WAAGHKOSSA-N terpin Chemical compound CC(C)(O)[C@H]1CC[C@@](C)(O)CC1 RBNWAMSGVWEHFP-WAAGHKOSSA-N 0.000 description 1
- 229950010257 terpin Drugs 0.000 description 1
- WUBVEMGCQRSBBT-UHFFFAOYSA-N tert-butyl 4-(trifluoromethylsulfonyloxy)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(=O)(=O)C(F)(F)F)=CC1 WUBVEMGCQRSBBT-UHFFFAOYSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- IXFPJGBNCFXKPI-FSIHEZPISA-N thapsigargin Chemical compound CCCC(=O)O[C@H]1C[C@](C)(OC(C)=O)[C@H]2[C@H](OC(=O)CCCCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]2OC(=O)[C@@](C)(O)[C@]21O IXFPJGBNCFXKPI-FSIHEZPISA-N 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 150000003556 thioamides Chemical class 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 229940015849 thiophene Drugs 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 229960001312 tiaprofenic acid Drugs 0.000 description 1
- 229960005221 timolol maleate Drugs 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical class N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- 229950002345 tiopinac Drugs 0.000 description 1
- 229950001669 tipredane Drugs 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-S tobramycin(5+) Chemical compound [NH3+][C@@H]1C[C@H](O)[C@@H](C[NH3+])O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H]([NH3+])[C@H](O)[C@@H](CO)O2)O)[C@H]([NH3+])C[C@@H]1[NH3+] NLVFBUXFDBBNBW-PBSUHMDJSA-S 0.000 description 1
- 229950003004 tolamolol Drugs 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- 229960002905 tolfenamic acid Drugs 0.000 description 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
- 229940035266 tolinase Drugs 0.000 description 1
- 229960002309 toloxatone Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229960002906 trimazosin Drugs 0.000 description 1
- YNZXWQJZEDLQEG-UHFFFAOYSA-N trimazosin Chemical compound N1=C2C(OC)=C(OC)C(OC)=CC2=C(N)N=C1N1CCN(C(=O)OCC(C)(C)O)CC1 YNZXWQJZEDLQEG-UHFFFAOYSA-N 0.000 description 1
- 229960003223 tripelennamine Drugs 0.000 description 1
- 229960001128 triprolidine Drugs 0.000 description 1
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 108010088854 urinastatin Proteins 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229940070384 ventolin Drugs 0.000 description 1
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 1
- 229960004982 vinblastine sulfate Drugs 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- 229960000744 vinpocetine Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 229950005485 vofopitant Drugs 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 229940002552 xenical Drugs 0.000 description 1
- 229950004681 zacopride Drugs 0.000 description 1
- 229940052204 zebeta Drugs 0.000 description 1
- 229950007802 zidometacin Drugs 0.000 description 1
- FIKYECRHLXONOX-UHFFFAOYSA-N zolasartan Chemical compound CCCCC1=NC(Cl)=C(C(O)=O)N1CC1=CC=C(OC(=C2Br)C=3C(=CC=CC=3)C3=NNN=N3)C2=C1 FIKYECRHLXONOX-UHFFFAOYSA-N 0.000 description 1
- 229950004433 zolasartan Drugs 0.000 description 1
- 229940061639 zonegran Drugs 0.000 description 1
- 229960002911 zonisamide Drugs 0.000 description 1
- 150000008494 α-glucosides Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明提供了制备鸟苷酸环化酶C激动剂的方法,具体地制备包含选自本文所述的SEQ ID NOs:1‑249的GCC激动剂序列的肽的方法。
Description
本申请是申请日为2012年3月1日的中国专利申请201280021221.6“制备鸟苷酸环化酶C 激动剂的方法”的分案申请。
相关申请
本申请要求2011年3月1日提交的美国临时申请号61/447,891(其内容整体通过引用并入)的权益和优先权。
技术领域
本发明涉及制备可用于治疗和预防各种疾病和病症的鸟苷酸环化酶C肽激动剂的方法。
背景技术
鸟苷酸环化酶C是鸟苷酸环化酶的跨膜形式,其表达在各种细胞包括胃肠道上皮细胞上(综述于Vaandrager 2002 Mol. Cell. Biochem. 230:73-83)。其最初作为由肠道细菌分泌且引起腹泻的热稳定毒素(ST)肽的肠道受体而被发现。ST肽与从肠粘膜和尿液中分离的两种肽鸟苷肽和尿鸟苷素(uroguanylin)共有相似的氨基酸一级结构
。
在肠道中,鸟苷肽和尿鸟苷素充当体液和电解质平衡的调节剂。响应于高口服盐摄入,这些肽释放进入肠腔,在肠腔中它们结合至定位于肠细胞(小肠和结肠的单层柱状上皮细胞)的管腔膜上的鸟苷酸环化酶C。鸟苷肽与鸟苷酸环化酶C的结合经由环单磷酸鸟苷(cGMP)的增加引发的复杂细胞内信号传递级联而诱导电解质和水排泄进入肠腔。
由鸟苷肽引发的cGMP介导的信号传递对于肠的正常运作是至关重要的。在这一过程中出现的任何异常现象都会导致胃肠功能病症,诸如肠易激综合症(IBS)和炎性肠病。炎性肠病是一组病症的统称,这种病症引起肠道发展成炎症,其特征在于组织发红和发肿。实例包括溃疡性结肠炎和克罗恩氏病。克罗恩氏病是一种严重的炎性疾病,这种疾病主要影响回肠和结肠,同时还可以发生在胃肠道的其他部分。溃疡性结肠炎特有地是结肠、大肠的炎性疾病。克罗恩氏病可以涉及肠道的所有层,并且在几片患病的肠道部分之间可以存在正常健康的肠,与克罗恩氏病不同,溃疡性结肠炎以一种连续的方式仅作用在结肠最里面的内衬(粘膜)。根据涉及胃肠道的何部分,克罗恩氏病可以称为回肠炎、局限性回肠炎、结肠炎等等。克罗恩氏病和溃疡性结肠炎与结肠痉挛综合症或者肠易激综合症不同,结肠痉挛综合症或者肠易激综合症是胃肠道的动力病症。肠胃炎症可以是慢性状况。据估计,多达1,000,000美国人都患有炎性肠病,其中男性患者和女性患者好像同样受影响。大多数病例在30岁之前被诊断出来,但更多疾病在六十、七十或者生命的更大的年龄阶段发生。
IBS和慢性特发性便秘是可引起极度肠不适和痛苦但与炎性肠病不同的病理状况,IBS不引起肠组织的严重炎症或改变,并且认为其不增加患结肠直肠癌的风险。过去,炎性肠病、乳糜泻和IBS被认为是完全独立的病症。现在,根据IBS中的炎症(虽然低度)以及IBS与乳糜泻之间重叠的症状的描述,该论点已遭到质疑。急性细菌性胃肠炎是迄今鉴定的随后发生感染后肠易激综合症的最强风险因素。临床风险因素包括延长的急性疾病和呕吐的不存在。遗传上确定的对炎性刺激的易感性也可以是患肠易激综合症的风险因素。潜在的病理生理学显示增加的肠通透性和低度炎症以及改变的动力和内脏敏感性(visceralsensitivity)。血清素(5-羟色胺[5-HT])是肠功能的关键调节剂,已知其在IBS的病理生理学中起着主要作用。5-HT的活性受cGMP调节。
尽管IBS和炎性肠病(IBD)的确切原因是未知的,但是胃肠粘膜的持续更新的过程的中断可能促进IBD的疾病病理和IBS加重。胃肠道内衬的更新过程是有效且动态的过程,该过程包括对不需要的受损细胞持续的增殖和补充。胃肠道粘膜内衬细胞的增殖速率非常高,仅次于造血系统。胃肠道体内平衡取决于肠道粘膜内衬上皮细胞的增殖和程序性细胞死亡(细胞凋亡)两者。细胞不断的从绒毛损失进入肠道内腔,并通过在隐窝处以基本上相等的速率通过细胞增殖,随后其向上移动到绒毛而进行补充。肠上皮的细胞增殖和细胞凋亡的速率可在许多环境中(例如响应于生理学刺激诸如衰老、炎性信号、激素、肽、生长因子、化学品和膳食习惯)增加或减小。此外,增加的增殖速率通常与周转时间的减少和增殖区域的扩大相关。增殖指数在病理状态诸如溃疡性结肠炎和其他肠胃病症中高得多。肠增生是胃肠炎症的主要促进因素。细胞凋亡和细胞增殖一起调节细胞数量且确定增殖指数。降低的细胞凋亡速率通常与异常生长、发炎、和赘生转化有关。因此,增殖增加和/或细胞死亡减少可以增加肠道组织的增殖指数,其进而可以导致胃肠道炎性疾病。
除了尿鸟苷素和鸟苷肽作为肠液和离子分泌的调节剂的作用外,这些肽还可通过维持增殖与细胞凋亡之间的平衡参与胃肠粘膜的持续更新。例如,尿鸟苷素和鸟苷肽似乎可以通过控制细胞离子流动而促进细胞凋亡。考虑到炎性状况在西方社会的流行率,存在改善炎性状况,特别是胃肠道的炎性状况治疗选择的需要。
鸟苷酸环化酶C激动剂的肽激动剂(“GCC激动剂”)描述于美国专利号7,041,786、7,799,897和美国专利申请公开号US2009/0048175、US 2010/0069306、US 2010/0120694、US 2010/0093635、和US 2010/0221329。然而,药物应用的肽的固相合成提出了多个具体问题,诸如总产量低(例如,低于10%)。
发明内容
本发明提供制备肽、尤其是包含鸟苷酸环化酶C(“GCC”)的肽激动剂序列的肽的方法。GCC激动剂序列选自SEQ ID NOs:1-249。GCC激动剂序列的长度是n个氨基酸单元,N-端单元在位置1且C-末端单元在位置n。
本发明的方法包括合适肽片段的固相和/或溶液相合成,随后在溶液中的片段缩合以形成线性粗肽,和任选的线性粗肽的半胱氨酸氨基酸残基的氧化环化以形成环化的最终产物。具体而言,该方法包括以下步骤:
提供第一片段,所述第一片段具有GCC激动剂序列的从位置j到位置k的氨基酸单元的第一序列,其中j是1和n-1之间的整数,k是2和n之间的整数且大于j,且所述第一片段除了位置j的氨基酸单元的氨基或者位置k的氨基酸单元的羧基之外受保护,
提供第二片段,所述第二片段具有GCC激动剂序列的从位置h到位置j-1的氨基酸单元的第二序列或具有GCC激动剂序列的从位置k+1到位置m的氨基酸单元的第三序列,其中h是1和n-2之间的整数且小于j,m是k+2和n之间的整数,且所述第二片段除了位置j-1的氨基酸单元的羧基或者位置k+1的氨基酸单元的氨基之外受保护,和
经由溶液相合成将所述第一片段和所述第二片段偶联以得到具有GCC激动剂序列的从位置h到位置k的氨基酸单元序列的受保护的肽,或具有GCC激动剂序列的从位置j到位置m的氨基酸单元序列的受保护的肽。
本发明的方法可以包括以下实施方案中所述的一个或多个特征。
在一个实施方案中,GCC激动剂序列选自SEQ ID NOs:1、8、9、55、56、58、和59。
在一个实施方案中,GCC激动剂序列是SEQ ID NO:1或9。在一个实施方案中,h是1,j是7,且k是16。更具体地,第一片段具有SEQ ID NO:1或9的从位置7到位置16的氨基酸单元序列,且第二片段具有SEQ ID NO:1或9的从位置1到位置6的氨基酸单元序列。在另一个实施方案中,h是7,j是15,且k是16。更具体地,第一片段具有SEQ ID NO:1或9的从位置15到位置16的氨基酸单元序列,第二片段具有SEQ ID NO:1或9的从位置7到位置14的氨基酸单元序列,且经由偶联第一片段和第二片段产生的受保护的肽具有SEQ ID NO:1或9的从位置7到位置16的氨基酸单元序列。在一个实施方案中,本发明的方法进一步包括将具有SEQ IDNO:1或9的从位置7到位置16的氨基酸单元序列的受保护的肽的位置7的氨基酸单元的氨基脱保护,以得到位置-7反应性肽。在一个实施方案中,本发明的方法进一步包括提供具有SEQ ID NO:1或9的从位置1到位置6的氨基酸单元序列的第三片段,其中所述第三片段除位置6的氨基酸的羧基之外受保护。在一个实施方案中,该方法进一步包括经由溶液相合成将第三片段和位置-7反应性肽偶联,以得到具有SEQ ID NO:1或9的从位置1到位置16的氨基酸单元序列的受保护的线性肽。在一个实施方案中,该方法进一步包括将受保护的线性肽脱保护,以得到脱保护的线性肽。在一个实施方案中,该方法进一步包括氧化脱保护的线性肽,以得到具有SEQ ID NO:1或9的GCC激动剂序列的肽。
在一个实施方案中,第一片段和第二片段中的每一个不超过10个氨基酸单元长度(例如2-10个氨基酸单元长度,3-9个氨基酸单元长度,或4-8个氨基酸单元长度)。
在一个实施方案中,第二片段具有GCC激动剂序列的位置h到位置j-1的氨基酸单元的第二序列,且第二片段的位置j-1的氨基酸单元和第一片段的位置k的氨基酸单元中的任一个或两个选自甘氨酸、脯氨酸、亮氨酸、丙氨酸和精氨酸。在一个实施方案中,位置j-1和k的氨基酸单元中的至少一个是甘氨酸或脯氨酸。
在一个实施方案中,第二片段具有GCC激动剂序列的位置k+1到位置m的氨基酸单元的第三序列,且第三片段的位置m的氨基酸单元和第一片段的位置k的氨基酸单元中的任一个或两个选自甘氨酸、脯氨酸、亮氨酸、丙氨酸和精氨酸。在一个实施方案中,位置m和k的氨基酸单元中的至少一个是甘氨酸或脯氨酸。
在一个实施方案中,k是n。在一个实施方案中,第二片段具有GCC激动剂序列的位置h到位置j-1的氨基酸单元的第二序列,且位置j-1的氨基酸单元选自甘氨酸、脯氨酸、亮氨酸、丙氨酸和精氨酸。在一个实施方案中,位置j-1的氨基酸单元是甘氨酸或脯氨酸。在一个实施方案中,本发明的方法进一步包括将具有GCC激动剂序列的从位置h到位置k的氨基酸单元序列的受保护的肽的位置h的氨基酸单元的氨基脱保护,以得到位置-h反应性肽。在一个实施方案中,该方法进一步包括提供具有GCC激动剂序列的从位置1到位置h-1的氨基酸单元序列的第四片段,其中所述第四片段除位置h-1的氨基酸单元的羧基之外受保护。在一个实施方案中,第四片段不超过10个氨基酸单元长度(例如2-10个氨基酸单元长度,3-9个氨基酸单元长度,或4-8个氨基酸单元长度)。在一个实施方案中,该方法进一步包括经由溶液相合成将第四片段和位置-h反应性肽偶联,以得到具有GCC激动剂序列的从位置1到位置n的氨基酸单元序列的受保护的线性肽。在一个实施方案中,该方法进一步包括将受保护的线性肽脱保护,以得到具有GCC激动剂序列的从位置1到位置n的氨基酸单元序列的受保护的线性肽。在一个实施方案中,本发明的方法进一步包括氧化脱保护的线性肽,以得到包含选自SEQ ID NOs:1-249的GCC激动剂序列的肽。
在一个实施方案中,经由固相肽合成提供目标肽片段中的至少一种(例如,第一片段、第二片段、第三片段和/或第四片段)。在一个实施方案中,固相肽合成是Fmoc固相合成。在一个实施方案中,在2-氯三苯甲基树脂(诸如具有1% DVB和范围为0.3 mmol/g至1.2mmol/g (例如,0.9-1.1 mmol/g)的取代率的2-氯三苯甲基树脂)上进行Fmoc固相合成。
与常规的逐步固相肽合成(SPPS)相比,本发明的方法出乎意料地产生高纯度(例如,> 96%)、高产率(例如,> 14%)的GCC激动剂肽,其中具有96%纯度水平的肽的总产率是约5%。对于合成GCC肽,本发明的片段缩合方法(即,杂合溶液和固相方法)也需要比常规SPPS少得多的时间。除增加的产率和减少的时间所提供的成本效率之外,本发明的方法也可以容易地扩展用于商业化生产。
在另一个方面,本发明的特征在于通过本文所述的方法制备的肽,例如,GCC激动剂肽。
在又另一个方面,本发明还提供纯化包含选自SEQ ID NOs:1-249的GCC激动剂序列的肽的方法。该方法包括将肽吸附到聚合吸附柱上,任选地用去离子水冲洗肽,用溶剂混合物(如醇水溶液)从聚合吸附柱将任选冲洗的肽洗脱以形成肽溶液,从肽溶液去除部分或所有溶剂混合物(例如水和醇)以沉淀肽,和任选地将醚添加至脱水肽以促进肽的沉淀。
在一个实施方案中,在不需要添加醚的情况下在真空下通过去除水和醇浓缩肽溶液而沉淀肽。在另一个实施方案中,添加醚以促进沉淀,例如,通过加速沉淀过程。
在一个实施方案中,当,例如,吸附的肽基本上不含水溶性盐(例如,磷酸盐或乙酸盐)时,在吸附到聚合吸附柱上之后冲洗肽是没有必要的。在该上下文中,“基本上”不含水溶性盐意味着肽的盐含量优选小于5%、小于4.5%、小于4.25%、小于4%、小于3.5%、小于3%、小于2.5%、小于2%、小于1.5%、小于1%、小于0.5%、小于0.25%、或小于0.1%的肽总重量。
在一个实施方案中,聚合吸附柱包含聚苯乙烯树脂。具体地,选择树脂,从而使得洗脱或解吸的纯化的肽不少于80%吸附在树脂上的肽量,例如,不少于85%,不少于90%,或不少于95%。在一个实施方案中,树脂由平均孔径大于5 nm、例如约6-8 nm、10-15 nm、15-20 nm、或25-30 nm的交联聚苯乙烯形成。
在一个实施方案中,用于洗脱肽的溶剂混合物包含水,例如,水和一种或多种可以与水形成共沸物的第二溶剂的混合物,所述第二溶剂诸如乙醇、异丙醇、叔丁醇、2-丁醇、1-氯-2-丙醇、1-甲氧基-2-丙醇、2-甲氧基-乙醇、2-甲基-2-丙醇、乙酸、乙酸甲酯、和乙酸丙酯。一种或多种第二溶剂可以是如ICH指南中定义的3类溶剂(或低毒性溶剂)。在另一个实施方案中,用于洗脱的溶剂混合物包含醚,诸如乙醇/醚或异丙醇/醚的混合物。
在一个实施方案中,醇水溶液包括异丙醇、丙醇、叔丁醇、2-丁醇、或乙醇。
在一个实施方案中,醚包含二乙醚或MTBE。
在一个实施方案中,该方法进一步包括在纯化前通过用包含铵盐(例如乙酸铵)、乙酸和/或乙酸盐(例如乙酸钠)的水溶液洗涤肽而将肽盐交换。在一个实施方案中,如果该方法包括盐交换步骤,则该方法还包括在吸附在聚合树脂柱上后用去离子水冲洗肽以便将肽脱盐。
在一个实施方案中,该方法进一步包括在盐交换步骤之后纯化之前冻干肽。
在一个实施方案中,该方法进一步包括在添加醚之后,例如,在减压下干燥沉淀的肽。
在一个实施方案中,纯化的肽选自SEQ ID NOs:1、8、9、和56。优选地,纯化的肽是SEQ ID NO:1或9。
与常规的纯化方法诸如冻干相比,本发明的纯化方法出乎意料地产生高纯度(例如,> 96%)和高堆积密度和/或振实密度(例如,> 0.3 g/mL)的GCC激动剂肽,在冻干中纯化的肽的堆积密度和/或振实密度比通过本发明的方法纯化的肽的堆积密度和/或振实密度约低10倍。与常规的冻干相比,本发明的纯化方法也需要少得多的时间,这可能导致拓扑异构体含量、脱酰胺化降解产物和其他杂质的减少。与常规的冻干相比,本发明的纯化方法也容易扩展用于商业化生产。
在又另一个方面,本发明的特征在于通过本文所述的方法纯化的肽,例如,GCC激动剂肽。纯化的肽可以具有下列特征中的一种或多种。
在一个实施方案中,纯化的肽具有不小于0.05 g/mL、不小于0.1 g/mL、不小于0.2g/mL、不小于0.3 g/mL、不小于0.4 g/mL、或不小于0.5 g/mL的堆积密度。例如,纯化的肽具有范围为0.05 g/mL和2 g/mL之间的堆积密度。
在一个实施方案中,纯化的肽具有不小于0.08 g/mL、不小于0.1 g/mL、不小于0.15 g/mL、不小于0.2 g/mL、不小于0.3 g/mL、不小于0.4 g/mL、不小于0.5 g/mL、或不小于0.6 g/mL的振实密度。例如,纯化的肽具有范围为0.08 g/mL和2 g/mL之间的振实密度。
在一个实施方案中,纯化的肽具有不小于96%、不小于97%、或不小于98%的层析纯度。例如,GCC激动剂肽具有不超过4%、不超过3.5%、不超过3%、不超过2.5%、不超过2%、不超过1.5%、或不超过1%的层析杂质含量。层析杂质含量被确定为通过HPLC的杂质的总面积百分比。层析杂质含量包括拓扑异构体含量。杂质不包括用于药物制剂的任何药学可接受的赋形剂。
在一个实施方案中,纯化的肽基本上不含由肽制备方法导致的污染物,诸如方法中使用的有机溶剂,例如,铵、乙腈、乙酰胺、醇(例如甲醇、乙醇或异丙醇)、TFA、醚或其他污染物。在该上下文中,“基本上”不含污染物意味着在纯化过程结束时肽的污染物含量优选小于0.5%、小于0.3%、小于0.25%、小于0.1%、小于0.05%、小于0.04%、小于0.03%、小于0.02%、小于0.01%、小于0.005%、小于0.003%、或小于0.001%的肽总重量。例如,纯化的肽含有<0.01%乙酰胺、<0.3%铵离子、<0.01%乙腈、和/或0.1%TFA。污染物的含量可以通过常规方法诸如气相层析法来确定。优选地,本发明的纯化的肽中的残留溶剂低于ICH指南,例如,IMPURITIES:GUIDELINE FOR RESIDUAL SOLVENTS Q3C(R5) (获得自http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3C/Step4/Q3C_R5_Step4.pdf)中设定的限值。例如,纯化的肽含有<410 ppm乙腈(例如,≤40 ppm或≤ 20ppm),<5000 ppm乙醇(例如,≤140 ppm),<5000 ppm异丙醇,< 5000 ppm乙酸乙酯(例如,≤20 ppm),<3000 ppm甲醇(例如,≤250 ppm),<5000 ppm MTBE (例如,≤20 ppm),< 290ppm己烷,和/或< 5000 ppm庚烷或戊烷。
在一个实施方案中,纯化的肽基本上不含拓扑异构体。在该上下文中,“基本上”不含拓扑异构体意味着在纯化过程结束时肽的拓扑异构体含量优选小于2%、小于1.5%、小于1.25%、小于1%、小于0.9%、小于0.8%、小于0.7%、小于0.6%、小于0.5%、小于0.4%、小于0.3%、小于0.2%、或小于0.1%的肽总重量。
在一个实施方案中,纯化的肽基本上不含水。在该上下文中,“基本上”不含水意味着在纯化过程结束时肽的水含量优选小于7%、小于6%、小于5%、小于4.5%、小于4.25%、小于4%、小于3.5%、小于3%、小于2.5%、小于2%、小于1.5%、小于1%、小于0.5%、小于0.25%、或小于0.1%的肽总重量。
在一个实施方案中,纯化的肽包括SEQ ID NO:1的GCC激动剂序列。
在一个实施方案中,纯化的肽包括SEQ ID NO:9的GCC激动剂序列。
本发明还涉及含有通过本文所述的方法制备和/或纯化的肽的制剂(例如,口服制剂),和具体地含有0.05-10 mg (例如,0.1 mg、0.3 mg或0.5 mg)的纯化的肽的低剂量制剂。低剂量制剂可以进一步具有如PCT/US2011/051805中所述的一种或多种另外特征,且可以通过本文公开的方法诸如干掺合来制备。
根据下列详细描述和权利要求,本发明的其他特征和有利方面将变得显然并且包括在所述详细描述和权利要求中。
附图简要说明
图1是显示通过筛分分析的关于冻干的plecanatide和沉淀的plecanatide的粒径分布的图。
图2是冻干的plecanatide的光学显微镜图像。
图3是沉淀的plecanatide的光学显微镜图像。
具体实施方式
本发明提供了制备肽(例如,肽GCC激动剂)的方法,特别是杂合溶液和固相方法。本发明的方法包括经由固相和/或溶液相合成提供两个或更多个目标肽的片段,和经由溶液相合成将它们偶联以获得目标肽。该方法还可以包括,如果需要,氧化环化通过片段偶联形成的线性肽的半胱氨酸氨基酸残基,以产生环化的肽。
上文描述的片段可以通过标准溶液相肽合成或固相肽合成技术来制备,其中肽键通过第一个氨基酸的氨基(即,NH2)与第二个氨基酸的羧基(即,COOH)的直接缩合(消除一个水分子)而产生。在一个实施方案中,至少一个片段通过固相肽合成制备。
通过直接缩合进行的肽键合成(如上阐述的)需要抑制第一个氨基酸的氨基和第二个氨基酸的羧基的反应特征。掩蔽取代基(masking substituent) (即,保护基)必须能够容易地去除它们,而不诱导不稳定的肽分子的断裂。术语“保护的肽”或“保护的肽片段”是指一种肽或肽片段,其中其组成氨基酸上的所有反应性基团都被保护基团所掩蔽,除非另有规定。术语“脱保护的肽”或“脱保护的肽片段”是指一种肽或肽片段,其中其组成氨基酸上的所有反应性基团都没有被保护基团所掩蔽,除非另有规定。术语“反应性基团”是指形成肽键的基团和干扰肽键形成的基团,诸如氨基、羧基、羟基、和巯基(如在半胱氨酸中)基团。氨基的保护基团的实例包括但并不限于9-芴基甲氧基羰基(Fmoc)、叔丁氧基羰基(Boc)、苯甲酰基(Bz)、乙酰基(Ac)、和苄基(Bn)。羧基的保护基团的实例包括三苯甲基(三苯基甲基,Trt)和O-叔丁基(OtBu)。巯基的保护基团的实例包括乙酰胺基甲基(Acm)、叔丁基(tBu)、3-硝基-2-吡啶亚磺酰基(NPYS)、2 -吡啶-亚磺酰基(Pyr)、和三苯甲基(Trt)。其他保护基团的实例描述于Greene, T.W., Wuts, P.G. M., Protective Groups in Organic Synthesis, 第3 版, John Wiley & Sons:New York, 1999,其上下文通过引用并入本文。
在一个优选的实施方案中,本发明的方法用于制备SP-304 (plecanatide)。具体地,如下制备三个肽片段A、B和C,然后通过片段A、B和C的缩合装配线性肽序列:通过来自2-氯-三苯甲基氯树脂的固相制备片段A,Boc-Asn(Trt)-Asp(OtBu)-Glu(OtBu)-Cys(Trt)-Glu(OtBu)-Leu-OH;通过来自2-氯三苯甲基氯树脂的固相制备片段B,Fmoc-Cys(Acm)-Val-Asn-Val-Ala-Cys(Trt)-Thr(tBu)-Gly-OH;通过溶液相合成制备片段C,Cys(Acm)-Leu-OtBu,在溶液相中偶联片段B和C以产生片段B-C和偶联片段A和B-C以产生线性肽A-B-C。
如下面方案1中所示,可以使用超强酸敏感的2-氯三苯甲基氯(2-ClTrt)树脂和Fmoc-保护的氨基酸衍生物通过Fmoc SPPS来制备侧链保护的片段A (BocAA1-6OH)和B(FmocAA7-14OH)。
片段C (HAA15-16OtBu)可通过溶液相合成制备,然后在溶液相中被偶联至片段B(FmocAA7-14OH),以得到片段B-C (FmocAA7-16OtBu)。如下面方案2中所示,然后Fmoc保护基团可以从片段B-C (FmocAA7-16OtBu)去除,以得到HAA7-16OtBu,然后将所述HAA7-16OtBu偶联至片段A (BocAA1-6OH),以得到侧链保护的线性SP-304 (BocAA1-16OtBu)。
侧链保护的线性SP-304 (BocAA1-16OtBu)可以用三氟乙酸/三异丙基硅烷/乙二硫醇(TFA/TIS/EDT)处理,以得到部分保护的SP-304 (HAA1-16OH),在所述SP-304 (HAA1-16OH)中,2 S-Acm基团(如上述方案2中所示)是完整的。如下面方案3和4中所示,部分保护的线性SP-304 (HAA1-16OH)可以被H2O2氧化,随后同时去除S-Acm基团和与碘形成二硫键,以得到粗双环SP-304。
然后,上述方案3中所示,通过将溶液上样至聚苯乙烯吸附树脂(例如,D101 (AnhuiSanxing (China);交联的聚苯乙烯;表面积500-550 m2/g;平均孔径:9-10 nm;孔体积:1.18-1.24 ml/g;堆积密度:0.65-0.70 g/ml;比密度:1.03-1.07 g/ml;水分:67-75%;粒径:0.315~1.25 mm ≧95%;有效直径:0.4~0.7 mm;均匀系数:≤1.6%)、DA201C、DA201H、ADS-8、和ADS-5)柱,用洗脱剂(例如,90%乙醇水溶液)从柱中洗脱双环SP-304,在减压下浓缩收集的SP-304溶液,且用甲基叔丁基醚(MTBE)沉淀SP-304而纯化和浓缩粗双环SP-304的溶液。然后沉淀可以通过过滤或离心收集,高真空下干燥,以得到固体形式的SP-304。
如上述方案4中所示,粗双环SP-304的溶液也可以用各种缓冲系统中的乙腈(ACN)、甲醇和/或水直接在制备型HPLC C18柱上进行纯化。粗双环SP-304也可以经由本领域技术人员已知的其他方法进行纯化。
本领域普通技术人员将认识到,在固相合成中,脱保护和偶联反应必须要完成并且侧链封闭基团在整个合成中必须是稳定的。
N末端的乙酰化可通过在从树脂切割之前将最终的肽与醋酸酐反应来实现。C-酰胺化使用Boc技术,使用适当的树脂诸如甲基二苯甲基胺(methylbenzhydrylamine)树脂来实现。
在溶液相合成中,可使用多种偶联方法和保护基团(参见,Gross和Meienhofer,编,"The Peptides:Analysis, Synthesis, Biology,"第1-4卷(Academic Press,1979);Bodansky和Bodansky,"The Practice of Peptide Synthesis,"第2版(Springer Verlag,1994))。此外,中间的纯化和线性按比例放大是可能的。本领域普通技术人员将理解,溶液合成需要考虑主链和侧链保护基团和活化方法。此外,细心的片段选择是在片段缩合过程中使外消旋最小化所必需的。例如,当片段包含C末端Gly或Pro时,外消旋最小化。溶解性也是考虑因素。固相肽合成在有机合成过程中使用不溶性聚合物进行支持。聚合物支持的肽链允许使用简单的洗涤和过滤步骤而无需在中间步骤进行繁琐的纯化。固相肽合成通常可按照Merrifield等人,J. Am. Chem. Soc., 1963, 85:2149的方法来进行,其包括使用被保护的氨基酸在树脂载体上装配线性肽链。固相肽合成通常利用Boc或Fmoc策略,两者在本领域内是众所周知的。
本发明的方法可以用于制备本领域中已知的任何基于肽的GCC激动剂,诸如尿鸟苷素、鸟苷肽、淋巴鸟苷素(lymphoguanylin)、利那洛肽(linaclotide)、ST肽、SP-304、和SP-333的类似物。这种尿鸟苷素、鸟苷肽、淋巴鸟苷素、利那洛肽、SP-304、SP-333和细菌ST肽的类似物的非限制性实例描述于下列部分1.1中。在某些实施方案中,该方法用于制备基本上由选自SEQ ID NOs:1-249的氨基酸序列组成的肽。在一个优选的实施方案中,肽因而基本上由选自SEQ ID NOs:1、8、9、55、和56的氨基酸序列组成。术语“基本上由…组成”是指在其氨基酸序列与参考肽相同的肽,或在结构或功能方面与参考肽基本上没有不同的肽。如果肽的一级氨基酸序列与参考肽相比变化超过3个氨基酸,或如果其细胞cGMP产生的激活与参考肽相比减少超过50%,那么该肽与参考肽基本上不同。优选地,基本上相似的肽的变化不超过2个氨基酸且在激活cGMP产生方面变化不超过约25%。在优选的实施方案中,由本发明的方法制备的GCC激动剂是包含至少12个氨基酸残基的肽,且最优选包含12至26个氨基酸的肽。
在另一个实施方案中,本发明的方法用于制备SP-353 (其是细菌ST肽类似物)。用于杂合合成SP-353的总体策略包括固相和溶液相合成来产生合适的肽片段(参见下文方案5和6),随后区段缩合以形成线性粗肽(参见下文方案7),和天然氧化折叠以形成环化的最终产物(参见下文方案7)。同样的策略也可用于产生表II中所示的类似氨基酸序列的其他ST肽类似物(诸如SP-354、利那洛肽等)。
在又另一个实施方案中,本发明的方法用于制备SP-333。用于杂合合成SP-333的总体策略包括固相和溶液相合成来产生合适的肽片段(参见下文方案8和9),随后区段缩合以形成线性粗肽(参见下文方案9),和氧化折叠以形成环化的最终产物,纯化,且冻干(参见下文方案10)。
在另一个方面,本发明还提供了纯化肽(例如,肽GCC激动剂)的方法。纯化肽(包括通过本文公开的杂合方法合成的肽)的总体策略包括,例如,下文方案11中所示的步骤。据了解,方案11中的某些步骤可以重复(例如,用去离子水冲洗柱)或不存在(例如,脱水后的盐交换或醇去除)以优化纯化方法。
在又另一个方面,本发明提供了通过本文所述的沉淀方法纯化的纯化肽,例如,肽GCC激动剂。优选地,纯化的肽是SP-304 (SEQ ID NO:1)或SP-333 (SEQ ID NO:9)。在一个实施方案中,纯化的SP-304或SP-333具有不小于0.05 g/mL、不小于0.1 g/mL、不小于0.2 g/mL、不小于0.3 g/mL、不小于0.4 g/mL、或不小于0.5 g/mL的堆积密度。在一个优选的实施方案中,纯化的SP-304或SP-333具有约0.05-2 g/mL、约0.2-0.7 g/mL、约0.3-0.6 g/mL、或约0.4-0.5 g/mL的堆积密度。在一个实施方案中,纯化的SP-304或SP-333具有不小于0.08 g/mL、不小于0.1 g/mL、不小于0.15 g/mL、不小于0.2 g/mL、不小于0.3 g/mL、不小于0.4 g/mL、不小于0.5 g/mL、或不小于0.6 g/mL的堆积密度。例如,纯化的SP-304或SP-333具有0.08-2 g/mL、约0.4-0.9 g/mL、约0.5-0.8 g/mL、或约0.6-0.7 g/mL的堆积密度。在一个实施方案中,纯化的肽SP-304或SP-333含有< 0.01%乙酰胺(例如,<28ppm)、<0.3%铵离子(例如,<0.25%)、<0.01%乙腈(例如,<20 ppm)、和/或< 0.1% TFA(例如,≤0.09%)。在一个实施方案中,纯化的肽SP-304或SP-333具有0.4-0.5 g/mL的堆积密度,具有0.6-0.7 g/mL的振实密度,且含有< 0.01%乙酰胺(例如,<28ppm)、<0.3%铵离子(例如,<0.25%)、<0.01%乙腈(例如,<20 ppm)、和/或< 0.1% TFA(例如,≤0.09%)。
1.1 GCC激动剂
通过本发明的方法制备的GCC激动剂可以结合至鸟苷酸环化酶C且刺激细胞内cGMP的产生。任选地,GCC激动剂诱导细胞凋亡且抑制上皮细胞增殖。术语“鸟苷酸环化酶C”是指鸟苷酸环化酶的跨膜形式,其充当由肠道细菌分泌的热稳定毒素(ST)肽的肠道受体。鸟苷酸环化酶C也是天然存在的肽鸟苷肽和尿鸟苷素的受体。尚未排除对于这些肽中的每一种存在不同受体的可能性。因此,术语“鸟苷酸环化酶C”也可包括一类在胃肠道粘膜内衬的上皮细胞上表达的跨膜鸟苷酸环化酶受体。
术语“GCC激动剂”是指肽和非肽化合物两者,诸如结合至肠道鸟苷酸环化酶C且刺激细胞内cGMP产生的化合物。当GCC激动剂是肽时,该术语包括这种结合至鸟苷酸环化酶C且刺激细胞内cGMP产生的肽和前肽(pro-peptide)的生物活性片段。
1.1.1 GCC激动剂肽
通过本发明的方法制备的GCC激动剂优选为肽。在一些实施方案中,GCC激动剂肽是少于30个氨基酸长度。在具体实施方案中,GCC激动剂肽是少于或等于30、25、20、15、14、13、12、11、10、或5个氨基酸长度。用于本发明的制剂和方法中的GCC激动剂肽的实例包括美国专利号7,879,802和8,034,782和美国公开号US 2010-0069306和US 2010-0120694(其中每篇都通过引用整体并入本文)中描述的那些。
可以通过本发明的方法制备的GCC激动剂肽的具体实例包括下文表I-VII中描述的那些。如表I-VII中使用,术语“PEG3”或“3PEG”是指聚乙二醇诸如氨基乙氧基-乙氧基-乙酸(AeeA),和其聚合物。术语“Xaa”指任意天然的或非天然的氨基酸或氨基酸类似物。术语“Maa”指半胱氨酸(Cys)、青霉胺(Pen)高半胱氨酸或3-巯基脯氨酸。术语“Xaan1”意指长度为1、2或3个残基的任意天然的或非天然的氨基酸或氨基酸类似物的氨基酸序列;Xaan2意指长度为0或1个残基的氨基酸序列;以及Xaan3意指长度为0、1、2、3、4、5或6个残基的氨基酸序列。此外,Xaa、Xaan1、Xaan2或Xaan3所示的任意氨基酸可以是L-氨基酸、D-氨基酸、甲基化的氨基酸或其任何组合。任选地,由表中式I-XX所示的任何GCC激动剂肽可在N末端、C末端或两者上包含一个或多个聚乙二醇残基。
在某些实施方案中,通过本发明方法制备的GCC 激动剂包含选自SEQ ID NOs:1-249的肽,其序列如下文表I-VII 所述。在一个实施方案中,通过本发明方法制备的GCC 激动剂包含由SEQ ID NOs:1、8、9、55或56命名的肽。
在某些实施方案中,通过本发明方法制备的GCC 激动剂包含与选自SEQ ID NOs:1-249的肽基本上等同的肽。术语“基本上等同”指具有与结合结构域的氨基酸序列等同的氨基酸序列的肽,其中某些残基可被缺失或被其他氨基酸替代,而不削弱肽结合肠鸟苷酸环化酶受体并且刺激流体和电解质运输的能力。
在某些实施方案中,GCC激动剂肽是尿鸟苷素或细菌ST肽的类似物。尿鸟苷素是具有尿钠排泄活性的循环肽激素。ST肽是热稳定肠毒素家族(ST肽)的成员,其由大肠杆菌(E.coli)的致病性菌株和激活鸟苷酸环化酶受体并且引起分泌性腹泻的其他肠细菌分泌。与细菌ST肽不同,尿鸟苷素对鸟苷酸环化酶受体的结合依赖于肠的生理pH。因此,预期尿鸟苷素以pH依赖性的方式调节流体和电解质运输而不引起严重的腹泻。
通过本发明方法制备的GCC 激动剂肽可以是L-氨基酸、D-氨基酸或两者的组合的聚合物。例如在多个实施方案中,所述肽为D逆-反肽(retro-inverso peptides)。术语“逆-反异构体(Retro-Inverso Isomer)”指其中序列的方向被反转并且每一个氨基酸残基的手性被倒转的线性肽的异构体。参见例如,Jameson等人,Nature, 368, 744-746 (1994);Brady等人,Nature, 368, 692-693 (1994)。组合D-对映体与逆向合成(reversesynthesis)的净结果是每一个酰胺键中的羰基和氨基基团的位置被交换,而每一个α碳上的侧链基团的位置得到保持。除非另外明确地指出,否则认为,可通过合成相应天然L-氨基酸序列的反向序列来将本发明的任何给定的L-氨基酸序列产生为D逆-反肽。
通过本发明方法制备的GCC 激动剂肽能够诱导表达鸟苷酸环化酶C的细胞和组织中的细胞内cGMP 产生。在某些实施方案中,与天然存在的GCC激动剂诸如尿鸟苷素、鸟苷肽或ST肽相比较,GCC激动剂肽刺激5%、10%、20%、30%、40%、50%、75%、90%或更多的细胞内cGMP。任选地,与SP-304(SEQ ID NO:1)相比较,GCC激动剂肽刺激5%、10%、20%、30%、40%、50%、75%、90%或更多细胞内cGMP。在进一步实施方案中,GCC激动剂肽刺激细胞凋亡,例如程序化细胞死亡或激活囊性纤维化跨膜传导调节蛋白(CFTR)。
在一些实施方案中,本发明的方法制备的GCC激动剂肽比天然存在的GCC激动剂和/或SP-304(SEQ ID NO:1)、SP-339 (利那洛肽) (SEQ ID NO:55)或SP-340 (SEQ ID NO:56)更稳定。例如,与天然存在的GCC激动剂和/或SP-304、SP-339 (利那洛肽)或SP-340相比,GCC激动剂肽降解2%、3%、5%、10%、15%、20%、30%、40%、50%、75%、90%或更少。在某些实施方案中,用于本发明的制剂和方法的GCC激动剂肽比天然存在的GCC激动剂和/或SP-304(SEQID NO:1)、SP-339 (利那洛肽) (SEQ ID NO:55)或SP-340 (SEQ ID NO:56)对于蛋白水解消化作用更稳定。在一个实施方案中,将GCC激动剂肽聚乙二醇化,以使得该肽对胃肠道酶的蛋白水解更耐受。在一个优选的实施方案中,用氨基乙氧基-乙氧基-乙酸(Aeea)基团在其C末端、在其N末端或两个末端将GCC激动剂肽聚乙二醇化。
通过本发明方法制备的GCC激动剂肽的具体实例包括选自SEQ ID NOs:1-249的肽。
在一个实施方案中,GCC激动剂肽是具有式X- XVII (例如SEQ ID NOs:87-98)中任一个的氨基酸序列的肽。
在一些实施方案中,GCC激动剂肽包括具有式I的氨基酸序列的肽,其中式I的至少一个氨基酸为D-氨基酸或甲基化的氨基酸和/或位置16上的氨基酸为丝氨酸。优选地,式I的位置16上的氨基酸为D-氨基酸或甲基化的氨基酸。例如,式I的位置16上的氨基酸为d-亮氨酸或d-丝氨酸。任选地,式I的位置1-3上的一个或多个氨基酸为D-氨基酸或甲基化的氨基酸,或D-氨基酸或甲基化的氨基酸的组合。例如,式I的Asn1、Asp2或Glu3 (或其组合)为D-氨基酸或甲基化的氨基酸。优选地,式I的位置Xaa6上的氨基酸为亮氨酸、丝氨酸或酪氨酸。
在可选择的实施方案中,GCC激动剂肽包括具有式II的氨基酸序列的肽,其中式II的至少一个氨基酸为D-氨基酸或甲基化的氨基酸。优选地,由式II的Xaan2表示的氨基酸为D-氨基酸或甲基化的氨基酸。在一些实施方案中,由式II的Xaan2表示的氨基酸为亮氨酸、d-亮氨酸、丝氨酸或d-丝氨酸。优选地,由式II的Xaan1表示的一个或多个氨基酸为D-氨基酸或甲基化的氨基酸。优选地,式II的位置Xaa6上的氨基酸为亮氨酸、丝氨酸或酪氨酸。
在一些实施方案中,GCC激动剂肽包括具有式III的氨基酸序列的肽,其中式III的至少一个氨基酸为D-氨基酸或甲基化的氨基酸和/或Maa不是半胱氨酸。优选地,式III的Xaan2表示的氨基酸为D-氨基酸或甲基化的氨基酸。在一些实施方案中,由式III的Xaan2表示的氨基酸为亮氨酸、d-亮氨酸、丝氨酸或d-丝氨酸。优选地,由式III的Xaan1表示的一个或多个氨基酸为D-氨基酸或甲基化的氨基酸。优选地,式III的位置Xaa6上的氨基酸为亮氨酸、丝氨酸或酪氨酸。
在其他实施方案中,GCC激动剂肽包括具有式IV的氨基酸序列的肽,其中式IV的至少一个氨基酸为D-氨基酸或甲基化的氨基酸和/或Maa不是半胱氨酸。优选地,式IV的Xaan2为D-氨基酸或甲基化的氨基酸。在一些实施方案中,由式IV的Xaan2表示的氨基酸为亮氨酸、d-亮氨酸、丝氨酸或d-丝氨酸。优选地,由式IV的Xaan1表示的一个或多个氨基酸为D-氨基酸或甲基化的氨基酸。优选地,由式IV的Xaa6表示的氨基酸为亮氨酸、丝氨酸或酪氨酸。
在进一步实施方案中,GCC激动剂肽包括具有式V的氨基酸序列的肽,其中式V的至少一个氨基酸为D-氨基酸或甲基化的氨基酸。优选地,式V的位置16上的氨基酸为D-氨基酸或甲基化的氨基酸。例如,式V的位置16(即,Xaa16)上的氨基酸为d-亮氨酸或d-丝氨酸。任选地,式V的位置1-3上的一个或多个氨基酸为D-氨基酸或甲基化的氨基酸或D-氨基酸或甲基化的氨基酸的组合。例如,式V的Asn1、Asp2或Glu3 (或其组合)为D-氨基酸或甲基化的氨基酸。优选地,式V的Xaa6表示的氨基酸为亮氨酸、丝氨酸或酪氨酸。
在其他实施方案中,GCC激动剂肽包括具有式VI、VII、VIII或IX的氨基酸序列的肽。优选地,式VI、VII、VIII或IX的位置6上的氨基酸为亮氨酸、丝氨酸或酪氨酸。在一些方面,式VI、VII、VIII或IX的位置16上的氨基酸为亮氨酸或丝氨酸。优选地,式V的位置16上的氨基酸为D-氨基酸或甲基化的氨基酸。
在其他实施方案中,GCC激动剂肽包括具有式X、XI、XII、XIII、XIV、XV、XVI或XVII的氨基酸序列的肽。任选地,式X、XI、XII、XIII、XIV、XV、XVI或XVII的一个或多个氨基酸为D-氨基酸或甲基化的氨基酸。优选地,根据式X、XI、XII、XIII、XIV、XV、XVI或XVII的肽的羧基端上的氨基酸为D-氨基酸或甲基化的氨基酸。例如,根据式X、XI、XII、XIII、XIV、XV、XVI或XVII的肽的羧基端上的氨基酸为D-酪氨酸。
优选地,由式XIV的Xaa6表示的氨基酸为酪氨酸、苯丙氨酸、或丝氨酸。最优选地,由式XIV的Xaa6表示的氨基酸为苯丙氨酸或丝氨酸。优选地,由式XV、XVI或XVII的Xaa4表示的氨基酸为酪氨酸、苯丙氨酸或丝氨酸。最优选地,式V、XVI或XVII的氨基酸位置Xaa4为苯丙氨酸或丝氨酸。
在一些实施方案中,GCRA肽包括包含式XVIII的氨基酸序列的肽。优选地,式XVIII的位置1上的氨基酸为谷氨酸、天冬氨酸、谷氨酰胺或赖氨酸。优选地,式XVIII的位置2和3上的氨基酸为谷氨酸或天冬氨酸。优选地,位置5上的氨基酸为谷氨酸。优选地,式XVIII的位置6上的氨基酸为异亮氨酸、缬氨酸、丝氨酸、苏氨酸或酪氨酸。优选地,式XVIII的位置8上的氨基酸为缬氨酸或异亮氨酸。优选地,式XVIII的位置9上的氨基酸为天冬酰胺。优选地,式XVIII的位置10上的氨基酸为缬氨酸或甲硫氨酸。优选地,式XVIII的位置11上的氨基酸为丙氨酸。优选地,式XVIII的位置13上的氨基酸为苏氨酸。优选地,式XVIII的位置14上的氨基酸为甘氨酸。优选地,式XVIII的位置16上的氨基酸为亮氨酸、丝氨酸或苏氨酸。
在可选择的实施方案中,GCRA肽包括包含式XIX的氨基酸序列的肽。优选地,式XIX的位置1上的氨基酸为丝氨酸或天冬酰胺。优选地,式XIX的位置2上的氨基酸为组氨酸或天冬氨酸。优选地,式XIX的位置3上的氨基酸为苏氨酸或谷氨酸。优选地,式XIX的位置5上的氨基酸为谷氨酸。优选地,式XIX的位置6上的氨基酸为异亮氨酸、亮氨酸、缬氨酸或酪氨酸。优选地,式XIX的位置8、10、11或13上的氨基酸为丙氨酸。优选地,式XIX的位置9上的氨基酸为天冬酰胺或苯丙氨酸。优选地,式XIX的位置14上的氨基酸为甘氨酸。
在进一步实施方案中,GCRA肽包括包含式XX的氨基酸序列的肽。优选地,式XX的位置1上的氨基酸为谷氨酰胺。优选地,式XX的位置2或3上的氨基酸为谷氨酸或天冬氨酸。优选地,式XX的位置5上的氨基酸为谷氨酸。优选地,式XX的位置6上的氨基酸为苏氨酸、谷氨酰胺、酪氨酸、异亮氨酸或亮氨酸。优选地,式XX的位置8上的氨基酸为异亮氨酸或缬氨酸。优选地,式XX的位置9上的氨基酸为天冬酰胺。优选地,式XX的位置10上的氨基酸为甲硫氨酸或缬氨酸。优选地,式XX的位置11上的氨基酸为丙氨酸。优选地,式XX的位置13上的氨基酸为苏氨酸。优选地,式XX的位置1上的氨基酸为甘氨酸。优选地,式XX的位置15上的氨基酸为酪氨酸。任选地,式XX的位置15上的氨基酸在长度上为2个氨基酸并且为半胱氨酸(Cys)、青霉胺(Pen)高半胱氨酸或3-巯基脯氨酸以及丝氨酸、亮氨酸或苏氨酸。
在某些实施方案中,GCC激动剂肽的一个或多个氨基酸被非天然存在的氨基酸或天然或非天然存在的氨基酸类似物替代。这样的氨基酸和氨基酸类似物在本领域内是已知的。参见例如,Hunt, “The Non-Protein Amino Acids,” Chemistry and Biochemistry of the Amino Acids, Barrett, Chapman, and Hall, 1985。在一些实施方案中,氨基酸被天然存在的、非必需氨基酸,例如,牛磺酸替代。可以被非蛋白氨基酸替代的天然存在的氨基酸的非限制性实例包括以下:(1) 芳香族氨基酸可被3,4-二羟基-L-苯丙氨酸、3-碘-L-酪氨酸、三碘甲状腺原氨酸、L-甲状腺素、苯基甘氨酸(Phg)或正-酪氨酸(norTyr)替代;(2) Phg和norTyr以及其他氨基酸包括Phe和Tyr可被例如卤素、-CH3、-OH、-CH2NH3、-C(O)H、-CH2CH3、-CN、-CH2CH2CH3、-SH或其他基团取代;(3) 谷氨酰胺残基可用γ-羟基-Glu或γ-羧基-Glu取代;(4) 酪氨酸残基可用α取代的氨基酸诸如L-α-甲基苯丙氨酸或用类似物诸如:3-氨基-Tyr;Tyr(CH3);Tyr(PO3(CH3)2);Tyr(SO3H);β-环己基-Ala;β-(1-环戊烯基)-Ala;β-环戊基-Ala;β-环丙基-Ala;β-喹啉基-Ala;β-(2-噻唑基)-Ala;β-(三唑-1-基)-Ala;β-(2-吡啶基)-Ala;β-(3-吡啶基)-Ala;氨基-Phe;氟-Phe;环己基-Gly;tBu-Gly;β-(3-苯并噻吩基)-Ala;β-(2-噻吩基)-Ala;5-甲基-Trp;和A-甲基-Trp取代;(5) 脯氨酸残基可用高脯氨酸(L哌可酸);羟基-Pro;3,4-脱氢-Pro;4-氟-Pro或α-甲基-Pro或N(α)-C(α)环化氨基酸类似物(具有结构:n=0,1,2,3)取代;以及(6) 丙氨酸残基可用α-取代或N-甲基化的氨基酸诸如α-氨基异丁酸(aib)、L/D-α-乙基丙氨酸(L/D-异缬氨酸)、L/D-甲基缬氨酸或L/D-α-甲基亮氨酸或非天然氨基酸诸如β-氟-Ala取代。丙氨酸还可用:n=0、1、2、3取代。甘氨酸残基可用α-氨基异丁酸(aib)或L/D-α-乙基丙氨酸(L/D-异缬氨酸)取代。
非天然氨基酸的进一步实例包括:酪氨酸的非天然类似物;谷氨酰胺的非天然类似物;苯丙氨酸的非天然类似物;丝氨酸的非天然类似物;苏氨酸的非天然类似物;烷基、芳基、酰基、叠氮基、氰基、卤素、肼、酰肼、羟基、烯基、炔基、醚、巯基、磺酰基、硒基、酯、硫代酸、硼酸盐(borate)、硼酸盐(boronate)、磷(phospho)、膦酰基、膦、杂环、烯酮、亚胺、醛、羟胺、酮或氨基取代的氨基酸或其任意组合;具有光激活交联剂的氨基酸;自旋标记的氨基酸;荧光氨基酸;具有新官能团的氨基酸;与另一种分子共价或非共价相互作用的氨基酸;结合金属的氨基酸;在非天然酰胺化的位置上被酰胺化的氨基酸、含金属的氨基酸;放射性氨基酸;photocaged和/或可光异构化(photoisomerizable)氨基酸;含生物素或生物素类似物的氨基酸;糖基化或碳水化合物修饰的氨基酸;含酮氨基酸;包含聚乙二醇或聚醚的氨基酸;重原子取代的氨基酸(例如,含氘、氚、13C、15N或18O的氨基酸);化学可切割或光可切割的氨基酸;具有长侧链的氨基酸;包含毒性基团的氨基酸;糖取代的氨基酸,例如糖取代的丝氨酸等;包含碳-连接的糖的氨基酸;氧化还原活性氨基酸;含α-羟基的酸;含氨基硫羰酸的氨基酸;α,α二取代的氨基酸;β-氨基酸;除脯氨酸外的环状氨基酸;O-甲基-L-酪氨酸;L-3-(2-萘基)丙氨酸;3-甲基-苯丙氨酸;对-乙酰基-L-苯丙氨酸;O-4-烯丙基-L-酪氨酸;4-丙基-L-酪氨酸;三-O-乙酰基-GlcNAc β-丝氨酸;L-多巴;氟化苯丙氨酸;异丙基-L-苯丙氨酸;对-叠氮基-L-苯丙氨酸;对-酰基-L-苯丙氨酸;对-苯甲酰基-L-苯丙氨酸;L-磷酸丝氨酸;膦酰基丝氨酸;膦酰基酪氨酸;对-碘-苯丙氨酸;4-氟苯基甘氨酸;对-溴苯丙氨酸;对-氨基-L-苯丙氨酸;异丙基-L-苯丙氨酸;L-3-(2-萘基)丙氨酸;D-3-(2-萘基)丙氨酸(dNal);含氨基-,异丙基-或O-烯丙基-的苯丙氨酸类似物;多巴,0-甲基-L-酪氨酸;糖基化氨基酸;对-(炔丙基氧基)苯丙氨酸;二甲基-赖氨酸;羟基-脯氨酸;巯基丙酸;甲基-赖氨酸;3-硝基-酪氨酸;正亮氨酸;焦谷氨酸;Z(苄氧羰基);ε-乙酰基-赖氨酸;β-丙氨酸;氨基苯甲酰基衍生物;氨基丁酸(Abu);瓜氨酸;氨基己酸;氨基异丁酸(AIB);环己基丙氨酸;d-环己基丙氨酸;羟脯氨酸;硝基-精氨酸;硝基-苯丙氨酸;硝基-酪氨酸;正缬氨酸;八氢吲哚羧酸;鸟氨酸(Orn);青霉胺(PEN);四氢异喹啉;乙酰氨基甲基保护的氨基酸和PEG化的氨基酸。非天然氨基酸和氨基酸类似物的进一步实例可见于U.S.20030108885、U.S.20030082575、US20060019347(第410-418段)和其中引用的参考文献中。本发明的多肽可包括进一步修饰,包括US20060019347,第589段中描述的修饰。包含非天然存在的氨基酸的示例性GCC激动剂肽包括,例如,SP-368和SP-369。
在一些实施方案中,GCC激动剂肽是环肽。GCC激动剂环肽可通过本领域已知的方法来制备。例如,大环化通常通过在肽N-和C-末端之间、在侧链与N-或C-末端之间[例如,利用K3Fe(CN)6,在pH 8.5下](Samson等人,Endocrinology, 137:5182-5185(1996))或在两个氨基酸侧链诸如半胱氨酸之间形成酰胺键来实现。参见例如,DeGrado, Adv Protein Chem, 39:51-124 (1988)。在多个实施方案中,GCC激动剂肽为[4,12; 7,15]双环。
在某些实施方案中,通常在GCC激动剂肽中形成二硫键的一个或两个Cys残基可被高半胱氨酸、青霉胺、3-巯基脯氨酸(Kolodziej等人1996 Int. J. Pept. Protein Res.48:274);β,β二甲基半胱氨酸(Hunt等人1993 Int. J. Pept. Protein Res. 42:249)或二氨基丙酸(Smith等人1978 J. Med. Chem. 2 1:117)替代,以在正常二硫键的位置上形成可选择的内部交联。
在某些实施方案中,在GCC激动剂肽中的一个或多个二硫键被可选择的共价交联替代,例如酰胺连接(-CH2CH(O)NHCH2-或- CH2NHCH(O)CH2-)、酯连接、硫酯连接、内酰胺桥、氨甲酰连接、脲连接(urea linkage)、硫脲连接、磷酸酯连接、烷基连接(-CH2CH2CH2CH2-)、烯基连接(-CH2CH=CHCH2-)、醚连接(-CH2CH2OCH2-或-CH2OCH2CH2-)、硫醚连接(-CH2CH2SCH2-或- CH2SCH2CH2-)、胺连接(-CH2CH2NHCH2-或-CH2NHCH2CH2-)或硫代酰胺连接(-CH2C(S)NHCH2-或-CH2NHC (S)CH2-)。例如,Ledu等人(Proc. Natl. Acad. Sci. 100:11263-78,2003)描述了用于制备内酰胺和酰胺交联的方法。包含内酰胺桥的示例性GCC激动剂肽包括例如SP-370。
在某些实施方案中,GCC激动剂肽的一个或多个常规多肽键被可选择的键替代。此类替代可增强多肽的稳定性。例如,用可选择的键替代残基氨基末端与芳香族残基(例如Tyr、Phe、Trp)之间的多肽键可减少被羧肽酶切割,并且可增加在消化道中的半衰期。可替代多肽键的键包括:逆-反键(retro-inverso bond)(C(O)-NH而非NH-C(O);还原的酰胺键(NH-CH2);硫亚甲基键(S-CH2或CH2-S);氧亚甲基键(O-CH2或CH2-O);乙烯键(CH2-CH2);硫代酰胺键(C(S)-NH);反式-烯键(CH=CH);氟取代的反式-烯键(CF=CH);酮亚甲基键(C(O)-CHR或CHR-C(O),其中R为H或CH3;和氟-酮亚甲基键(C(O)-CFR或CFR-C(O),其中R为H或F或CH3。
在某些实施方案中,使用标准修饰对GCC激动剂肽进行修饰。修饰可在氨基(N-)、
羧基(C-)端、内部或任何上述位置的组合上进行。在本文描述的一个方面,在肽上可存在超
过一种类型的修饰。修饰包括但不限于:乙酰化、酰胺化、生物素化、苯乙烯醛基化、法尼基
化、甲酰化、豆蔻酰化、棕榈酰化、磷酸化(Ser、Tyr或Thr)、硬脂酰化、琥珀酰化、磺酰化和环
化(通过二硫桥或酰胺环化)和通过Cys3或Cys5的修饰。本文中描述的GCC激动剂肽还可利
用2,4-二硝基苯基(DNP)、DNP-赖氨酸来修饰,利用7-氨基-4-甲基-香豆素(AMC)、荧光素、
NBD(7-硝基苯并-2-氧杂-1,3-二唑)、对硝基苯胺、罗丹明B、EDANS(5-((2-氨基乙基)氨基)
萘-1-磺酸)、dabcyl、dabsyl、丹磺酰基、德克萨斯红、FMOC和Tamra(四甲基罗丹明)来进行
修饰。还可将本文中描述的GCC激动剂肽缀合至例如聚乙二醇(PEG);烷基(例如,C1-C20直
链或支链烷基);脂肪酸部分;PEG、烷基和脂肪酸部分的组合(参见,美国专利6,309,633;
Soltero等人,2001 Innovations in Pharmaceutical Technology 106-110);BSA和KLH
(钥孔血蓝蛋白)。PEG和可用于修饰本发明的多肽的其他聚合物的添加描述于US20060
19347部分IX中。
GCC激动剂肽也可以是本文所述的GCC激动剂肽的衍生物。例如,衍生物包括其中某些氨基酸已被缺失或被替换的GCC激动剂肽的杂合体和修饰形式。修饰也可包括糖基化。优选地,当修饰是氨基酸取代时,它是在被预测为对于肽的生物活性非必需的氨基酸残基的一个或多个位置的保守取代。“保守取代”是其中氨基酸残基用具有相似侧链的氨基酸残基替代的取代。具有相似侧链的氨基酸残基的家族已在本领域进行了定义。这些家族包括具有下述的氨基酸:碱性侧链(例如,赖氨酸、精氨酸、组氨酸)、酸性侧链(例如,天冬氨酸、谷氨酸)、不带电荷的极性侧链(例如,甘氨酸、天冬酰胺、谷氨酰胺、丝氨酸、苏氨酸、酪氨酸、半胱氨酸)、非极性侧链(例如,丙氨酸、缬氨酸、亮氨酸、异亮氨酸、脯氨酸、苯丙氨酸、甲硫氨酸、酪氨酸)、β-分支侧链(例如,苏氨酸、缬氨酸、异亮氨酸)和芳香族侧链(例如,酪氨酸、苯丙氨酸、色氨酸、组氨酸)。
在一个实施方案中,通过本文所述的方法制备的GCC激动剂肽进行随机诱变,以鉴定具有生物活性的突变体。
在一个实施方案中,本发明的方法可用于制备基本上与本文所述的GCC激动剂肽同源的GCC激动剂肽。这种基本上同源的肽可借助与针对本文所述的GCC激动剂肽的抗体的交叉反应而分离。
可以通过本发明的方法制备的GCC激动剂肽的进一步实例可见于下文表I-VII中。
1.1.2 GCC激动剂肽及其片段的可选择的制备方法
GCC激动剂肽和它们的片段可使用本领域公认的技术诸如分子克隆、肽合成或位点定向诱变来制备。
除上述常规的溶液或固相肽合成之外,GCC激动剂肽或它们的片段可通过现代克隆技术来产生。例如,在细菌(包括但不限于大肠杆菌)中或在用于多肽或蛋白质产生的其他现有系统(例如,枯草芽孢杆菌(Bacillus subtilis)、使用果蝇Sf9细胞的杆状病毒表达系统、酵母或丝状真菌表达系统、哺乳动物细胞表达系统)中产生GCC激动剂肽,或可化学合成它们。如果将在细菌例如大肠杆菌中产生GCC激动剂肽或变异肽,那么编码多肽的核酸分子还可编码允许成熟多肽从细胞分泌的前导序列。因此,编码多肽的序列可包括例如天然存在的细菌ST多肽的前序列(pre sequence)和前体序列(pro sequence)。可从培养基纯化分泌的成熟多肽。
可将编码本文中描述的GCC激动剂肽的序列插入能够在细菌细胞中递送和维持核酸分子的载体。可将DNA分子插入自主复制载体(适当的载体包括例如pGEM3Z和pcDNA3,及其衍生物)。载体核酸可以是细菌或噬菌体DNA,诸如λ噬菌体或M13及其衍生物。可构建包含本文中描述的核酸的载体,然后转化宿主细胞诸如细菌。适当的细菌宿主包括但不限于,大肠杆菌、枯草芽孢杆菌、假单胞菌属(Pseudomonas)、沙门氏菌属(Salmonella)。除编码核酸分子以外,基因构建体还包括允许表达的元件,诸如启动子和调控序列。表达载体可包含控制转录起始的转录控制序列,诸如启动子、增强子、操纵子和阻遏物序列。
各种转录控制序列对于本领域技术人员来说是众所周知的。表达载体还可包括翻译调控序列(例如,非翻译5′序列、非翻译3′序列或内部核糖体进入位点)。载体可以能够自主复制或其可整合入宿主DNA,以在多肽产生过程中确保稳定性。
还可将包括本文中描述的GCC激动剂肽的蛋白质编码序列融合至编码多肽亲和标签例如谷胱甘肽S-转移酶(GST)、麦芽糖E结合蛋白、蛋白A、FLAG标签、六组氨酸、myc标签或流感病毒HA标签的核酸,以帮助纯化。亲和标签或报告基因融合将目标多肽的读框与编码亲和标签的基因的读框连接,以便产生翻译融合物。融合基因的表达导致包含目标多肽和亲和标签的单个多肽的翻译。在一些使用亲和标签的情况下,在亲和标签与目标多肽的读框之间融合编码蛋白酶识别位点的DNA序列。
适用于在除细菌以外的蛋白质表达系统中产生本文中描述的GCC激动剂肽和变体的未成熟和成熟形式且本领域技术人员众所周知的的基因构建体和方法可用于在生物系统中产生多肽。
本文中公开的肽可通过连接第二分子来进行修饰,所述第二分子赋予所述肽期望的性质诸如增加的体内半衰期,例如聚乙二醇化。此类修饰也落在本文使用的术语“变体”的范围内。
1.2 使用方法
本发明提供了用于在需要其的受试者中治疗或预防胃肠病症和增加胃肠蠕动的方法,其通过将有效量的GCC激动剂或其制剂施用于所述受试者而实现。可以根据本发明的方法治疗或预防的胃肠病症的非限制性实例包括肠易激综合症(IBS)、非溃疡性消化不良、幽门螺旋杆菌感染有关的溃疡、慢性假性肠梗塞、功能性消化不良、结肠假性梗阻、十二指肠胃反流、胃食管返流病(GERD)、肠梗阻(例如,术后肠梗阻)、胃肌轻瘫、胃灼热(GI道中的高酸性)、便秘(例如,与药物诸如阿片样物质、骨关节炎药物、或骨质疏松药物的使用相关的便秘);术后便秘、与神经性病症相关的便秘、克罗恩病和溃疡性结肠炎。
在一个实施方案中,本发明提供了用于治疗或预防胃肠蠕动病症、肠道易激综合症、功能性胃肠病、胃食管返流疾病、十二指肠胃反流、功能性胃灼热、消化不良、功能性消化不良、无溃疡性消化不良、胃轻瘫、慢性假性肠梗塞、假性结肠梗塞、肥胖症、充血性心力衰竭或良性前列腺增生的方法。
在一个实施方案中,本发明提供了用于在需要其的受试者中治疗或预防便秘和/或增加胃肠蠕动的方法,其通过将有效量的GCC激动剂或其制剂施用于所述受试者而实现。临床公认的定义便秘的标准是以肠运动的频率、排泄物的粘度和肠运动的轻松度进行定义。便秘的一个共同定义为每周少于三次肠运动。其他定义包括不规则的坚硬的粪便或者过度用力排便(Schiller 2001 Aliment Pharmacol Ther 15:749-763)。便秘可以是原发性的(功能性便秘或慢通过性便秘)或继发于包括神经系统、代谢或内分泌病症的其他因素。这些病症包括糖尿病、甲状腺功能减退、甲状腺功能亢进、低钙血症、多发性硬化症、帕金森病、脊髓损害、多发性神经纤维瘤、自主神经病、查加斯病、先天性巨结肠病和囊性纤维病。便秘也可能是由于手术的原因或由于使用诸如镇痛药(如阿片样物质)、抗高血压药、抗惊厥剂、抗抑郁药、解痉药和抗精神病药导致的。
在各个实施方案中,便秘和治疗药物的使用有关;便秘和神经病症有关;便秘是术后便秘;便秘和胃肠病有关;便秘是特发性的(功能性便秘或慢通过性便秘);便秘与神经系统、代谢或内分泌病症有关(例如,糖尿病、甲状腺功能减退、甲状腺功能亢进、低钙血症、多发性硬化症、帕金森病、脊髓损害、多发性神经纤维瘤、自主神经病、查加斯病、先天性巨结肠病或囊性纤维病)。便秘也可能是由于手术的原因或由于使用诸如镇痛药(如阿片样物质)、抗高血压药、抗惊厥剂、抗抑郁药、解痉药和抗精神病药导致的。
在一个实施方案中,本发明提供了用于在需要其的受试者中治疗或预防慢性特发性便秘和增加胃肠蠕动的方法,其通过将有效量的GCC激动剂或其制剂施用于所述受试者而实现。
本文使用的术语“治疗”是指与待治疗的胃肠病症相关的至少一种临床症状的减少、部分改善、减轻或缓解。术语“预防”是指与待预防的胃肠病症相关的至少一种临床症状的发作或进展的抑制或延迟。如本文使用的术语“有效量”是指为受试者提供一些改进或益处的量。在某些实施方案中,有效量是提供待治疗的胃肠病症的至少一种临床症状的一些减轻、缓解和/或下降的量。在其他实施方案中,有效量是提供与待预防的胃肠病症相关的至少一种临床症状的发作或进展的一些抑制或延迟的量。治疗效果不需要是彻底或治愈的,只要为受试者提供一些益处。术语“受试者”优选是指人受试者,但也可指优选选自小鼠、大鼠、狗、猫、牛、马或猪的非人灵长类动物或其他哺乳动物。
本发明还提供了用于在需要其的受试者中治疗胃肠癌症的方法,其通过将有效量的GCC激动剂或其制剂施用于所述受试者而实现。可以根据本发明的方法治疗的胃肠癌症的非限制性实例包括胃癌、食道癌、胰腺癌、结肠直肠癌、肠癌、肛门癌、肝癌、胆囊癌、或结肠癌。
本发明也提供了用于治疗脂质代谢病症、胆的病症、炎性病症、肺病症、癌症、心脏病症包括心血管病症、眼病症、口腔病症、血液病症、肝病症、皮肤病症、前列腺病症、内分泌病症、和肥胖症的方法。
脂质代谢病症包括但不限于血脂异常、高脂血症、高胆固醇血症、高甘油三酯血症、谷固醇血症、家族性高胆固醇血症、黄瘤、组合高脂血症、卵磷脂胆固醇酰基转移酶缺乏症、丹吉尔病、无β脂蛋白血症、勃起功能病症、脂肪肝病和肝炎。
胆的病症包括胆囊病症诸如如胆结石、胆囊癌胆管炎或原发性硬化性胆管炎;或胆管病症诸如如胆囊炎、胆管癌或片形吸虫病。
炎性病症包括组织和器官炎症诸如肾炎症(例如,肾炎)、胃肠系统炎症(例如,克罗恩病和溃疡性结肠炎);坏死性小肠结肠炎(NEC);胰腺炎症(例如,胰腺炎)、胰功能不全、肺部炎症(例如,支气管炎或哮喘)或皮肤炎症(例如,银屑病、湿疹)。
肺病症包括例如慢性阻塞性肺病(COPD)和纤维化。
癌症包括组织和器官癌发生包括转移,诸如如胃肠癌,(例如,胃癌、食管癌、胰腺癌、结肠直肠癌、肠癌、肛门癌、肝癌、胆囊癌或结肠癌;肺癌;甲状腺癌;皮肤癌(例如,黑色素瘤);口腔癌;尿道癌(例如膀胱癌或肾癌);血癌(例如骨髓瘤或白血病)或前列腺癌。
心脏病症包括例如充血性心力衰竭、气管心脏高血压、高胆固醇或高甘油三酯。心血管病症包括例如动脉瘤、心绞痛、动脉粥样硬化、脑血管意外(中风)、脑血管病、充血性心力衰竭、冠状动脉疾病、心肌梗塞(心脏病发作)或外周血管疾病。
肝病症包括例如肝硬化和纤维化。此外,GC-C激动剂还可用于促进肝移植患者的肝再生。眼病症包括例如升高的眼内压、青光眼、干眼、视网膜变性、泪腺的病症和眼炎。皮肤病症包括例如干燥病。口腔病症包括例如干口(口腔干燥症)、干燥综合症、齿龈疾病(例如,牙周病)或唾液腺管阻塞或机能病症。前列腺病症包括例如良性前列腺增生(BPH)。内分泌病症包括例如糖尿病、甲状腺功能亢进症、甲状腺功能减退症和囊性纤维化。
1.2.1 治疗有效剂量
通过给受试者例如哺乳动物诸如需要其的人施用治疗有效剂量的GCC激动剂肽来治疗、预防或缓解病症。本发明部分基于在人临床试验中意料之外的结果,所述结果表明,本发明的制剂在比基于动物研究预计的低得多的剂量是治疗有效的。根据本发明的一个方面,治疗有效剂量为0.01毫克(mg)至10 mg/每单位剂量。术语“单位剂量”指单次药物递送实体,例如片剂、胶囊、溶液、吸入制剂、控释或缓释制剂 (例如,Cosmo Pharmaceuticals的MMX®技术)。在一个实施方案中,有效剂量在0.01 mg和9 mg之间。在另一个实施方案中,有效剂量在0.01 mg和5 mg之间。在另一个实施方案中,有效剂量在0.01 mg和3 mg之间。在另一个实施方案中,有效剂量在0.10 mg和5 mg之间。在另一个实施方案中,有效剂量在0.10mg和3 mg之间。在一个实施方案中,单位剂量是 .01 mg、.05 mg、0.1 mg、0.2 mg、0.3 mg、0.5 mg、1.0 mg、1.5 mg、2.0 mg、2.5 mg、3.0 mg、5 mg、或10 mg。在一个实施方案中,单位剂量是0.3 mg、1.0 mg、3.0 mg、9.0 mg、或9.5 mg。
GCC激动剂肽可以以单位剂量形式与一种或多种药学可接受的赋形剂一起存在于药物组合物中。存在的肽的量应当在给患者施用时足以具有积极治疗效果。什么构成“积极治疗效果”将取决于待治疗的具体状况并且可包括易于被本领域技术人员认可的状况的任何显著改善。
优选口服施用上述方法中使用的GCC激动剂。剂型包括溶液、悬浮液、乳剂、片剂和胶囊。
可将总日剂量以单次剂量或以多次亚剂量给患者施用。通常,可每日2至6次,优选每日2至4次,甚至更优选每日2至3次施用亚剂量。优选地,每天施用单次剂量。
GCC激动剂可作为唯一的活性剂施用或可与一种或多种另外的活性剂组合来进行施用。在所有情况下,应当使用现有技术作为指导,以在治疗上有效的剂量施用其他活性剂。可以以单一组合物的形式施用GCC激动剂或相继地与一种或多种另外的活性剂施用GCC激动剂。在一个实施方案中,将GCC激动剂与一种或多种下述的抑制剂组合施用:cGMP依赖性磷酸二酯酶诸如舒林酸砜、扎普司特、莫他匹酮、伐地那非或西地那非。在另一个实施方案中,将GCC激动剂与一种或多种化学治疗剂组合施用。在另一个实施方案中,将GCC激动剂与一种或多种或抗炎药诸如甾体或非甾体抗炎药(NSAIDS)诸如阿司匹林组合施用。
组合治疗可通过施用两种或更多种试剂(例如本文中描述的GCC激动剂肽和另一种化合物,配制所述试剂的每一种并将其单独施用)或以单一制剂施用两种或更多种试剂)来实现。组合治疗还可包括其他组合。例如,可将两种试剂配制在一起,将其与包含第三试剂的单独制剂结合施用。虽然可在组合治疗中同时施用两种或更多种试剂,但它们不必一定如此。例如,第一试剂(或试剂的组合)的施用可先于第二试剂(或试剂的组合)的施用数分钟、数小时、数天或数周。因此,可在彼此相隔数分钟内,或彼此相隔1、2、3、6、9、12、15、18或24小时内或彼此相隔1、2、3、4、5、6、7、8、9、10、12、14天内或彼此相隔2、3、4、5、6、7、8、9或10周内施用两种或更多种试剂。在一些情况下,甚至更长的间隔也是可能的。虽然在许多情况下,期望组合治疗中使用的两种或更多种试剂同时存在于患者体内,但不必一定如此。
可将本文中描述的GCC激动剂肽与磷酸二酯酶抑制剂例如舒林酸砜、扎普司特、西地那非、伐地那非或他达拉非组合以进一步增强靶组织或器官中的cGMP水平。
组合治疗还可包括组合使用的一种或多种试剂的两次或更多次施用。例如,如果组合使用试剂X和试剂Y,那么可以以任何组合相继地施用它们一次或多次,例如以顺序X-Y- X、X-X-Y、Y-X-Y、Y-Y-X、X-X-Y-Y等施用。
1.2.2 组合治疗的示例性药剂
本发明的GCC激动剂制剂可以单独施用或与作为治疗方案的部分的一种或多种另外治疗剂组合施用,用于治疗或预防胃肠疾病或病症。在一些实施方案中,GCC激动剂制剂包含一种或多种另外的治疗剂。在其他实施方案中,GCC激动剂与所述一种或多种另外的治疗剂分开配制。根据本实施方案,GCC激动剂与所述一种或多种另外的治疗剂同时施用,相继施用,或在不同时间施用。在一个实施方案中,GCC激动剂制剂与选自以下的一种或多种另外治疗剂组合施用:磷酸二酯酶抑制剂、环核苷酸(诸如cGMP和cAMP)、轻泻剂(诸如SENNA或METAMUCIL)、粪便软化剂、用于IBD的抗肿瘤坏死因子α的治疗剂(诸如REMICADE、ENBREL、或HUMIRA)、和抗炎药(诸如COX-2抑制剂、柳氮磺吡啶、5-ASA衍生物和NSAIDS)。在某些实施方案中,GCC激动剂制剂与有效剂量的cGMP特异性磷酸二酯酶(cGMP-PDE)抑制剂或同时或相继与所述GCC激动剂组合施用。cGMP-PDE抑制剂包括,例如,舒林酸砜、扎普司特、莫他匹酮、伐地那非、和西地那非。在另一个实施方案中,GCC激动剂制剂与环核苷酸转运蛋白抑制剂组合施用。可以与本发明的GCC激动剂制剂组合施用的治疗剂的进一步实例在下面部分中给出。
1.2.2.1 治疗胃肠癌症的药剂
本文描述的GCC激动剂制剂可以与一种或多种抗癌剂组合使用,所述抗癌剂包括但不限于,烷基化剂、表鬼臼毒素、硝基脲类药物、代谢拮抗剂、长春花生物碱、蒽环(anthracycline)抗生素、氮芥类试剂等。具体的抗癌剂包括他莫昔芬、红豆杉醇(taxol)、依托泊苷和5-氟代尿嘧啶。在一个实施方案中,GCC激动剂制剂与抗病毒剂或单克隆抗体组合使用。
可以与本发明的GCC激动剂制剂组合使用用于治疗结肠癌的抗癌剂的非限制性实例包括抗增殖剂、用于DNA修饰或修复的试剂、DNA合成抑制剂、DNA/RNA转录调节剂、RNA加工抑制剂、影响蛋白质表达、合成和稳定性的试剂、影响蛋白质定位或它们发挥它们的生理作用的能力的试剂、干扰蛋白质-蛋白质或蛋白质-核酸相互作用的试剂、通过RNA干扰起作用的试剂、任何化学性质的受体结合分子(包括小分子和抗体)、被靶向的毒素、酶激活剂、酶抑制剂、基因调节剂、HSP-90抑制剂、干扰微管或其他细胞骨架组分或细胞粘附和运动的分子、用于光线疗法的试剂和治疗辅助剂(therapy adjunct)。
代表性抗增殖剂包括N-乙酰基-D-鞘氨醇(C.sub.2神经酰胺)、芹菜配基、盐酸黄连素、二氯亚甲基二磷酸二钠盐(dichloromethylene diphosphonic acid disodiumsalt)、芦荟大黄素(loe-emodine)、大黄素、HA 14-1、N-己酰-D-鞘氨醇(C.sub.6神经酰胺)、7b-羟基胆固醇、25-羟基胆固醇、贯叶金丝桃素、小白菊内酯和雷帕霉素。用于DNA修饰和修复的代表性试剂包括阿非迪霉素、硫酸博来霉素、卡铂、卡莫司汀、苯丁酸氮芥、环磷酰胺一水合物、环磷酰胺一水合物ISOPAC.RTM.、顺氯氨铂(cis-diammineplatinum(II)dichloride)(顺铂)、七叶亭(esculetin)、美法仑、甲氧胺盐酸盐、丝裂霉素C、米托蒽醌二盐酸盐、奥沙利铂和链脲菌素。
代表性DNA合成抑制剂包括(.+-.)甲氨蝶呤(氨甲蝶呤)、3-氨基-1,2,4-苯并三嗪1,4-二氧化物、氨喋呤、胞嘧啶b-D-呋喃阿拉伯糖苷(Ara-C)、胞嘧啶b-D-呋喃阿拉伯糖苷(Ara-C)盐酸盐、2-氟腺嘌呤-9-b-D-呋喃阿拉伯糖苷(脱磷酸氟达拉滨(Fludarabine des-phosphate)、F-ara-A)、5-氟-5′-脱氧尿苷、5-氟尿嘧啶、更昔洛韦、羟基脲、6-巯基嘌呤和6-硫鸟嘌呤。
代表性DNA/RNA转录调节剂包括放线菌素D、盐酸柔红霉素、5,6-二氯苯并咪唑1-b-D-呋喃型核糖苷、盐酸多柔比星、高三尖杉酯碱和盐酸伊达比星。
代表性酶激活剂和抑制剂包括弗司扣林、DL-氨鲁米特、apicidin、Bowman-Birk抑制剂、紫铆因、(S)-(+)-喜树碱、姜黄素、(-)-鱼藤素、(-)-depudecin、盐酸多西环素、依托泊苷、福美坦、福司曲星钠盐、硬毛素(hispidin)、2-亚氨基-1-咪唑啉醋酸(环肌酸)、oxamflatin、4-苯丁酸、roscovitine、丙戊酸钠、曲古抑菌素A、酪氨酸磷酸化抑制剂AG 34、酪氨酸磷酸化抑制剂AG 879、尿胰蛋白酶抑制剂片段、丙戊酸(2-丙戊酸)和XK469。
代表性基因调节剂包括5-氮杂-2′-脱氧胞苷、5-氮杂胞苷、维生素D3(VitaminD3)、ciglitizone、醋酸环丙孕酮、15-脱氧- D.sup.12,14-前列腺素J.sub.2、表睾酮、氟他胺、甘草酸铵盐(甘草皂苷)、4-羟泰米芬、米非司酮、盐酸普鲁卡因胺、盐酸雷洛昔芬、全-反视黄醛(维生素A醛)、视黄酸(维生素A酸)、9-顺-视黄酸、13-顺-视黄酸、视黄酸对-羟基苯胺(p-hydroxyanilide)、视黄醇(维生素A)、他莫昔芬、他莫昔芬柠檬酸盐、十四烷基硫代乙酸和曲格列酮。
代表性HSP-90抑制剂包括17-(烯丙基氨基)-17-去甲氧基格德霉素和格尔德霉素。
代表性微管抑制剂包括秋水仙素、多拉司他汀15、诺考达唑、紫杉烷类和特别地紫杉醇、鬼臼毒素、根霉素、长春碱硫酸盐、长春新碱硫酸盐以及长春地辛硫酸盐和长春瑞滨(诺维本)二酒石酸盐。
用于进行光线疗法的代表性试剂包括光敏卟啉环、金丝桃素、5-甲氧补骨脂素、8-甲氧补骨脂素、补骨脂素和熊脱氧胆酸。
用作治疗辅助剂的代表性试剂包括氨磷汀、4-氨基-1,8-萘二甲酰亚胺、布雷菲德菌素A、西咪替丁、磷霉素二钠盐(phosphomycin disodium salt)、亮丙瑞林(亮丙瑞林)醋酸盐、促黄体激素释放激素(LH-RH)醋酸盐、凝集素、盐酸罂粟碱、皮斐松-a(pifithrin-a)、(-)-氢溴酸东莨菪碱和毒胡萝卜素。
试剂还可以是抗VEGF(血管内皮生长因子)试剂,这样的试剂在本领域内是已知的。几种抗体和小分子目前用于临床试验中或已证明通过抑制VEGF起作用诸如阿瓦斯丁(Bevacizumab)、SU5416、SU11248和BAY 43-9006。所述试剂还可针对生长因子受体例如EGF/Erb-B家族的生长因子受体例如EGF受体(易瑞沙或吉非替尼,以及塔西法或厄洛替尼)、Erb-B2受体(赫赛汀或曲妥珠单抗)、其他受体(例如利妥昔单抗或Rituxan/美罗华)、酪氨酸激酶、非受体酪氨酸激酶、细胞丝氨酸/苏氨酸激酶(包括MAP激酶)和其病症促成肿瘤生成的各种其他蛋白质(例如小/Ras家族和大/异源三聚体G蛋白)。靶向那些分子的几种抗体和小分子目前在不同的开发阶段(包括批准用于治疗或临床试验)。
在一个优选的实施方案中,本发明提供了用于在需要其的受试者中治疗结肠癌的方法,其通过将GCC激动剂制剂与选自以下的一种或多种抗癌剂组合施用于所述受试者而实现:紫杉醇、多西他赛、他莫昔芬、长春瑞滨、吉西他滨、顺铂、依托泊苷、托泊替康、伊立替康、阿那曲唑、利妥昔单抗、曲妥珠单抗、氟达拉滨、环磷酰胺、吉妥珠单抗(gentuzumab)、卡铂、干扰素和多柔比星。在特定实施方案中,抗肿瘤剂是紫杉醇。在进一步的实施方案中,本方法还包含选自5-FU、多柔比星、长春瑞滨、环磷酰胺和顺铂的抗肿瘤剂。
1.2.2.2 治疗克罗恩病的试剂
在一个实施方案中,将本发明的GCC激动剂制剂作为与一种或多种另外的治疗剂的组合治疗的部分进行施用而用于治疗克罗恩病。一种或多种另外的治疗剂的非限制性实例包括柳氮磺吡啶和其他含氨水杨酸的药物,通常称为5-ASA试剂,诸如安萨科(Asacol)、奥柳氮钠、或颇得斯安、或英夫利昔单抗(REMICADE)。在某些实施方案中,一种或多种另外的试剂是皮质类固醇或免疫抑制试剂诸如6-巯基嘌呤或硫唑嘌呤。在另一个实施方案中,一种或多种另外的试剂是止泻药诸如地芬诺酯、洛哌丁胺或可待因。
1.2.2.3 治疗溃疡性结肠炎的试剂
在一个实施方案中,将本发明的GCC激动剂制剂作为与一种或多种另外的治疗剂的组合治疗的部分进行施用而用于治疗溃疡性结肠炎。用于治疗溃疡性结肠炎的试剂与用于治疗克罗恩病的试剂部分重叠。可以与本发明的GCC激动剂制剂组合使用的一种或多种另外治疗剂的非限制性实例包括氨基水杨酸酯/盐(aminosalicylates)(含有5-氨基水扬酸(5-ASA)的药物)诸如柳氮磺吡啶、奥沙拉秦、氨水杨酸和巴柳氮。其他可用的治疗剂包括皮质类固醇诸如泼尼松和氢化可的松,免疫调节剂诸如硫唑嘌呤、6-巯基-嘌呤(6-MP)、细胞因子、白细胞介素和淋巴因子,以及抗TNF-α试剂,包括噻唑烷二酮类或格列酮类(glitazones)诸如罗格列酮和吡格列酮。在一个实施方案中,一种或多种另外的治疗剂包括全部环孢霉素A和6-MP或硫唑嘌呤用来治疗活跃的严重溃疡性结肠炎。
1.2.2.4 治疗便秘/肠易激综合症的试剂
在一个实施方案中,将本发明的GCC激动剂制剂作为与一种或多种另外的治疗剂的组合治疗的部分进行施用而用于治疗便秘,诸如与肠易激综合症相关的便秘。一种或多种另外的治疗剂的非限制性实例包括轻泻剂诸如SENNA、MIRALAX、Lactulose、PEG或聚波卡非钙(calcium polycarbophil))、粪便软化剂(stool softener)(诸如矿物油或多库酯钠)、膨胀剂(诸如欧车前亲水胶(METAMUCIL)或麸)、试剂诸如ZELNORM (也称为替加色罗)、和抗胆碱药物诸如BENTYL和LEVSIN。
1.2.2.5 用于治疗术后肠阻塞的试剂
在一个实施方案中,将本发明的GCC激动剂制剂作为与一种或多种另外的治疗剂的组合治疗的部分进行施用而用于治疗术后肠阻塞。一种或多种另外的治疗剂的非限制性实例包括ENTEREG (爱维莫潘;以前称为ado lor/ ADL 8-2698)、考尼伐坦和US 6,645,959中描述的相关试剂。
1.2.2.6 抗肥胖剂
在一个实施方案中,将本发明的GCC激动剂制剂作为与一种或多种另外的治疗剂的组
合治疗的部分进行施用而用于治疗肥胖。一种或多种另外的治疗剂的非限制性实例包括11
βHSD-I(11-β羟基类固醇脱氢酶1型)抑制剂,诸如BVT 3498,BVT 2733,3-(1-金刚烷基)-4-
乙基-5-(乙基硫)-4H-1,2,4-三唑,3-(1-金刚烷基)-5-(3,4,5-三甲氧基苯基)-4-甲基-
4H-1,2,4-三唑,3-金刚烷基-4,5,6,7,8,9,10,11,12,3a-十氢-1,2,4-三唑并[4,3-a][11]
轮烯和WO01/90091、WOO 1/90090、WOO 1/90092和WO02/072084中公开的那些化合物;5HT拮
抗剂诸如WO03/037871、WO03/037887等中的那些;5HTIa调节剂诸如卡比多巴、苄丝肼以及
US6207699、WO03/031439等中公开的那些;5HT2c(血清素受体2c)激动剂,诸如BVT933、
DPCA37215、IK264、PNU 22394、WAY161503、R-1065、SB 243213(Glaxo Smith Kline)和YM
348以及US3914250、WO00/77010、WO02/36596、WO02/48124、WO02/10169、WO01/66548、WO02/
44152、WO02/51844、WO02/40456和WO02/40457中公开的那些;5HT6受体调节剂,诸如WO03/
030901、WO03/035061、WO03/039547等中的那些;酰基-雌激素,诸如油酰基-雌酮,公开于
del Mar-Grasa,M.等人,Obesity Research,9:202-9(2001)和日本专利申请号JP
2000256190中;厌食双环化合物诸如1426(Aventis)和1954(Aventis),以及WO00/18749、
WO01/32638、WO01/62746、WO01/62747和WO03/015769中公开的化合物;CB1(大麻素-1受体)
拮抗剂/逆激动剂诸如利莫那班(Acomplia;Sanofi)、SR-147778(Sanofi)、SR-141716
(Sanofi)、BAY 65-2520(Bayer)和SLV 319(Solvay),以及专利公开 中公开的那些;CCK-A(胆囊收缩素-A)激动剂,诸如AR-R
15849、GI 181771(GSK)、JMV-180、A-71378、A-71623和SR146131(Sanofi),以及US5739106
中公开的那些;CNTF(纤毛神经营养因子),诸如GI-181771(Glaxo-SmithKline)、SRl 46131
(Sanofi Synthelabo)、butabindide、PD 170,292和PD 149164(Pfizer);CNTF衍生物,诸如
Axokine®(Regeneron)以及WO94/09134、WO98/22128和WO99/43813中公开的那些;二肽基
肽酶IV(DP-IV)抑制剂,诸如异亮氨酸噻唑烷、缬氨酸吡咯烷(pyrrolidide)、NVP-DPP728、
LAF237、P93/01、P 3298、TSL 225(色氨酰-1,2,3,4-四氢异喹啉-3-羧酸;由Yamada等人,
Bioorg. & Med. Chem. Lett. 8 (1998) 1537-1540公开)、TMC-2A/2B/2C、CD26抑制剂、FE
999011、P9310/K364、VIP 0177、SDZ 274-444、2-氰基吡咯烷和4-氰基吡咯烷如由Ashworth
等人,Bioorg. & Med. Chem. Lett.,第6卷,No.22,pp 1163-1166和2745-2748(1996)中公
开的,以及专利公开 中公开的化合物;生长激素促
泌素(secretagogue)受体激动剂/拮抗剂,诸如NN703、海沙瑞林、MK-0677(Merck)、SM-
130686、CP-424391(Pfizer)、LY 444,711(Eli Lilly)、L-692,429和L-163,255、以及诸如
USSN 09/662448、US临时申请60/203335、US6358951、US2002049196、US2002/022637、WO01/
56592和WO02/32888中公开的那些;H3(组胺H3)拮抗剂/逆激动剂,诸如噻普酰胺、3-(1H-咪
唑-4-基)丙基N-(4-戊烯基)氨基甲酸酯)、clobenpropit、iodophenpropit、imoproxifan、
GT2394(Gliatech)和A331440、O-[3-(1H-咪唑-4-基)丙醇]氨基甲酸酯(Kiec-Kononowicz,
K.等人.,Pharmazie,55:349-55(2000)),含哌啶组胺H3-受体拮抗剂(Lazewska,D.等人.,
Pharmazie,56:927-32(2001),二苯甲酮衍生物和相关化合物(Sasse,A.等人,Arch.Pharm.
(Weinheim)334:45-52(2001)),取代的N-苯基氨基甲酸酯(Reidemeister,S.等人.,
Pharmazie,55:83-6(2000)),和proxifan衍生物(Sasse,A.等人.,J. Med. Chem. 43:
3335-43 (2000))以及组胺H3受体调节剂诸如WO02/15905、WO03/024928和WO03/024929中
公开的那些;瘦素衍生物,诸如 中公开的那些;瘦
素,包括重组人瘦素(PEG-OB,Hoffman La Roche)和重组甲硫氨酰基人瘦素(Amgen);脂酶
抑制剂,诸如四氢泥泊司它汀(奥利司他/ Xenical®)、Triton WR1 339、RHC80267、泥泊司
它汀、茶皂素、磷酸二乙基伞酮、FL-386、WAY-121898、Bay-N-3176、缬氨内酯、esteracin、抑
脂酶免疫酮A(ebelactone A)、抑脂酶免疫酮B和RHC 80267以及专利公开WO01/77094、
US4598089、US4452813、USUS5512565、US5391571、US5602151、US4405644、US4189438和
US4242453中公开的那些;脂类代谢调节剂诸如山楂酸、高根二醇(erythrodiol)、熊果酸乌
发醇、白桦脂酸、桦木醇等以及WO03/011267中公开的化合物;Mc4r(黑皮质素4受体)激动
剂,诸如CHIR86036(Chiron),ME-10142,ME-10145和HS-131(Melacure)以及PCT公开号 中公开的那些;Mc5r(黑皮质素5受体)调节剂,诸如WO97/19952,WO00/
15826,WO00/15790,US20030092041中公开的那些;黑色素-浓缩激素1受体(MCHR)拮抗剂,
诸如T-226296(Takeda),SB 568849,SNP-7941(Synaptic),以及专利公开 中公开的那些;
mGluR5调节剂诸如 等中公开的那些;血清素能试剂
(serotoninergic agents),诸如芬氟拉明(例如Pondimin®(苯乙胺,N-乙基-α-甲基-3-
(三氟甲基)-,盐酸)、罗宾斯)、右芬氟拉明(诸如Redux®(苯乙胺,N-乙基-α-甲基-3-(三氟
甲基)-,盐酸)、Interneuron)和西布曲明((Meridia®, Knoll/Reductil™)包括外消旋混
合物,如光学纯异构体(+)和(-),以及其药学可接受的盐、溶剂、水合物、笼形包合物和药物
前体,包括其盐酸西布曲明一水合物盐以及US4746680、US4806570和US5436272、
US20020006964、WOO 1/27068和WOO 1/62341中公开的化合物;NE(去甲肾上腺素)转运抑制
剂,诸如GW 320659、despiramine、他舒普仑和诺米芬辛;NPY 1拮抗剂、诸如BIBP3226、J-
115814、BIBO 3304、LY-357897、CP-671906、GI- 264879A以及 中公开的那些;NPY5(神经肽Y Y5)拮抗剂,诸如 以及专利公开 等人,J. Med.
Chem. 43:4288-4312 (2000)中公开的那些化合物;阿片样物质拮抗剂,诸如纳美芬(REVEX
®)、3-甲氧基纳曲酮、甲基纳曲酮、纳洛酮和纳曲酮(例如PT901;Pain Therapeutics,
Inc.)以及US20050004155和WO00/21509中公开的那些;阿立新拮抗剂,诸如SB-334867-A以
及专利公开
中公开的那些;PDE抑制剂(例如通过抑制磷酸二酯酶减缓环AMP(cAMP)和/或环GMP(cGMP)
的降解的化合物,其可导致cAMP和cGMP的细胞内浓度的相对增加;
可能的PDE抑制剂主要是在由PDE3抑制剂组成的种类、由PDE4抑制剂组成的
种类和/或由PDE5抑制剂组成的种类中被编号的那些物质,特别是可称为PDE3/4抑
制剂的混合类型或PDE3/4/5抑制剂的混合类型的那些物质),诸如专利公开 中公开的那些,以及PDE5抑制剂(诸如RX-RA-69、
SCH-51866、KT-734、维司力农、扎普司特、SKF-96231、ER-21355、BF/GP-385、NM-702和西地
那非(Viagra™))、PDE4抑制剂(诸如依他唑酯、ICI63197、RP73401、imazolidinone(RO-20-
1724)、MEM 1414(R1533/R1500;Pharmacia Roche)、登布茶碱、咯利普兰、氧格雷酯、硝喹
宗、Y-590、DH-6471、SKF-94120、莫他匹酮、利沙齐农、吲哚利旦、奥普力农、阿替唑仑、KS-
506-G、dipamfylline、BMY-43351、阿替唑仑、阿罗茶碱、非明司特、PDB-093、UCB-29646、
CDP-840、SKF-107806、吡拉米司特、RS-17597、RS-25344-000、SB-207499、TIBENELAST、SB-
210667、SB-211572、SB-211600、SB-212066、SB-212179、GW-3600、CDP-840、莫哌达醇、阿那
格雷、异丁司特、氨力农、匹莫苯、西洛他唑、喹齐酮和N-(3,5-二氯吡啶-4-基)-3-环丙基甲
氧基4-二氟甲氧基苯甲酰胺、PDE3抑制剂(诸如ICI153,100,bemorandane(RWJ 22867)、
MCI-154、UD-CG 212、硫马唑、ampizone、西洛酰胺、卡巴折伦、匹罗昔酮、伊马唑旦、CI-930、
氰胍佐旦、阿地本旦、沙特力农、SKF-95654、SDZ-MKS-492、349-U-85、emoradan、EMD-53998、
EMD-57033、NSP-306、NSP-307、瑞维齐农、NM-702、WIN-62582和WIN-63291、依诺昔酮和米力
农、PDE3/4抑制剂( 诸如苯芬群、曲喹辛、ORG-30029、扎达维林、L-686398、SDZ-ISQ-844、
ORG-20241、EMD-54622和托拉芬群)以及其他PDE抑制剂(诸如长春西丁(vinpocetin)、罂粟
碱、恩丙茶碱、西洛司特、依诺昔酮、己酮可可碱、罗氟司特、他达拉非(Cialis®)、茶碱和伐
地那非(Levitra®);神经肽Y2(NPY2)激动剂包括但不限于:多肽YY及其片段和变体(例如
YY3-36(PYY3-36)(N.Engl.J.Med.349:941,2003;IKPEAPGE DASPEELNRY YASLRHYLNL
VTRQRY (SEQ ID NO:250))以及PYY激动剂诸如WO02/47712、WO03/026591、WO03/057235和
WO03/027637中公开的那些;血清素重摄取抑制剂,诸如,帕罗西汀、氟西汀(Prozac™)、氟
伏沙明、舍曲林、西酞普兰和丙咪嗪以及US6162805、US6365633、WO03/00663、WOO 1/27060
和WOO 1/162341中公开的那些;甲状腺激素β激动剂,诸如KB-2611(KaroBioBMS)以及WO02/
15845、WO97/21993、WO99/00353、GB98/284425、美国临时申请号60/183,223和日本专利申
请号JP 2000256190中公开的那些;UCP-I(解偶联蛋白-1)、2或3激活剂,诸如植烷酸,4-
[(E)-2-(5,6,7,8-四氢-5,5,8,8-四甲基-2-萘基)-1-丙烯基]苯甲酸(TTNPB),视黄酸以及
WO99/00123中公开的那些;β3(β肾上腺素能受体3)激动剂,诸如 中公开的那些;去甲肾上腺素能试剂包括但不限于安非拉
酮(诸如Tenuate®(1-丙酮,2-(二乙基氨基)-1-苯基-,盐酸),Merrell)、右苯丙胺(也称为
硫酸右苯丙胺、右旋苯丙胺(dexamphetamine)、硫酸右旋苯丙胺(dexedrine)、Dexampex、
Ferndex、Oxydess II、Robese,Spancap #1)、马吲哚((或5-(对氯苯基)-2,5-二氢-3H-咪唑
并[2,1-a]异吲哚-5-醇)诸如Sanorex®,Novartis或Mazanor®,Wyeth Ayerst)、苯基丙醇
胺(或苯甲醇,α-(1-氨基乙基)-,盐酸)、芬特明((或苯酚,3-[[4,5-二氢-1H-咪唑-2-基)乙
基](4-甲基苯基)氨基],一盐酸)诸如Adipex-P®,Lemmon,FASTIN®,Smith-Kline
Beecham和Ionamin®,Medeva),苯甲曲秦((或(2S,3S)-3,4-二甲基-2苯基吗啉L-(+)-酒石
酸盐(1∶1))诸如Metra® (Forest)、Plegine® (Wyeth- Ay erst)、Prelu-2®
(Boehringer Ingelheim)和Statobex® (Lemmon)、酒石酸非那明(诸如Thephorin®(2,3,
4,9-四氢-2-甲基-9-苯基-1H-茚酚[2,1-c]吡啶L-(+)-酒石酸盐(1∶1)),Hoffmann-
LaRoche)、甲基苯丙胺(诸如Desoxyn®,Abbot((S)-N,(α)-二甲基苯乙胺盐酸))和酒石酸
苯甲曲秦(诸如Bontril® Slow-Release Capsules,Amarin(-3,4-二甲基-2-苯基吗啉酒
石酸盐);脂肪酸氧化正调节物/诱导物诸如Famoxin®(Genset);单胺氧化酶抑制剂包括但
不限于贝氟沙通、吗氯贝胺、溴法罗明、phenoxathine、乙磺普隆、befol、托洛沙酮、坡尔吲
哚(pirlindol)、阿米夫胺、sercloremine、巴嗪普令、拉扎贝胺、米拉醋胺、卡罗沙酮以及由
WO01/12176公开的其他某些化合物;和其他抗-肥胖剂诸如5HT-2激动剂、ACC(乙酰基-CoA
羧化酶)抑制剂诸如WO03/072197中公开的那些、α-硫辛酸(α-LA)、AOD9604、食欲抑制剂诸
如WO03/40107中公开的那些、ATL-962(Alizyme PLC)、苯佐卡因、盐酸苄非他明(Didrex)、
墨角藻(focus vesiculosus)、BRS3(铃蟾肽受体亚型3)激动剂、安非他酮、咖啡因、CCK激动
剂、壳聚糖、铬、缀合亚油酸、促肾上腺皮质素释放激素激动剂、去氢表雄酮、DGAT1(二酰基
甘油酰基转移酶1)抑制剂、DGAT2(二酰基甘油酰基转移酶2)抑制剂、二羧酸盐转运蛋白抑
制剂、麻黄、艾塞那肽-4(glp-1的抑制剂)FAS(脂肪酸合酶)抑制剂( 诸如浅蓝菌素和C75)、
脂肪吸收抑制剂(诸如WO03/053451等中的那些)、脂肪酸转运蛋白抑制剂、天然水溶性纤维
(诸如蚤草、车前草(plantago)、古柯(guar)、燕麦、果胶)、加兰肽拮抗剂、山羊豆属
(galega)(山羊芸香、法国紫丁香(French Lilac))、藤黄果、石蚕属植物(germander)(欧洲
苦草(teucrium chamaedrys))、葛瑞林抗体和葛瑞林拮抗剂(诸如WO01/87335和WO02/
08250中公开的那些)、影响胰岛细胞分泌的多肽激素及其变体、诸如胰泌素/肠抑胃肽
(GIP)/血管活性肠肽(VIP)/垂体腺苷酸环化酶激活肽(PACAP)/胰高血糖素样多肽II(GLP-
II)/肠高血糖素/胰高血糖素基因家族和/或肾上腺髓质素/淀粉不溶素(amylin)/降钙素
基因相关肽(CGRP)基因家族的激素,包括GLP-1(胰高血糖素样多肽1)激动剂(例如(1)艾塞
那肽-4、(2)US20050130891中描述的那些GLP-1分子,包括以其C末端羧化或酰胺化形式存
在的或以经修饰的GLP-I多肽存在的GLP-1(7-34)、GLP-1(7-35)、GLP-1(7-36)或GLP-1(7-
37)及其修饰,包括US20050130891的第17-44段中描述的那些,和衍生自GLP-1-(7-34)COOH
的衍生物,其使用具有下列通式的相应酰胺:R-NH-HAEGTFTSDVSYLEGQAAKEFIAWLVK-CONH2
(SEQ ID NO:251),其中R=H或具有1至10个碳原子的有机化合物。优选地,R是羧酸的残基。
特别优选的是下列羧酸残基:甲酰基、乙酰基、丙酰、异丙酰基、甲基、乙基、丙基、异丙基、n-
丁基、仲-丁基、叔-丁基)和glp-1(胰高血糖素样多肽-1)、糖皮质激素拮抗剂、葡萄糖载体
抑制剂、生长激素促泌素(诸如US5536716中公开的和明确描述的那些)、白细胞介素-6(IL-
6)及其调节剂(如WO03/057237等中的)、L-肉碱、Mc3r(黑皮质素3受体)激动剂、MCH2R(黑色
素浓缩激素2R)激动剂/拮抗剂、黑色素浓缩激素拮抗剂、黑皮质素激动剂(诸如Melanotan
II或WO 99/64002和WO 00/74679中描述的那些)、nomame herba、磷酸盐转动蛋白抑制剂、
phytopharm化合物57(CP 644,673)、丙酮酸盐、SCD-I(硬脂酰-CoA去饱和酶-1)抑制剂、T71
(Tularik,Inc.,Boulder CO)、托吡酯(Topimax®,指定为已显示增加体重减轻的抗惊厥
药)、转录因子调节剂(诸如WO03/026576中公开的那些)、β-羟基类固醇脱氢酶-1抑制剂(β-
HSD-I)、β-羟基-β-甲基丁酸酯、p57(Pfizer)、唑尼沙胺(Zonegran™,指定为已显示导致体
重减轻的抗-癫痫药),和US20030119428的第20-26段中公开的试剂。
1.2.2.7 磷酸二酯酶抑制剂
在某些实施方案中,组合治疗的治疗方案包括施用一种或多种磷酸二酯酶(“PDE”)抑
制剂。PDE抑制剂通过抑制磷酸二酯酶而减缓环AMP (cAMP)和/或环GMP (cGMP)的降解,其
可以导致cAMP和/或cGMP的细胞内浓度相对增加。可用于和本发明的GCC激动剂组合使用的
PDE抑制剂的非限制性实例包括PDE3抑制剂、PDE4抑制剂和/或PDE5抑制剂,特别是可以被
命名为混合型PDE3/4抑制剂或混合型PDE3/4/5抑制剂的那些物质。此类PDE抑制剂的非限
制性实例在下列专利申请和专利中描述: 。
可举例提及的PDE5抑制剂为RX-RA-69、SCH-51866、KT-734、维司力农、扎普司特、SKF-
96231、ER-21355、BF/GP-385、NM-702和西地那非(Viagra®)。可举例提及的PDE4抑制剂为
RO-20-1724、MEM 1414(R1533/R1500;Pharmacia Roche)、登布茶碱、咯利普兰、氧格雷酯、
硝喹宗、Y-590、DH-6471、SKF-94120、莫他匹酮、利沙齐农、吲哚利旦、奥普力农、阿替唑仑、
KS-506-G、DIPAMFYLLINE、BMY-43351、阿替唑仑、阿罗茶碱、非明司特、PDB-093、UCB-29646、
CDP-840、SKF-107806、PICLAMILAST、RS-17597、RS-25344-000、SB-207499、硫苯司特、SB-
210667、SB-211572、SB-211600、SB-212066、SB-212179、GW-3600、CDP-840、莫哌达醇、阿那
格雷、异丁司特、氨力农、匹莫苯、西洛他唑、喹齐酮和N-(3,5-二氯吡啶-4-基)-3-环丙基甲
氧基4-二氟甲氧基苯甲酰胺。可举例提及的PDE3抑制剂为硫马唑、AMPIZONE、西洛酰胺、卡
巴折伦、匹罗昔酮、伊马唑旦、CI-930、氰胍佐旦、阿地本旦、沙特力农、SKF-95654、SDZ-MKS-
492、349-U-85、EMORADAN、EMD-53998、EMD-57033、NSP-306、NSP-307、瑞维齐农、NM-702、
WIN-62582和WIN-63291、依诺昔酮和米力农。可通过举例说明提及的PDE3/4抑制剂是苯芬
群BENAFENTRINE、曲喹辛、ORG-30029、扎达维林、L-686398、SDZ-ISQ-844、ORG-20241、EMD-
54622和托拉芬群。其他PDE抑制剂包括:西洛司特、己酮可可碱、罗氟司特、他达拉非
(Cialis®)、茶碱和伐地那非(Levitra®)、扎普司特(PDE5特异性的)。GCC激动剂。
1.2.2.8 镇痛剂
在某些实施方案中,组合治疗的方案包括施用一种或多种镇痛剂,例如镇痛化合物或镇痛多肽。在一些实施方案中,GCC激动剂制剂与一种或多种镇痛剂同时或相继施用。在其他实施方案中,GCC激动剂共价连接或结合至镇痛剂以产生治疗性缀合物。可用的镇痛剂的非限制性实例包括钙通道阻断剂、5HT受体拮抗剂(例如5HT3、5HT4和5HT1受体拮抗剂)、阿片样物质受体激动剂(洛哌丁胺、非多托秦和芬太尼)、NK1受体拮抗剂、CCK受体激动剂(例如,氯谷胺),NK1受体拮抗剂、NK3受体拮抗剂、去甲肾上腺素-血清素重摄取抑制剂(NSRI)、辣椒素和大麻受体激动剂以及sialorphin。各个种类的镇痛剂的进一步实例在本领域中是已知的。
在一个实施方案中,镇痛剂是选自sialorphin-相关多肽的镇痛多肽,包括包含氨基酸序列QHNPR (SEQ ID NO:252)的那些,包括:VQHNPR (SEQ ID NO: 253);VRQHNPR (SEQID NO: 254);VRGQHNPR (SEQ ID NO: 255);VRGPQHNPR (SEQ ID NO: 256);VRGPRQHNPR(SEQ ID NO: 257);VRGPRRQHNPR (SEQ ID NO: 258);和RQHNPR (SEQ ID NO: 259)。Sialorphin-相关多肽结合脑啡肽酶并且抑制脑啡肽酶介导的物质P和Met-正脑啡肽的降解。因此,其为脑啡肽酶的抑制剂的化合物或多肽是有用的镇痛剂,可将其与本文中描述的GCC激动剂一起施用或共价连接至GCC激动剂以形成治疗性缀合物。Sialophin和相关多肽描述于美国专利6,589,750;U.S.20030078200 A1;和WO 02/051435 A2中。
在另一个实施方案中,将本发明的GCC激动剂制剂作为与阿片样物质受体拮抗剂或激动剂的组合治疗方案的部分进行施用。在一个实施方案中,GCC激动剂与阿片样物质受体拮抗剂或激动剂经由共价键连接在一起。阿片样物质受体拮抗剂的非限制性实例包括纳洛酮、纳曲酮、甲基纳洛酮、纳美芬、cypridime、β富纳曲胺、纳洛肼、纳曲吲哚、nor-binaltorphimine、正脑啡肽五肽(HOE825;Tyr-D-Lys-Gly-Phe-L-高丝氨酸(SEQ ID NO:260))、三甲丁酯(trimebutine)、血管活性肠多肽、胃泌素、胰高血糖素。阿片样物质受体激动剂的非限制性实例包括非多托秦、阿西马朵林和酮基环佐辛,以及WO03/097051和WO05/007626中描述的化合物、吗啡、地芬诺酯、氟雷法胺(H-Tyr-D-Ala-Phe(F)-Phe-NH2(SEQ IDNO:261);WO 01/019849 A1)和洛哌丁胺。
可以连同本发明的GCC激动剂制剂用于组合治疗中的镇痛剂的进一步非限制性实
例包括二肽Tyr-Arg (京都啡肽); 嗜铬粒蛋白-来源的多肽(CgA 47-66;参见例如,Ghia等
人 2004 Regulatory polypeptides 119:199); CCK受体激动剂诸如雨蛙肽; 芋螺毒素多
肽; 胸腺素的肽类似物(FR申请2830451); CCK(CCKa或CCKb)受体拮抗剂,包括氯谷胺和
右氯谷胺(氯谷胺的R-同分异构体)(WO 88/05774); 5-HT4激动剂诸如替加色罗
(Zelnorm®),莫沙必利,甲氧氯普胺,扎考必利,西沙必利,伦扎必利,苯并咪唑酮
衍生物诸如BIMU 1和BIMU 8以及利沙必利;钙通道阻断剂诸如齐考诺肽和例如 中描述的相关化合物;NK1受体拮抗剂诸如阿瑞匹坦(Merck & Co Inc)、沃氟
匹坦(vofopitant)、依洛匹坦(Pfizer,Inc.)、R-673(Hoffmann-La Roche Ltd)、SR-48968
(Sanofi Synthelabo)、CP-122,721(Pfizer,Inc.)、GW679769(Glaxo Smith Kline)、TAK-
637(Takeda/Abbot)、SR-14033和例如EP 873753 A1、US 20010006972 A1、US 20030109417
A1、WO 01/52844 A1中描述的相关化合物(综述参见Giardina等人2003.Drugs 6:758);NK-
2受体拮抗剂诸如奈帕度坦(Menarini Ricerche SpA)、沙瑞度坦(Sanofι-Synthelabo)、
GW597599(Glaxo Smith Kline)、SR-144190(Sanofι-Synthelabo)和UK-290795(Pfizer
Inc);NK3受体拮抗剂诸如奥沙奈坦(SR-142801;Sanofι-Synthelabo)、SSR-241586、他奈坦
和例如 中描述的相关化合物;去甲肾上腺素-血清素重
摄取抑制剂(NSRI)诸如米那普仑和WO 03/077897中描述的相关化合物;以及辣椒素受体拮
抗剂诸如arvanil和WO 01/64212 A1中描述的相关化合物。
除了sialorphin-相关多肽外,镇痛多肽包括:AspPhe、内吗啡肽-1、内吗啡肽-2、痛稳素、达拉根(dalargin)、醋酸亮丙瑞林、齐考诺肽和物质P。
1.2.2.9 胰岛素和胰岛素调节剂
本文中描述的GCC激动剂肽可与胰岛素和相关化合物(包括灵长类动物、啮齿类动物或兔胰岛素,包括其生物活性变体,包括等位基因变体,更优选可以以重组形式获得的人胰岛素)一起用于组合治疗。人胰岛素的来源包括药学可接受的和无菌的制剂,诸如可从EliLilly (Indianapolis, Ind. 46285)获得的制剂,如Humulin™ (人胰岛素rDNA源)。参见,THE PHYSICIAN'S DESK REFERENCE,55.sup.th Ed. (2001) Medical Economics,Thomson Healthcare (公开了其他适当的人胰岛素)。
本文中描述的GCC肽可以与在注射后增强受试者的胰岛素效应或水平的试剂例如格列吡嗪和/或罗格列酮一起用于组合治疗。本文中描述的多肽和激动剂可与SYMLIN®(醋酸普兰林肽)和Exenatide®(合成的艾塞那肽-4;39个氨基酸的多肽)一起用于组合治疗。
1.2.2.10 抗高血压药
本文中描述的GCC激动剂肽可与抗高血压药一起用于组合治疗,抗高血压药包括但不
限于:(1)利尿剂,诸如噻嗪类,包括氯噻酮、氯噻嗪、二氯苯磺胺、氢氟噻嗪、吲达帕胺、泊利
噻嗪和氢氯噻嗪;髓袢利尿剂,诸如布美他尼、依他尼酸、呋塞米和托拉塞米;保钾药、诸如
阿米洛利和氨苯蝶啶;碳酸酐酶抑制剂、渗透剂(诸如甘油)和醛固酮拮抗剂,诸如螺内酯、
依普利酮等;(2)β-肾上腺素阻断剂诸如醋丁洛尔、阿替洛尔、倍他洛尔、贝凡洛尔、比索洛
尔、波吲洛尔、卡替洛尔、卡维地洛、塞利洛尔、艾司洛尔、茚诺洛尔、美托洛尔、纳多洛尔、奈
必洛尔、喷布洛尔、吲哚洛尔、普萘洛尔、索他洛尔、特他洛尔、替利洛尔和噻吗洛尔等;(3)
钙通道阻断剂诸如氨氯地平、阿雷地平、阿折地 平、巴尼地平、贝尼地平、苄普地尔、
cinaldipine、氯维地平、地尔硫卓、依福地平、非洛地平、戈洛帕米、伊拉地平、拉西地平、来
米地平、乐卡地平、尼卡地平、硝苯地平、尼伐地平、尼莫地平、尼索地平、尼群地平、马尼地
平、普拉地平和维拉帕米等;(4)血管紧张素转换酶(ACE)抑制剂诸如贝那普利;卡托普利;
西那普利;西拉普利;地拉普利;依那普利;enalopril;福辛普利;咪达普利;赖诺普利;
losinopril;莫昔普利;喹那普利;喹普利拉;雷米普利;培哚普利;perindropril;
quanipril;螺普利;tenocapril;群多普利和佐芬普利等;(5)中性肽链内切酶抑制剂诸如
奥马曲拉、cadoxatril和依卡曲尔、fosidotril、山帕曲拉、AVE7688、ER4030等;(6)内皮缩
血管肽拮抗剂诸如替唑生坦、A308165和YM62899等;(7)血管扩张剂诸如肼苯哒嗪、可乐定、
米诺地尔和烟醇等;(8)血管紧张素II受体拮抗剂诸如aprosartan、坎地沙坦、依普罗沙坦、
厄贝沙坦、氯沙坦、奥美沙坦、普拉沙坦、他索沙坦、替米沙坦、缬沙坦和EXP-3137、FI6828K
和RNH6270等;(9)α/β肾上腺素阻断剂诸如尼普地洛、阿罗洛尔和氨磺洛尔等;(10)α1阻断
剂诸如特拉唑嗪、乌拉地尔、哌唑嗪、坦洛新、布那唑嗪、曲马唑嗪、多沙唑嗪、萘哌地尔、吲
哚拉明、WHP 164和XENOlO等;(11)α2激动剂诸如洛非西定、噻美尼定、莫索尼定、利美尼定
和guanobenz等;(12)醛固酮抑制剂等;和(13)血管生成素-2-结合剂诸如WO03/030833中公
开的那些。可与本文中描述的多肽和激动剂组合使用的具体抗高血压药包括但不限于:利
尿剂,诸如噻嗪类(例如,氯噻酮、环噻嗪(CAS RN 2259-96-3)、氯噻嗪(CAS RN 72956-09-
3,其可如US2809194中所公开的进行制备)、二氯苯磺胺、氢氟噻嗪、吲达帕胺、泊利噻嗪、
bendroflumethazide、methyclothazide、泊利噻嗪、trichlormethazide、氯噻酮、吲达帕
胺、美托拉宗、喹乙宗、阿尔噻嗪(CAS RN 5588-16-9,其可如英国专利号902,658中所公开
的进行制备)、苄噻嗪(CAS RN 91-33-8,其可如US3108097中所公开的进行制备)、布噻嗪
(其可如英国专利号861,367中所公开的进行制备)和氢氯噻嗪)、髓袢利尿剂(例如布美他
尼、依他尼酸、呋塞米和托拉塞米)、保钾药(例如阿米洛利和氨苯蝶啶(CAS Number 396-
01- O))和醛固酮拮抗剂(例如螺内酯(CAS Number 52-01-7)、依普利酮等);β-肾上腺素阻
断剂诸如胺碘酮(可达龙、Pacerone)、盐酸丁萘酮心安(CAS RN 31969-05-8, Parke-
Davis)、醋丁洛尔(±N-[3-乙酰基-4-[2-羟基-3-[(1甲基乙基)氨基]丙氧基]苯基-丁酰胺
或(±)-3′-乙酰基-4′-[2-羟基-3-(异丙基氨基)丙氧基]丁酰苯胺)、盐酸醋丁洛尔(例如
Sectral®,Wyeth-Ayerst)、盐酸阿普洛尔(CAS RN 13707-88-5参见荷兰专利申请No.6,
605,692)、阿替洛尔(例如Tenormin®,AstraZeneca)、盐酸卡替洛尔(例如Cartrol®
Filmtab®, Abbott )、盐酸塞利洛尔(CAS RN 57470-78-7,也参见US4034009)、盐酸塞他
洛尔(CAS RN 77590-95-5,也参见US4059622)、盐酸拉贝洛尔(例如Normodyne®,
Schering)、盐酸艾司洛尔(例如Brevibloc®, Baxter),盐酸左倍他洛尔(例如Betaxon™
Ophthalmic Suspension, Alcon)、盐酸左布诺洛尔(例如Betagan® Liquifϊlm® 和C
CAP® Compliance Cap, Allergan)、纳多洛尔(例如纳多洛尔,Mylan)、普拉洛尔(CAS RN
6673-35-4,也参见US3408387)、盐酸普萘洛尔(CAS RN 318- 98-9)、盐酸索他洛尔(例如
Betapace AF™,Berlex)、噻吗洛尔(2-丙醇,1-[(1,1-二甲基乙基)氨基]-3-[[4-4(4-吗啉
基)-1,2,5-噻二唑-3-基]氧]-,半水化物,(S)-,CAS RN 91524-16-2),马来酸噻吗洛尔
(S)-I-[(1,1-二甲基乙基)氨基]-3-[[4-(4-吗啉基)-1,2,5-噻二唑-3-基]氧]-2-丙醇
(Z)-2-丁烯二酸(1∶1)盐,CAS RN 26921-17-5)、比索洛尔(2-丙醇,1-[4-[[2-(1-甲基乙氧
基)乙氧基]-甲基]苯氧基]-3-[(1-甲基乙基)氨基]-,(±),CAS RN 66722-44-9),延胡索
酸比索洛尔(诸如(±)-1-[4-[[2-(1-甲基乙氧基)乙氧基]甲基]苯氧基]-3-[(1-甲基乙
基)氨基]-2-丙醇(E)-2-丁烯二酸(2∶1)(盐),例如,Zebeta™,Lederle Consumer)、
nebivalol(2H-1-苯并吡喃-2-甲醇,αα′-[亚胺基二(亚甲基)]二[6-氟-3,4-二氢-,CAS RN
99200-09-6,也参见美国专利No.4,654,362)、盐酸环丙洛尔,诸如2-丙醇,1-[4-[2-(环丙
基甲氧基)乙氧基]苯氧基]-3-[1-甲基乙基)氨基]-,盐酸盐,A.A.S. RN 63686-79-3)、盐
酸右旋心得安(2-丙醇,1-[1-甲基乙基)-氨基]-3-(1-奈氧基)-盐酸(CAS RN 13071-11-
9)、盐酸二醋洛尔(乙酰胺,N-[3-乙酰基-4-[2-羟基-3-[(1-甲基-乙基)氨基]丙氧基][苯
基]-,一盐酸CAS RN 69796-04-9)、盐酸地来洛尔(苯甲酰胺,2-羟基-5-[1-羟基-2-[1-甲
基-3-苯基丙基)氨基]乙基]-,一盐酸,CAS RN 75659-08-4)、盐酸己丙洛尔(2-丙醇,1-(2-
环己基苯氧 基)-3-[(1-甲基乙基)氨基]-,盐酸盐CAS RN 59333-90-3)、硫酸氟司洛尔(苯
甲酸,2-氟-3-[[2-[氨基羰基)氨基]-二甲基乙基]氨基]-2-羟基丙基酯,(+)-硫酸盐(1∶1)
(盐),CAS RN 88844-73-9;盐酸美他洛尔(甲基磺酰胺,N-[4-[1-羟基-2-(甲基氨基)丙基]
苯基-,一盐酸CAS RN 7701-65-7)、美托洛尔2-丙醇,1-[4-(2-甲氧基乙基)苯氧基]-3-[1-
甲基乙基)氨基]-;CAS RN 37350-58-6)、酒石酸美托洛尔(诸如2-丙醇,1-[4-(2-甲氧基乙
基)苯氧基]-3-[(1-甲基乙基)氨基]-,例如,Lopressor®, Novartis )、硫酸帕马洛尔(氨
基甲酸,[2-[4-[2-羟基-3-[(1-甲基乙基)氨基]丙氧基]苯基-乙基]-,甲酯,(±)硫酸盐
(盐)(2∶1),CAS RN 59954-01-7)、硫酸喷布洛尔(2-丙醇,1-(2-环戊基苯氧基)-3-[1,1-二
甲基乙基)氨基]1,(S)-,硫酸盐(2∶1)(盐),CAS RN 38363-32-5)、普拉洛尔(乙酰胺,N-[4-
[2-羟基-3-[(1-甲基乙基)氨基]-丙氧基]苯基]-,CAS RN 6673-35-4);盐酸甲硫心安(丙
醇,1-[(1-甲基乙基)氨基]-3-[2-(甲基硫)-苯氧基]-,盐酸,(±),CAS RN 39832-43-4)、
妥拉洛尔(苯甲酰胺,4-[2-[[2-羟基-3-(2-甲基苯氧基)-丙基]氨基]乙氧基]-,CAS RN
38103-61-6)、波吲洛尔,茚诺洛尔,吲哚洛尔,普萘洛尔,特他洛尔和替利洛尔等;钙通道阻
断剂诸如氨氯地平的苯磺酸盐(诸如3-乙基-5-甲基-2-(2-氨基乙氧基甲基)-4-(2-氯苯
基)-1,4-二氢-6-甲基-3,5-吡啶二羧酸苯磺酸盐,例如Norvasc®, Pfizer)、马来酸克仑
硫卓(1,5-苯并硫氮杂卓-4(5H)-酮,3-(乙酰基氧)-8-氯-5-[2-(二甲基氨基)乙基]-2,3-
二氢-2-(4-甲氧基苯基)-(2S-顺)-,(Z)-2-丁烯二酸酯(1∶1),也参见US4567195)、伊拉地
平(3,5-吡啶二羧酸,4-(4-苯并呋吖基)-1,4-二氢-2,6-二甲基-,甲基1-甲基乙基酯,
(±)-4(4-苯并呋吖基)-1,4-二氢-2,6-二甲基-3,5-吡啶二羧酸盐,也参见US4466972);尼
莫地平(诸如异丙基(2-甲氧基乙基)1,4-二氢-2,6-二甲基-4-(3-硝基苯基)-3,5-吡啶-二
羧酸,例如Nimotop®, Bayer)、非洛地平(诸如乙基甲基4-(2,3-二氯苯基)-1,4-二氢-2,
6-二甲基-3,5-吡啶二羧酸-,例如Plendil® Extended-Release, AstraZeneca LP)、尼伐
地平(3,5-吡啶二羧酸,2-氰基-1,4-二氢-6-甲基-4-(3-硝基苯基)-,3-甲基5-(1-甲基乙
基)酯,也参见US3799934)、硝苯地平(诸如3,5-吡啶二羧酸,1,4-二氢-2,6-二甲基-4-(2-
硝基苯基)-,二甲基酯,例如Procardia XL® Extended Release Tablets, Pfizer)、盐酸
地尔硫卓(诸如1,5-苯并硫氮杂卓-4(5H)-酮,3-(乙酰基氧)-5[2-(二甲基氨基)乙基]-2,-
3-二氢-2(4-甲氧基苯基)-,一盐酸盐,(+)-顺式,例如Tiazac®, Forest)、盐酸维拉帕米
(诸如苯乙腈,(α)-[[3-[[2-(3,4-二甲氧基苯基)乙基]甲基氨基]丙基]-3,4-二甲氧基-
(α)-(1-甲基乙基)盐酸,例如,Isoptin® SR, Knoll Labs)、盐酸替鲁地平(3,5-吡啶二羧
酸,2-[(二甲基氨基)甲基]4-[2-[(1E)-3-(1,1-二甲基乙氧基)-3-氧-1-丙烯基]苯基]-1,
4-二氢-6-甲基-,二乙基酯,一盐酸) CAS RN 108700- 03-4)、贝磷地尔(膦酸,[2-(2-苯氧
基乙基)-1,3-丙烷-二基]二-,四丁基酯CAS RN 103486-79-9)、福司地尔(膦酸,[[4-(2-苯
并噻唑基)苯基]甲基]-,二乙酯CAS RN 75889-62-2)、阿雷地平、阿折地平、巴尼地平、贝尼
地平、苄普地尔、cinaldipine、氯维地平、依福地平、戈洛帕米、拉西地平、来米地平、乐卡地
平、马来酸莫那匹尔(1-哌嗪丁酰胺,N-(6,11-二氢二苯并(b,e)噻庚英-11-基)4-(4-氟苯
基)-,(+)-,(Z)-2-丁烯二酸酯(1∶1)(±)-N-(6,11-二氢二苯并(b,e)噻庚英-11-基)-4-
(p-氟苯基)-1-哌嗪丁酰胺马来酸盐(1∶1) CAS RN 132046-06-1)、尼卡地平、尼索地平、尼
群地平、马尼地平、普拉地平等;T-通道钙拮抗剂诸如米贝拉地尔;血管紧张素转换酶(ACE)
抑制剂诸如贝那普利、盐酸贝那普利(诸如3-[[1-(乙氧基羰基)-3-苯基-(1S)-丙基]氨
基]-2,3,4,5-四氢-2-氧-1H-1-(3S)-苯并氮杂卓-1-乙酸一盐酸,例如,Lotrel®,
Novartis)、卡托普利(诸如1-[(2S)-3-巯基-2-甲基丙酰基]-L-脯氨酸,例如,卡托普利,
Mylan, CAS RN 62571-86-2和US4046889中公开的其他试剂)、西那普利(和US4452790中公
开的其他试剂)、阿拉普利(cetapril)(阿拉普利(alacepril),Eur. Therap. Res. 39:671
(1986); 40:543 (1986)中公开的Dainippon),J. Cardiovasc. Pharmacol. 9:39 (1987)
中公开的西拉普利(Hoffman-LaRoche)、地拉普利(地拉普利盐酸(2H-1,2,4-苯并噻二嗪-
7-氨苯磺胺,3-二环[2.2.1]庚-5-烯-2-基-6-氯-3,4-二氢-,1,1-二氧化物CAS RN 2259-
96-3);公开于US4385051)、依那普利(US4374829中公开的其他试剂)、enalopril、
enaloprilat、福辛普利((诸如L-脯氨酸,4-环己基-1-[[[2-甲基-1-(1-氧丙氧基)丙氧基]
(4-苯基丁基)亚膦酰]乙酰基]-,钠盐,例如,Monopril, Bristol-Myers Squibb和
US4168267中公开的其他试剂)、福辛普利钠(L-脯氨酸,4-环己基-1-[[(R)-[(1S)-2-甲基-
1-(1-氧-丙氧基)丙氧基)、咪达普利、吲哚普利(Schering,J. Cardiovasc. Pharmacol.
5:643, 655 (1983)中公开的)、赖诺普利(Merck)、losinopril、莫昔普利、盐酸莫昔普利
(3-异喹啉羧酸,2-[(2S)-2-[[(1S)-1-(乙氧基羰基)-3-苯基丙基]氨基]-1-氧丙基]-1,2,
3,4-四氢-6,7-二甲氧基-,一盐酸,(3S)- CAS RN 82586-52-5,喹那普利,喹普利拉,EP
79022和Curr. Ther. Res. 40:74 (1986)中公开的雷米普利(Hoechsst)、培哚普利特丁胺
(诸如2S,3aS,7aS-1-[(S)-N-[(S)-1-羧基丁基]丙氨酰]六氢-二氢吲哚羧酸,1-乙酯,具有
叔-丁基胺(1∶1)的化合物,例如,Aceon®, Solvay)、培哚普利(Servier, Eur. J. clin.
Pharmacol. 31 :519 (1987)中公开的)、quanipril(US4344949中公开的)、螺普利
(Schering,Acta. Pharmacol. Toxicol. 59 (Supp. 5):173 (1986)中公开的)、
tenocapril、群多普利、佐芬普利(和US4316906中描述的其他试剂)、伦唑普利(芬替普利,
Clin. Exp. Pharmacol. Physiol. 10:131 (1983)中公开的)、匹伏普利、YS980、替普罗肽
(缓激肽增强剂BPP9a CAS RN 35115-60-7)、BRL 36,378(Smith Kline Beecham,参见
EP80822和EP60668)、MC-838(Chugai,参见CA. 102:72588v和Jap. J. Pharmacol. 40:373
(1986), CGS 14824 (Ciba-Geigy,3-([1-乙氧基羰基-3-苯基-(1S)-丙基]氨基)-2,3,4,
5-四氢-2-氧-1-(3S)-苯并氮杂卓-1乙酸HCl,参见英国专利No.2103614),CGS 16,617
(Ciba-Geigy,3(S)-[[(1S)-5-氨基-1-羧基戊基]氨基]-2,3,4,5-四氢-2-氧-1H-1-苯并氮
杂卓-1-乙酸,参见US4473575),Ru 44570(Hoechst,参见Arzneimittelforschung 34:1254
(1985)),R 31-2201(Hoffman-LaRoche,参见FEBS Lett.165:201(1984))、CI925
(Pharmacologist 26:243, 266 (1984))、WY-44221(Wyeth,参见J. Med. Chem. 26:394
(1983)),和US2003006922(第28段落,US4337201,US4432971(膦酰胺酯)中公开的那些;中
性肽链内切酶抑制剂诸如奥马曲拉(Vanlev®)、CGS 30440、cadoxatril和依卡曲尔、法西
多曲(也称为aladotril或alatriopril)、山帕曲拉、mixanpril和格莫曲拉、AVE7688、
ER4030和US5362727、US5366973、US5225401、US4722810、US5223516、US4749688、
US5552397、US5504080、US5612359、US5525723、EP0599444、EP0481522、EP0599444、
EP0595610、EP0534363、EP534396、EP534492、EP0629627中公开的那些;内皮缩血管肽拮抗
剂诸如替唑生坦、A308165和YM62899等;血管扩张剂诸如肼苯哒嗪(阿普利素灵),可乐定
(盐酸可乐定(1H-咪唑-2-胺,N-(2,6-二氯苯基)4,5-二氢-,一盐酸CAS RN 4205-91-8)、氯
压定、米诺地尔(loniten)、烟醇(roniacol)、盐酸地尔硫卓(诸如1,5-苯并硫氮杂卓-4
(5H)-酮,3-(乙酰基氧)-5[2-(二甲基氨基)乙基]-2,-3-二氢-2(4-甲氧基苯基)-,一盐酸,
(+)-顺,例如Tiazac®, Forest)、二硝酸异山梨酯(诸如1,4:3,6-二酐-D-葡萄糖醇2,5-二
硝酸盐例如,Isordil® Titradose®, Wyeth- Ayerst)、单硝酸异山梨酯(诸如1,4:3,6-
二酐-D-葡萄糖醇-1,5-硝酸盐,有机硝酸盐,例如,Ismo®, Wyeth-Ayerst),硝酸甘油(诸
如2,3丙烷三醇三硝酸盐,例如,Nitrostat® Parke- Davis)、盐酸维拉帕米(诸如苯乙腈,
(±)-(α)[3-[[2-(3,4二甲氧基苯基)乙基]甲基氨基]丙基]-3,4-二甲氧基-(α)-(1-甲基
乙基)盐酸,例如,Covera HS® Extended-Release, Searle)、卡波罗孟(其可如US
3282938中所公开的制备)、clonitate(Annalen 1870 155)、氢普拉明(其可如DE2521113中
所公开的制备)、利多氟嗪(其可如US3267104中所公开的制备);普尼拉明(其可如
US3152173中所公开的制备)、丙帕硝酯(其可如法国专利No. 1,103,113中所公开的制备)、
盐酸米氟嗪(1-哌嗪乙酰胺,3-(氨基羰基)4-[4,4-二(4-氟苯基)丁基]-N-(2,6-二氯苯
基)-,二氢氯化物CAS RN 83898-67-3)、米克昔定(苯乙胺,3,4-二甲氧基-N-(1-甲基-2-吡
咯烷亚基)-吡咯烷,2-[(3,4-二甲氧基苯乙基)亚胺基]-1-甲基-1-甲基-2-[(3,4-二甲氧
基苯乙基)亚胺基]吡咯烷CAS RN 27737-38-8)、吗多明(1,2,3-噁二唑,5-[(乙氧基羰基)
氨基]-3-(4-吗啉基)-,内盐CAS RN 25717-80-0)、单硝酸异山梨酯(D-葡糖醇,1,4:3,6-二
酐-,5-硝酸盐CAS RN 16051-77-7)、丁四硝酯(1,2,3,4-丁烷四醇,四硝酸盐,(2R,3S)-
rel-CAS RN 7297-25-8)、氯硝甘油(1,2-丙二醇,3-氯-,二硝酸盐(7CI, 8CI, 9CI) CAS
RN 2612-33-1)、双嘧达莫,2,2',2",2'"-[(4,8-二-1-哌啶基嘧啶并[5,4-d]嘧啶-2,6-二
基)二氮川]四-CAS RN 58-32-2)、尼可地尔(CAS RN 65141-46-03-)、吡啶甲酰胺(N-[2-
(硝氧)乙基]-尼索地平3,5-吡啶二羧酸,1,4-二氢-2,6-二甲基-4-(2-硝基苯基)-,甲基2-
甲基丙基酯CAS RN 63675-72-9)、硝苯地平3,5-吡啶二羧酸,1,4-二氢-2,6-二甲基-4-(2-
硝基苯基)-,二甲基酯CAS RN 21829-25-4)、马来酸哌克昔林(哌啶,2-(2,2-二环己基乙
基)-,(2Z)-2-丁烯二酸酯(1 :1) CAS RN 6724-53-4)、盐酸氧烯洛尔(2-丙醇,1-[(1-甲基
乙基)氨基]-3-[2-(2-丙烯基氧)苯氧基]-,盐酸盐CAS RN 6452-73-9)、戊硝醇(1,3-丙二
醇,2,2-二[(硝氧)甲基]-,一硝酸盐(酯)CAS RN 1607-17-6)、维拉帕米(苯乙腈,α-[3-
[[2-(3,4-二甲氧基苯基)乙基]-甲基氨基]丙基]-3,4-二甲氧基-α-(1-甲基乙基)- CAS
RN 52-53-9)等;血管紧张素II受体拮抗剂诸如,aprosartan、佐拉沙坦、奥美沙坦、普拉沙
坦、FI6828K、RNH6270、坎地沙坦(1H-苯并咪唑-7-羧酸,2-乙氧基-1-[[2′-(1H-四唑-5-基)
[1,1′-二苯基]4-基]甲基]- CAS RN 139481-59-7)、坎地沙坦环庚塞((+/-)-1-(环己基羰
基氧)乙基-2-乙氧基-1-[[2′-(1H-四唑-5-基)二苯基-4-基]-1H-苯并咪唑羧酸盐,CAS RN
145040-37-5,US5703110和US5196444)、依普罗沙坦(3-[1-4-羧基苯基甲基)-2-n-丁基-咪
唑-5-基]-(2-噻吩基甲基)丙烯酸,US5185351和US5650650)、厄贝沙坦(2-n-丁基-3-[[2′-
(1h-四唑-5-基)二苯基-4-基]甲基]1,3-二氮杂螺[4,4]壬-1-烯-4-酮,US5270317和
US5352788)、氯沙坦(2-N-丁基-4-氯-5-羟基甲基-1-[(2′-(1H-四唑-5-基)二苯基-4-基)-
甲基]咪唑,钾盐,US5138069,US5153197和US5128355)、他索沙坦(5,8-二氢-2,4-二甲基-
8-[(2′-(1H-四唑-5-基)[1,r-二苯基]4-基)甲基]-吡啶并[2,3-d]嘧啶-7(6H)-酮,
US5149699)、替米沙坦(4′-[(1,4-二甲基-2′-丙基-(2,6′-二-1H-苯并咪唑)-r-基)]-[1,
1′-二苯基]-2-羧酸,CAS RN 144701-48-4, US5591762)、米法沙坦、阿比沙坦、缬沙坦
(Diovan® (Novartis),(S)-N-戊酰-N-[[2′-(1H-四唑-5-基)二苯基-4-基)甲基]缬氨酸,
US5399578)、EXP-3137(2-N-丁基-4-氯-1-[(2′-(1H-四唑-5-基)二苯基-4-基)-甲基]咪
唑-5-羧酸,US5138069,US5153197和US5128355)、3-(2′-(四唑-5-基)-1,r-联苯-4-基)甲
基-5,7-二甲基-2-乙基-3H-咪唑并[4,5-b]吡啶,4′[2-乙基-4-甲基-6-(5,6,7,8-四氢咪
唑并[1,2-a]吡啶-2-基]-苯并咪唑-1-基]-甲基]-1,r-二苯基]-2-羧酸,2-丁基-6-(1-甲
氧基-1-甲基乙基)-2-[2′-)IH-四唑-5-基)二苯基-4-基甲基]guinazolin-4(3H)-酮,3-
[2′-羧基二苯基-4-基)甲基]-2-环丙基-7-甲基-3H-咪唑并[4,5-b]吡啶,2-丁基-4-氯-1-
[(2′-四唑-5-基)二苯基-4-基)甲基]咪唑-羧酸,2-丁基-4-氯-1-[[2′-(1H-四唑-5-基)
[1,1′-二苯基]-4-基]甲基]-1H-咪唑-5-羧酸-1-(乙氧基羰基-氧)乙酯钾盐,2-丁基-4-
(甲基硫)-1-[[2-[[[(丙基氨基)羰基]氨基]-磺酰](1,1′-二苯基)-4-基]甲基]-1H-咪唑-
5-羧酸二钾盐,甲基-2-[[4-丁基-2-甲基-6-氧-5-[[2′-(1H-四唑-5-基)-[1,1′-二苯基]-
4-基]甲基]-1-(6H)-嘧啶基]甲基]-3-噻吩羧酸酯,5-[(3,5-二丁基-1H-1,2,4-三唑-1-
基)甲基]-2-[2-(1H-四唑-5-基苯基)]吡啶,6-丁基-2-(2-苯基乙基)-5[[2′-(1H-四唑-5-
基)[1,1′-二苯基]-4-甲基]嘧啶-4-(3H)-酮D,L赖氨酸盐,5-甲基-7-n-丙基-8-[[2′-(1H-
四唑-5-基)二苯基-4-基]甲基]-[1,2,4]-三唑并[1,5-c]嘧啶-2(3H)-酮,2,7-二乙基-5-
[[2′-(5-四唑)二苯基-4-基]甲基]-5H-吡唑并[1,5-b][1,2,4]三唑钾盐,2-[2-丁基-4,5-
二氢-4-氧-3-[2′-(1H-四唑-5-基)-4-二苯基甲基]-3H-咪唑[4,5-c]吡啶-5-基甲基]苯甲
酸,乙酯,钾盐,3-甲氧基-2,6-二甲基-4-[[2′(1H-四唑-5-基)-1,1′-二苯基-4-基]甲氧
基]吡啶,2-乙氧基-1-[[2′-(5-氧-2,5-二氢-1,2,4-恶二唑-3-基)二苯基-4-基]甲基]-
1H-苯并咪唑-7-羧酸,1-[N-(2’-(1H-四唑-5-基)二苯基-4-基-甲基)-N-戊酰氨基甲基)环
戊烷-1-羧酸,7-甲基-2n-丙基-3-[[2′1H-四唑-5-基)二苯基-4-基]甲基]-3H-咪唑并[4,
5-6]吡啶,2-[5-[(2-乙基-5,7-二甲基-3H-咪唑并[4,5-b]吡啶-3-基)甲基]-2-喹啉基]苯
甲酸钠,2-丁基-6-氯-4-羟基甲基-5-甲基-3-[[2′-(1H-四唑-5-基)二苯基-4-基]甲基]吡
啶,2-[[[2-丁基-1-[(4-羧基苯基)甲基]-1H-咪唑-5-基]甲基]氨基]苯甲酸四唑-5-基)二
苯基-4-基]甲基]嘧啶-6-酮,4(S)-[4-(羧基甲基)苯氧基]-N-[2(R)-[4-(2-磺胺苯酰)咪
唑-1-基]辛酰基]-L-脯氨酸,1-(2,6-二甲基苯基)-4-丁基-1,3-二氢-3-[[6-[2-(1H-四
唑-5-基)苯基]-3-吡啶基]甲基]-2H-咪唑-2-酮,5,8-桥亚乙基-5,8-二甲基-2-n-丙基-5,
6,7,8-四氢-1-[[2′(1H-四唑-5-基)二苯基-4-基]甲基]-1H,4H-1,3,4a,8a-四氮杂环戊烯
萘-9-酮,4-[1-[2′-(1,2,3,4-四唑-5-基)二苯-4-基)甲基氨基]-5,6,7,8-四氢-2-三氟甲
磺酰基喹唑啉,2-(2-氯苯甲酰)亚胺基-5-乙基-3-[2′-(1H-四唑-5-基)二苯基-4-基)甲
基-1,3,4-噻二唑啉,2-[5-乙基-3-[2-(1H-四唑-5-基)二苯基-4-基]甲基-1,3,4-噻唑啉-
2-亚基]氨基羰基-1-环戊烯羧酸二钾盐,和2-丁基-4-[N-甲基-N-(3-甲基巴豆酰)氨基]-
1-[[2’-(1H-四唑-5-基)二苯基-4-基]甲基]-1H-咪唑-5-羧酸1-乙氧基羰基氧乙基酯,专
利公开 中公开的那些,以及其药
学可接受的盐和酯;α/β肾上腺素阻断剂(adrenergic blockers)诸如尼普地洛、阿罗洛尔、
氨磺洛尔、溴苄铵托西酸盐(CAS RN:61-75-6),甲磺酸双氢麦角胺(诸如ergotaman-3′,6′,
18-三酮,9,-10-二氢-12′-羟基-2′-甲基-5′-(苯基甲基)-,(5′(α))-,单甲磺酸酯,例如,
DHE 45® Injection, Novartis)、卡维地洛(诸如(±)-1-(咔唑-4-基氧)-3-[[2-(o-甲氧
基苯氧基)乙基]氨基]-2-丙醇,例如,Coreg®, SmithKline Beecham)、拉贝洛尔(诸如5-
[1-羟基-2-[(1-甲基-3-苯基丙基)氨基]乙基]水杨酰基酰胺一盐酸,例如,Normodyne®,
Schering)、溴苄铵托西酸盐(Benzenemethanaminium,2-溴-N-乙基-N,N-二甲基-,与4-甲
基苯磺酸的盐(1∶1) CAS RN 61-75-6)、甲磺酸酚妥拉明(苯酚,3-[[(4,5-二氢-1H-咪唑-
2-基)甲基](4-甲基苯基)氨基]-,单甲磺酸(盐) CAS RN 65-28-1)、酒石酸苯哌乙噁哚
(5H-1,3-二氧基[4,5-f]吲哚,7-[2-[4-(2-甲氧基苯基)-1-哌嗪]乙基]-,(2R,3R)-2,3-二
羟基丁二酸(1∶1) CAS RN 5591-43-5)、盐酸佐勒汀(哌嗪,1-苯基4-[2-(1H-四唑-5-基)乙
基]-,一盐酸(8Cl,9Cl)CAS RN 7241-94-3)等;α肾上腺素能受体阻断剂,诸如阿夫唑嗪
(CAS RN:81403-68-1)、特拉唑嗪、乌拉地尔、哌唑嗪(Minipress®)、坦洛新、布那唑嗪、曲
马唑嗪、多沙唑嗪、萘哌地尔、吲哚拉明、WHP 164、XENOlO、盐酸苯螺旋酮(其可如US3399192
中所公开的制备)、proroxan(CAS RN 33743-96-3)和盐酸拉贝洛尔及其组合;α2激动剂诸
如甲基多巴、甲基多巴HCL、洛非西定、噻美尼定、莫索尼定、利美尼定、guanobenz等;醛固酮
抑制剂等;肾素抑制剂包括阿利吉仑(SPPlOO;Novartis/Speedel);血管生成素-2-结合剂
诸如WO03/030833中公开的那些;抗-心绞痛剂诸如雷诺嗪(盐酸1-哌嗪乙酰胺,N-(2,6-二
甲基苯基)-4-[2-羟基-3-(2-甲氧基苯氧基)丙基]-,二盐酸CAS RN 95635- 56-6)、盐酸倍
他洛尔(2-丙醇,1-[4-[2(环丙基甲氧基)乙基]苯氧基]-3-[(1-甲基乙基)氨基]-,盐酸CAS
RN 63659-19-8)、盐酸布托丙茚(甲酮,[4-[3(二丁基氨基)丙氧基]苯基(2-乙基-3-吲嗪
基)-,一盐酸CAS RN 62134-34-3)、马来酸盐1-哌嗪乙酸桂哌酯cinepazet maleatel-
Piperazineacetic acid,4-[1-氧-3-(3,4,5-三甲氧基苯基)-2-丙烯基]-,乙基酯,(2Z)-
2-丁烯二酸酯(1∶1) CAS RN 50679-07-7)、托西芬(苯磺酰胺,4-甲基-N-[[[(1S)-1-甲基-
2-苯基乙基]氨基]羰基]- CAS RN 32295-184)、盐酸维拉帕米(苯乙腈,α-[3-[[2-(3,4-二
甲氧基苯基)乙基]甲基氨基]丙基]-3,4-二甲氧基-α-(1-甲基乙基)-,一盐酸CAS RN 152-
114),吗多明(1,2,3-噁二唑,5-[(乙氧基羰基)氨基]-3-(4-吗啉基)-,内盐CAS RN 25717-
80-0)和盐酸雷诺嗪(1-哌嗪乙酰胺,N-(2,6-二甲基苯基)4-[2-羟基-3-(2-甲氧基苯氧基)
丙基]-,二盐酸CAS RN 95635-56-6);托西芬(苯磺酰胺,4-甲基-N-[[[(1S)-1-甲基-2-苯
基乙基]氨基]羰基]- CAS RN 32295-184);肾上腺素能兴奋剂诸如盐酸胍法辛(诸如N-脒
基-2-(2,6-二氯苯基)乙酰胺盐酸盐,例如可获自Robins的Tenex®片剂);与氢氯噻嗪(诸
如6-氯-3,4-二氢-2H-1,2,4-苯并噻二嗪-7-磺酰胺1,1-二氧化物组合的甲基多巴-氢氯噻
嗪(诸如左旋-3-(3,4-二羟基苯基)-2-甲基丙氨酸),例如,组合例如,可获自Merck的
Aldoril®片剂)、甲基多巴-氯噻嗪(诸如6-氯-2H-1,2,4-苯并噻二嗪-7-磺酰胺1,1-二氧
化物和如上所述的甲基多巴,例如,Aldoclor®, Merck)、盐酸可乐定(诸如2-(2,6-二氯苯
基氨基)-2-咪唑啉盐酸和氯噻酮(诸如2-氯-5-(1-羟基-3-氧-1-异吲哚啉基)苯磺酰胺),
例如,Combipres®, Boehringer Ingelheim)、盐酸可乐定(诸如2-(2,6-二氯苯基氨基)-
2-咪唑啉盐酸,例如,Catapres®, Boehringer Ingelheim)、可乐定(1H-咪唑-2-胺,N-(2,
6-二氯苯基)4,5-二氢- CAS RN 4205-90-7)、Hyzaar (Merck;氯沙坦和氢氯噻嗪的组合)、
Co-Diovan(Novartis;缬沙坦和氢氯噻嗪的组合,Lotrel(Novartis;贝那普利和氨氯地平
的组合)和Caduet(Pfizer;氨氯地平和阿托伐他汀的组合),和US20030069221中公开的那
些试剂。
1.2.2.11 用于治疗呼吸病症的试剂
本文中描述的GCC激动剂肽可与用于治疗呼吸和其他病症的一种或多种下列试剂一起用于组合治疗,所述试剂包括但不限于:(1)β-激动剂包括但不限于:沙丁胺醇(PRO VENTIL®、S ALBUT AMOl®、VENTOLIN®)、班布特罗、比托特罗、克仑特罗、非诺特罗、福莫特罗、异他林(BRONKOSOL®、BRONKOMETER®)、奥西那林(ALUPENT®、METAPREL®)、吡布特罗(MAXAIR®)、瑞普特罗、利米特罗、沙美特罗、特布他林(BRETHAIRE®、BRETHINE®、BRICANYL®)、肾上腺素、异丙肾上腺素(ISUPREL®)、肾上腺素酒石酸氢盐(PRIMATENE®)、麻黄素、奥西那林、非诺特罗和异他林;(2)类固醇(steroids),包括但不限于倍氯米松、丙酸倍氯米松、倍他米松、布地奈德、bunedoside、布替可特、地塞米松、氟尼缩松、氟可丁、氟替卡松、氢化可的松、甲基泼尼松、莫米松、泼尼松龙、泼尼松、替泼尼旦、tixocortal、曲安西龙和醋酸曲安西龙;(3)β2-激动剂-皮质类固醇组合[例如,沙美特罗-氟替卡松(AD VAIR®)、福莫特罗-布地奈德(S YMBICORT®)];(4)白三烯D4受体拮抗剂/白三烯拮抗剂/LTD4拮抗剂(即,能够阻断、抑制、减少或另外地中断白三烯与Cys LTI受体之间的相互作用的任何化合物)包括但不限于:zafhiukast、孟鲁司特、孟鲁司特钠(SINGULAIR®)、普仑司特、伊拉司特、泊比司特、SKB-106,203和美国专利No.5,565,473中描述的被描述为具有LTD4拮抗活性的化合物; (5)5-脂氧合酶抑制剂和/或白三烯生物合成抑制剂[例如,齐留通和BAY1005(CA registry 128253-31-6)];(6)组胺H1受体拮抗剂/抗组胺剂(即,能够阻断、抑制、减少或另外地中断组胺与其受体之间的相互作用的任何化合物)包括但不限于:阿司咪唑、阿伐斯汀、安他唑啉、阿扎他定、氮卓斯汀、astamizole、溴苯那敏、马来酸溴苯那敏、卡比沙明、卡瑞斯汀、西替利嗪、氯苯那敏、马来酸氯苯那敏、西咪替丁氯马斯汀、赛克力嗪、赛庚啶、去羧乙氧基氯雷他定、右氯苯那敏、二甲茚定、苯海拉明、二苯拉林、琥珀酸多西拉敏、多西拉敏、依巴斯汀、乙氟利嗪、依匹斯汀、法莫替丁、非索非那定、羟嗪、羟嗪、酮替芬、左卡巴斯汀、左西替利嗪、左西替利嗪、氯雷他定、美克洛嗪、美吡拉敏、美喹他嗪、甲地嗪、米安色林、咪唑斯汀、诺柏斯汀、去甲阿司咪唑、noraztemizole、苯茚胺、非尼拉敏、哌香豆司特、异丙嗪、pynlamine、美吡拉敏、雷尼替丁、替美斯汀、特非那定、异丁嗪、曲吡那敏和曲普利啶;(7)抗胆碱能药包括但不限于:阿托品、苯扎托品、比哌立登、flutropium、莨菪碱(例如Levsin®; Levbid®; Levsin/SL®、Anaspaz®、Levsinex timecaps®、NuLev®)、ilutropium、异丙托铵、异丙托溴铵、甲基东莨菪碱、奥昔布宁、利喷西平、东莨菪碱和噻托溴铵;(8)抗咳嗽药,包括但不限于:右美沙芬、可待因和氢吗啡酮;(9)解充血药包括但不限于:假麻黄素和苯丙醇胺;(10)祛痰药包括但不限于:guafenesin、guaicolsulfate、萜二醇(terpin)、氯化铵、甘油guaicolate和碘化甘油;(11)支气管扩张药包括但不限于:茶碱和氨茶碱;(12)抗炎药包括但不限于:氟比洛芬,双氯芬酸、吲哚美辛、酮洛芬、S-酮洛酚、替诺昔康;(13)PDE(磷酸二酯酶)抑制剂包括但不限于本文中公开的那些; (14)重组人源化单克隆抗体[例如奥马珠单抗(也称为奥马佐单抗),rhuMab和他利珠单抗];(15)人源化肺表面活性剂包括表面活性蛋白SP-B、SP-C或SP-D的重组形式[例如SURFAXIN®,以前称为dsc-104(Discovery Laboratories)],(16)抑制上皮钠通道(ENaC)的试剂诸如阿米洛利和相关化合物;(17)用于治疗肺部感染的抗微生物剂诸如阿昔洛韦,阿米卡星、阿莫西林、多西环素、三甲氧苄二氨嘧啶磺胺甲基异恶唑、两性霉素B、阿奇霉素、克拉霉素、罗红霉素、克拉霉素、头孢菌素类(头孢西丁、头孢美唑等)、环丙沙星、乙胺丁醇、庆大霉素、更昔洛韦、亚胺培南、异烟肼、伊曲康唑、青霉素、利巴韦林、利福平、利福布汀、金刚烷胺、金刚乙胺、链霉素、妥布霉素和万古霉素;(18)通过Ca++依赖性氯通道激活氯分泌的试剂(诸如嘌呤型受体(P2Y(2)激动剂);(19)降低痰粘度的试剂,诸如人重组DNA酶1,(Pulmozyme®);(20)非类固醇抗炎药(阿西美辛、对乙酰氨基酚、乙酰水杨酸、阿氯芬酸、阿明洛芬、阿扎丙宗、阿司匹林、苯噁洛芬、bezpiperylon、布氯酸、卡洛芬、环氯茚酸、双氯芬酸、双氯芬酸、二氟尼柳、diflusinal、依托度酸、芬布芬、芬布芬、芬氯酸、芬克洛酸、非诺洛芬、芬替酸、非普拉宗、氟芬那酸、氟苯柳、氟苯柳、氟洛芬、氟比洛芬、氟比洛芬、呋罗芬酸、异丁芬酸、布洛芬、吲哚美辛、吲哚美辛、吲哚洛芬、伊索克酸、伊索昔康、酮洛芬、酮洛芬、酮咯酸、甲氯芬那酸、甲氯芬那酸、甲芬那酸、甲芬那酸、咪洛芬、莫非布宗、萘丁美酮奥沙普秦、萘普生、萘普生、尼氟酸、奥沙普秦、oxpinac、羟布宗、非那西丁、保泰松、保泰松、吡罗昔康、吡罗昔康、吡洛芬、普拉洛芬、舒多昔康、替诺昔康、柳氮磺吡啶、舒林酸、舒林酸、舒洛芬、噻洛芬酸、硫平酸、硫噁洛芬、托芬那酸、托美丁、托美丁、齐多美辛、佐美酸和佐美酸;和(21)雾化抗氧化剂治疗剂诸如S-亚硝基谷胱甘肽。
1.2.2.12 抗-糖尿病剂
可将本文中描述的GCC激动剂肽与一种或多种抗-糖尿病剂一起用于组合治疗,所述
抗-糖尿病剂包括但不限于:PPARγ激动剂诸如格列酮类(例如,WAY-120,744、AD 5075、巴
格列酮、环格列酮、达格列酮(CP-86325、Pfizer)、恩格列酮(CP-68722、Pfizer)、
isaglitazone(MIT/J&J)、MCC-555(US5594016中公开的Mitsibishi)、吡格列酮(诸
如Actos™吡格列酮;Takeda)、罗格列酮(Avandia™;Smith Kline Beecham)、马来酸
罗格列酮、曲格列酮(Rezulin®,于US4572912中公开的)、利格列酮(CS-O11,
Sankyo)、GL-262570(Glaxo Welcome)、BRL49653(于WO98/05331中公开的)、 中公开的化合物及其药学可接受的盐;双胍类诸如盐酸二甲
双胍(N,N-二甲基亚胺基二碳酸亚胺二酰胺盐酸盐,诸如Glucophage™,Bristol-Myers
Squibb);盐酸二甲双胍和格列本脲,诸如Glucophage™,Bristol-Myers Squibb);丁福明
(亚胺基二碳酸亚胺二酰胺,N-丁基-);etoformine(1-丁基-2-乙基双胍,Schering A.G.);
其他二甲双胍盐形式(包括其中盐选自醋酸盐、苯甲酸盐、柠檬酸盐、ftimarate、双羟萘酸
盐、氯苯氧乙酸盐、羟乙酸盐、palmoate、天冬氨酸、甲磺酸盐(methanesulphonate)、马来酸
盐、对氯苯氧异丁酸盐、甲酸盐(formate)、乳酸盐、琥珀酸盐、硫酸盐、酒石酸盐、环己烷羧
酸盐、己酸盐、辛酸盐、癸酸盐、十六酸盐、十八酸盐、苯磺酸盐、三甲基苯甲酸盐、对甲苯磺
酸盐、金刚烷甲酸盐、乙醛酸、谷氨酸盐、吡咯烷酮羧酸盐、萘磺酸盐、1-葡萄糖磷酸盐、硝酸
盐、亚硫酸盐、连二硫酸盐和磷酸盐)和苯乙双胍;蛋白酪氨酸磷酸酶-IB(PTP-IB)抑制剂,
诸如 中描述的那些,及其药学可接受的盐和酯;磺酰
脲例如醋酸己脲(例如醋磺己脲,Eli Lilly)、磺胺丁脲、氯磺丙脲(例如Diabinese®,
Pfizer)、格列胺脲(Pfizer)、格列齐特(例如Diamcron,Servier Canada Inc)、格列美脲
(例如US4379785中公开的,诸如Amaryl,Aventis)、格列戊脲、格列吡嗪(例如Glucotrol或
Glucotrol XL Extended Release,Pfizer)、格列喹酮、格列索脲、格列本脲/优降糖
(glibenclamide)(例如Micronase或Glynase Prestab,Pharmacia & Upjohn和Diabeta,
Aventis)、妥拉磺脲(例如Tolinase)和甲苯磺丁脲(例如Orinase)及其药学可接受的盐和
酯;氯茴苯酸类(meglitinides)诸如瑞格列奈(例如Pranidin®, Novo Nordisk)、KAD1229
(PF/Kissei)和那格列胺(例如Starlix®, Novartis)及其药学可接受的盐和酯;α葡糖苷
水解酶抑制剂(或葡糖苷抑制剂)诸如阿卡波糖(例如US4904769中公开的Precose™,
Bayer)、米格列醇(诸如US4639436中公开的GLYSET™,Pharmacia & Upjohn)、卡格列波糖
(甲基6-脱氧-6-[(2R,3R,4R,5S)-3,4,5-三羟基-2-(羟基甲基)哌啶基]-α-D-吡喃葡萄糖
苷,Marion Merrell Dow)、伏格列波糖(Takeda)、脂解素、乙格列酯、普那米星-Q、
salbostatin、 (聚胺)中公开的化合物;α-淀粉酶抑
制剂诸如淀粉酶抑肽、萃他丁和A1-3688以及US4451455、US4623714和US4273765中公开的
化合物;SGLT2抑制剂,包括US6414126和US6515117中公开的那些;aP2抑制剂诸如
US6548529中公开的那些;胰岛素促泌剂诸如利诺格列、A-4166、毛喉素、二丁基cAMP、异丁
基甲基黄嘌呤(IBMX),及其药学可接受的盐和酯;脂肪酸氧化抑制剂,诸如氯莫克舍和乙莫
克舍,及其药学可接受的盐和酯;A2拮抗剂,诸如咪格列唑、伊格列哚、德格列哚、咪唑克生、
earoxan和氟洛克生,及其药学可接受的盐和酯;胰岛素和相关化合物(例如胰岛素模拟物)
诸如biota、LP-100、novarapid、地特胰岛素、赖脯胰岛素、甘精胰岛素、锌胰岛素注射液(缓
慢的和超缓慢的)、Lys-Pro胰岛素、GLP-I(1-36)酰胺、GLP-I(73-7)(insulintropin,公开
于US5614492)、LY-315902(Lilly)、GLP-I(7-36)-NH2)、AL-401(Autoimmune)、US4579730、
US4849405、US4963526、US5642868、US5763396、US5824638、US5843866、US6153632、
US6191105和WO 85/05029中公开的某些化合物以及灵长类动物、啮齿类动物或兔胰岛素包
括其生物活性变体,包括等位基因变体,更优选可以以重组形式获得的人胰岛素(人胰岛素
的来源包括药学可接受的和无菌的制剂诸如可从Eli Lilly(Indianapolis, Ind. 46285)
获得的人胰岛素如Humulin™ (人胰岛素rDNA来源),也参见THE PHYSICIAN'S DESK
REFERENCE, 55.sup.th Ed. (2001) Medical Economics, Thomson Healthcare (公开了
其他适当的人胰岛素);非-噻唑啉二酮类诸如JT-501和法格立他扎(GW-2570/GI-262579)
及其药学可接受的盐和酯;PPARα/γ双激动剂诸如AR-HO39242 (Aztrazeneca)、GW-409544
(Glaxo-Wellcome)、BVT-142、CLX-0940、GW-1536、GW-1929、GW-2433、KRP-
297 (Kyorin Merck;5-[(2,4-二氧噻唑烷基)甲基]甲氧基-N-[[4-(三氟甲基)苯
基]甲基]苯甲酰胺)、L-796449、LR-90、MK-0767(Merck/Kyorin/Banyu)、SB
219994、莫格列他(BMS)、替格列扎(Astrazeneca)、瑞格列扎(JTT-501)以及 2000年9月18日提交的美国申请系列No. 09/
664,598、Murakami等人Diabetes 47, 1841-1847 (1998)中公开的那些,及其药学可接受
的盐和酯;其他胰岛素增敏药物;VPAC2受体激动剂;GLK调节剂,诸如WO03/015774中公开的
那些;类视色素调节剂诸如WO03/000249中公开的那些;GSK 3β/GSK 3抑制剂诸如4-[2-(2-
溴苯基)-4-(4-氟苯基-1H-咪唑-5-基]吡啶和WO03/024447、WO03/037869、WO03/037877、
WO03/037891、WO03/068773、EP1295884、EP1295885等中公开的那些化合物等;糖原磷酸化
酶(HGLPa)抑制剂诸如CP-368,296、CP-316,819、BAYR3401和WOO 1/94300、WO02/20530、
WO03/037864中公开的化合物以及其药学可接受的盐或酯;ATP消耗促进剂诸如WO03/
007990中公开的那些;TRB3抑制剂;辣椒素受体配体诸如WO03/049702中公开的那些;降血
糖试剂诸如WO03/015781和WO03/040114中公开的那些;糖原合酶激酶3抑制剂诸如WO03/
035663中公开的那些,试剂例如WO99/51225、US20030134890、WO01/24786和WO03/059870公
开的那些;胰岛素-反应DNA结合蛋白-1(IRDBP-I),如WO03/057827等中公开的;腺苷A2拮抗
剂诸如WO03/035639、WO03/035640等中公开的那些;PPARδ激动剂诸如GW 501516、GW
590735以及JP10237049和WO02/14291中公开的化合物;二肽基肽酶IV(DP-IV)抑制剂,诸如
异亮氨酸噻唑烷、NVP-DPP728A (1-[[[2-[(5-氰基嘧啶-2-基)氨基]乙基]氨基]乙酰基]-
2-氰基-(S)-吡咯烷,由Hughes等人,Biochemistry, 38(36), 11597-11603, 1999公开
的)、P32/98、NVP-LAF-237、P3298、TSL225(色氨酰-1,2,3,4-四氢-异喹啉-3-羧酸,由
Yamada等人,Bioorg. & Med. Chem. Lett. 8 (1998) 1537-1540公开的),缬氨酸吡咯烷、
TMC-2A/2B/2C、CD-26抑制剂、FE999011、P9310/K364、VIP 0177、DPP4、SDZ 274-444、2-氰基
吡咯啶和4-氰基吡咯啶,如由Ashworth等人,Bioorg. & Med. Chem. Lett.,第6卷,No.22,
pp 1163-1166和2745-2748(1996)公开的,和 (公开的
化合物包括 中公开的化合物;GLP-I激动
剂诸如艾塞那肽-3和艾塞那肽-4(包括称为Exenatide®的39个氨基酸多肽的合成的艾塞
那肽-4),和US2003087821和NZ 504256中公开的化合物,及其药学可接受的盐和酯;肽包括
安林肽和Symlin®(醋酸普兰林肽)的肽;和糖激酶激活剂诸如US2002103199(稠合的杂芳
族化合物)和WO02/48106(异吲哚啉-1-酮-取代的丙酰胺化合物)中公开的那些。
本文提到的所有专利、专利申请和出版物通过引用完整地并入本文。然而,当含有明确定义的专利、专利申请或出版物通过引用并入时,应当理解,那些明确定义适用于它们存在于其中的并入的专利、专利申请或出版物,且不适用于该申请文本的其他部分。在冲突的情况下,以本说明书(包括定义)为准。不承认本文引用的参考文献是本发明的现有技术。
应当理解,尽管本发明结合其优选具体实施方案已进行描述,但前述描述意在说明而非限制本发明的范围。本领域技术人员将理解,可以进行各种变化,且对应物在不脱离本发明范围的情况下可以进行取代,且进一步地,其他方面、优点和改变对于本发明涉及领域的技术人员而言是显而易见的。
实施例
实施例1:SP-304的侧链保护的片段的制备
Fmoc-AA-OH连接至2-ClTrt树脂
将2-ClTrt树脂(10 g,取代率(substitution) =1.0 mmol/g树脂)悬浮在100 mL二氯甲烷(DCM)中持续5分钟,然后排空。使用在80 mL DCM中的1.5当量的Fmoc-氨基酸和1.7当量的二异丙基乙胺(DIEA)(用最小量的二甲基甲酰胺(DMF)来完全溶解氨基酸)进行酯化反应,持续2小时。用60 mL DCM洗涤得到的树脂,且用60 mL DIEA /甲醇(1:9,v/v)溶液进行封端,持续30分钟。然后将负载的树脂用DCM (6倍体积)洗涤2次,用DMF(6倍体积)洗涤3次且用甲基叔丁基醚(MTBE)(6倍体积)洗涤3次,且在高真空下干燥。通过Fmoc释放试验确定Fmoc-保护树脂的取代率。最后,将Fmoc基团用在DMF (10倍体积)中5%哌啶、1% 1,8-二氮杂双环[5.4.0]十一碳-7-烯(DBU)和1% N-羟基苯并三唑(HOBt)的混合物进行脱保护2次,洗涤树脂,且在高真空下干燥以得到用于肽合成的最终树脂。实验结果列于下表VIII中。
表VIII. H-Gly-2ClTrt和H-Leu-2ClTrt树脂的制备
侧链保护的片段A和B的合成
将H-Gly-2-ClTrt树脂或H-Leu-2-ClTrt树脂悬浮在DMF (10倍体积)中持续20分钟,然后排空。得到的树脂用DMF洗涤(10倍体积),持续5分钟。使用标准Fmoc化学进行链装配。通常,将1.5当量的Fmoc氨基酸和1.5当量的HOBt溶解在DMF(4.5倍体积)中,随后添加1.5当量的DIEA。然后,用冰水浴将得到的溶液冷却至低于5℃,且通过添加1.5当量的HBTU活化。将DCM(1.5倍体积)添加至树脂,然后添加活化的Fmoc氨基酸溶液。将得到的混合物在室温下搅拌2小时,且通过Kaiser试验监测酰化反应的完成。如果Kaiser试验表明2小时后存在未反应的胺,那么需要以相同方案使用1.0当量的Fmoc氨基酸、1.0当量的HOBt和1.0当量的DIEA进行重新偶联。通常通过用乙酸酐/吡啶/ DMF溶液的混合物乙酰化未反应的胺而实现封端。通过以从C到N-末端的顺序用对应的Fmoc氨基酸衍生物重复上述封端程序而装配肽序列。通过以DCM/DMF方案使用2.0当量的Fmoc-Cys(Trt)-OH或Fmoc-Cys(Acm)-OH、2.0当量的HOBt和2.0当量的DIC原位活化而实现Fmoc-Cys(Trt)-OH或Fmoc-Cys(Acm)-OH残基的偶联以使得半胱氨酸的外消旋作用最小化。
合成步骤完成之后,用DMF(10倍体积)、MTBE(10倍体积)、DMF(10体积,3次)和MTBE(10体积,3次)彻底洗涤肽树脂,且随后在真空烘箱中干燥至恒重。
使用1%TFA/DCM (10倍体积)从树脂上裂解侧链保护的肽,持续3次,每次5分钟,且每次将裂解级分收集到吡啶上(在每个裂解级分中与TFA 1:1体积比)。肽树脂用DCM(7.5倍体积)洗涤。组合级分,且在真空下浓缩至初始体积的10%,且将得到的溶液用乙醇(3倍体积)重构,且浓缩至初始体积的50%。最后,通过添加水(1倍体积)沉淀肽。通过真空过或离心收集固体,且用水洗涤两次。将产物在真空中干燥至恒重,且进行HPLC和ES-MS分析。实验结果提供于下表IX中。
表IX. A和B片段的制备
*计算值=平均分子质量;实测值=通过ES-MS测量的单一同位素质量。
实施例2:SP-304的片段在溶液中的缩合
片段C:H-AA15-16OtBu (1-1)的合成
将Fmoc-Cys(Acm)-OH (124.38克, 0.3 mol)、H-Leu-OtBu.HCl (67.12克, 0.3 mol)、和HOBt (40.54克, 0.3 mol)在DMF (600 mL)中的溶液冷却至-5℃。添加2-[1H-苯并三唑-1-基]-1,1,3,3-四甲基脲六氟磷酸酯(HBTU) (113.79克, 0.3 mol),且完全溶解。在良好搅拌下在相同温度经105分钟期间逐滴添加DIEA (183.1 mL, 1.05 mol),将混合物的pH保持在6和7之间。在0℃继续搅拌15分钟,且用TLC监测反应。用乙酸乙酯(EtOAc)(600 mL)和5% H3PO4 (300 mL)稀释反应混合物。分出有机层,且用EtOAc(600 mL)萃取水层。用5%H3PO4 (2次)、H2O (1次)、饱和的NaHCO3 (3次)、H2O (2次)、和盐水(2次)洗涤组合的萃取液。溶液用无水MgSO4干燥,过滤,且在真空中蒸发至干燥。将产物从石油醚/EtOAc (3:1)重结晶且干燥:166.75克(得率95.0%,纯度99.0%)。
在搅拌下将Fmoc-Cys(Acm)-Leu-OtBu (166.75克, 0.277 mol)溶解在10%哌啶/DCM溶液(810 mL)中。用TLC监测反应。在3小时内完成反应后,使用旋转蒸发仪去除溶剂和挥发性物质。获得的油状物质用石油醚研磨,以通过倾析以去除副产物。将残留物糖浆投入EtOAc中,用NaH2PO4/Na2HPO4 (pH=6)的混合溶液、然后饱和的NaHCO3、纯H2O和盐水洗涤。用无水MgSO4干燥有机层。溶剂和挥发性物质的蒸发得到油状产物H-Cys(Acm)-Leu-OtBu (1-1) (73.23克,得率73.1%,纯度:98.0%)。
片段B-C:HAA7-16OtBu (2-3)的合成
将Fmoc-AA7-14OH (1׳) (198.3克,124.0 mmol)、H-AA15-16OtBu (1-1) (52.3克,148.8 mmol)和Cl-HOBt (21.0克,124.0 mmol)在DMF (2500 mL)中的溶液冷却至-5℃。添加HBTU (51.7克,136.4 mmol),且完全溶解。然后在搅拌下添加DIEA (54.1 mL, 310mmol),将混合物的pH保持在6和7之间。在0-5℃继续搅拌30分钟。使反应混合物缓慢升温至20-27℃且继续搅拌1个半小时。然后,将混合物倒入预冷(10-20℃)的0.5 N HCl水溶液(20L)。悬浮液在20-25℃下储存45分钟。通过将悬浮液过滤通过中间孔隙率的烧结玻璃漏斗且随后用0.5N HCl水溶液(3500 mL,2次)、纯水(3500 mL)、饱和的NaHCO3水溶液(3500 mL,2次)和纯水(3500 mL,2次)和二乙醚(2000 mL,2次)洗涤而收集固体。最后,在高真空下在室温在干燥器中干燥湿的粗肽FmocAA7-16OtBu (2-3),得到产物238.22克(纯度85.27%,得率98.9%)。
完全保护的A-B-C:BocAA1-16OtBu (3-3)的合成
将HAA7-16OtBu (2-3) (183.67克,106.71 mmol)、BocAA1-6-OH (2׳) (157.65克,106.71 mmol)、和6-Cl-HOBt (18.141克,106.71 mmol)在DMF (3 L)中的溶液冷却至-3至0℃。添加HBTU (44.523克,117.38 mmol),且完全溶解。然后在搅拌下添加DIEA(55.8 mL,320.13 mmol),将混合物的pH保持在6。在-5至0℃继续搅拌20分钟。使反应混合物缓慢升温至25 ℃且继续搅拌2.5小时,随后进一步添加HBTU (4.048克,10.671 mmol)和DIEA (2mL)。再继续搅拌1.5小时。将得到的混合物倒入MeOH (15 L)中,收集沉淀物,且用MeOH/DMF混合物(5:1, v/v) (2次,3 L)、0.1N HCl (3 L,2次)、饱和的NaHCO3 (2次)、纯水(3次)、二乙醚(2次)洗涤,且在真空下干燥,得到产物BocAA1-16OtBu (3-3) (278.0克,得率82.0%。注:在脱保护后测定纯度)。
部分保护的线性SP-304:HAA1-16OH (4-4)的合成
在氮气下将TFA/TIS/EDT (8:1:1, 2400 mL)的混合物冷却至(0-5℃),且分份添加Boc-AA1-16OtBu (3-3) (201克)。在0 - 10℃下将得到的悬浮液搅拌30分钟,然后用水浴使反应溶液升温至20-25℃(10分钟),且在相同温度下继续搅拌另外1小时50分钟。将反应混合物倒入预冷却(10℃)的MTBE(18L)中。在添加肽/TFA溶液过程中提供一些热量,内部温度上升至25℃。然后将得到的悬浮液储存在冰-水浴(5-10℃)中40分钟。通过过滤收集沉淀物,用MTBE (2000 mL,4次)洗涤,且用P2O5在真空中干燥,得到148.37克的灰白色产物,HAA1-16OH (4-4)(纯度:62.23%,ES -MS,MW:计算值= 1828.07,实测值=1826.67)。
实施例3:氧化环化反应和通过聚苯乙烯吸附树脂纯化SP-304
将HAA1-16OH (4-4) (0.58克)溶解在5 mL乙腈中,且用575 mL纯水稀释。用25%氨水溶液将溶液调节至pH 8-9,添加3%过氧化氢(0.58 mL),然后将反应混合物保持一小时,通过HPLC监测二硫键形成。然后将氮气通过反应混合物,且用乙酸将溶液酸化至pH 3-4(71.8% HPLC,从峰面积估算的回收率为98.5%)。在良好搅拌下经10分钟期间将1%碘/ACN逐滴添加至得到的混合物中,直至黄色的碘持续存在。在17-20℃继续搅拌30分钟。通过添加0.5M抗坏血酸水溶液猝灭碘,直至黄色消失。然后,用25%氨水溶液将混合物的pH调节至6-7(51.0% HPLC,从峰面积估算的回收率为50%)。
将聚苯乙烯吸附树脂(D101)填充至3(ID) × 9(L) CM柱中,且以3 CV/小时的流速用6个柱体积(CV)的乙醇、4 CV的纯水、2 CV的5% HCl水溶液、4 CV的纯水、2 CV 的2%NaOH水溶液和4 CV的纯水充分平衡。然后以2 CV/h将氧化的肽溶液上样至柱中。上样后,用2 CV纯水以2 CV/h洗柱。通过将80%乙醇水溶液以2 CV/h上样至柱进行洗脱。收集且组合在215 nm具有UV吸收的级分(125 mL)。然后将组合的级分在真空下蒸发至初始体积的10%,且用125 mL冷MTBE(10倍体积)沉淀悬浮液。通过过滤收集固体且真空干燥,得到粗SP-304(0.282克,55.0%HPLC)。
实施例4:氧化环化反应和通过RP-HPLC纯化SP-304
在连续搅拌下经由机械搅拌器将如实施例2中所述制备的粗肽(4-4)溶解在10% ACN水溶液中至约1.25 g/L的浓度。用20%氨水将肽溶液的pH调节至8.5-9.0,且将得到的溶液剧烈搅拌,向大气开放。添加过氧化氢 (3%,0.25当量),且在室温下继续搅拌60分钟。HPLC分析显示线性肽的完全消耗。然后,用10% AcOH水溶液将溶液酸化至pH 3-4。用纯水将得到的溶液稀释至约1 g/L的浓度。在剧烈搅拌下经10分钟的期间添加碘(ACN中1.3%),直至黄色的碘持续存在。以约半小时的时间间隔,样品取自混合物且通过RP-HPLC进行分析。单环的肽峰逐渐降低,出现一个新的峰(双环的肽)。当单环的肽峰消失时,氧化反应完成。通过少量的抗坏血酸中和过量的碘。将得到的溶液上样至填充Kromasil 100Å, 10µm硅胶的C18RP-HPLC柱上。将双环的肽溶液上样后,将3倍柱体积的90%流动相A(H2O中1.0%TEA、0.5%H3PO4,pH=7)和10%流动相B(乙腈)的溶液上样以洗出线(lines)。然后,在80分钟内从10%B到30%B操作梯度。当主峰开始洗脱时,以记录的时间间隔收集级分。通过分析型RP-HPLC监测各级分的纯度。相应地合并纯度≤95%(不符合主要合并标准)的级分,且使用上述相同的缓冲系统和梯度洗脱参数向前处理。合并所有纯度≥95%的级分,且贮存于2-8℃。用纯水将纯化的肽溶液以1:1比例稀释,然后上样到相同的RP-HPLC柱。通过用2-3倍柱体积的0.5M乙酸铵水溶液洗柱、随后在50分钟内从90% C (0.2% AcOH水溶液)和10%流动相D(ACN)至50%流动相C和50%流动相D的梯度洗脱完成反离子交换。以记录的时间间隔收集级分且通过分析型RP-HPLC进行监测。收集级分(≥95%)且冻干,以获得最终的干燥肽68.0g (96.1%纯)。
实施例5:通过RP-HPLC纯化后SP-304的脱盐和分离
如实施例4中所述通过RP-HPLC纯化plecanatide后,将其进行脱盐和分离。简而言之,将乙酸铵/乙腈/水缓冲液中纯化的plecanatide上样到填充聚合吸附剂(大孔吸附树脂)的柱上,且然后通过醇/水的混合物进行洗脱。最后,在减压下浓缩肽醇溶液,用醚(例如,二乙醚或MTBE)沉淀,且在真空下干燥,以得到最终产物。
树脂(聚合吸附剂)筛选
树脂预处理:将聚合吸附剂,DA201-C(来自Jiangsu Suqing, China;交联聚苯乙烯;表面积1200-1400 m2/g;平均孔径:3-4 nm;孔体积:1.1-1.2 ml/g;堆积密度:0.68-0.75 g/ml;比密度:1.03-1.1 g/ml;湿度:50-60%;粒径:0.315~1.25 mm ≧95%;有效直径:0.4~0.7mm;均匀系数:≤1.6%),DA201-H(来自Jiangsu Suqing, China;交联聚苯乙烯;表面积≥800 m2/g;平均孔径:6-8 nm;孔体积:1.5-1.8 ml/g;堆积密度:0.65-0.70 g/ml;比密度:1.02-1.07 g/ml;湿度:55%-65%,粒径:0.315~1.25 mm ≧95%;有效直径:0.4~0.7 mm;均匀系数:≤1.6% ),ADS-5(来自Nankai Hecheng, China;交联聚苯乙烯;表面积:520-600m2/g;平均孔径:25-30 nm;堆积密度:0.7-0.8 g/ml;湿度:60-70%;粒径:0.315~1.25 mm≧95%;均匀系数:≤1.6%),和ADS-8(来自Nankai Hecheng, China;交联聚苯乙烯;表面积:450-500 m2/g;平均孔径:12-16 nm;堆积密度:0.65-0.75 g/ml;湿度:60-70%;粒径:0.315~1.25 mm ≧95%;均匀系数:≤1.6%)悬浮在4-6倍体积的乙醇中过夜。从沉降的树脂倾析或吸去上清液。添加6-8倍体积的去离子水且以轻微高处(overhead)搅拌下悬浮树脂。再次,从沉降的树脂倾析或吸去上清液。重复上述水处理和倾析步骤直到细粉出现最少。
柱填充和再生:分别通过使用温和搅拌用1-2倍体积的去离子水重悬上述预处理的树脂以形成树脂浆料。将树脂浆料缓慢倒入柱内侧以防止空气滞留。树脂浆料已完全转入柱中后,使用含去离子水的喷瓶冲洗柱内部。打开柱的出口以形成沉降的树脂床(ID=4cm, H=10cm)。然后通过4 CV的去离子水、2CV的5% HCl水溶液、4 CV的去离子水、2CV的2%NaOH水溶液和最后4 CV的去离子水以3CV/每小时的流速依次洗涤树脂床,直到洗脱液的pH为约7。
上样样品的制备:将2000mg冻干plecanatide溶解在60mL ACN和150mL 0.2% AcOH水溶液的混合物中(用10%氨水溶液将AcOH水溶液的pH调节至4)。用1.2 µm尼龙膜过滤后,用0.2% AcOH水溶液(pH4)将过滤液稀释至250 mL,且分成4份(各62.5 mL)用于上样。
将样品上样至柱:分别以2CV/h的流速将62.5 mL上述肽溶液上样至上述4个柱上。收集上样洗脱液,且通过RP-HPLC检测以评价各树脂的吸附容量。各树脂的吸附容量结果显示在下表X中。
表X
HPLC方法:HPLC仪器:Shimadzu LC-10AD vp;柱:Kromasil, C18, 4.6x250mm;流动相A:0.1%TFA/水;流动相B:0.1%TFA/ACN;检测在:215nm;柱温度:40℃;流速:1.0mL/min;梯度:30 min内25%B到45%B。
吸附容量计算:通过上样到各柱上的肽的吸附率(其通过吸附至各树脂柱上的肽的量除以各上样样品中的肽量(500mg)来计算)显示各树脂的吸附容量。通过下式计算各柱中吸附的肽量:
吸附的肽量=上样样品中的肽量-上样洗脱液中的肽量= 500mg- 62.5mLx (1.6mg/mLx 洗脱液的HPLC峰面积/肽标准溶液的HPLC峰面积)
用去离子水洗涤柱:然后以2CV/h用2CV的去离子水洗涤上述上样柱以去除盐。收集洗涤的洗脱液,且通过RP-HPLC分析以确定使用上述相同方法通过水解吸的肽量。各树脂的肽解吸率列在下表XI中。
表XI
用90%乙醇/水解吸肽:2CV的水洗涤后,然后以2 CV/h通过1-2CV的90%乙醇/水洗脱各柱中吸附的肽。收集洗脱液,且通过RP-HPLC分析以确定使用上述相同方法通过90%乙醇解吸的肽量。各树脂的肽解吸率列在下表XII中。
表XII
从乙醇溶液分离肽:在减压下浓缩从各柱收集的肽/乙醇/水溶液,用MTBE沉淀,过滤且在真空下干燥,以得到最终产物。通过各柱处理的肽的总得率显示在下表XIII中。
表XIII
树脂筛选结论:从上面的数据(表X至表XIII),在实验中的树脂间,对于plecanatide,DA201-H树脂给出了最佳的吸附容量和最佳的解吸(通过乙醇)性能。
脱盐和分离过程优化
洗脱溶剂选择:异丙醇和乙醇是用于从聚合吸附剂洗脱肽的两种常用溶剂。表XIV显示根据v/v % 异丙醇(或乙醇):水能够溶解在乙醇或异丙醇水溶液中的plecanatide的量。
表XIV
肽/醇溶液中的水可通过共沸蒸馏去除。表XV显示乙醇/水和异丙醇/水的二元共沸物的特性。
表XV
组分A | 组分B | 沸点A | 沸点B | 共沸沸点 | 共沸物Wt.% A |
水 | 乙醇 | 100℃ | 78.3℃ | 78.2℃ | 4 % |
水 | 异丙醇 | 100℃ | 82.3℃ | 80.3℃ | 12.6 % |
Plecanatide的降解将发生在肽/醇/水溶液的长期储存和浓缩过程期间。表XVI表明在23℃下plecanatide在75% IPA/水溶液和90% EtOH/水中的稳定性数据。
表XVI
* HPLC方法:HPLC仪器:Shimadzu LC-10AD vp:柱:Kromasil, C18, 4.6x250mm;流动相A:0.1%TFA/水;流动相B:0.1%TFA/ACN;检测在:215nm;柱温度:40℃;流速:1.0mL/min;梯度:30 min内25%B到45%B。
根据获得的测试数据,plecanatide在23℃下在6小时内在醇/水溶液中是相当稳定的。
使用不同v/v %的异丙醇/水混合物进行洗脱实验。肽洗脱液的解吸率和水含量列在下表XVII中。
表XVII
v/v % IPA/水 | 75% IPA/水 | 95% IPA/水 | 100% IPA/水 |
肽中的水含量* | 65.9% | 53.0% | 49.8% |
解吸率 | 100% | 100% | 90% |
75%异丙醇/水作为洗脱溶液:将500mg plecanatide(98.1%纯)溶解在16 mLACN和49 mL 0.2% AcOH水溶液的混合物中(通过添加10% NH4OH水溶液将0.2%AcOH溶液的pH调节至4.0)。通过1.2 µm尼龙膜过滤后,以2CV/h将肽溶液上样至填充DA201-H 树脂(ID=4cm,H=10cm,通过上述程序填充和预处理)的柱上。上样后,以2CV/h用2 CV去离子水洗涤柱。然后,以2CV/h通过1.5CV 75% IPA/水洗脱肽。通过RP-HPLC监测洗脱。收集洗脱液(124mL,98.3%纯)。Karl Fisher分析表明水(65.9% wt. %)。将上面收集的124mL肽/IPA/水洗脱液(97.6%纯,在2-8℃下储存2天过程中发生略微降解)置于1-颈500 mL圆底烧瓶中。然后将烧瓶在减压下(60 Pa)下置于旋转蒸发器上,且部分地浸在23℃水浴中。通过在2小时内将约622mL异丙醇减料(feed-stripping)至溶液初始体积的约1/3而形成带白色的悬浮液(97.7%纯)。Karl Fisher分析表明水(0.17% wt. %)。向浓缩物中添加350 mL预冷二乙醚,通过以3500 rpm离心3分钟而收集固体,且在真空下干燥,得到333 mg的最终产物(得率66.6%,97.2% HPLC纯)。
95%异丙醇/水作为洗脱溶液I:将500mg plecanatide(98.1%纯)溶解在16 mLACN和49 mL 0.2% AcOH水溶液的混合物中(通过添加10% NH4OH水溶液将0.2%AcOH溶液的pH调节至4.0)。通过1.2 µm尼龙膜过滤后,以2CV/h将肽溶液上样至填充DA201-H 树脂(ID=4cm,H=10cm,通过上述程序预处理)的柱上。上样后,以2CV/h用2 CV去离子水洗涤柱。然后,以2CV/h通过1.5CV 95% IPA/水洗脱肽。通过RP-HPLC监测洗脱。收集洗脱液(117mL,98.1%纯)。Karl Fisher分析表明水(52% wt. %)。将上面收集的117mL肽/IPA/水洗脱液置于1-颈500 mL圆底烧瓶中。然后将烧瓶在减压下(50 Pa)下置于旋转蒸发器上,且部分地浸在23℃水浴中。通过在130min内减料(feed-stripping)约470mL异丙醇而形成带白色的固体(97.9%纯)。向上述固体添加50 mL预冷二乙醚以形成悬浮液,且在23℃下在减压(50Pa)下在旋转蒸发器下蒸发至干燥。产率为430mg的终产物(86%)。HPLC纯度为97.9%。
95%异丙醇/水作为洗脱溶液II:将500 mg plecanatide(98.1%纯)溶解在16 mLACN和49 mL 0.2% AcOH水溶液的混合物中(通过添加10% NH4OH水溶液将0.2%AcOH溶液的pH调节至4.0)。通过1.2 µm尼龙膜过滤后,以2CV/h将肽溶液上样至填充DA201-H 树脂(ID=4cm,H=10cm,通过上述程序填充和预处理)的柱上。上样后,以2CV/h用2 CV去离子水洗涤柱。然后,以2CV/h通过1.5CV 95% IPA/水洗脱肽。通过RP-HPLC监测洗脱。收集洗脱液(118mL,98.2%纯)。Karl Fisher分析表明水(53% wt. %)。将上面收集的118mL肽/IPA/水洗脱液置于1-颈500 mL圆底烧瓶中。然后将烧瓶在减压下(50 Pa)下置于旋转蒸发器上,且部分地浸在23℃水浴中。通过在100min内减料(feed-stripping)约330mL异丙醇而形成带白色的悬浮液(~40mL)(97.7%纯)。向上述悬浮液添加400 mL预冷二乙醚以形成悬浮液。在室温静置1小时后,通过以3500 rpm离心3分钟而收集固体,且在真空下干燥,得到370 mg的最终产物。产率为74%。HPLC纯度为97.9%。
95%异丙醇/水作为洗脱溶液III:以与上述类似的方式将10g plecanatide脱盐且沉淀。有趣的是,沉淀产率改善到93%,这是显著的产率增加。沉淀后的HPLC纯度为98.47%。
实施例6:冻干的SP-304和沉淀的SP-304的表征
分析如实施例4中所述通过冻干纯化的plecanatide和如实施例5中所述通过沉淀纯化的plecanatide,以确定显著的化学杂质值,如乙酰胺、TFA、铵离子和乙腈的水平。结果列于下表中。
乙酰胺 | TFA | 铵离子 | 乙腈 | |
冻干的plecanatide | 356 ppm | 0.14% | 1.58% | 40 ppm |
沉淀的plecanatide | < 28 ppm (方法的LOQ) | 0.09% | 0.23% | 未检测到(20 ppm LOQ) |
如以上结果表明,沉淀过程提供了不期望的过程杂质的水平的显著降低。
测量如实施例4中所述通过冻干纯化的plecanatide和如实施例5中所述通过沉淀纯化的plecanatide,以获得其堆积密度、振实密度、粒径分布和形状。
设备:(1)振实密度测试仪型号TD-1020;(2)声频筛分离器型号L3P;(3)光学显微镜LINITRON 2850。
方法:
1) 堆积密度和振实密度测量:改良的USP 1方法
a. 100.0 mL量筒用于冻干的plecanatide
b. 10.0 mL量筒用于沉淀的plecanatide
2) 粒径分布分析
a. 使用的筛:200、140、100、60、40 和30目。
b. 样品量:2g冻干的plecanatide和6.4g沉淀的plecanatide
3) 光学显微分析:粒径和形状
a. 将干燥粉末手工分散到微观板上
b. 放大倍数:100 x
c. 在正常光条件下(没有偏振滤光片)。
结果:
(1) 物理外观:冻干的plecanatide是轻的蓬松的白色粉末。沉淀的plecanatide是略微灰白色粉末。
(2) 堆积密度和振实密度:表XVIII提供冻干和沉淀的Plecanatide样品二者的堆积和振实密度数据:
表XVIII
Plecanatide样品 | 堆积密度,g/mL | 振实密度,g/mL |
冻干的,批号101221 | 0.0332 | 0.0680 |
沉淀的,批号120210 | 0.486 | 0.641 |
如从数据可以看出,沉淀的plecanatide出乎意外地明显比冻干的plecanatide更加致密。沉淀的plecanatide在加工过程中具有更低生成粉尘的趋势,这提供了增加的安全性和降低的加工损失的优点。
(3) 粒径分布:表XIX总结了粒径分布分析。图1图示提供了数据。
表XIX
如表XIX和图1所表明,对于两种类型的plecanatide,粒径分布是不同的。在分析过程中,观察到,沉淀的plecanatide含有一些较大的颗粒,这可能容易粉碎。还注意到,冻干的plecanatide似乎是薄片状的且粘附到筛的顶部和底部,而对于沉淀的plecanatide则没有观察到粘附。这表明沉淀的plecanatide的更好的加工特性。
(4) 粒径和形状:图2和3分别提供了冻干的和沉淀的plecanatide样品的光学显微镜分析。如在图2中可以看到,冻干的plecanatide是无定形形式,且具有不规则形状的颗粒。它们与躺在彼此顶部的颗粒形成物理聚集物。在图3中,沉淀的plecanatide显示可辨别的个别颗粒。根据颗粒外观和形状,沉淀的plecanatide将具有更好的流动特性,且因此可以促进制造过程中的固体加工。
冻干和沉淀形式的plecanatide已经显示通过密度、粒径分布和形状分析可辨别的物理外观和特性。在减少粉尘生成、更少粘附到加工设备上和可能更少的加工损失的方面,沉淀形式更适合用于在制造过程中的固体剂型加工。
沉淀形式更适合用于在制造过程中加工固体剂型(例如,低剂量的固体剂型)。更高密度的沉淀物质将减少称重、转移和掺合过程中的气溶胶或“粉尘”损失。已经显示不同的颗粒形状减少由粘附到筛(screen)或筛(seive)引起的损失。更高的密度应改善含量均匀度,因为药物颗粒的大小和密度更紧密地匹配赋形剂的大小和密度。
实施例7:沉淀的SP-304的低剂量制剂
如下文所述,进一步加工如实施例5中所述通过沉淀纯化的plecanatide以制备低剂量制剂。
干掺合批次的组成
项目编号 | 成分 | 浓度% w/w |
1 | SP-304 | 0.3246 |
2 | 微晶纤维素(Avicel PH 102) | 99.43 |
3 | 硬脂酸镁 | 0.2500 |
4 | HPMC胶囊壳 | n/a |
总计 | 100 |
掺合
将Avicel PH 102筛选通过60目筛。然后通过过筛的Avicel PH 102将V型掺合器(1Qt、4Qt、和16 Qt)粉尘化。SP-304过筛通过200目筛网,且上样至1-Qt V型掺合器。然后,将约80 g Avicel PH 102添加到1-Qt掺合器,且将混合物以25 rpm掺合10分钟。然后将混合物转移到4-Qt V型混合器(其由过筛的Avicel PH 102预粉尘化)。用Avicel冲洗1-Qt掺合器且将冲洗材料转移到4-Qt掺合器。重复冲洗,直至将所有SP-304转移到4-Qt掺合器。将约200g Avicel添加到4-Qt V型掺合器,且将混合物掺合10分钟。然后将得到的掺合物过筛通过60目筛网,且然后转移到预粉尘化的16-Qt掺合器(用1500g Avicel粉尘化)。用Avicel冲洗4-Qt掺合器且将冲洗材料转移到16-Qt掺合器。将剩余的Avicel添加到16-Qt V型掺合器,且将混合物掺合10分钟。将得到的掺合物通过Comil,用过量的Avicel冲洗,且然后返回至16-Qt掺合器,且进一步掺合5分钟。称取适当量的硬脂酸镁,过筛通过60目筛网,且添加至16-Qt掺合器中。将得到的混合物掺合2分钟。然后将得到的混合物或封装在胶囊中或压缩以形成片剂。
封装
设置MG2 Planeta胶囊填充器。确定空胶囊壳的平均重量,且计算目标胶囊填充重量(±5%)。将来自从上面过程的掺合物添加至胶囊填充器的料斗且开始封装。手工调整运行重量参数。然后根据目标填充重量分选得到的胶囊。
压缩
设置Fette压片机。然后将掺合混合物上样至粉末料斗且安装工具作业。各片剂的重量设定为100 mg±5%,硬度设定为4-6 Kp。测量片剂的重量、硬度、和厚度且每隔5至10分钟进行记录。还进行脆度测量以确保满意的产品。
序列表
<110> SYNERGY PHARMACEUTICALS, INC.
<120> 制备鸟苷酸环化酶C激动剂的方法
<130> 40737-508001WO
<140> PCT/US2012/027287
<141> 2012-03-01
<150> US 61/447,891
<151> 2011-03-01
<160> 261
<170> PatentIn version 3.5
<210> 1
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 1
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 2
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 2
Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 3
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 3
Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys
1 5 10
<210> 4
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 4
Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10
<210> 5
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 5
Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys
1 5 10
<210> 6
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 6
Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10
<210> 7
<211> 12
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 7
Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys
1 5 10
<210> 8
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<400> 8
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 9
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<400> 9
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 10
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> 其中ASP是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<400> 10
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 11
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> 其中ASP是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> 其中GLU是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<400> 11
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 12
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<400> 12
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 13
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> 其中LEU是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<400> 13
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 14
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 14
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys
1 5 10 15
<210> 15
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中位置1的ASN连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中位置16的LEU连接于聚乙二醇
<400> 15
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 16
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中位置1的ASN连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中位置16的LEU连接于聚乙二醇
<400> 16
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 17
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中位置1的ASN连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> 其中ASP是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中位置16的LEU连接于聚乙二醇
<400> 17
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 18
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中位置16的LEU连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<400> 18
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 19
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中位置1的ASN连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<400> 19
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 20
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中位置1的ASN连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<400> 20
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 21
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中位置16的LEU连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<400> 21
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 22
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中位置1的ASN连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> 其中ASP是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> 其中GLU是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中位置16的LEU连接于聚乙二醇
<400> 22
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 23
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中位置1的ASN连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> 其中ASP是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> 其中GLU是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<400> 23
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 24
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> 其中ASP是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> 其中GLU是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中位置16的LEU连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<400> 24
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 25
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> 其中ASP是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中位置16的LEU连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<400> 25
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 26
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中位置1的ASN连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> 其中ASP是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<400> 26
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 27
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中x是3-(2-萘基)丙氨酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中x是D-氨基酸
<400> 27
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Xaa
1 5 10 15
<210> 28
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MOD_RES
<222> (8)..(8)
<223> 其中x是2-氨基异丁酸, Aib
<220>
<221> MOD_RES
<222> (10)..(10)
<223> 其中x是2-氨基异丁酸, Aib
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<400> 28
Asn Asp Glu Cys Glu Leu Cys Xaa Asn Xaa Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 29
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> 其中位置7的ASP连接于内酰胺桥
<220>
<221> MISC_FEATURE
<222> (15)..(15)
<223> 其中位置15的x是鸟氨酸
<220>
<221> MOD_RES
<222> (15)..(15)
<223> 其中x是鸟氨酸, Orn
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<400> 29
Asn Asp Glu Cys Glu Leu Asp Val Asn Val Ala Cys Thr Gly Xaa Leu
1 5 10 15
<210> 30
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<400> 30
Asn Asp Glu Cys Glu Tyr Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 31
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<400> 31
Asn Asp Glu Cys Glu Ser Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 32
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中位置1的ASN连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中位置16的LEU连接于聚乙二醇
<400> 32
Asn Asp Glu Cys Glu Tyr Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 33
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中位置1的ASN连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<400> 33
Asn Asp Glu Cys Glu Tyr Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 34
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中位置16的LEU连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<400> 34
Asn Asp Glu Cys Glu Tyr Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 35
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中位置1的ASN连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中位置16的LEU连接于聚乙二醇
<400> 35
Asn Asp Glu Cys Glu Ser Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 36
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中位置1的ASN连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<400> 36
Asn Asp Glu Cys Glu Ser Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 37
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中位置16的LEU连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<400> 37
Asn Asp Glu Cys Glu Ser Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 38
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 38
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 39
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中位置1的ASN连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中位置16的SER连接于聚乙二醇
<400> 39
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 40
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中位置1的ASN连接于聚乙二醇
<400> 40
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 41
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中位置16的SER连接于聚乙二醇
<400> 41
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 42
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中位置1的ASN连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中SER是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中位置16的SER连接于聚乙二醇
<400> 42
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 43
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中位置1的ASN连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中SER是D-氨基酸
<400> 43
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 44
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中位置16的SER连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中SER是D-氨基酸
<400> 44
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 45
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (5)..(6)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (8)..(11)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (13)..(14)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<400> 45
Asn Asp Glu Cys Xaa Xaa Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa
1 5 10 15
<210> 46
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> 其中x是0或1个残基长度的任何天然或非天然氨基酸或氨基酸类似物,
并且可以是L-氨基酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> 其中x是0或1个残基长度的任何天然或非天然氨基酸或氨基酸类似物,
并且可以是L-氨基酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (5)..(6)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (8)..(11)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (13)..(14)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中x是0或1个残基长度的任何天然或非天然氨基酸或氨基酸类似物,
并且可以是L-氨基酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<400> 46
Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa
1 5 10 15
<210> 47
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> 其中x是0或1个残基长度的任何天然或非天然氨基酸或氨基酸类似物,
并且可以是L-氨基酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> 其中x是0或1个残基长度的任何天然或非天然氨基酸或氨基酸类似物,
并且可以是L-氨基酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (15)..(15)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中x是0或1个残基长度的任何天然或非天然氨基酸或氨基酸类似物,
并且可以是L-氨基酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<400> 47
Xaa Xaa Xaa Xaa Glu Xaa Xaa Val Asn Val Ala Xaa Thr Gly Xaa Xaa
1 5 10 15
<210> 48
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> 其中x是0或1个残基长度的任何天然或非天然氨基酸或氨基酸类似物,
并且可以是L-氨基酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> 其中x是0或1个残基长度的任何天然或非天然氨基酸或氨基酸类似物,
并且可以是L-氨基酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (5)..(6)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (8)..(11)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (13)..(14)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (15)..(15)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中x是0或1个残基长度的任何天然或非天然氨基酸或氨基酸类似物,
并且可以是L-氨基酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<400> 48
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15
<210> 49
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (5)..(6)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (10)..(11)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (13)..(14)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<400> 49
Asn Asp Asp Cys Xaa Xaa Cys Xaa Asn Xaa Xaa Cys Xaa Xaa Cys Xaa
1 5 10 15
<210> 50
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (5)..(6)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (10)..(11)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (13)..(14)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<400> 50
Asn Glu Glu Cys Xaa Xaa Cys Xaa Asn Xaa Xaa Cys Xaa Xaa Cys Xaa
1 5 10 15
<210> 51
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> 其中GLU是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (5)..(6)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (10)..(11)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (13)..(14)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<400> 51
Asn Glu Asp Cys Xaa Xaa Cys Xaa Asn Xaa Xaa Cys Xaa Xaa Cys Xaa
1 5 10 15
<210> 52
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> 其中ASP是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (5)..(6)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (10)..(11)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (13)..(14)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<400> 52
Asn Asp Glu Cys Xaa Xaa Cys Xaa Asn Xaa Xaa Cys Xaa Xaa Cys Xaa
1 5 10 15
<210> 53
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> 其中ASP是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> 其中GLU是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (5)..(6)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (10)..(11)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (13)..(14)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<400> 53
Asn Asp Glu Cys Xaa Xaa Cys Xaa Tyr Xaa Xaa Cys Xaa Xaa Cys Xaa
1 5 10 15
<210> 54
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> 其中GLU是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> 其中GLU是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (5)..(6)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (10)..(11)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (13)..(14)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<400> 54
Asn Glu Glu Cys Xaa Xaa Cys Xaa Tyr Xaa Xaa Cys Xaa Xaa Cys Xaa
1 5 10 15
<210> 55
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 55
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10
<210> 56
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 56
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys
1 5 10
<210> 57
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中位置1的CYS连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (14)..(14)
<223> 其中位置14的TYR连接于聚乙二醇
<400> 57
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10
<210> 58
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 58
Asn Phe Cys Cys Glu Ser Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 59
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 59
Asn Phe Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 60
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (14)..(14)
<223> 其中TYR是D-氨基酸
<400> 60
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10
<210> 61
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中位置1的CYS连接于聚乙二醇
<400> 61
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10
<210> 62
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 62
Asn Phe Cys Cys Glu Thr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 63
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中TYR是D-氨基酸
<400> 63
Asn Phe Cys Cys Glu Ser Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 64
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<400> 64
Asn Phe Cys Cys Glu Ser Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 65
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中TYR是D-氨基酸
<400> 65
Asn Phe Cys Cys Glu Ser Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 66
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中TYR是D-氨基酸
<400> 66
Asn Phe Cys Cys Glu Thr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 67
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<400> 67
Asn Phe Cys Cys Glu Thr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 68
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中TYR是D-氨基酸
<400> 68
Asn Phe Cys Cys Glu Thr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 69
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中TYR是D-氨基酸
<400> 69
Asn Phe Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 70
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<400> 70
Asn Phe Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 71
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中TYR是D-氨基酸
<400> 71
Asn Phe Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 72
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (14)..(14)
<223> 其中位置14的TYR连接于聚乙二醇
<400> 72
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10
<210> 73
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中位置1的CYS连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> 其中位置13的CYS连接于聚乙二醇
<400> 73
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys
1 5 10
<210> 74
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中位置1的CYS连接于聚乙二醇
<400> 74
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys
1 5 10
<210> 75
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> 其中位置13的CYS连接于聚乙二醇
<400> 75
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys
1 5 10
<210> 76
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中位置1的ASN连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中位置16的TYR连接于聚乙二醇
<400> 76
Asn Phe Cys Cys Glu Ser Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 77
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中位置1的ASN连接于聚乙二醇
<400> 77
Asn Phe Cys Cys Glu Ser Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 78
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中位置16的TYR连接于聚乙二醇
<400> 78
Asn Phe Cys Cys Glu Ser Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 79
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中位置1的ASN连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中位置16的TYR连接于聚乙二醇
<400> 79
Asn Phe Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 80
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中位置1的ASN连接于聚乙二醇
<400> 80
Asn Phe Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 81
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中位置16的TYR连接于聚乙二醇
<400> 81
Asn Phe Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 82
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中位置1的ASN连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中位置16的TYR连接于聚乙二醇
<400> 82
Asn Phe Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 83
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中位置1的ASN连接于聚乙二醇
<400> 83
Asn Phe Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 84
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中位置16的TYR连接于聚乙二醇
<400> 84
Asn Phe Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 85
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 85
Cys Cys Glu Ser Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10
<210> 86
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 86
Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10
<210> 87
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 87
Cys Cys Glu Ser Cys Cys Asn Pro Ala Cys Thr Gly Cys
1 5 10
<210> 88
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 88
Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys
1 5 10
<210> 89
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(2)
<223> 其中x是青霉胺
<220>
<221> MISC_FEATURE
<222> (5)..(6)
<223> 其中x是青霉胺
<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> 其中x是青霉胺
<220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> 其中x是青霉胺
<400> 89
Xaa Xaa Glu Tyr Xaa Xaa Asn Pro Ala Xaa Thr Gly Xaa Tyr
1 5 10
<210> 90
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(2)
<223> 其中x是青霉胺
<220>
<221> MISC_FEATURE
<222> (5)..(6)
<223> 其中x是青霉胺
<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> 其中x是青霉胺
<220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> 其中x是青霉胺
<400> 90
Xaa Xaa Glu Tyr Xaa Xaa Asn Pro Ala Xaa Thr Gly Xaa
1 5 10
<210> 91
<211> 22
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(6)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸d
<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (15)..(17)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (19)..(20)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (22)..(22)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<400> 91
Xaa Xaa Xaa Xaa Xaa Xaa Asn Tyr Cys Cys Xaa Tyr Cys Cys Xaa Xaa
1 5 10 15
Xaa Cys Xaa Xaa Cys Xaa
20
<210> 92
<211> 22
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(6)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (15)..(17)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (19)..(20)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸d
<220>
<221> MISC_FEATURE
<222> (22)..(22)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<400> 92
Xaa Xaa Xaa Xaa Xaa Xaa Asn Phe Cys Cys Xaa Phe Cys Cys Xaa Xaa
1 5 10 15
Xaa Cys Xaa Xaa Cys Xaa
20
<210> 93
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (9)..(11)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (13)..(14)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<400> 93
Asn Phe Cys Cys Xaa Phe Cys Cys Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa
1 5 10 15
<210> 94
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> 其中x是青霉胺
<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> 其中x是青霉胺
<220>
<221> MISC_FEATURE
<222> (9)..(11)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (13)..(14)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<400> 94
Asn Phe Xaa Cys Xaa Phe Cys Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys Xaa
1 5 10 15
<210> 95
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (3)..(4)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (5)..(6)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (7)..(8)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (9)..(11)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (13)..(14)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (15)..(15)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<400> 95
Asn Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15
<210> 96
<211> 14
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(2)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (5)..(6)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<400> 96
Xaa Xaa Glu Xaa Xaa Xaa Asn Pro Ala Xaa Thr Gly Xaa Tyr
1 5 10
<210> 97
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(2)
<223> 其中x是半胱氨酸、或青霉胺、高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (5)..(6)
<223> 其中x是半胱氨酸、或青霉胺、高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> 其中x是半胱氨酸、或青霉胺、高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> 其中x是半胱氨酸、或青霉胺、高半胱氨酸或3-巯基脯氨酸
<400> 97
Xaa Xaa Glu Xaa Xaa Xaa Asn Pro Ala Xaa Thr Gly Xaa
1 5 10
<210> 98
<211> 20
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,可以是0或1个残基
长度,并且可以是L-氨基酸、或D-氨基酸、或甲基化或非甲基化的氨
基酸
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,可以是0或1个残基
长度,并且可以是L-氨基酸、或D-氨基酸、或甲基化或非甲基化的氨
基酸
<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,可以是0或1个残基
长度,并且可以是L-氨基酸、或D-氨基酸、或甲基化或非甲基化的氨
基酸
<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,可以是0或1个残基
长度,并且可以是L-氨基酸、或D-氨基酸、或甲基化或非甲基化的氨
基酸
<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,可以是0或1个残基
长度,并且可以是L-氨基酸、或D-氨基酸、或甲基化或非甲基化的氨
基酸
<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,可以是0或1个残基
长度,并且可以是L-氨基酸、或D-氨基酸、或甲基化或非甲基化的氨
基酸
<220>
<221> MISC_FEATURE
<222> (7)..(8)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (9)..(10)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (11)..(12)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (13)..(15)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (17)..(18)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (19)..(19)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (20)..(20)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,可以是0或1个残基
长度,并且可以是L-氨基酸、或D-氨基酸、或甲基化或非甲基化的氨
基酸
<400> 98
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Xaa Xaa
20
<210> 99
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU缀合于胺
<400> 99
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 100
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中SER是D-氨基酸
<400> 100
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 101
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中SER是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中SER缀合于胺
<400> 101
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 102
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中TYR是D-氨基酸
<400> 102
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 103
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中TYR是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中TYR缀合于胺
<400> 103
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 104
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中x是焦谷氨酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU缀合于胺
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU是D-氨基酸
<400> 104
Xaa Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 105
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU连接于聚乙二醇
<400> 105
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 106
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN连接于聚乙二醇
<400> 106
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 107
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中LEU连接于聚乙二醇
<400> 107
Asn Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 108
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(3)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (5)..(6)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (8)..(11)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (13)..(14)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (15)..(15)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<400> 108
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15
<210> 109
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 109
Asn Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 110
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 110
Glu Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 111
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 111
Glu Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 112
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 112
Glu Glu Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 113
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 113
Glu Glu Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 114
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 114
Asp Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 115
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 115
Asp Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 116
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 116
Asp Glu Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 117
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 117
Asp Glu Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 118
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 118
Gln Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 119
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 119
Gln Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 120
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 120
Gln Glu Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 121
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 121
Gln Glu Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 122
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 122
Lys Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 123
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 123
Lys Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 124
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 124
Lys Glu Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 125
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 125
Lys Glu Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 126
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 126
Glu Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 127
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 127
Glu Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 128
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 128
Glu Glu Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 129
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 129
Glu Glu Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 130
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 130
Asp Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 131
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 131
Asp Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 132
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 132
Asp Glu Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 133
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 133
Asp Glu Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 134
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 134
Gln Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 135
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 135
Gln Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 136
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 136
Gln Glu Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 137
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 137
Gln Glu Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 138
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 138
Lys Asp Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 139
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 139
Lys Asp Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 140
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 140
Lys Glu Asp Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 141
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 141
Lys Glu Glu Cys Glu Leu Cys Val Asn Val Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 142
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 142
Glu Asp Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 143
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 143
Glu Asp Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 144
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 144
Glu Glu Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 145
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 145
Glu Glu Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 146
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 146
Asp Asp Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 147
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 147
Asp Asp Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 148
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 148
Asp Glu Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 149
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 149
Asp Glu Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 150
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 150
Gln Asp Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 151
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 151
Gln Asp Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 152
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 152
Gln Glu Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 153
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 153
Gln Glu Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 154
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 154
Lys Asp Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 155
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 155
Lys Asp Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 156
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 156
Lys Glu Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 157
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 157
Lys Glu Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Leu
1 5 10 15
<210> 158
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 158
Glu Asp Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 159
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 159
Glu Asp Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 160
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 160
Glu Glu Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 161
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 161
Glu Glu Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 162
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 162
Asp Asp Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 163
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 163
Asp Asp Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 164
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 164
Asp Glu Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 165
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 165
Asp Glu Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 166
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 166
Gln Asp Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 167
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 167
Gln Asp Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 168
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 168
Gln Glu Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 169
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 169
Gln Glu Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 170
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 170
Lys Asp Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 171
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 171
Lys Asp Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 172
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 172
Lys Glu Asp Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 173
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 173
Lys Glu Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 174
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(3)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (5)..(6)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (8)..(11)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (13)..(14)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (15)..(15)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<400> 174
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15
<210> 175
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 175
Ser His Thr Cys Glu Ile Cys Ala Phe Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 176
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 176
Ser His Thr Cys Glu Ile Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 177
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 177
Ser His Thr Cys Glu Leu Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 178
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 178
Ser His Thr Cys Glu Val Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 179
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 179
Ser His Thr Cys Glu Tyr Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 180
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 180
Ser His Thr Cys Glu Ile Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 181
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 181
Ser His Thr Cys Glu Leu Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 182
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 182
Ser His Thr Cys Glu Val Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 183
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 183
Ser His Thr Cys Glu Tyr Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 184
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 184
Ser His Thr Cys Glu Ile Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 185
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 185
Ser His Thr Cys Glu Leu Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 186
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 186
Ser His Thr Cys Glu Val Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 187
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 187
Ser His Thr Cys Glu Tyr Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 188
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 188
Ser His Thr Cys Glu Ile Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 189
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 189
Ser His Thr Cys Glu Leu Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 190
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 190
Ser His Thr Cys Glu Val Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 191
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 191
Ser His Thr Cys Glu Tyr Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 192
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 192
Asn Asp Glu Cys Glu Ile Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 193
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 193
Asn Asp Glu Cys Glu Leu Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 194
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 194
Asn Asp Glu Cys Glu Val Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 195
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 195
Asn Asp Glu Cys Glu Tyr Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 196
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 196
Asn Asp Glu Cys Glu Ile Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 197
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 197
Asn Asp Glu Cys Glu Leu Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 198
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 198
Asn Asp Glu Cys Glu Val Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 199
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 199
Asn Asp Glu Cys Glu Tyr Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 200
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 200
Asn Asp Glu Cys Glu Ile Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 201
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 201
Asn Asp Glu Cys Glu Leu Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 202
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 202
Asn Asp Glu Cys Glu Val Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 203
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 203
Asn Asp Glu Cys Glu Tyr Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 204
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 204
Asn Asp Glu Cys Glu Ile Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 205
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 205
Asn Asp Glu Cys Glu Leu Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 206
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 206
Asn Asp Glu Cys Glu Val Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 207
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 207
Asn Asp Glu Cys Glu Tyr Cys Ala Asn Ala Ala Cys Ala Gly Cys
1 5 10 15
<210> 208
<211> 17
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(3)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (5)..(6)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (8)..(11)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> 其中x是半胱氨酸、青霉胺高半胱氨酸或3-巯基脯氨酸
<220>
<221> MISC_FEATURE
<222> (13)..(14)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (15)..(15)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,并且可以是L-氨基
酸、或D-氨基酸、或甲基化或非甲基化的氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,可以是0或1个残基
长度,并且可以是L-氨基酸、或D-氨基酸、或甲基化或非甲基化的氨
基酸
<220>
<221> MISC_FEATURE
<222> (17)..(17)
<223> 其中x是任何天然或非天然氨基酸或氨基酸类似物,可以是0或1个残基
长度,并且可以是L-氨基酸、或D-氨基酸、或甲基化或非甲基化的氨
基酸
<400> 208
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Xaa
<210> 209
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 209
Gln Glu Glu Cys Glu Leu Cys Ile Asn Met Ala Cys Thr Gly Tyr
1 5 10 15
<210> 210
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 210
Gln Glu Glu Cys Glu Thr Cys Ile Asn Met Ala Cys Thr Gly Tyr
1 5 10 15
<210> 211
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 211
Gln Asp Glu Cys Glu Thr Cys Ile Asn Met Ala Cys Thr Gly Tyr
1 5 10 15
<210> 212
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 212
Gln Asp Asp Cys Glu Thr Cys Ile Asn Met Ala Cys Thr Gly Tyr
1 5 10 15
<210> 213
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 213
Gln Glu Asp Cys Glu Thr Cys Ile Asn Met Ala Cys Thr Gly Tyr
1 5 10 15
<210> 214
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 214
Gln Glu Glu Cys Glu Glu Cys Ile Asn Met Ala Cys Thr Gly Tyr
1 5 10 15
<210> 215
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 215
Gln Asp Glu Cys Glu Glu Cys Ile Asn Met Ala Cys Thr Gly Tyr
1 5 10 15
<210> 216
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 216
Gln Asp Asp Cys Glu Glu Cys Ile Asn Met Ala Cys Thr Gly Tyr
1 5 10 15
<210> 217
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 217
Gln Glu Asp Cys Glu Glu Cys Ile Asn Met Ala Cys Thr Gly Tyr
1 5 10 15
<210> 218
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 218
Gln Glu Glu Cys Glu Tyr Cys Ile Asn Met Ala Cys Thr Gly Tyr
1 5 10 15
<210> 219
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 219
Gln Asp Glu Cys Glu Tyr Cys Ile Asn Met Ala Cys Thr Gly Tyr
1 5 10 15
<210> 220
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 220
Gln Asp Asp Cys Glu Tyr Cys Ile Asn Met Ala Cys Thr Gly Tyr
1 5 10 15
<210> 221
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 221
Gln Glu Asp Cys Glu Tyr Cys Ile Asn Met Ala Cys Thr Gly Tyr
1 5 10 15
<210> 222
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 222
Gln Glu Glu Cys Glu Ile Cys Ile Asn Met Ala Cys Thr Gly Tyr
1 5 10 15
<210> 223
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 223
Gln Asp Glu Cys Glu Ile Cys Ile Asn Met Ala Cys Thr Gly Tyr
1 5 10 15
<210> 224
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 224
Gln Asp Asp Cys Glu Ile Cys Ile Asn Met Ala Cys Thr Gly Tyr
1 5 10 15
<210> 225
<211> 15
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 225
Gln Glu Asp Cys Glu Ile Cys Ile Asn Met Ala Cys Thr Gly Tyr
1 5 10 15
<210> 226
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 226
Gln Glu Glu Cys Glu Thr Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 227
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 227
Gln Asp Glu Cys Glu Thr Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 228
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 228
Gln Asp Asp Cys Glu Thr Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 229
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 229
Gln Glu Asp Cys Glu Thr Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 230
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 230
Gln Glu Glu Cys Glu Glu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 231
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 231
Gln Asp Glu Cys Glu Glu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 232
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 232
Gln Asp Asp Cys Glu Glu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 233
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 233
Gln Glu Asp Cys Glu Glu Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 234
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 234
Gln Glu Glu Cys Glu Tyr Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 235
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 235
Gln Asp Glu Cys Glu Tyr Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 236
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 236
Gln Asp Asp Cys Glu Tyr Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 237
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 237
Gln Glu Asp Cys Glu Tyr Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 238
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 238
Gln Glu Glu Cys Glu Ile Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 239
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 239
Gln Asp Glu Cys Glu Ile Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 240
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 240
Gln Asp Asp Cys Glu Ile Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 241
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 241
Gln Glu Asp Cys Glu Ile Cys Ile Asn Met Ala Cys Thr Gly Cys Ser
1 5 10 15
<210> 242
<211> 22
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 242
Asn Ser Ser Asn Ser Ser Asn Tyr Cys Cys Glu Lys Cys Cys Asn Pro
1 5 10 15
Ala Cys Thr Gly Cys Tyr
20
<210> 243
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN连接于聚乙二醇
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中TYR连接于聚乙二醇
<400> 243
Asn Phe Cys Cys Glu Thr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 244
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN连接于聚乙二醇
<400> 244
Asn Phe Cys Cys Glu Thr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 245
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中TYR连接于聚乙二醇
<400> 245
Asn Phe Cys Cys Glu Thr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 246
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 246
Asn Phe Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 247
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中TYR是D-氨基酸
<400> 247
Asn Phe Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 248
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> 其中TYR是D-氨基酸
<400> 248
Asn Phe Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 249
<211> 16
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中ASN是D-氨基酸
<400> 249
Asn Phe Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr
1 5 10 15
<210> 250
<211> 34
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<400> 250
Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn
1 5 10 15
Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Val Thr Arg Gln
20 25 30
Arg Tyr
<210> 251
<211> 27
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 其中HIS缀合于具有通式R-NH的胺,并且其中R是氢或具有1、2、3、4、
5、6、7、8、9或10个碳原子的有机化合物
<220>
<221> MISC_FEATURE
<222> (27)..(27)
<223> 其中LYS缀合于胺
<400> 251
His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Tyr Leu Glu Gly Gln
1 5 10 15
Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys
20 25
<210> 252
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的 Sialorphin-相关的多肽
<400> 252
Gln His Asn Pro Arg
1 5
<210> 253
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的 Sialorphin-相关的多肽
<400> 253
Val Gln His Asn Pro Arg
1 5
<210> 254
<211> 7
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的 Sialorphin-相关的多肽
<400> 254
Val Arg Gln His Asn Pro Arg
1 5
<210> 255
<211> 8
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的 Sialorphin-相关的多肽
<400> 255
Val Arg Gly Gln His Asn Pro Arg
1 5
<210> 256
<211> 9
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的 Sialorphin-相关的多肽
<400> 256
Val Arg Gly Pro Gln His Asn Pro Arg
1 5
<210> 257
<211> 10
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的 Sialorphin-相关的多肽
<400> 257
Val Arg Gly Pro Arg Gln His Asn Pro Arg
1 5 10
<210> 258
<211> 11
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的 Sialorphin-相关的多肽
<400> 258
Val Arg Gly Pro Arg Arg Gln His Asn Pro Arg
1 5 10
<210> 259
<211> 6
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的 Sialorphin-相关的多肽
<400> 259
Arg Gln His Asn Pro Arg
1 5
<210> 260
<211> 5
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的脑啡肽五肽
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> 其中LYS是D-氨基酸
<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> 其中x是L-高丝氨酸
<400> 260
Tyr Lys Gly Phe Xaa
1 5
<210> 261
<211> 4
<212> PRT
<213> 人工序列
<220>
<223> 化学合成的氟雷法胺
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> 其中ALA是D-氨基酸
<220>
<221> MOD_RES
<222> (3)..(3)
<223> 其中PHE在4-位的苯基处被氟化
<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> 其中PHE连接于胺
<400> 261
Tyr Ala Phe Phe
1
Claims (31)
1.制备包含GCC激动剂序列的肽的方法,所述GCC激动剂序列选自SEQ ID NOs:1-44和99-107,其中所述GCC激动剂序列是n个氨基酸单元长度,N-末端单元在位置1且C-末端单元在位置n,所述方法包括:
提供第一片段,所述第一片段具有所述GCC激动剂序列的从位置j到位置k的氨基酸单元的第一序列,其中j是1和n-1之间的整数,k是2和n之间的整数且大于j,且所述第一片段除了位置j的氨基酸单元的氨基或者位置k的氨基酸单元的羧基之外受保护,
提供第二片段,所述第二片段具有所述GCC激动剂序列的从位置h到位置j-1的氨基酸单元的第二序列或具有所述GCC激动剂序列的从位置k+1到位置m的氨基酸单元的第三序列,其中h是1和n-2之间的整数且小于j,m是k+2和n之间的整数,且所述第二片段除了位置j-1的氨基酸单元的羧基或者位置k+1的氨基酸单元的氨基之外受保护,其中所述第一片段和第二片段中的至少一种经由固相肽合成提供,且
经由溶液相合成将所述第一片段和所述第二片段偶联以得到具有所述GCC激动剂序列的从位置h到位置k的氨基酸单元序列的受保护的肽,或具有所述GCC激动剂序列的从位置j到位置m的氨基酸单元序列的受保护的肽,
其中所述肽通过包括以下的方法纯化:将所述肽吸附到聚合吸附柱上,任选地用去离子水冲洗所述肽,用异丙醇水溶液从所述聚合吸附柱将任选冲洗的肽洗脱下来以形成肽溶液,从所述肽溶液去除水和异丙醇以沉淀所述肽,和任选地将醚添加至脱水肽以促进所述肽的沉淀,且其中所述肽具有不小于0.1 g/mL的堆积密度。
2.权利要求1的方法,其中所述GCC激动剂序列选自SEQ ID NOs:1、8和9。
3.权利要求1的方法,其中所述GCC激动剂序列选自SEQ ID NOs:1和9。
4.权利要求3的方法,其中h是7,j是15,且k是16。
5.权利要求4的方法,进一步包括将具有所述GCC激动剂序列的从位置7到位置16的氨基酸单元序列的受保护的肽的位置7的氨基酸单元的氨基脱保护,以得到位置-7反应性肽。
6.权利要求5的方法,进一步包括提供具有所述GCC激动剂序列的从位置1到位置6的氨基酸单元序列的第三片段,其中所述第三片段除了位置6的氨基酸的羧基之外受保护。
7.权利要求6的方法,进一步包括经由溶液相合成将所述第三片段和所述位置-7反应性肽偶联,以得到具有所述GCC激动剂序列的从位置1到位置16的氨基酸单元序列的受保护的线性肽。
8.权利要求7的方法,进一步包括将受保护的线性肽脱保护,以得到脱保护的线性肽。
9.权利要求8的方法,进一步包括氧化所述脱保护的线性肽,以得到包含选自SEQ IDNOs:1和9的GCC激动剂序列的肽。
10.权利要求1的方法,其中所述第一片段和第二片段中的每一种不超过10个氨基酸单元长度。
11.权利要求10的方法,其中所述第二片段具有所述GCC激动剂序列的位置h到位置j-1的氨基酸单元的第二序列,且所述第二片段的位置j-1的氨基酸单元和所述第一片段的位置k的氨基酸单元中的任一个或两个选自甘氨酸、脯氨酸、亮氨酸、丙氨酸和精氨酸。
12.权利要求10的方法,其中所述第二片段具有所述GCC激动剂序列的位置h到位置j-1的氨基酸单元的第二序列,且所述第二片段的位置j-1的氨基酸单元和所述第一片段的位置k的氨基酸单元中的任一个或两个选自甘氨酸和脯氨酸。
13.权利要求10的方法,其中所述第二片段具有所述GCC激动剂序列的位置k+1到位置m的氨基酸单元的第三序列,且所述第二片段的位置m的氨基酸单元和所述第一片段的位置k的氨基酸单元中的任一个或两个选自甘氨酸、脯氨酸、亮氨酸、丙氨酸和精氨酸。
14.权利要求10的方法,其中所述第二片段具有所述GCC激动剂序列的位置k+1到位置m的氨基酸单元的第三序列,且所述第二片段的位置m的氨基酸单元和所述第一片段的位置k的氨基酸单元中的任一个或两个选自甘氨酸和脯氨酸。
15.权利要求1的方法,其中k是 n,所述第二片段具有所述GCC激动剂序列的位置h到位置j-1的氨基酸单元的第二序列,且位置j-1的氨基酸单元选自甘氨酸、脯氨酸、亮氨酸、丙氨酸和精氨酸。
16.权利要求15的方法,进一步包括将具有所述GCC激动剂序列的从位置h到位置k的氨基酸单元序列的受保护的肽的位置h的氨基酸单元的氨基脱保护,以得到位置-h反应性肽。
17.权利要求16的方法,进一步包括提供具有所述GCC激动剂序列的从位置1到位置h-1的氨基酸单元序列的第四片段,其中所述第四片段除了位置h-1的氨基酸单元的羧基之外受保护。
18.权利要求17的方法,其中所述第四片段不超过10个氨基酸单元长度。
19.权利要求17的方法,进一步包括经由溶液相合成将所述第四片段和所述位置-h反应性肽偶联,以得到具有所述GCC激动剂序列的从位置1到位置n的氨基酸单元序列的受保护的线性肽。
20.权利要求19的方法,进一步包括将所述受保护的线性肽脱保护,以得到具有所述GCC激动剂序列的从位置1到位置n的氨基酸单元序列的受保护的线性肽。
21.权利要求20的方法,进一步包括氧化所述脱保护的线性肽,以得到包含选自SEQ IDNOs:1-44和99-249的GCC激动剂序列的肽。
22.权利要求1的方法,其中所述醇水溶液包含异丙醇。
23.权利要求1的方法,其中所述醚包含二乙醚。
24.权利要求1的方法,进一步包括在所述纯化之前通过用包含铵盐的水溶液洗涤所述肽而将所述肽进行盐交换。
25.权利要求24的方法,进一步包括在所述盐交换步骤之后所述纯化之前冻干所述肽。
26.权利要求1的方法,其中所述肽具有不小于95%的层析纯度。
27.权利要求1的方法,其中所述肽基本上不含水。
28.权利要求1的方法,其中所述肽基本上不含选自乙腈、乙酰胺、醇类、铵、和TFA的杂质。
29.权利要求1的方法,其中所述肽基本上不含拓扑异构体。
30.权利要求1的方法,其中所述肽包含SEQ ID NO:1的GCC激动剂序列。
31.权利要求1的方法,其中所述肽包含SEQ ID NO:9的GCC激动剂序列。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161447891P | 2011-03-01 | 2011-03-01 | |
US61/447891 | 2011-03-01 | ||
CN201280021221.6A CN103764672A (zh) | 2011-03-01 | 2012-03-01 | 制备鸟苷酸环化酶c激动剂的方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280021221.6A Division CN103764672A (zh) | 2011-03-01 | 2012-03-01 | 制备鸟苷酸环化酶c激动剂的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108676076A true CN108676076A (zh) | 2018-10-19 |
Family
ID=46758495
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610963128.7A Pending CN107090016A (zh) | 2011-03-01 | 2012-03-01 | 制备鸟苷酸环化酶c激动剂的方法 |
CN201810573998.2A Pending CN108676076A (zh) | 2011-03-01 | 2012-03-01 | 制备鸟苷酸环化酶c激动剂的方法 |
CN201280021221.6A Pending CN103764672A (zh) | 2011-03-01 | 2012-03-01 | 制备鸟苷酸环化酶c激动剂的方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610963128.7A Pending CN107090016A (zh) | 2011-03-01 | 2012-03-01 | 制备鸟苷酸环化酶c激动剂的方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280021221.6A Pending CN103764672A (zh) | 2011-03-01 | 2012-03-01 | 制备鸟苷酸环化酶c激动剂的方法 |
Country Status (13)
Country | Link |
---|---|
US (3) | US9580471B2 (zh) |
EP (2) | EP3366698A1 (zh) |
JP (3) | JP6251038B2 (zh) |
KR (1) | KR102034748B1 (zh) |
CN (3) | CN107090016A (zh) |
AU (4) | AU2012223337C1 (zh) |
CA (2) | CA3100941C (zh) |
DK (1) | DK2681236T3 (zh) |
EA (1) | EA201391254A1 (zh) |
ES (1) | ES2664873T3 (zh) |
IL (1) | IL228187B (zh) |
MX (2) | MX357121B (zh) |
WO (1) | WO2012118972A2 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114573662A (zh) * | 2021-09-30 | 2022-06-03 | 深圳翰宇药业股份有限公司 | 一种普卡那肽铵盐的制备方法 |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102034748B1 (ko) | 2011-03-01 | 2019-10-21 | 시너지 파마슈티컬즈 인코포레이티드 | 구아닐레이트 사이클라제 c 작용제의 제조 방법 |
CA2902348C (en) | 2013-02-25 | 2021-11-30 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
AU2014235215A1 (en) | 2013-03-15 | 2015-10-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
JP2016514670A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト |
BR112015030326A2 (pt) * | 2013-06-05 | 2017-08-29 | Synergy Pharmaceuticals Inc | Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos |
WO2015022575A2 (en) | 2013-08-13 | 2015-02-19 | Auro Peptides Ltd | A process for the preparation of gc-c agonist |
AU2014331812B2 (en) * | 2013-10-09 | 2019-01-17 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
CN103694320B (zh) * | 2013-12-11 | 2015-11-11 | 深圳翰宇药业股份有限公司 | 一种普利卡那肽的制备方法 |
WO2016038497A1 (en) | 2014-09-08 | 2016-03-17 | Auro Peptides Ltd | A process for the preparation of linaclotide |
CN104530198B (zh) * | 2014-12-09 | 2017-09-15 | 兰州大学 | 一种片段缩合制备醋酸去氨加压素的方法 |
WO2017123634A1 (en) | 2016-01-11 | 2017-07-20 | Synergy Pharmaceuticals, Inc. | Formulations and methods for treating ulcerative colitis |
CN108864254B (zh) * | 2017-05-10 | 2021-03-16 | 深圳翰宇药业股份有限公司 | 一种普利卡那肽的制备方法 |
US11458129B2 (en) * | 2017-11-02 | 2022-10-04 | California Institute Of Technology | Neurokinin antagonists and uses thereof |
WO2019090000A1 (en) | 2017-11-02 | 2019-05-09 | California Institute Of Technology | Expression of neuropeptides |
CN108003222A (zh) * | 2017-12-31 | 2018-05-08 | 江苏诺泰澳赛诺生物制药股份有限公司 | 一种普利卡那肽的固相合成方法 |
WO2019215753A2 (en) | 2018-05-07 | 2019-11-14 | Mylan Laboratories Ltd | Process for preparation of pure plecanatide |
EA202191604A1 (ru) * | 2018-12-08 | 2021-10-27 | Энжене Биосайенз Лимитед | Усовершенствованный способ приготовления плеканатида |
US20220235096A1 (en) * | 2019-06-10 | 2022-07-28 | Auro Peptides Ltd | An improved process for the preparation of Plecanatide |
CN114945580B (zh) * | 2020-01-15 | 2023-12-15 | 北京费森尤斯卡比医药有限公司 | 用于合成南吉博肽的方法 |
JP7162853B1 (ja) * | 2021-07-02 | 2022-10-31 | ペプチスター株式会社 | 液相ペプチド合成用担体結合ペプチドの分析方法 |
CN113801197B (zh) * | 2021-08-03 | 2023-11-03 | 中肽生化有限公司 | 一种普卡那肽的制备方法 |
WO2023084320A1 (en) * | 2021-11-11 | 2023-05-19 | V-Ensure Pharma Technologies Private Limited | Reconstitutable, single use antidiabetic compositions |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4072586A (en) * | 1975-12-10 | 1978-02-07 | Diamond Shamrock Technologies S.A. | Manganese dioxide electrodes |
CN101010335A (zh) * | 2004-03-09 | 2007-08-01 | 米克罗比亚股份有限公司 | 治疗胃肠病的方法和组合物 |
US20100152118A1 (en) * | 2007-06-04 | 2010-06-17 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
Family Cites Families (201)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1116676B (de) | 1955-03-14 | 1961-11-09 | Thomae Gmbh Dr K | Verfahren zur Herstellung von Pyrimido [5, 4-d] pyrimidinen |
GB1051218A (zh) | 1963-03-09 | |||
US3636039A (en) | 1970-02-24 | 1972-01-18 | Hoffmann La Roche | Substituted benzylimidazolidinones |
GB1361441A (en) | 1970-05-13 | 1974-07-24 | Sandoz Ltd | Benzonaphthyridine derivatives |
GB1338235A (en) | 1970-12-15 | 1973-11-21 | May & Baker Ltd | Azapurinones |
BE794964A (fr) | 1972-02-04 | 1973-08-02 | Bristol Myers Co | Nouveaux agents hypotenseurs et procede pour les preparer |
JPS5229318B2 (zh) | 1972-03-30 | 1977-08-01 | ||
DE2305339C3 (de) | 1973-02-03 | 1980-05-08 | Dr. Karl Thomae Gmbh, 7950 Biberach | Imidazo [4,5-b] pyridine, ihre Herstellung und ihre Verwendung als Cardiötonica |
AR205004A1 (es) | 1973-10-30 | 1976-03-31 | Ishikawa M | Procedimiento para preparar derivados de 6,8-dialquil-7-alcoxi-carbonil-4-hidroximetil-1-ftalazona y la 7,8-lactona |
GB1491510A (en) | 1973-12-14 | 1977-11-09 | Hisamitsu Pharmaceutical Co | 1-nitrophenylquinazoline-2,4(1h,3h)-diones |
DE2462367A1 (de) | 1974-01-22 | 1976-11-11 | Wuelfing J A Fa | 7-(oxoalkyl)-1,3-dialkylxanthine enthaltende arzneimittelzubereitungen |
DE2413935A1 (de) | 1974-03-20 | 1975-10-16 | Schering Ag | 4-(polyalkoxy-phenyl)-2-pyrrolidone |
US3914250A (en) | 1974-08-01 | 1975-10-21 | American Home Prod | 1,4-Diazepino{8 6,5,4-jk{9 carbazoles |
FR2296427A1 (fr) * | 1974-12-31 | 1976-07-30 | Choay Sa | Agent peptidique de regulation de la glycemie |
US4072746A (en) | 1975-10-14 | 1978-02-07 | Sterling Drug Inc. | 3-Amino-5-(pyridinyl)-2(1H)-pyridinones |
NZ187452A (en) | 1977-06-10 | 1980-05-27 | Otsuka Pharma Co Ltd | N- substituted-aminocarbonylpropoxy-carbostyrils and their preparation |
DE2727481A1 (de) | 1977-06-18 | 1979-01-11 | Basf Ag | Dihydropyridazone und dihydropyridazone enthaltende therapeutische mittel |
NL7807507A (nl) | 1977-07-25 | 1979-01-29 | Hoffmann La Roche | Tricyclische verbindingen. |
CA1114379A (en) | 1977-11-03 | 1981-12-15 | Pfizer Corporation | Piperidino-phthalazines |
JPS5527105A (en) | 1978-08-11 | 1980-02-27 | Dai Ichi Seiyaku Co Ltd | Imidazothienopyrimidinones compound |
DE2837161A1 (de) | 1978-08-25 | 1980-03-06 | Thomae Gmbh Dr K | Neue benzimidazole und deren verwendung |
JPS5535019A (en) | 1978-09-01 | 1980-03-11 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
DE2845220A1 (de) | 1978-10-17 | 1980-04-30 | Yoshitomi Pharmaceutical | Pyridazinon-derivate, ihre salze mit saeuren, verfahren zu ihrer herstellung und ihre verwendung bei der behandlung von thrombosen und hypertonie |
DE2847693A1 (de) | 1978-11-03 | 1980-05-22 | Hoechst Ag | Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen |
NZ193935A (en) | 1979-06-18 | 1985-05-31 | Richardson Merrell Inc | 4-aroyl-imidazol-2-one derivatives;pharmaceutical compositions |
GB2063249A (en) | 1979-10-09 | 1981-06-03 | Mitsubishi Yuka Pharma | 4-Phenylphthalazine derivatives |
IL61501A (en) | 1979-11-26 | 1984-06-29 | Sterling Drug Inc | 5-(pyridinyl)-2(1h)-pyridinones,their preparation and pharmaceutical compositions containing them |
JPS5777676A (en) | 1980-10-31 | 1982-05-15 | Otsuka Pharmaceut Co Ltd | Carbostyril derivative |
US4405628A (en) | 1981-03-05 | 1983-09-20 | Merrell Dow Pharmaceuticals Inc. | 4-Pyridylimidazolones and method of use |
HU190412B (en) | 1981-09-17 | 1986-09-29 | Warner-Lambert Co,Us | Process for producing substituted 4,5-dihiydro-6-bracket-substituted-bracket closed-phenyl-3-bracket-2h-bracket closed-pyridazinones and 6-bracket-substituted-bracket closed-phenyl-3-bracket-2h-bracket closed-pyridazinones |
EP0096517A3 (en) | 1982-06-05 | 1985-04-03 | Smith Kline & French Laboratories Limited | Aryl pyrazinones |
DE3241102A1 (de) | 1982-11-06 | 1984-05-10 | A. Nattermann & Cie GmbH, 5000 Köln | Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung |
US4490371A (en) | 1983-02-16 | 1984-12-25 | Syntex (U.S.A.) Inc. | N,N-Disubstituted-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-B]quinazolinyl)oxyalkylamides |
GB8400863D0 (en) | 1984-01-13 | 1984-02-15 | Smith Kline French Lab | Chemical compounds |
GB8406906D0 (en) | 1984-03-16 | 1984-04-18 | Akzo Nv | Benzo-thiazole and benzothiophene derivatives |
DK159431C (da) | 1984-05-10 | 1991-03-18 | Byk Gulden Lomberg Chem Fab | 6-phenyl-3(2h)-pyridazinoner, fremgangsmaade til fremstilling deraf, laegemidler indeholdende disse samt anvendelse af forbindelserne til fremstilling af laegemidler |
PL147842B1 (en) | 1984-05-12 | 1989-08-31 | Method of obtaining novel pyroisobenzimidazoles | |
CA1248099A (en) | 1984-05-14 | 1989-01-03 | David W. Robertson | Indoline and 2-indolinone derivatives |
DE3424685A1 (de) | 1984-07-05 | 1986-02-06 | Beiersdorf Ag, 2000 Hamburg | Neue substituierte phenylpiperazinyl-propanole, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen |
JPS61218589A (ja) | 1985-03-26 | 1986-09-29 | Eisai Co Ltd | 5―(6―イミダゾ〔1,2―a〕ピリジニル)ピリジン誘導体 |
ZW20586A1 (en) | 1985-10-17 | 1988-05-25 | Smith Kline French Lab | Chemical compounds |
WO1987006576A1 (en) | 1986-04-29 | 1987-11-05 | Pfizer Inc. | Calcium independent camp phosphodiesterase inhibitor antidepressant |
DE3779374D1 (en) | 1986-08-28 | 1992-07-02 | Sandoz Ag | Xanthinderivate. |
NZ222843A (en) | 1986-12-22 | 1989-10-27 | Ortho Pharma Corp | Benzoxazinyl- and benzothiazinyl-tetrahydropyridazinones and intermediates, and medicaments |
GB8630702D0 (en) | 1986-12-23 | 1987-02-04 | Wellcome Found | Quinoline compound |
CA1303037C (en) | 1987-02-02 | 1992-06-09 | Smith Kline & French Laboratories Limited | Purinone derivatives as bronchodilators vasodilators and anti-allergic agents |
IT1217123B (it) | 1987-02-05 | 1990-03-14 | Rotta Research Lab | Derivati otticamente attivi dell acido 5 pentilammino 5 oxo pentanoico r ad attivita antagonista della colecistochinina e procedimento per la loro preparazione |
AU614965B2 (en) | 1987-06-06 | 1991-09-19 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Thiadiazinones |
NZ225447A (en) | 1987-07-20 | 1991-12-23 | Merck & Co Inc | Piperazinyl derivatives of purine and purine isosteres and pharmaceutical compositions |
JP2717687B2 (ja) | 1988-02-13 | 1998-02-18 | 日本曹達株式会社 | ピリダジノン誘導体及びその製造方法 |
US5142096A (en) | 1988-03-31 | 1992-08-25 | Kyowa Hakko Kogyo Co., Ltd. | 2,4-dihydroxy-3,5,6-trimethylbenzoic acid compounds |
GB8906792D0 (en) | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
US5236918A (en) | 1989-04-17 | 1993-08-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | 6-aryl-3-cyanaminopyridazines, their preparation and use and medicaments containing them |
NZ234186A (en) | 1989-07-07 | 1991-10-25 | Janssen Pharmaceutica Nv | Imidazo quinazolin-one derivatives and pharmaceutical compositions |
GB9413975D0 (en) | 1994-07-11 | 1994-08-31 | Fujisawa Pharmaceutical Co | New heterobicyclic derivatives |
US4943573A (en) | 1989-11-01 | 1990-07-24 | Bristol-Myers Squibb Company | Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility |
HU215441B (hu) | 1989-11-13 | 1999-04-28 | Pfizer Inc. | Eljárás az endo-biciklo [2.2.1]-heptan-2-ol előállítására és az ebből kapott hatóanyagok enzimatikus úton történő elválasztására |
GB8929208D0 (en) | 1989-12-27 | 1990-02-28 | Almirall Lab | New xanthine derivatives |
US4963561A (en) | 1990-02-28 | 1990-10-16 | Sterling Drug Inc. | Imidazopyridines, their preparation and use |
RU2054004C1 (ru) | 1990-04-25 | 1996-02-10 | Ниссан Кемикал Индастриз Лтд. | Производные 3(2н)-пиридазинона или их фармацевтически приемлемые соли и фармацевтическая композиция на их основе |
MY105344A (en) | 1990-05-16 | 1994-09-30 | Byk Gulden Lomberg Chemische Fabrik | New sulphonyl compounds |
GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
EP0538384A4 (en) | 1990-07-10 | 1995-04-12 | Smithkline Beecham Corp | Oxamides |
EP0540626A1 (en) * | 1990-07-24 | 1993-05-12 | Eastman Chemical Company | Process for synthesizing peptides |
US5124455A (en) | 1990-08-08 | 1992-06-23 | American Home Products Corporation | Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents |
DE59109027D1 (en) | 1990-10-16 | 1998-08-13 | Byk Gulden Lomberg Chem Fab | Arylpyridazinone |
GB9027055D0 (en) | 1990-12-13 | 1991-02-06 | Sandoz Ltd | Organic compounds |
JPH04234389A (ja) | 1990-12-28 | 1992-08-24 | Sapporo Breweries Ltd | ナフチリジン誘導体及びそれを有効成分とする抗潰瘍剤 |
US5141931A (en) | 1991-01-03 | 1992-08-25 | Sterling Winthrop Inc. | 5-Quinolinylpyridinones, cardiotonic compositions and methods |
IE71647B1 (en) | 1991-01-28 | 1997-02-26 | Rhone Poulenc Rorer Ltd | Benzamide derivatives |
IE73235B1 (en) | 1991-03-25 | 1997-05-21 | Akzo Nv | 4-aryl-thiazole or imidazole derivatives |
EP0581805A1 (de) | 1991-04-26 | 1994-02-09 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Neue pyridazine |
US5191084A (en) | 1991-05-01 | 1993-03-02 | American Home Products Corporation | Phenyl pyrazolidinones as bronchodilators and anti-inflammatory agents |
GB9116039D0 (en) | 1991-07-25 | 1991-09-11 | Ucb Sa | Substituted cyclopropylamino-1,3,5-triazines |
PT100905A (pt) | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
ES2135416T3 (es) | 1991-10-09 | 1999-11-01 | Syntex Inc | Compuestos de piridopiridazinonas y piridazintionas con actividad inhibidora de la pde iv. |
US5824645A (en) | 1991-12-30 | 1998-10-20 | Neurex Corporation | Method of treating inflammation |
CA2151741C (en) | 1991-12-30 | 2001-12-11 | Alan Justice | Methods of producing analgesia and enhancing opiate analgesia |
WO1993015044A1 (en) | 1992-01-29 | 1993-08-05 | Smithkline Beecham Corporation | N-benzyloxamic acid, oxamate, and oxamide derivatives and their use as tnf and pde iv inhibitors |
WO1993015045A1 (en) | 1992-01-29 | 1993-08-05 | Smithkline Beecham Corporation | N-(3-phenylpropyl)oxamic acid, oxamate, and oxamide derivatives |
GB9204808D0 (en) | 1992-03-04 | 1992-04-15 | Rhone Poulenc Rorer Ltd | Novel compositions of matter |
US5264437A (en) | 1992-03-20 | 1993-11-23 | Syntex (U.S.A.) Inc. | Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones |
WO1993019751A1 (en) | 1992-04-02 | 1993-10-14 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor |
JP3199380B2 (ja) | 1992-04-02 | 2001-08-20 | スミスクライン・ビーチャム・コーポレイション | 化合物 |
AU3738293A (en) | 1992-04-02 | 1993-11-08 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
SK279958B6 (sk) | 1992-04-02 | 1999-06-11 | Smithkline Beecham Corporation | Zlúčeniny s protialergickým a protizápalovým účink |
DE69309030T2 (de) | 1992-06-15 | 1997-09-25 | Celltech Therapeutics Ltd | Trisubstituierte phenylderivate als selektive phosphodiesterase iv inhibitoren |
JP2657760B2 (ja) | 1992-07-15 | 1997-09-24 | 小野薬品工業株式会社 | 4−アミノキナゾリン誘導体およびそれを含有する医薬品 |
ES2227519T3 (es) | 1992-07-28 | 2005-04-01 | Aventis Pharma Limited | Inhibidores de c-amp-fosfodiesterasa. |
DK0660711T3 (da) | 1992-09-14 | 1999-10-18 | Forssmann Wolf Georg Prof Dr | Hidtil ukendt anvendelse af phosphodiesterase IV-inhibitorer |
ATE234270T1 (de) | 1992-12-02 | 2003-03-15 | Pfizer | Cathecoldiether als selektive pde iv hemmungsmittel |
TW263495B (zh) | 1992-12-23 | 1995-11-21 | Celltech Ltd | |
GB9304919D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
US5455252A (en) | 1993-03-31 | 1995-10-03 | Syntex (U.S.A.) Inc. | Optionally substituted 6,8-quinolines |
US5459151A (en) | 1993-04-30 | 1995-10-17 | American Home Products Corporation | N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents |
GB9309324D0 (en) | 1993-05-06 | 1993-06-16 | Bayer Ag | Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives |
GB9311282D0 (en) | 1993-06-01 | 1993-07-21 | Rhone Poulenc Rorer Ltd | New compositions of matter |
JPH0710875A (ja) | 1993-06-21 | 1995-01-13 | Green Cross Corp:The | 選択的ホスホジエステラーゼiv阻害剤 |
GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
ES2176252T3 (es) | 1993-07-02 | 2002-12-01 | Altana Pharma Ag | Benzamidas sustituidas con fluoro-alcoxi y su utilizacion como agentes inhibidores de fosfodiesterasas de nucleotidos ciclicos. |
RU2131876C1 (ru) | 1993-07-06 | 1999-06-20 | Пфайзер Инк. | Бициклические тетрагидропиразолпиридины или их фармацевтически приемлемые соли, фармацевтическая композиция, способ ингибирования фосфодиэстеразы, способ лечения |
GB9315595D0 (en) | 1993-07-28 | 1993-09-08 | Res Inst Medicine Chem | New compounds |
DE69430747T2 (de) | 1993-07-28 | 2003-03-06 | Aventis Pharma Ltd | Verbindungen als pde iv und tnf inhibitoren |
JPH09501420A (ja) | 1993-07-30 | 1997-02-10 | スミスクライン・ビーチャム・コーポレイション | 3−シアノ−3−(3,4−二置換)フェニルシクロヘキシル−1−カルボキシレート類 |
EP0714397A1 (en) | 1993-08-19 | 1996-06-05 | Smithkline Beecham Corporation | Phenethylamine compounds |
US5665754A (en) | 1993-09-20 | 1997-09-09 | Glaxo Wellcome Inc. | Substituted pyrrolidines |
JPH09503503A (ja) | 1993-10-01 | 1997-04-08 | スミスクライン・ビーチャム・コーポレイション | 化合物、組成物ならびにアレルギーおよび炎症の治療 |
WO1995009836A1 (en) | 1993-10-01 | 1995-04-13 | Smithkline Beecham Corporation | Cyanocyclohexane compounds, compositions, and uses thereof |
WO1995009624A1 (en) | 1993-10-01 | 1995-04-13 | Smithkline Beecham Corporation | Compounds, compositions and treatment of allergies and inflammation |
AU7957794A (en) | 1993-10-01 | 1995-05-01 | Smithkline Beecham Corporation | Anti-allergic, anti-inflammatory compounds, compositions and uses |
GB9322828D0 (en) | 1993-11-05 | 1993-12-22 | Sandoz Ltd | Organic compounds |
US5502072A (en) | 1993-11-26 | 1996-03-26 | Pfizer Inc. | Substituted oxindoles |
BR9408174A (pt) | 1993-11-26 | 1997-05-27 | Pfizer | Compostos isoxazolina como agentes antiinflamatórios |
DE69422061T2 (de) | 1993-11-26 | 2000-03-30 | Pfizer | 3-phenyl-2-isoxazoline derivate als entzündugshemmende mittel |
GB9326600D0 (en) | 1993-12-22 | 1994-03-02 | Celltech Ltd | Chemical compounds |
ATE260911T1 (de) | 1993-12-22 | 2004-03-15 | Celltech R&D Ltd | Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe |
US5508300A (en) | 1994-01-14 | 1996-04-16 | Pfizer Inc. | Dihydro pyrazolopyrroles, compositions and use |
JP2928079B2 (ja) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | 1−(置換ベンジル)−3−(置換アリール)縮合ピラゾール類、その製造法及びその用途 |
WO1995022520A1 (en) | 1994-02-17 | 1995-08-24 | American Home Products Corporation | Substituted biphenyl derivatives as phosphodiesterase inhibitors |
CA2143143A1 (en) | 1994-03-08 | 1995-09-09 | Toshihiko Tanaka | 3-phenylpyrrolidine derivatives |
GB9404706D0 (en) | 1994-03-11 | 1994-04-27 | Smithkline Beecham Corp | Compounds |
WO1995027692A1 (en) | 1994-04-08 | 1995-10-19 | Smithkline Beecham Corporation | Subtituted biphenyl tnf inhibitors |
DK0758233T3 (da) | 1994-04-21 | 2004-03-22 | Schering Ag | PDE IV-inhibitorer til behandling af multipel sklerose |
HRP950288A2 (en) | 1994-05-31 | 1997-08-31 | Bayer Ag | Oxalylamino-benzofuran- and benzothienyl-derivatives |
GB9410877D0 (en) | 1994-05-31 | 1994-07-20 | Bayer Ag | Heterocyclycarbonyl substituted benzoduranyl-and-thiophenyl-alkanecarboxyclic acid derivatives |
ES2127966T3 (es) | 1994-05-31 | 1999-05-01 | Bayer Ag | Derivados de amino-benzofurilo y -benzotienilo. |
US5786354A (en) | 1994-06-21 | 1998-07-28 | Celltech Therapeutics, Limited | Tri-substituted phenyl derivatives and processes for their preparation |
GB9412383D0 (en) | 1994-06-21 | 1994-08-10 | Celltech Ltd | Chemical compound |
CA2193725A1 (en) | 1994-06-24 | 1996-01-04 | David Cavalla | Aryl derivative compounds and uses to inhibit phosphodiesterase iv acti vity |
US5466697A (en) | 1994-07-13 | 1995-11-14 | Syntex (U.S.A.) Inc. | 8-phenyl-1,6-naphthyridin-5-ones |
RU2138498C1 (ru) | 1994-07-22 | 1999-09-27 | Бык Гульден Ломберг Хемише Фабрик Гмбх | Дигидробензофураны, способ их получения и фармацевтическая композиция на их основе |
AU699489B2 (en) | 1994-10-12 | 1998-12-03 | Euro-Celtique S.A. | Novel benzoxazoles |
US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
DK1629849T4 (en) | 1997-01-07 | 2017-12-04 | Amylin Pharmaceuticals Llc | Pharmaceutical compositions comprising exedins and agonists thereof |
US6589750B2 (en) | 1997-02-20 | 2003-07-08 | Institut Pasteur | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
EP1032587B2 (en) | 1997-11-14 | 2013-03-13 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
AU1590699A (en) * | 1997-11-20 | 1999-06-15 | Ortho-Mcneil Pharmaceutical, Inc. | Liquid phase process for the preparation of gnrh peptides |
EP1062222A1 (en) | 1998-03-09 | 2000-12-27 | Fondatech Benelux N.V. | Serine peptidase modulators |
DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
DE19844547C2 (de) | 1998-09-29 | 2002-11-07 | Aventis Pharma Gmbh | Polycyclische Dihydrothiazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US6344481B1 (en) | 1999-03-01 | 2002-02-05 | Pfizer Inc. | Thyromimetic antiobesity agents |
ES2223537T3 (es) | 1999-06-15 | 2005-03-01 | Bristol-Myers Squibb Pharma Company | Gamma-carbolinas condensadas con heterociclos sustituidas. |
US6207699B1 (en) | 1999-06-18 | 2001-03-27 | Richard Brian Rothman | Pharmaceutical combinations for treating obesity and food craving |
PT1593387E (pt) | 1999-06-23 | 2009-03-18 | Pasteur Institut | Composições para o tratamento de desordens comportamentais e deficiências interpessoais. |
SE9903291D0 (sv) | 1999-09-15 | 1999-09-15 | Astra Ab | New process |
IL149400A0 (en) | 1999-11-05 | 2002-11-10 | Aventis Pharma Gmbh | Indeno-, naphtho-, and benzocyclohepta-dihydrothiazole derivatives, the production thereof and their use as anorectic medicaments |
WO2001054698A1 (en) | 2000-01-26 | 2001-08-02 | Warner-Lambert Company | Method for preventing or treating postoperative ileus |
PL357547A1 (en) | 2000-02-23 | 2004-07-26 | Aventis Pharma Deutschland Gmbh | 8,8a-dihydro-indeno[1,2-d]thiazole derivatives, substituted in position 8a, a method for their production and their use as medicaments, e.g. anorectic agents |
PT1261593E (pt) | 2000-02-26 | 2004-01-30 | Aventis Pharma Gmbh | Derivados de 8,8a-di-hidro-ideno¬1,2-d|tiazole que possuem na posicao 2 um substituinte com uma estrutura de sulfona; procedimentos para a sua sintese e a sua utilizacao como farmacos |
EP1132389A1 (en) | 2000-03-06 | 2001-09-12 | Vernalis Research Limited | New aza-indolyl derivatives for the treatment of obesity |
WO2001078781A2 (en) | 2000-04-19 | 2001-10-25 | Johns Hopkins University | Methods for prevention and treatment of gastrointestinal disorders |
SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
ES2250459T3 (es) | 2000-07-31 | 2006-04-16 | F. Hoffmann-La Roche Ag | Derivados de piperazina. |
BR0114708A (pt) | 2000-10-16 | 2003-07-01 | Hoffmann La Roche | Compostos, composições farmacêuticas que compreendem os mesmos, utilização dos compostos, processo de tratamento de distúrbios e de obesidade, e processos para a preparação dos compostos e de uma composição |
AU2002227170A1 (en) | 2000-11-03 | 2002-05-15 | Wyeth | Cycloalkyl(b)(1,4)diazepino(6,7,1-hi)indoles and derivatives |
KR100846339B1 (ko) | 2000-11-20 | 2008-07-15 | 바이오비트럼 에이비(피유비엘) | 세로토닌 5ht-2 수용체의 아고니스트 또는안타고니스트로서의 피페라지닐피라진 화합물 |
EA005975B1 (ru) | 2000-11-20 | 2005-08-25 | Биовитрум Аб | Соединения пиперазинилпиразинов в качестве антагонистов серотонин 5-ht2 рецептора |
AU2002221902B2 (en) | 2000-12-06 | 2006-11-23 | F. Hoffmann-La Roche Ag | Fused heteroaromatic glucokinase activators |
US6482951B2 (en) | 2000-12-13 | 2002-11-19 | Hoffmann-La Roche Inc. | Isoindolin-1-one glucokinase activators |
GB0030710D0 (en) | 2000-12-15 | 2001-01-31 | Hoffmann La Roche | Piperazine derivatives |
EP1216707B1 (en) | 2000-12-22 | 2005-02-09 | Institut Pasteur | Process for screening ligand molecules that specifically bind to the NEP binding site for the QHNPR pentapeptide |
CA2432085C (en) | 2000-12-27 | 2009-02-24 | F. Hoffmann-La Roche Ag | Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands |
BR0206831A (pt) | 2001-02-02 | 2004-07-06 | Takeda Chemical Industries Ltd | Composto, cristal, agente farmacêutico, agentes para profilaxia ou tratamento de diabetes, de complicações diabéticas, de tolerância prejudicada à glucose e de obesidade, inibidor de peptidase, uso de um composto, e, método de produção de um composto |
GB0105772D0 (en) | 2001-03-08 | 2001-04-25 | Sterix Ltd | Use |
US7041786B2 (en) | 2001-03-29 | 2006-05-09 | Callisto Pharmaceuticals | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
FR2824825B1 (fr) | 2001-05-15 | 2005-05-06 | Servier Lab | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
JP2004535433A (ja) | 2001-06-20 | 2004-11-25 | メルク エンド カムパニー インコーポレーテッド | 糖尿病治療用のジペプチジルペプチダーゼ阻害薬 |
CA2450475A1 (en) | 2001-06-20 | 2003-01-03 | Linda Brockunier | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
CN1471538A (zh) | 2001-06-27 | 2004-01-28 | 前体生物药物股份有限公司 | 用于竞争性调节二肽基肽酶iv催化的肽结构 |
ES2296962T3 (es) | 2001-06-27 | 2008-05-01 | Smithkline Beecham Corporation | Pirrolidinas como inhibidores de dipeptidil peptidasa. |
DE60235212D1 (de) | 2001-06-27 | 2010-03-11 | Smithkline Beecham Corp | Fluoropyrrolidine als Dipeptidylpeptidasehemmer |
ATE370943T1 (de) | 2001-06-27 | 2007-09-15 | Smithkline Beecham Corp | Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren |
DE60225556D1 (de) | 2001-07-03 | 2008-04-24 | Novo Nordisk As | Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes |
UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
DE10139416A1 (de) | 2001-08-17 | 2003-03-06 | Aventis Pharma Gmbh | Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US6667322B2 (en) | 2001-10-05 | 2003-12-23 | Wyeth | Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole |
FR2830451B1 (fr) | 2001-10-09 | 2004-04-30 | Inst Nat Sante Rech Med | Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur |
EP1434578A1 (en) | 2001-10-09 | 2004-07-07 | PHARMACIA & UPJOHN COMPANY | Arylsulphonyl-substituted tetrahydro- and hexahydro-carbazoles as 5-ht-6 receptor ligands |
PT1438045E (pt) | 2001-10-23 | 2007-05-31 | Biovitrum Ab | Utilização de derivados de indole e indolina para o tratamento da obesidade ou para a redução de ingestão de alimentos |
SE0103648D0 (sv) | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic quinolone compounds |
SE0103644D0 (sv) | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic isoquinoline compounds |
JP2005511594A (ja) | 2001-11-09 | 2005-04-28 | ビオヴィトルム・アクチボラゲット | 肥満の治療における、もしくは摂食量の減少のためのスルホンアミド誘導体の使用 |
US20060160989A1 (en) * | 2002-03-25 | 2006-07-20 | Council Of Scientic And Industrial Research | Polypeptide useful as antiallergic/antiasthmatic activity, methods for the preparation thereof, pharmaceutical compositions containing such polypeptide and use thereof |
JP4276462B2 (ja) * | 2002-04-11 | 2009-06-10 | アスビオファーマ株式会社 | 修飾ペプチドの製造方法 |
CN100411618C (zh) | 2002-05-17 | 2008-08-20 | 迪欧加药品公司 | 有效的选择性阿片受体调制剂化合物的用途 |
DE10331723A1 (de) | 2003-07-11 | 2005-06-16 | Merck Patent Gmbh | Kappa-Agonisten |
RU2009144972A (ru) | 2007-05-04 | 2011-06-10 | Айронвуд Фармасьютикалз, Инк. (Us) | Композиции и способы лечения нарушений, ассоциированных с задержкой соли или жидкости |
EP2170930B3 (en) | 2007-06-04 | 2013-10-02 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
AU2009256156B2 (en) | 2008-06-04 | 2014-09-18 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP2328910B1 (en) | 2008-06-04 | 2014-08-06 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
US20120039949A1 (en) * | 2008-09-04 | 2012-02-16 | Ironwood Pharmaceuticals, Inc. | Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral Administration |
US20100221329A1 (en) * | 2008-12-03 | 2010-09-02 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase c agonists and methods of use |
ES2439998T3 (es) * | 2009-04-10 | 2014-01-27 | Corden Pharma Colorado, Inc. | Procedimiento para aislar linaclotida |
JP6393037B2 (ja) * | 2010-09-15 | 2018-09-19 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼcアゴニストの製剤および使用方法 |
US9616097B2 (en) * | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
KR102034748B1 (ko) * | 2011-03-01 | 2019-10-21 | 시너지 파마슈티컬즈 인코포레이티드 | 구아닐레이트 사이클라제 c 작용제의 제조 방법 |
-
2012
- 2012-03-01 KR KR1020137025708A patent/KR102034748B1/ko active IP Right Grant
- 2012-03-01 US US14/001,638 patent/US9580471B2/en active Active
- 2012-03-01 JP JP2013556862A patent/JP6251038B2/ja active Active
- 2012-03-01 CN CN201610963128.7A patent/CN107090016A/zh active Pending
- 2012-03-01 DK DK12752488.2T patent/DK2681236T3/en active
- 2012-03-01 WO PCT/US2012/027287 patent/WO2012118972A2/en active Application Filing
- 2012-03-01 EP EP17211211.2A patent/EP3366698A1/en not_active Withdrawn
- 2012-03-01 EA EA201391254A patent/EA201391254A1/ru unknown
- 2012-03-01 EP EP12752488.2A patent/EP2681236B1/en active Active
- 2012-03-01 CN CN201810573998.2A patent/CN108676076A/zh active Pending
- 2012-03-01 CA CA3100941A patent/CA3100941C/en active Active
- 2012-03-01 ES ES12752488.2T patent/ES2664873T3/es active Active
- 2012-03-01 MX MX2013010053A patent/MX357121B/es active IP Right Grant
- 2012-03-01 CN CN201280021221.6A patent/CN103764672A/zh active Pending
- 2012-03-01 AU AU2012223337A patent/AU2012223337C1/en active Active
- 2012-03-01 CA CA2828346A patent/CA2828346C/en active Active
-
2013
- 2013-08-29 IL IL22818713A patent/IL228187B/en active IP Right Grant
- 2013-09-02 MX MX2018007955A patent/MX2018007955A/es unknown
-
2016
- 2016-09-16 AU AU2016228268A patent/AU2016228268A1/en not_active Abandoned
-
2017
- 2017-01-13 US US15/405,787 patent/US10421787B2/en active Active
- 2017-11-24 JP JP2017225475A patent/JP6691904B2/ja active Active
-
2018
- 2018-06-07 AU AU2018204038A patent/AU2018204038A1/en not_active Abandoned
-
2019
- 2019-08-21 US US16/546,707 patent/US20200040038A1/en not_active Abandoned
-
2020
- 2020-01-31 JP JP2020014819A patent/JP2020063310A/ja active Pending
- 2020-05-15 AU AU2020203186A patent/AU2020203186A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4072586A (en) * | 1975-12-10 | 1978-02-07 | Diamond Shamrock Technologies S.A. | Manganese dioxide electrodes |
CN101010335A (zh) * | 2004-03-09 | 2007-08-01 | 米克罗比亚股份有限公司 | 治疗胃肠病的方法和组合物 |
US20100152118A1 (en) * | 2007-06-04 | 2010-06-17 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
Non-Patent Citations (5)
Title |
---|
廖江清 等: "《药学前沿》", 31 July 2004, 中国医药科技出版社 * |
廖玉华 等: "《心血管病免疫学》", 29 February 2008, 北京科学出版社 * |
王德心: "《固相有机合成原理及应用指南》", 30 September 2004, 化学工业出版社 * |
秦伯益: "《新药评价概论》", 31 July 1989, 人民卫生出版社 * |
陆彬: "《药剂学》", 31 January 2003, 中国医药科技出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114573662A (zh) * | 2021-09-30 | 2022-06-03 | 深圳翰宇药业股份有限公司 | 一种普卡那肽铵盐的制备方法 |
CN114573662B (zh) * | 2021-09-30 | 2024-06-11 | 深圳翰宇药业股份有限公司 | 一种普卡那肽铵盐的制备方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020205349B2 (en) | Ultra-pure agonists of guanylate cyclase C, method of making and using same | |
CN108676076A (zh) | 制备鸟苷酸环化酶c激动剂的方法 | |
CA2730603C (en) | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | |
AU2009256156B2 (en) | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | |
CA2688161C (en) | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | |
AU2009256157B2 (en) | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200415 Address after: Ai Erlandubailin Applicant after: Doctor medical Ireland Limited Address before: New York, USA Applicant before: SYNERGY PHARMACEUTICALS, Inc. |